

Trastuzumab Emtansine for HER2-Positive Advanced B

New England Journal of Medicine

367, 1783-1791

DOI: [10.1056/nejmoa1209124](https://doi.org/10.1056/nejmoa1209124)

Citation Report

#	ARTICLE	IF	CITATIONS
1	ecancermedalscience. Ecancermedalscience, 2014, 8, 441.	0.6	30
4	The Promise of Antibody-Drug Conjugates. New England Journal of Medicine, 2012, 367, 1847-1848.	13.9	45
5	Drug Conjugates Such as Antibody Drug Conjugates (ADCs), Immunotoxins and Immunoliposomes Challenge Daily Clinical Practice. International Journal of Molecular Sciences, 2012, 13, 16020-16045.	1.8	40
6	Oncology in 2012: from personalized medicine to precision medicine. Targeted Oncology, 2012, 7, 211-212.	1.7	4
8	Principles of cancer treatment by immunotherapy. Surgery, 2012, 30, 198-202.	0.1	1
9	Targeted therapy for HER2 positive breast cancer. Journal of Hematology and Oncology, 2013, 6, 38.	6.9	70
10	Antibody-Drug Conjugates. Methods in Molecular Biology, 2013, , .	0.4	24
11	Acid-cleavable thiomaleamic acid linker for homogeneous antibody-drug conjugation. Chemical Communications, 2013, 49, 8187.	2.2	67
12	Antibody-Drug Conjugate (ADC) Clinical Pipeline: A Review. Methods in Molecular Biology, 2013, 1045, 1-27.	0.4	127
13	Selecting an Optimal Antibody for Antibody-Drug Conjugate Therapy: Internalization and Intracellular Localization. Methods in Molecular Biology, 2013, 1045, 41-49.	0.4	28
14	Resistance to Immunotherapeutic Antibodies in Cancer. Resistance To Targeted Anti-cancer Therapeutics, 2013, , .	0.1	2
15	The Future of Chemotherapy in the Era of Personalized Medicine. Current Breast Cancer Reports, 2013, 5, 57-68.	0.5	2
16	Impact of Genetic Targets on Cancer Therapy. Advances in Experimental Medicine and Biology, 2013, 779, v-vi.	0.8	1
17	Current Status of Anti-Human Epidermal Growth Factor Receptor 2 Therapies: Predicting and Overcoming Herceptin Resistance. Clinical Breast Cancer, 2013, 13, 223-232.	1.1	64
18	Molecular Subtyping of Brain Metastases and Implications for Therapy. Current Treatment Options in Oncology, 2013, 14, 514-527.	1.3	23
19	Met, IGF1R, and Other New Targets in Upper GI Malignancies. Current Treatment Options in Oncology, 2013, 14, 321-336.	1.3	2
20	Use of Pertuzumab for the Treatment of HER2-Positive Metastatic Breast Cancer. Advances in Therapy, 2013, 30, 645-658.	1.3	21
21	Preclinical and clinical pharmacokinetic/pharmacodynamic considerations for antibody-drug conjugates. Expert Review of Clinical Pharmacology, 2013, 6, 541-555.	1.3	26

#	ARTICLE	IF	CITATIONS
22	Pertuzumab for the treatment of metastatic breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 907-918.	1.1	7
23	An Integrated Multiple-Analyte Pharmacokinetic Model to Characterize Trastuzumab Emtansine (T-DM1) Clearance Pathways and to Evaluate Reduced Pharmacokinetic Sampling in Patients with HER2-Positive Metastatic Breast Cancer. <i>Clinical Pharmacokinetics</i> , 2013, 52, 657-672.	1.6	36
25	Patient-derived xenografts, the cancer stem cell paradigm, and cancer pathobiology in the 21st century. <i>Laboratory Investigation</i> , 2013, 93, 970-982.	1.7	163
26	Breast Cancer Metastasis. <i>American Journal of Pathology</i> , 2013, 183, 1084-1095.	1.9	67
27	Challenges imposed by the complexity of cancer genome. <i>Lancet Oncology</i> , The, 2013, 14, e291-e292.	5.1	0
28	Targeting Receptor Tyrosine Kinases in Solid Tumors. <i>Surgical Oncology Clinics of North America</i> , 2013, 22, 685-703.	0.6	8
29	A HER2-targeted RNA aptamer molecule labeled with ^{99m} Tc for single-photon imaging in malignant tumors. <i>Nuclear Medicine and Biology</i> , 2013, 40, 980-986.	0.3	36
30	AGO Recommendations for Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2013. <i>Breast Care</i> , 2013, 8, 181-185.	0.8	68
31	Companion Diagnostics in Oncology - Current Status and Future Aspects. <i>Oncology</i> , 2013, 85, 59-68.	0.9	32
32	Optimal Sequencing of Anti-HER2 Therapy Throughout the Continuum of HER2-Positive Breast Cancer: Evidence and Clinical Considerations. <i>Drugs</i> , 2013, 73, 1665-1680.	4.9	6
33	Structural Basis for Eliciting a Cytotoxic Effect in HER2-Overexpressing Cancer Cells via Binding to the Extracellular Domain of HER2. <i>Structure</i> , 2013, 21, 1979-1991.	1.6	111
34	SEOM clinical guidelines for the management of metastatic breast cancer 2013. <i>Clinical and Translational Oncology</i> , 2013, 15, 1004-1010.	1.2	4
35	Strategies for advancing cancer nanomedicine. <i>Nature Materials</i> , 2013, 12, 958-962.	13.3	717
36	Exploiting Endocytosis for Nanomedicines. <i>Cold Spring Harbor Perspectives in Biology</i> , 2013, 5, a016980-a016980.	2.3	173
37	Smart Nanoscale Drug Delivery Platforms from Stimuli-Responsive Polymers and Liposomes. <i>Macromolecules</i> , 2013, 46, 9169-9180.	2.2	114
38	Orthogonal Assembly of a Designed Ankyrin Repeat Proteinâ€™Cytotoxin Conjugate with a Clickable Serum Albumin Module for Half-Life Extension. <i>Bioconjugate Chemistry</i> , 2013, 24, 1955-1966.	1.8	53
39	Biological therapies in breast cancer: Common toxicities and management strategies. <i>Breast</i> , 2013, 22, 1009-1018.	0.9	26
40	Antibody Therapeutics in Cancer. <i>Science</i> , 2013, 341, 1192-1198.	6.0	474

#	ARTICLE	IF	CITATIONS
41	Challenges in the Treatment of Older Breast Cancer Patients. Hematology/Oncology Clinics of North America, 2013, 27, 785-804.	0.9	13
42	Treating the HER2 Pathway in Early and Advanced Breast Cancer. Hematology/Oncology Clinics of North America, 2013, 27, 751-765.	0.9	15
44	External Quality Assessment (EQA) program for the preanalytical and analytical immunohistochemical determination of HER2 in breast cancer: an experience on a regional scale. Journal of Experimental and Clinical Cancer Research, 2013, 32, 58.	3.5	9
45	Primer on tumor immunology and cancer immunotherapy. , 2013, 1, 12.		63
46	Antibody-“drug conjugates (ADCs)” new targeted therapies. Memo - Magazine of European Medical Oncology, 2013, 6, 223-224.	0.3	0
47	T-DM1 in breast cancer therapeutics: the first drug of its generation. Memo - Magazine of European Medical Oncology, 2013, 6, 267-270.	0.3	0
48	Novel Therapies for Metastatic HER2 Positive Breast Cancer. Current Breast Cancer Reports, 2013, 5, 331-340.	0.5	0
49	Time to stop operating on breast cancer patients with pathological complete response?. European Journal of Surgical Oncology, 2013, 39, 924-930.	0.5	29
50	HER Story: The Next Chapter in HER-2-Directed Therapy for Advanced Breast Cancer. Oncologist, 2013, 18, 1153-1166.	1.9	16
51	Cardiotoxicity of novel HER2-targeted therapies. Current Medical Research and Opinion, 2013, 29, 1015-1024.	0.9	80
52	Trastuzumab emtansine in breast cancer. Expert Opinion on Biological Therapy, 2013, 13, 607-614.	1.4	7
53	Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. Journal of Clinical Oncology, 2013, 31, 3997-4013.	0.8	3,276
54	Endocytosis and Cancer. Cold Spring Harbor Perspectives in Biology, 2013, 5, a016949-a016949.	2.3	314
55	Antibody-“drug conjugates:. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 13695-13695.	3.3	35
56	New drugs, new knowledge, new targets. Nature Reviews Clinical Oncology, 2013, 10, 75-76.	12.5	9
57	Phase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. Journal of Clinical Oncology, 2013, 31, 1157-1163.	0.8	342
58	Distribuci3n fenot3pica del carcinoma de mama en Venezuela. Revista De Senologia Y Patologia Mamaria, 2013, 26, 129-133.	0.0	0
59	Targeted Therapy for Breast Cancer. American Journal of Pathology, 2013, 183, 1096-1112.	1.9	100

#	ARTICLE	IF	CITATIONS
60	A Pooled Analysis of 2618 Patients Treated With Trastuzumab Beyond Progression for Advanced Breast Cancer. <i>Clinical Breast Cancer</i> , 2013, 13, 81-87.	1.1	39
61	Targeted cancer therapy – Are the days of systemic chemotherapy numbered?. <i>Maturitas</i> , 2013, 76, 308-314.	1.0	88
62	Destination Known: Targeted Drug Delivery in Atherosclerosis and Thrombosis. <i>Drug Development Research</i> , 2013, 74, 460-471.	1.4	16
64	Preclinical safety profile of trastuzumab emtansine (T-DM1): Mechanism of action of its cytotoxic component retained with improved tolerability. <i>Toxicology and Applied Pharmacology</i> , 2013, 273, 298-313.	1.3	162
65	Lapatinib in early breast cancer – questions to be resolved. <i>Lancet Oncology</i> , The, 2013, 14, 11-12.	5.1	46
66	Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer. <i>Current Medical Research and Opinion</i> , 2013, 29, 405-414.	0.9	76
67	Multiplex Flow Cytometry Barcoding and Antibody Arrays Identify Surface Antigen Profiles of Primary and Metastatic Colon Cancer Cell Lines. <i>PLoS ONE</i> , 2013, 8, e53015.	1.1	26
68	Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. <i>Current Opinion in Immunology</i> , 2013, 25, 268-276.	2.4	352
69	The war on cancer: are we winning?. <i>Tumor Biology</i> , 2013, 34, 1275-1284.	0.8	42
70	Epidermal growth factor receptor gene copy number may predict lapatinib sensitivity in HER2-positive metastatic breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 699-706.	0.9	16
71	Glucose conjugation for the specific targeting and treatment of cancer. <i>Chemical Science</i> , 2013, 4, 2319.	3.7	306
72	Antibody Drug Conjugates as Cancer Therapeutics. <i>Antibodies</i> , 2013, 2, 113-129.	1.2	83
73	Drug-conjugated antibodies for the treatment of cancer. <i>British Journal of Clinical Pharmacology</i> , 2013, 76, 248-262.	1.1	126
74	HER2 Expression Beyond Breast Cancer: Therapeutic Implications for Gynecologic Malignancies. <i>Molecular Diagnosis and Therapy</i> , 2013, 17, 85-99.	1.6	163
75	Monoclonal antibody-based therapies in cancer: Advances and challenges. , 2013, 138, 452-469.		96
76	Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA) Tj ETQq1 1 0.784314 rgBT /Overlock <i>Lancet Oncology</i> , The, 2013, 14, 461-471.	5.1	849
77	Antibody-based therapy in colorectal cancer. <i>Immunotherapy</i> , 2013, 5, 533-545.	1.0	31
78	Update on Clinical Trials: Genetic Targets in Breast Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2013, 779, 35-54.	0.8	6

#	ARTICLE	IF	CITATIONS
79	Tubulin: an example of targeted chemotherapy. <i>Future Medicinal Chemistry</i> , 2013, 5, 339-352.	1.1	67
80	Development of a diketopiperazine-forming dipeptidyl Gly-Pro spacer for preparation of an antibody-drug conjugate. <i>MedChemComm</i> , 2013, 4, 792.	3.5	19
81	Single-Antibody, Targeted Nanoparticle Delivery of Camptothecin. <i>Molecular Pharmaceutics</i> , 2013, 10, 2558-2567.	2.3	55
82	Anti-tumor activity of a novel monoclonal antibody, NPC-1C, optimized for recognition of tumor antigen MUC5AC variant in preclinical models. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 1011-1019.	2.0	22
83	Companion Biomarkers: Paving the Pathway to Personalized Treatment for Cancer. <i>Clinical Chemistry</i> , 2013, 59, 1447-1456.	1.5	44
84	MSP-RON signalling in cancer: pathogenesis and therapeutic potential. <i>Nature Reviews Cancer</i> , 2013, 13, 466-481.	12.8	169
85	Molecular imaging for monitoring treatment response in breast cancer patients. <i>European Journal of Pharmacology</i> , 2013, 717, 2-11.	1.7	14
86	Trastuzumab Emtansine: First Global Approval. <i>Drugs</i> , 2013, 73, 755-765.	4.9	69
88	Bioanalysis special focus issue on antibody-drug conjugates. <i>Bioanalysis</i> , 2013, 5, 981-983.	0.6	18
89	Pertuzumab: evolving therapeutic strategies in the management of HER2-overexpressing breast cancer. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 779-790.	1.4	12
90	Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives. <i>Annals of Oncology</i> , 2013, 24, 1740-1748.	0.6	74
91	pH-Responsive Theranostic Polymer-Caged Nanobins: Enhanced Cytotoxicity and T ₁ MRI Contrast by Her2 Targeting. <i>Particle and Particle Systems Characterization</i> , 2013, 30, 770-774.	1.2	11
92	Bevacizumab confers additional advantage to the combination of trastuzumab plus pertuzumab in trastuzumab-refractory breast cancer model. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 733-745.	1.1	10
95	AACR Cancer Progress Report 2013. <i>Clinical Cancer Research</i> , 2013, 19, S1-S98.	3.2	55
96	Changing T-cell enigma: Cancer killing or cancer control?. <i>Cell Cycle</i> , 2013, 12, 3335-3342.	1.3	13
97	⁶⁴ Cu-DOTA-Trastuzumab PET Imaging in Patients with HER2-Positive Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1869-1875.	2.8	235
99	Immunotherapeutic strategies to target prognostic and predictive markers of cancer. <i>Biomarkers in Medicine</i> , 2013, 7, 23-35.	0.6	9
100	What do providers, payers and patients need from comparative effectiveness research on diagnostics? The case of HER2 / Neu testing in breast cancer. <i>Journal of Comparative Effectiveness Research</i> , 2013, 2, 461-477.	0.6	7

#	ARTICLE	IF	CITATIONS
101	Emerging Paradigms in Cardiomyopathies Associated With Cancer Therapies. <i>Circulation Research</i> , 2013, 113, 754-764.	2.0	132
102	Overview of diagnostic/targeted treatment combinations in personalized medicine for breast cancer patients. <i>Pharmacogenomics and Personalized Medicine</i> , 2013, 7, 1.	0.4	10
103	Ado-Trastuzumab Emtansine and Radium 223 Dichloride. <i>Hospital Pharmacy</i> , 2013, 48, 729-733.	0.4	0
104	Targeting HER2 by monoclonal antibodies for cancer therapy. , 2013, , 283-305.		3
105	Which patients with metastatic breast cancer benefit from subsequent lines of treatment? An update for clinicians. <i>Therapeutic Advances in Medical Oncology</i> , 2013, 5, 334-350.	1.4	30
106	Multidimensional Challenges in Clinical Drug Development, Regulatory Approval, and Marketing. <i>Journal of Clinical Oncology</i> , 2013, 31, 1252-1253.	0.8	2
109	Targeting receptor tyrosine kinases in HER2-negative breast cancer. <i>Current Opinion in Oncology</i> , 2013, 25, 594-601.	1.1	9
110	Targeted therapies and clinical trials in ovarian cancer. <i>Annals of Oncology</i> , 2013, 24, x59-x63.	0.6	11
111	Targeted therapies of solid cancers. <i>Current Opinion in Oncology</i> , 2013, 25, 296-304.	1.1	21
112	Why Your Preferred Targeted Drugs May Become Unaffordable. <i>Cancer Research</i> , 2013, 73, 5849-5851.	0.4	9
113	HER2-Directed T-Cell Receptorâ€“Mimicking Antibody: A â€œMe Tooâ€•or an Example of Novel Antitumor Aggressive Mimicry?. <i>Journal of the National Cancer Institute</i> , 2013, 105, 161-163.	3.0	1
114	Antibodyâ€“drug conjugates for the treatment of B-cell non-Hodgkinâ€™s lymphoma and leukemia. <i>Future Oncology</i> , 2013, 9, 355-368.	1.1	27
115	Pertuzumab: Optimizing HER2 Blockade. <i>Clinical Cancer Research</i> , 2013, 19, 5552-5556.	3.2	58
116	Antibody-drug conjugates: the chemistry behind empowering antibodies to fight cancer. <i>Hematology American Society of Hematology Education Program</i> , 2013, 2013, 306-310.	0.9	31
117	Emerging strategies for the dual inhibition of HER2-positive breast cancer. <i>Current Opinion in Obstetrics and Gynecology</i> , 2013, 25, 55-65.	0.9	16
118	Biomarker discordance: Why it occurs and why it is important. <i>Cancer Biomarkers</i> , 2013, 12, 219-230.	0.8	1
119	The Cost of Cancer Careâ€“Balancing Our Duties to Patients Versus Society: Are They Mutually Exclusive?. <i>Oncologist</i> , 2013, 18, 347-349.	1.9	12
120	Biomarkers in the treatment of cancer: opportunities and pitfalls. <i>Clinical Chemistry and Laboratory Medicine</i> , 2013, 51, 1329-33.	1.4	12

#	ARTICLE	IF	CITATIONS
121	MSCs: Delivery Routes and Engraftment, Cell-Targeting Strategies, and Immune Modulation. <i>Stem Cells International</i> , 2013, 2013, 1-13.	1.2	346
122	Current Challenges for HER2 Testing in Diagnostic Pathology: State of the Art and Controversial Issues. <i>Frontiers in Oncology</i> , 2013, 3, 129.	1.3	73
123	Pharmacokinetics, Clinical Indications, and Resistance Mechanisms in Molecular Targeted Therapies in Cancer. <i>Pharmacological Reviews</i> , 2013, 65, 1351-1395.	7.1	33
124	Effects of Trastuzumab Emtansine (T&E) on QT Interval and Safety of Pertuzumab Plus T&E in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. <i>Clinical Pharmacology in Drug Development</i> , 2013, 2, 11-24.	0.8	33
125	Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates. <i>MABs</i> , 2013, 5, 13-21.	2.6	213
126	Trastuzumab emtansine for advanced HER2-positive breast cancer and beyond: genome landscape-based targets. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 5-8.	1.1	11
127	Novel multifunctional antibody approved for the treatment of breast cancer. <i>Oncolmmunology</i> , 2013, 2, e24567.	2.1	6
128	Discrepancies in cancer incidence and mortality and its relationship to health expenditure in the 27 European Union member states. <i>Annals of Oncology</i> , 2013, 24, 2897-2902.	0.6	56
130	Trastuzumab emtansine: the first targeted chemotherapy for treatment of breast cancer. <i>Future Oncology</i> , 2013, 9, 319-326.	1.1	60
131	Immunogenicity assays for antibody-drug conjugates: case study with ado-trastuzumab emtansine. <i>Bioanalysis</i> , 2013, 5, 1007-1023.	0.6	47
132	Trastuzumab emtansine in the treatment of HER-2-positive metastatic breast cancer patients. <i>Future Oncology</i> , 2013, 9, 955-957.	1.1	10
133	Tumor-Specific Activation of an EGFR-Targeting Probody Enhances Therapeutic Index. <i>Science Translational Medicine</i> , 2013, 5, 207ra144.	5.8	211
135	Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen-Specific T-cell Immunity in Head and Neck Cancer Patients. <i>Clinical Cancer Research</i> , 2013, 19, 1858-1872.	3.2	272
136	Quality-adjusted survival as an end point in breast cancer trials. <i>Clinical Investigation</i> , 2013, 3, 545-555.	0.0	2
137	A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies. <i>Blood</i> , 2013, 122, 3500-3510.	0.6	73
138	Long-term disease control with lapatinib and capecitabine in a patient with HER2-positive metastatic breast cancer pretreated with trastuzumab and trastuzumab-emtansine. <i>Tumori</i> , 2013, 99, e131-e133.	0.6	2
139	Breast Cancer, Version 3.2013. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 753-761.	2.3	134
142	Reply to A. Ocana et al. <i>Journal of Clinical Oncology</i> , 2013, 31, 1253-1254.	0.8	0

#	ARTICLE	IF	CITATIONS
143	Clinical outcomes and cardiac safety of continuous antiHer2 therapy in c-erbB2-positive metastatic breast cancer patients. <i>Journal of Chemotherapy</i> , 2013, 25, 369-375.	0.7	3
144	CD30-positive malignant lymphomas: time for a change of management?. <i>Haematologica</i> , 2013, 98, 1165-1168.	1.7	8
145	Regulation of Apoptosis by HER2 in Breast Cancer. <i>Journal of Carcinogenesis & Mutagenesis</i> , 2013, 2013, .	0.3	48
146	Paclitaxel and Trastuzumab as Maintenance Therapy in Patients with HER2-Positive Metastatic Breast Cancer Who Underwent High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation. <i>Journal of Cancer</i> , 2013, 4, 679-685.	1.2	4
147	Major clinical research advances in gynecologic cancer in 2012. <i>Journal of Gynecologic Oncology</i> , 2013, 24, 66.	1.0	36
148	Specific Targeted Therapy: A New Tool for the Destruction of Cancer. <i>Current Drug Therapy</i> , 2013, 8, 15-23.	0.2	0
149	Emerging targeted combinations in the management of breast cancer. <i>Breast Cancer: Targets and Therapy</i> , 2013, 5, 61.	1.0	4
150	When Standard Therapy Fails in Breast Cancer: Current and Future Options for HER2-Positive Disease. <i>Journal of Clinical Trials</i> , 2013, 03, 1000129.	0.1	8
151	Recent development of antibody drug conjugate. <i>Drug Delivery System</i> , 2013, 28, 424-429.	0.0	1
152	Flotillin2 Expression Correlates with HER2 Levels and Poor Prognosis in Gastric Cancer. <i>PLoS ONE</i> , 2013, 8, e62365.	1.1	37
153	Bayesian Mixture Models for Assessment of Gene Differential Behaviour and Prediction of pCR through the Integration of Copy Number and Gene Expression Data. <i>PLoS ONE</i> , 2013, 8, e68071.	1.1	0
154	Advances in Anticancer Antibody-Drug Conjugates and Immunotoxins. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2013, 9, 35-65.	0.8	31
155	Linked-In: Design and Efficacy of Antibody Drug Conjugates in Oncology. <i>Oncotarget</i> , 2013, 4, 397-412.	0.8	40
157	Trastuzumab emtansine in the treatment of HER2-positive metastatic breast cancer in Japanese patients. <i>Breast Cancer: Targets and Therapy</i> , 2014, 6, 37.	1.0	0
158	Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine. <i>Pharmacogenomics and Personalized Medicine</i> , 2014, 7, 329.	0.4	19
159	Microtubule inhibitor-based antibody–drug conjugates for cancer therapy. <i>OncoTargets and Therapy</i> , 2014, 7, 2227.	1.0	36
160	Recent advances in the development of breast cancer vaccines. <i>Breast Cancer: Targets and Therapy</i> , 2014, 6, 159.	1.0	18
161	Microtubule-targeting agents in oncology and therapeutic potential in hepatocellular carcinoma. <i>OncoTargets and Therapy</i> , 2014, 7, 575.	1.0	45

#	ARTICLE	IF	CITATIONS
162	Trastuzumab beyond Progression in Advanced Breast Cancer: National Guidance versus Oncologist's Decision. <i>Oncology</i> , 2014, 86, 22-23.	0.9	3
163	Meeting Highlights: The First Korean Breast Cancer Treatment Consensus Conference. <i>Journal of Breast Cancer</i> , 2014, 17, 308.	0.8	3
164	Potential of antibody–drug conjugates and novel therapeutics in breast cancer management. <i>OncoTargets and Therapy</i> , 2014, 7, 491.	1.0	19
165	Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer. <i>Breast Cancer: Targets and Therapy</i> , 2014, 6, 103.	1.0	26
166	Insulin-Like Growth Factors, Insulin, and Growth Hormone Signaling in Breast Cancer: Implications for Targeted Therapy. <i>Endocrine Practice</i> , 2014, 20, 1214-1221.	1.1	20
167	Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention. <i>Oncotarget</i> , 2014, 5, 4603-4650.	0.8	231
168	IgE-based Immunotherapy of Cancer -A Comparative Oncology Approach. <i>Journal of Carcinogenesis & Mutagenesis</i> , 2014, 05, 1000176.	0.3	15
169	Therapeutic options for HER-2 positive breast cancer: Perspectives and future directions. <i>World Journal of Clinical Oncology</i> , 2014, 5, 440.	0.9	11
170	Activity of T-DM1 in HER-2 positive central nervous system breast cancer metastases. <i>BMJ Case Reports</i> , 2014, 2014, bcr2014205680-bcr2014205680.	0.2	28
171	Activity of T-Dm1 in Her2-Positive Breast Cancer Brain Metastases. <i>Annals of Oncology</i> , 2014, 25, iv122.	0.6	0
172	Disease Progression Pattern in Metastatic Breast Cancer Patients (Mbc) Treated with Anti-Her2 Therapies. <i>Annals of Oncology</i> , 2014, 25, iv125.	0.6	0
176	Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy. <i>Clinical Cancer Research</i> , 2014, 20, 456-468.	3.2	153
177	Risk of selected gastrointestinal toxicities in breast cancer patients treated with regimens containing lapatinib; a pooled analysis of randomized controlled studies. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 1229-1242.	1.1	7
178	Subtyping of breast cancer using reverse phase protein arrays. <i>Expert Review of Proteomics</i> , 2014, 11, 757-770.	1.3	17
179	Antibody–Drug Conjugates Delivering DNA Cytotoxics. , 2014, , 479-490.		1
180	Trial Watch. <i>Oncoimmunology</i> , 2014, 3, e27048.	2.1	69
181	Molecular biomarkers in clinical development: what could we learn from the clinical trial registry?. <i>Personalized Medicine</i> , 2014, 11, 381-393.	0.8	2
182	The HER2 peptide nelipepimut-S (E75) vaccine (NeuVax®) in breast cancer patients at risk for recurrence: correlation of immunologic data with clinical response. <i>Immunotherapy</i> , 2014, 6, 519-531.	1.0	62

#	ARTICLE	IF	CITATIONS
185	Skin/nail infections with the addition of pertuzumab to trastuzumab-based chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2014, 148, 563-570.	1.1	14
187	Genome-based approaches for the diagnosis of breast cancer: a review with perspective. <i>Breast Cancer Management</i> , 2014, 3, 173-193.	0.2	0
188	Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1). <i>Cell Death and Disease</i> , 2014, 5, e1149-e1149.	2.7	52
189	HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development. <i>British Journal of Cancer</i> , 2014, 111, 1888-1898.	2.9	100
190	Successes and Limitations of Targeted Cancer Therapy in Breast Cancer. <i>Progress in Tumor Research</i> , 2014, 41, 15-35.	0.1	34
191	Gene Status in <i>HER2</i> Equivocal Breast Carcinomas: Impact of Distinct Recommendations and Contribution of a Polymerase Chain Reaction-Based Method. <i>Oncologist</i> , 2014, 19, 1118-1126.	1.9	37
192	Cancerâ€œtestis genes as candidates for immunotherapy in breast cancer. <i>Immunotherapy</i> , 2014, 6, 165-179.	1.0	40
193	Human Epidermal Growth Factor Receptor Family-Targeted Therapies in the Treatment of HER2-Overexpressing Breast Cancer. <i>Oncologist</i> , 2014, 19, 135-150.	1.9	57
194	Survival and Inflammation Promotion Effect of PTPRO in Fulminant Hepatitis Is Associated with NF- κ B Activation. <i>Journal of Immunology</i> , 2014, 193, 5161-5170.	0.4	21
195	HER2/neu: an increasingly important therapeutic target. Part 3: clinical applications and investigations. <i>Clinical Investigation</i> , 2014, 4, 791-823.	0.0	1
196	Does the use of lapatinib increase the risk of fatigue and hepatic toxicities in patients with solid tumors? A critical literature review and meta-analysis. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 999-1008.	1.0	12
197	Ado-trastuzumab emtansine for the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer. <i>American Journal of Health-System Pharmacy</i> , 2014, 71, 537-548.	0.5	6
198	Comparative Effectiveness of Two Metronomic Chemotherapy Schedulesâ€œOur Experience in the Preclinical Field. <i>Cancer Investigation</i> , 2014, 32, 92-98.	0.6	6
199	Immunotherapy for Gastrointestinal Malignancies. <i>Journal of Cancer Therapy</i> , 2014, 05, 622-646.	0.1	0
200	Ado-trastuzumab emtansine associated hyponatremia and intracranial hemorrhage. <i>Acta OncolÃ³gica</i> , 2014, 53, 1434-1436.	0.8	7
201	ErbB Receptors as Prognostic and Therapeutic Drug Targets in Bone and Soft Tissue Sarcomas. <i>Cancer Investigation</i> , 2014, 32, 533-542.	0.6	3
203	Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. <i>Archives of Pathology and Laboratory Medicine</i> , 2014, 138, 241-256.	1.2	961
204	Eribulin Mesylate in the management of metastatic breast cancer and other solid cancers: a drug review. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 649-665.	1.1	12

#	ARTICLE	IF	CITATIONS
205	Targeted therapy for renal cell carcinoma: The next lap. <i>Journal of Carcinogenesis</i> , 2014, 13, 3.	2.5	24
206	Cardiovascular Toxicities from Systemic Breast Cancer Therapy. <i>Frontiers in Oncology</i> , 2014, 4, 346.	1.3	21
208	Taxanes Plus Trastuzumab Compared To Oral Vinorelbine Plus Trastuzumab in HER2-Overexpressing Metastatic Breast Cancer. <i>Breast Care</i> , 2014, 9, 6-6.	0.8	8
209	From linear "dogma" and trastuzumab"emtansine to future transcriptional circuitry-based drug discovery for breast cancer. <i>Future Oncology</i> , 2014, 10, 145-148.	1.1	1
211	Phase II, open-label trial of lapatinib and vinorelbine in women with previously treated HER2-positive metastatic breast cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2014, 10, 368-375.	0.7	5
212	<i>ALK</i> Molecular Phenotype in Non-Small Cell Lung Cancer: CT Radiogenomic Characterization. <i>Radiology</i> , 2014, 272, 568-576.	3.6	140
213	Molecular Targeted β -Particle Therapy for Oncologic Applications. <i>American Journal of Roentgenology</i> , 2014, 203, 253-260.	1.0	62
214	Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancer. <i>Cancer</i> , 2014, 120, 2657-2664.	2.0	47
215	Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer. <i>Cancer</i> , 2014, 120, 642-651.	2.0	107
216	T-DM1, a novel antibody-drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo. <i>Cancer Medicine</i> , 2014, 3, 1256-1265.	1.3	42
217	1974-2014: Reflections on the evolution of clinical pharmacology in the past 40 years and a message to our readers. <i>British Journal of Clinical Pharmacology</i> , 2014, 77, 1-4.	1.1	0
218	Genome network medicine: innovation to overcome huge challenges in cancer therapy. <i>Wiley Interdisciplinary Reviews: Systems Biology and Medicine</i> , 2014, 6, 201-208.	6.6	8
219	ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). <i>Annals of Oncology</i> , 2014, 25, 1871-1888.	0.6	402
220	Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer. <i>Breast Cancer Research</i> , 2014, 16, R50.	2.2	49
221	A Feasibility Study of Cyclophosphamide, Trastuzumab, and an Allogeneic GM-CSF-Secreting Breast Tumor Vaccine for HER2+ Metastatic Breast Cancer. <i>Cancer Immunology Research</i> , 2014, 2, 949-961.	1.6	77
222	Trastuzumab in advanced breast cancer "a decade of experience in Germany. <i>BMC Cancer</i> , 2014, 14, 924.	1.1	12
223	Strategies for modern biomarker and drug development in oncology. <i>Journal of Hematology and Oncology</i> , 2014, 7, 70.	6.9	98
224	Anti-IGF-1R monoclonal antibody inhibits the carcinogenicity activity of acquired trastuzumab-resistant SKOV3. <i>Journal of Ovarian Research</i> , 2014, 7, 103.	1.3	6

#	ARTICLE	IF	CITATIONS
225	Investigational therapies targeting the ErbB family in oesophagogastric cancer. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 1349-1363.	1.9	3
226	Exposureâ€“Response Relationship of T-DM1: Insight Into Dose Optimization for Patients With HER2-Positive Metastatic Breast Cancer. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 95, 558-564.	2.3	56
227	Updates on the treatment of human epidermal growth factor receptor type 2-positive breast cancer. <i>Current Opinion in Obstetrics and Gynecology</i> , 2014, 26, 27-33.	0.9	7
228	Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2â€“Positive Metastatic Breast Cancer: An Integrated Safety Analysis. <i>Journal of Clinical Oncology</i> , 2014, 32, 2750-2757.	0.8	98
229	Modern Drug Development. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 2619.	3.8	5
230	Recent advances and future trends in the targeted therapy of metastatic gastric cancer. <i>Expert Review of Gastroenterology and Hepatology</i> , 2014, 8, 555-569.	1.4	5
231	Everolimus. <i>Recent Results in Cancer Research</i> , 2014, 201, 373-392.	1.8	54
232	Lapatinib-associated mucocutaneous toxicities are clinical predictors of improved progression-free survival in patients with human epidermal growth factor receptor (HER2)-positive advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014, 148, 197-209.	1.1	6
233	Future Directions for Monitoring Treatment Responses in Breast Cancer. <i>Journal of Cancer</i> , 2014, 5, 69-78.	1.2	3
234	Unintended Consequences of Expensive Cancer Therapeuticsâ€“The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and Creativity. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2014, 140, 1225.	1.2	263
235	Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications. <i>Molecular Biology International</i> , 2014, 2014, 1-9.	1.7	761
236	Targeting HER2 amplifications in gastric cancer. <i>Gastrointestinal Cancer: Targets and Therapy</i> , 2014, , 11.	5.5	1
237	Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models. <i>Breast Cancer Research</i> , 2014, 16, R45.	2.2	56
238	Preclinical and clinical development of afatinib: a focus on breast cancer and squamous cell carcinoma of the head and neck. <i>Future Oncology</i> , 2014, 10, 21-40.	1.1	12
239	A review of clinical aspects of breast cancer. <i>International Review of Psychiatry</i> , 2014, 26, 4-15.	1.4	129
240	Novel taxanes. <i>Anti-Cancer Drugs</i> , 2014, 25, 593-598.	0.7	26
241	Individualizing breast cancer treatmentâ€“The dawn of personalized medicine. <i>Experimental Cell Research</i> , 2014, 320, 1-11.	1.2	26
242	Antiangiogenic Therapy in Patients With HER2-Positive Metastatic Breast Cancer: A Case Series. <i>Clinical Breast Cancer</i> , 2014, 14, e89-e94.	1.1	2

#	ARTICLE	IF	CITATIONS
243	Theranostic applications of antibodies in oncology. <i>Molecular Oncology</i> , 2014, 8, 799-812.	2.1	53
244	Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 689-699.	5.1	595
245	nab-Paclitaxel in combination with biologically targeted agents for early and metastatic breast cancer. <i>Cancer Treatment Reviews</i> , 2014, 40, 614-625.	3.4	39
246	Managing metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer in the older patient. <i>Journal of Geriatric Oncology</i> , 2014, 5, 2-7.	0.5	5
247	HER2-positive breast cancer: a new piece of the puzzle. <i>Lancet Oncology</i> , The, 2014, 15, 668-669.	5.1	2
248	Inadequate Family History Assessment by Oncologists is an Important Physician Barrier to Referral for Hereditary Breast Cancer Evaluation. <i>Clinical Oncology</i> , 2014, 26, 174-175.	0.6	4
249	The evolving role of cancer cell line-based screens to define the impact of cancer genomes on drug response. <i>Current Opinion in Genetics and Development</i> , 2014, 24, 114-119.	1.5	29
250	The success story of trastuzumab emtansine, a targeted therapy in HER2-positive breast cancer. <i>Targeted Oncology</i> , 2014, 9, 111-122.	1.7	26
251	Optimal tolerability and high efficacy of a modified schedule of lapatinib+capecitabine in advanced breast cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 221-226.	1.2	8
252	Surrogate endpoints in metastatic breast cancer treated with targeted therapies: an analysis of the first-line phase III trials. <i>Medical Oncology</i> , 2014, 31, 776.	1.2	26
253	The Fibroblast Growth Factor Receptor: A New Potential Target for the Treatment of Breast Cancer. <i>Current Breast Cancer Reports</i> , 2014, 6, 51-58.	0.5	2
254	Breast cancer brain metastases responding to primary systemic therapy with T-DM1. <i>Journal of Neuro-Oncology</i> , 2014, 116, 205-206.	1.4	61
255	Breast cancer. <i>Gynecologic Oncology</i> , 2014, 132, 264-267.	0.6	4
256	PI3K pathway inhibitors for the treatment of brain metastases with a focus on HER2+ breast cancer. <i>Journal of Neuro-Oncology</i> , 2014, 117, 7-13.	1.4	15
257	Management of Metastatic Breast Cancer with Second-Generation Antibody-Drug Conjugates: Focus on Glembatumumab Vedotin (CDX-011, CR011-vcMMAE). <i>BioDrugs</i> , 2014, 28, 253-263.	2.2	22
258	New HER2-Positive Targeting Agents in Clinical Practice. <i>Current Oncology Reports</i> , 2014, 16, 359.	1.8	16
259	A phase II, randomized, multicenter study evaluating the combination of lapatinib and vinorelbine in women with ErbB2 overexpressing metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014, 143, 493-505.	1.1	25
260	Targeting tumour-supportive cellular machineries in anticancer drug development. <i>Nature Reviews Drug Discovery</i> , 2014, 13, 179-196.	21.5	202

#	ARTICLE	IF	CITATIONS
261	A Small-Molecule Drug Conjugate for the Treatment of Carbonic Anhydrase IX Expressing Tumors. <i>Angewandte Chemie - International Edition</i> , 2014, 53, 4231-4235.	7.2	242
262	Antibody-Drug Conjugates: An Emerging Concept in Cancer Therapy. <i>Angewandte Chemie - International Edition</i> , 2014, 53, 3796-3827.	7.2	779
263	Precision treatment for cancer: Role of prognostic and predictive markers. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2014, 51, 30-45.	2.7	25
264	Antibody-Dependent Cellular Cytotoxicity (ADCC). , 2014, , 1-27.		22
266	An overview of clinical and commercial impact of drug delivery systems. <i>Journal of Controlled Release</i> , 2014, 190, 15-28.	4.8	379
267	Trends in cancer-targeted antibody-drug conjugates. <i>Targeted Oncology</i> , 2014, 9, 1-8.	1.7	7
268	ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics. <i>Cancer Cell</i> , 2014, 25, 282-303.	7.7	817
269	Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 580-591.	5.1	434
270	Trastuzumab Retreatment after Relapse on Adjuvant Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Final Results of the Retreatment after Herceptin Adjuvant Trial. <i>Clinical Oncology</i> , 2014, 26, 81-89.	0.6	26
272	Small Molecules in Oncology. <i>Recent Results in Cancer Research</i> , 2014, , .	1.8	4
273	The management of breast cancer. <i>Diagnostic and Interventional Imaging</i> , 2014, 95, 753-757.	1.8	10
274	Bridging Disulfides for Stable and Defined Antibody Drug Conjugates. <i>Bioconjugate Chemistry</i> , 2014, 25, 1124-1136.	1.8	220
275	The emergence of targeted drugs in breast cancer to prevent resistance to endocrine treatment and chemotherapy. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 681-700.	0.9	41
276	Smart drug delivery systems: from fundamentals to the clinic. <i>Chemical Communications</i> , 2014, 50, 7743-7765.	2.2	329
277	Systemic treatment of HER2-positive metastatic breast cancer: A systematic review. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2014, 10, 1-14.	0.7	14
278	Total Synthesis of the Antimitotic Marine Macrolide (Leiodermatolide). <i>Angewandte Chemie - International Edition</i> , 2014, 53, 2692-2695.	7.2	36
279	First-in-Human Molecular Imaging of HER2 Expression in Breast Cancer Metastases Using the ¹¹¹ In-ABY-025 Affibody Molecule. <i>Journal of Nuclear Medicine</i> , 2014, 55, 730-735.	2.8	211
280	Antibody-drug conjugates: current status and future directions. <i>Drug Discovery Today</i> , 2014, 19, 869-881.	3.2	380

#	ARTICLE	IF	CITATIONS
281	Cardiotoxicity of systemic agents used in breast cancer. <i>Breast</i> , 2014, 23, 317-328.	0.9	49
282	HER2 aberrations in cancer: Implications for therapy. <i>Cancer Treatment Reviews</i> , 2014, 40, 770-780.	3.4	184
283	Biomarkers of drugs targeting <sc>HER</sc>â€family signalling in cancer. <i>Journal of Pathology</i> , 2014, 232, 219-229.	2.1	49
284	Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER. <i>British Journal of Cancer</i> , 2014, 110, 2756-2764.	2.9	51
285	HER2 testing: Current status and future directions. <i>Cancer Treatment Reviews</i> , 2014, 40, 276-284.	3.4	127
286	The ErbB/HER family of protein-tyrosine kinases and cancer. <i>Pharmacological Research</i> , 2014, 79, 34-74.	3.1	1,028
287	A New Reagent for Stable Thiol-Specific Conjugation. <i>Bioconjugate Chemistry</i> , 2014, 25, 460-469.	1.8	48
288	Potential biomarkers of longâ€term benefit from singleâ€agent trastuzumab or lapatinib in HER2â€positive metastatic breast cancer. <i>Molecular Oncology</i> , 2014, 8, 20-26.	2.1	37
289	HER2-positive gastric cancer. <i>Gastric Cancer</i> , 2014, 17, 1-12.	2.7	272
291	Time for more optimism in metastatic breast cancer?. <i>Cancer Treatment Reviews</i> , 2014, 40, 220-228.	3.4	59
292	Production of Site-Specific Antibodyâ€Drug Conjugates Using Optimized Non-Natural Amino Acids in a Cell-Free Expression System. <i>Bioconjugate Chemistry</i> , 2014, 25, 351-361.	1.8	303
293	The immune system and response to HER2-targeted treatment in breast cancer. <i>Lancet Oncology</i> , The, 2014, 15, e58-e68.	5.1	244
294	Immunotherapy for prostate cancer: recent developments and future challenges. <i>Cancer and Metastasis Reviews</i> , 2014, 33, 641-655.	2.7	53
295	Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy. <i>Breast</i> , 2014, 23, 44-49.	0.9	25
296	Trastuzumab emtansine and stereotactic radiosurgery: an unexpected increase in clinically significant brain edema. <i>Neuro-Oncology</i> , 2014, 16, 1006-1009.	0.6	52
297	Treatment of HER2-positive breast cancer. <i>Breast</i> , 2014, 23, 128-136.	0.9	191
298	A cancer trial scandal and its regulatory backlash. <i>Nature Biotechnology</i> , 2014, 32, 27-31.	9.4	14
299	Advances and Future Directions in the Targeting of HER2-positive Breast Cancer: Implications for the Future. <i>Current Treatment Options in Oncology</i> , 2014, 15, 41-54.	1.3	13

#	ARTICLE	IF	CITATIONS
300	Anti-hepatoma human single-chain Fv antibody and adriamycin conjugates with potent antitumor activity. <i>International Immunopharmacology</i> , 2014, 18, 20-26.	1.7	9
301	Co-targeting estrogen receptor and HER2 pathways in breast cancer. <i>Breast</i> , 2014, 23, 2-9.	0.9	42
302	Targeting multiple pathways in breast cancer. <i>Breast Cancer Management</i> , 2014, 3, 87-101.	0.2	2
303	The challenge of targeted therapies for gastric cancer patients: the beginning of a long journey. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 925-942.	1.9	32
304	Safety and Efficacy of Neratinib in Combination With Capecitabine in Patients With Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 3626-3633.	0.8	118
305	Brain Metastases in Breast Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2014, 44, 1133-1140.	0.6	26
306	ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). <i>Breast</i> , 2014, 23, 489-502.	0.9	269
307	Barriers to advancing nanotechnology to better improve and translate nanomedicines. <i>Frontiers of Chemical Science and Engineering</i> , 2014, 8, 265-275.	2.3	19
309	Application of genotype-guided cancer therapy in solid tumors. <i>Pharmacogenomics</i> , 2014, 15, 79-93.	0.6	21
310	Antitumor Efficacy of a Bispecific Antibody That Targets HER2 and Activates T Cells. <i>Cancer Research</i> , 2014, 74, 5561-5571.	0.4	135
311	A Case of Vasculitis in a Breast Cancer Patient Treated With T-DM1. <i>Seminars in Oncology</i> , 2014, 41, e39-e45.	0.8	8
312	The Next Generation of Antibody Drug Conjugates. <i>Seminars in Oncology</i> , 2014, 41, 637-652.	0.8	53
313	Emerging classes of armed antibody therapeutics against cancer. <i>MedChemComm</i> , 2014, 5, 408.	3.5	41
314	Designing effective vaccines for colorectal cancer. <i>Immunotherapy</i> , 2014, 6, 913-926.	1.0	3
315	A bivalent small molecule-drug conjugate directed against carbonic anhydrase IX can elicit complete tumour regression in mice. <i>Chemical Science</i> , 2014, 5, 3640.	3.7	66
316	Trastuzumab emtansine: mechanisms of action and drug resistance. <i>Breast Cancer Research</i> , 2014, 16, 209.	2.2	407
317	Emerging immunotherapy strategies in breast cancer. <i>Immunotherapy</i> , 2014, 6, 195-209.	1.0	23
318	Dual HER2 blockade: preclinical and clinical data. <i>Breast Cancer Research</i> , 2014, 16, 419.	2.2	11

#	ARTICLE	IF	CITATIONS
319	A rapid, site-selective and efficient route to the dual modification of DARPin. <i>Chemical Communications</i> , 2014, 50, 4898-4900.	2.2	16
320	Antibody-“drug conjugates” A new wave of cancer drugs. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 5357-5363.	1.0	187
321	The solute carrier SLC35F2 enables YM155-mediated DNA damage toxicity. <i>Nature Chemical Biology</i> , 2014, 10, 768-773.	3.9	157
322	Metastatic breast cancer: prolongation of survival in routine care is restricted to hormone-receptor- and Her2-positive tumors. <i>SpringerPlus</i> , 2014, 3, 535.	1.2	34
323	Ado-trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: latest evidence and clinical potential. <i>Therapeutic Advances in Medical Oncology</i> , 2014, 6, 202-209.	1.4	63
324	Comparative Effectiveness of Neoadjuvant Therapy for HER2-Positive Breast Cancer: A Network Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	49
325	Significance of interleukin-13 receptor alpha 2-targeted glioblastoma therapy. <i>Neuro-Oncology</i> , 2014, 16, 1304-1312.	0.6	131
327	Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy. <i>Clinical Cancer Research</i> , 2014, 20, 1935-1945.	3.2	121
329	The development of immunoconjugates for targeted cancer therapy. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 637-648.	12.5	83
330	Site-Specific Trastuzumab Maytansinoid Antibody-“Drug Conjugates with Improved Therapeutic Activity through Linker and Antibody Engineering. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 7890-7899.	2.9	86
331	New protein kinase inhibitors in breast cancer: afatinib and neratinib. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 1277-1288.	0.9	29
332	Regioselective and Stoichiometrically Controlled Conjugation of Photodynamic Sensitizers to a HER2 Targeting Antibody Fragment. <i>Bioconjugate Chemistry</i> , 2014, 25, 611-617.	1.8	65
333	American Society of Clinical Oncology Perspective: Raising the Bar for Clinical Trials by Defining Clinically Meaningful Outcomes. <i>Journal of Clinical Oncology</i> , 2014, 32, 1277-1280.	0.8	354
334	Progression-free survival as an end-point in solid tumours - Perspectives from clinical trials and clinical practice. <i>European Journal of Cancer</i> , 2014, 50, 2303-2308.	1.3	32
335	An update on the medical management of breast cancer. <i>BMJ</i> , The, 2014, 348, g3608-g3608.	3.0	54
336	A versatile acid-labile linker for antibody-“drug conjugates. <i>MedChemComm</i> , 2014, 5, 1355-1358.	3.5	13
337	A Bispecific HER2-Targeting FynomAb with Superior Antitumor Activity and Novel Mode of Action. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 2030-2039.	1.9	38
338	Next generation maleimides enable the controlled assembly of antibody-“drug conjugates via native disulfide bond bridging. <i>Organic and Biomolecular Chemistry</i> , 2014, 12, 7261-7269.	1.5	135

#	ARTICLE	IF	CITATIONS
339	Antibody-drug conjugates: an emerging modality for the treatment of cancer. <i>Annals of the New York Academy of Sciences</i> , 2014, 1321, 41-54.	1.8	71
340	Targeted biopharmaceuticals for cancer treatment. <i>Cancer Letters</i> , 2014, 352, 145-151.	3.2	35
341	Trastuzumab Emtansine: A Novel Antibody-Drug Conjugate for HER2-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 15-20.	3.2	80
342	A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 13817-13821.	3.3	229
343	Targeted Therapy in Older Patients With Solid Tumors. <i>Journal of Clinical Oncology</i> , 2014, 32, 2635-2646.	0.8	36
344	Prise en charge du cancer du sein. <i>Diagnostic and Interventional Imaging</i> , 2014, 95, 740-744.	0.0	1
345	Therapeutic Antibodies in Breast Cancer. <i>Seminars in Oncology</i> , 2014, 41, 576-588.	0.8	3
346	Ado-trastuzumab Emtansine. <i>Annals of Pharmacotherapy</i> , 2014, 48, 1484-1493.	0.9	37
347	Prise en charge du cancer du sein, avancées et perspectives. <i>Medecine Nucleaire</i> , 2014, 38, 299-302.	0.2	0
348	Successes, toxicities and challenges in solid tumours. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 627-628.	12.5	23
351	Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials. <i>BMC Medicine</i> , 2014, 12, 132.	2.3	65
352	Next-generation optimized biotherapeutics – A review and preclinical study. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2014, 1844, 2053-2057.	1.1	18
353	Biomarker Testing for Breast, Lung, and Gastroesophageal Cancers at NCI Designated Cancer Centers. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	18
354	Preclinical Profile of the HER2-Targeting ADC SYD983/SYD985: Introduction of a New Duocarmycin-Based Linker-Drug Platform. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 2618-2629.	1.9	133
356	Patient priority in the era of patent expiries. <i>Lancet Oncology, The</i> , 2014, 15, e474.	5.1	0
357	Current and future role of neoadjuvant therapy for breast cancer. <i>Breast</i> , 2014, 23, 526-537.	0.9	162
358	Cystine-knot peptides: emerging tools for cancer imaging and therapy. <i>Expert Review of Proteomics</i> , 2014, 11, 561-572.	1.3	39
359	Therapeutic targeting of ERBB2 in breast cancer: understanding resistance in the laboratory and combating it in the clinic. <i>Journal of Molecular Medicine</i> , 2014, 92, 681-695.	1.7	15

#	ARTICLE	IF	CITATIONS
360	Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 399-410.	1.1	69
361	Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014, 145, 725-734.	1.1	67
362	Ado-trastuzumab emtansine-associated telangiectasias in metastatic breast cancer: a case series. <i>Breast Cancer Research and Treatment</i> , 2014, 146, 451-456.	1.1	25
363	Pneumonitis and pulmonary fibrosis associated with breast cancer treatments. <i>Breast Cancer Research and Treatment</i> , 2014, 146, 245-258.	1.1	48
364	Monoclonal antibodies as therapeutics in human malignancies. <i>Future Oncology</i> , 2014, 10, 609-636.	1.1	20
365	Breast cancer immunotherapy: monoclonal antibodies and peptide-based vaccines. <i>Expert Review of Clinical Immunology</i> , 2014, 10, 927-961.	1.3	33
366	Inferring primary tumor sites from mutation spectra: a meta-analysis of histology-specific aberrations in cancer-derived cell lines. <i>Human Molecular Genetics</i> , 2014, 23, 1527-1537.	1.4	19
367	Afatinib in the treatment of breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 1039-1047.	1.9	33
368	Phase IIa Trial of Trastuzumab Emtansine With Pertuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive, Locally Advanced, or Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 1437-1444.	0.8	72
369	Ado-trastuzumab Emtansine (T-DM1): An Antibody-Drug Conjugate (ADC) for HER2-Positive Breast Cancer. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 6949-6964.	2.9	401
370	FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 4436-4441.	3.2	251
371	Therapeutic Considerations When Treating HER2-positive Metastatic Breast Cancer. <i>Current Breast Cancer Reports</i> , 2014, 6, 169-182.	0.5	15
372	HER2 expression in primary gastric cancers and paired synchronous lymph node and liver metastases. A possible road to target HER2 with radionuclides. <i>Tumor Biology</i> , 2014, 35, 6319-6326.	0.8	5
373	Trastuzumab Emtansine: A Review of Its Use in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab-Based Therapy. <i>Drugs</i> , 2014, 74, 675-686.	4.9	34
374	The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. <i>BMC Cancer</i> , 2014, 14, 307.	1.1	21
375	Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance. <i>Molecular Cancer</i> , 2014, 13, 143.	7.9	55
376	Curative Properties of Noninternalizing Antibody-Drug Conjugates Based on Maytansinoids. <i>Cancer Research</i> , 2014, 74, 2569-2578.	0.4	119
377	Past, Present, and Future Challenges in Breast Cancer Treatment. <i>Journal of Clinical Oncology</i> , 2014, 32, 1979-1986.	0.8	180

#	ARTICLE	IF	CITATIONS
378	Advances in the approach to novel drug clinical development for breast cancer. Expert Opinion on Drug Discovery, 2014, 9, 647-668.	2.5	6
379	Impact of estrogen receptor (ER) and human epidermal growth factor receptor-2 (HER2) co-expression on breast cancer disease characteristics: implications for tumor biology and research. Breast Cancer Research and Treatment, 2014, 148, 437-444.	1.1	35
380	Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2014, 32, 2078-2099.	0.8	303
381	The 41st David A. Karnofsky Memorial Award Lecture: Academic Research Worldwideâ€“Quo Vadis?. Journal of Clinical Oncology, 2014, 32, 347-354.	0.8	35
382	Co-overexpression of HER2/HER3 is a predictor of impaired survival in breast cancer patients. Breast, 2014, 23, 637-643.	0.9	56
383	To Market, To Marketâ€“2013. Annual Reports in Medicinal Chemistry, 2014, 49, 437-508.	0.5	7
384	Clinical Outcome of HER2-positive Breast Cancer Patients after Failure on Adjuvant Trastuzumab: The Potential of the Time to Relapse. Clinical Oncology, 2014, 26, 174.	0.6	2
385	When is downstream pathway inhibition important?. Lancet Oncology, The, 2014, 15, 541-542.	5.1	0
386	Polymeric nanoparticle system to target activated microglia/macrophages in spinal cord injury. Journal of Controlled Release, 2014, 174, 15-26.	4.8	100
387	Long-term follow-up of patients with metastatic breast cancer treated by trastuzumab: Impact of institutions. Breast, 2014, 23, 165-169.	0.9	16
388	nab-Paclitaxel for the Treatment of Aggressive Metastatic Breast Cancer. Clinical Breast Cancer, 2014, 14, 221-227.	1.1	32
389	Resistance to human epidermal growth factor receptor type 2-targeted therapies. European Journal of Cancer, 2014, 50, 892-901.	1.3	47
390	Limited human epidermal growth factor receptor 2 discordance in metastatic breast cancer patients treated with trastuzumab, a population based study. European Journal of Cancer, 2014, 50, 885-891.	1.3	8
391	PM060184, a new tubulin binding agent with potent antitumor activity including P-glycoprotein over-expressing tumors. Biochemical Pharmacology, 2014, 88, 291-302.	2.0	49
392	Identification of quinones as HER2 inhibitors for the treatment of trastuzumab resistant breast cancer. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 126-131.	1.0	8
393	Personalized therapy for breast cancer. Clinical Genetics, 2014, 86, 62-67.	1.0	52
394	An improved radiolabelled RNA aptamer molecule for HER2 imaging in cancers. Journal of Drug Targeting, 2014, 22, 116-122.	2.1	38
395	Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Annals of Oncology, 2014, 25, 1544-1550.	0.6	1,022

#	ARTICLE	IF	CITATIONS
396	Pertuzumab for the Treatment of Breast Cancer. <i>Cancer Investigation</i> , 2014, 32, 430-438.	0.6	15
397	Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast cancer. <i>Cancer</i> , 2014, 120, 1932-1938.	2.0	35
398	Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2014, 32, 129-160.	0.8	74
399	The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model. <i>Leukemia</i> , 2014, 28, 1501-1510.	3.3	31
400	Nanotechnology: Deliver on a promise. <i>Nature</i> , 2014, 509, S58-S59.	13.7	32
401	State-of-the-art in design rules for drug delivery platforms: Lessons learned from FDA-approved nanomedicines. <i>Journal of Controlled Release</i> , 2014, 187, 133-144.	4.8	434
402	An Antibody-Drug Conjugate That Targets Tissue Factor Exhibits Potent Therapeutic Activity against a Broad Range of Solid Tumors. <i>Cancer Research</i> , 2014, 74, 1214-1226.	0.4	149
403	Central retesting of breast cancer with HER2 immunohistochemistry score of 0 or 1+ using silver-enhanced in situ hybridisation: a multicentre, prospective study in Greece. <i>Forum of Clinical Oncology</i> , 2014, 5, 20-28.	0.1	0
404	Precision medicine and personalized breast cancer: combination pertuzumab therapy. <i>Pharmacogenomics and Personalized Medicine</i> , 2014, 7, 95.	0.4	13
405	Nanomedicines for cancer therapy: state-of-the-art and limitations to pre-clinical studies that hinder future developments. <i>Frontiers in Chemistry</i> , 2014, 2, 69.	1.8	116
406	Role of human epidermal growth factor receptor 2 in gastric cancer: Biological and pharmacological aspects. <i>World Journal of Gastroenterology</i> , 2014, 20, 4526.	1.4	40
407	Treatment of Metastatic Breast Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 759-761.	2.3	9
408	NICE says drug for metastatic breast cancer is unaffordable for NHS. <i>BMJ, The</i> , 2014, 348, g2888-g2888.	3.0	5
409	Update on Adjuvant Chemotherapy for Early Breast Cancer. <i>Breast Cancer: Basic and Clinical Research</i> , 2014, 8, BCBCR.S9454.	0.6	33
410	Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients. <i>Breast Cancer Research</i> , 2014, 16, R70.	2.2	40
412	Early Biomarkers in Breast Cancer. , 2014, , 569-638.		0
415	Development strategy of KADCYLA (a HER2-targeted antibody and microtubule inhibitor conjugate) for the treatment of patients with inoperable or recurrent HER2-positive metastatic breast cancer. <i>Drug Delivery System</i> , 2014, 29, 460-467.	0.0	1
416	Current Approaches and Emerging Directions in HER2-resistant Breast Cancer. <i>Breast Cancer: Basic and Clinical Research</i> , 2014, 8, BCBCR.S9453.	0.6	21

#	ARTICLE	IF	CITATIONS
417	Phase II study of lapatinib in combination with vinorelbine, as first or second-line therapy in women with HER2 overexpressing metastatic breast cancer. SpringerPlus, 2014, 3, 108.	1.2	1
418	Second International Consensus Conference on Advanced Breast Cancer (ABC2), Lisbon, 11/09/2013: The German Perspective. Breast Care, 2014, 9, 52-59.	0.8	6
419	Long-term remission of a Her2/neu positive primary breast cancer under double monoclonal antibody therapy with trastuzumab and bevacizumab. Radiology and Oncology, 2014, 48, 184-188.	0.6	6
420	Characterization of EGFR family gene aberrations in cholangiocarcinoma. Oncology Reports, 2014, 32, 700-708.	1.2	47
422	Working with authors to develop high-quality, ethical clinical manuscripts: Guidance for the professional medical writer. Medical Writing, 2014, 23, 228-235.	0.0	3
423	AGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2014. Breast Care, 2014, 9, 202-209.	0.8	13
426	HER2 Status Determination. Medicine (United States), 2015, 94, e645.	0.4	2
428	AGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2015. Breast Care, 2015, 10, 199-205.	0.8	10
429	Rapid Response to Trastuzumab Emtansine in a Patient with HER2-Driven Lung Cancer. Journal of Thoracic Oncology, 2015, 10, e16-e17.	0.5	25
430	Antitumor effect of antitissue factor antibody-antibody-antitissue factor antibody-antitissue factor antibody conjugate in human pancreatic tumor xenografts. International Journal of Cancer, 2015, 137, 1457-1466.	2.3	62
431	New clinical advances in immunotherapy for the treatment of solid tumours. Immunology, 2015, 145, 182-201.	2.0	35
432	The importance of molecular markers for diagnosis and selection of targeted treatments in patients with cancer. Journal of Internal Medicine, 2015, 278, 545-570.	2.7	46
433	Tumor Heterogeneity in Breast Cancer. Advances in Anatomic Pathology, 2015, 22, 294-302.	2.4	12
436	Antibody-drug conjugates as novel anti-cancer chemotherapeutics. Bioscience Reports, 2015, 35, .	1.1	327
437	Optimizing Treatment of HER2-Positive Breast Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 649-651.	2.3	2
439	Protein and antibody functionalization using continuous flow microreactor technology. Journal of Flow Chemistry, 2015, 5, 151-154.	1.2	7
440	Licensed monoclonal antibodies and associated challenges. Human Antibodies, 2015, 23, 63-72.	0.6	10
441	Treating Triple-Negative Breast Cancer: Where Are We?. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, e8-e18.	2.3	1

#	ARTICLE	IF	CITATIONS
442	EGFR-expression in primary urinary bladder cancer and corresponding metastases and the relation to HER2-expression. On the possibility to target these receptors with radionuclides. <i>Radiology and Oncology</i> , 2015, 49, 50-58.	0.6	36
443	Predictive diagnosis of the risk of breast cancer recurrence after surgery by single-particle quantum dot imaging. <i>Scientific Reports</i> , 2015, 5, 14322.	1.6	24
446	Breast cancer brain metastases: the last frontier. <i>Experimental Hematology and Oncology</i> , 2015, 4, 33.	2.0	124
447	ASCO 2015: Highlights in breast cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2015, 8, 209-212.	0.3	0
448	Reinvention of chemotherapy. <i>Current Opinion in Oncology</i> , 2015, 27, 232-242.	1.1	12
449	Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells. <i>BMC Cancer</i> , 2015, 15, 726.	1.1	18
450	HER2/neu-directed therapy for biliary tract cancer. <i>Journal of Hematology and Oncology</i> , 2015, 8, 58.	6.9	191
451	Access to "investigational" cancer drugs: perspective of a trainee. <i>Internal Medicine Journal</i> , 2015, 45, 235-235.	0.5	0
452	New directions in the neoadjuvant treatment of HER2+ breast cancer. <i>Breast Cancer Management</i> , 2015, 4, 223-234.	0.2	0
453	Advances in the Molecular Analysis of Breast Cancer: Pathway toward Personalized Medicine. <i>Cancer Control</i> , 2015, 22, 211-219.	0.7	25
454	Beyond peptides and mAbs" current status and future perspectives for biotherapeutics with novel constructs. <i>Journal of Clinical Pharmacology</i> , 2015, 55, S4-20.	1.0	55
455	Biomedical Applications of Trastuzumab: As a Therapeutic Agent and a Targeting Ligand. <i>Medicinal Research Reviews</i> , 2015, 35, 849-876.	5.0	31
456	Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Metastatic Breast Cancer Previously Treated With Chemotherapy and 2 or More HER2-Targeted Agents. <i>Cancer Journal (Sudbury, Mass)</i> , 2015, 21, 357-364.	1.0	25
457	Targeted Delivery of Proteasome Inhibitors to Somatostatin"Receptor"Expressing Cancer Cells by Octreotide Conjugation. <i>ChemMedChem</i> , 2015, 10, 1969-1973.	1.6	3
458	New generations of targeted therapies fighting the resistance in solid tumors. <i>Current Opinion in Oncology</i> , 2015, 27, 243-249.	1.1	4
459	Challenges in the implementation of trastuzumab biosimilars. <i>Anti-Cancer Drugs</i> , 2015, 26, 1009-1016.	0.7	12
460	Palliative systemic therapy for young women with metastatic breast cancer. <i>Current Opinion in Supportive and Palliative Care</i> , 2015, 9, 301-307.	0.5	6
461	Resistance to Anti-HER2 Therapies in Breast Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e157-e164.	1.8	24

#	ARTICLE	IF	CITATIONS
462	Management of Older Women with Early-Stage Breast Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , 48-55.	1.8	15
463	Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer. Breast Cancer: Targets and Therapy, 2015, 7, 321.	1.0	14
464	The expanding role of pertuzumab in the treatment of HER2-positive breast cancer. Breast Cancer: Targets and Therapy, 2015, 7, 125.	1.0	8
465	Targeted Pathways in Breast Cancer: Molecular and Protein Markers Guiding Therapeutic Decisions. Current Molecular Pharmacology, 2015, 7, 4-21.	0.7	23
466	Downregulation of human epidermal growth factor receptor 2 by short hairpin RNA increases chemosensitivity of human ovarian cancer cells. Oncology Letters, 2015, 9, 2211-2217.	0.8	3
467	Safety and efficacy of the combination of T-DM1 with radiotherapy of the central nervous system in a patient with HER2-positive metastatic breast cancer: case study and review of the literature. Ecancermedicalsecience, 2015, 11, 586.	0.6	5
468	What Can We Learn about Antibody-Drug Conjugates from the T-DM1 Experience?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e117-e125.	1.8	13
470	Application of Metabolomics in Drug Resistant Breast Cancer Research. Metabolites, 2015, 5, 100-118.	1.3	50
471	Anticancer agent-incorporating immunomicelles. Drug Delivery System, 2015, 30, 10-15.	0.0	0
472	A Comprehensive Outline of Trastuzumab Resistance Biomarkers in HER2 Overexpressing Breast Cancer. Current Cancer Drug Targets, 2015, 15, 665-683.	0.8	42
473	Synergistic Interaction between Selective Drugs in Cell Populations Models. PLoS ONE, 2015, 10, e0117558.	1.1	12
474	Caveolin-1 Dependent Endocytosis Enhances the Chemosensitivity of HER-2 Positive Breast Cancer Cells to Trastuzumab Emtansine (T-DM1). PLoS ONE, 2015, 10, e0133072.	1.1	43
475	A Humanized Anti-CD22-Onconase Antibody-Drug Conjugate Mediates Highly Potent Destruction of Targeted Tumor Cells. Journal of Immunology Research, 2015, 2015, 1-14.	0.9	19
476	Adverse Events of Monoclonal Antibodies Used for Cancer Therapy. BioMed Research International, 2015, 2015, 1-13.	0.9	59
478	Monoclonal Antibodies for the Treatment of Cancer. , 2015, , 683-694.e3.		0
479	A common promoter hypomethylation signature in invasive breast, liver and prostate cancer cell lines reveals novel targets involved in cancer invasiveness. Oncotarget, 2015, 6, 33253-33268.	0.8	24
480	Breast cancer brain metastases responding to lapatinib plus capecitabine as second-line primary systemic therapy. Anti-Cancer Drugs, 2015, 26, 579-581.	0.7	6
481	Functional native disulfide bridging enables delivery of a potent, stable and targeted antibody-drug conjugate (ADC). Chemical Communications, 2015, 51, 10624-10627.	2.2	101

#	ARTICLE	IF	CITATIONS
482	Trastuzumab Labeled to High Specific Activity with ¹¹¹ In by Site-Specific Conjugation to a Metal-Chelating Polymer Exhibits Amplified Auger Electron-Mediated Cytotoxicity on HER2-Positive Breast Cancer Cells. <i>Molecular Pharmaceutics</i> , 2015, 12, 1951-1960.	2.3	26
483	Efficacy and Safety of HER2-Targeted Agents for Breast Cancer with HER2-Overexpression: A Network Meta-Analysis. <i>PLoS ONE</i> , 2015, 10, e0127404.	1.1	13
484	Preclinical and clinical development of an anti-kappa free light chain mAb for multiple myeloma. <i>Molecular Immunology</i> , 2015, 67, 89-94.	1.0	12
485	Building better monoclonal antibody-based therapeutics. <i>Nature Reviews Cancer</i> , 2015, 15, 361-370.	12.8	558
486	Molecular Diagnostic Testing in Breast Cancer. <i>Seminars in Oncology Nursing</i> , 2015, 31, 108-121.	0.7	12
487	Ado-Trastuzumab Emtansine. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2015, , 203-223.	0.2	1
488	Antibody Positron Emission Tomography Imaging in Anticancer Drug Development. <i>Journal of Clinical Oncology</i> , 2015, 33, 1491-1504.	0.8	93
489	Antibody-Mediated Delivery of Anti-KRAS-siRNA <i>In Vivo</i> Overcomes Therapy Resistance in Colon Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 1383-1394.	3.2	95
490	A Neoadjuvant, Randomized, Open-Label Phase II Trial of Afatinib Versus Trastuzumab Versus Lapatinib in Patients With Locally Advanced HER2-Positive Breast Cancer. <i>Clinical Breast Cancer</i> , 2015, 15, 101-109.	1.1	40
491	Enhanced antitumor effect of anti-tissue factor antibody-conjugated epirubicin-incorporating micelles in xenograft models. <i>Cancer Science</i> , 2015, 106, 627-634.	1.7	35
492	Targeted Agents for HER2-Positive Breast Cancer: Optimal Use in Older Patients. <i>Drugs and Aging</i> , 2015, 32, 975-982.	1.3	7
493	SLC46A3 Is Required to Transport Catabolites of Noncleavable Antibody Maytansine Conjugates from the Lysosome to the Cytoplasm. <i>Cancer Research</i> , 2015, 75, 5329-5340.	0.4	97
495	What is the benefit of treatment with multiple lines of chemotherapy for patients with metastatic breast cancer? A retrospective cohort study. <i>Cancer Epidemiology</i> , 2015, 39, 848-853.	0.8	8
496	The evolving understanding of small HER2-positive breast cancers: matching management to outcomes. <i>Future Oncology</i> , 2015, 11, 3261-3271.	1.1	2
497	High Turnover of Tissue Factor Enables Efficient Intracellular Delivery of Antibody-Drug Conjugates. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1130-1140.	1.9	67
498	Optimizing the Management of Metastatic HER2-Positive Breast Cancer. <i>Current Breast Cancer Reports</i> , 2015, 7, 190-202.	0.5	0
499	Current Medical Treatment of Patients with Non-Colorectal Liver Metastases: Primary Tumor Breast Cancer. <i>Visceral Medicine</i> , 2015, 31, 424-432.	0.5	2
500	Tumor immunology and cancer immunotherapy: summary of the 2014 SITC primer. , 2015, 3, .		12

#	ARTICLE	IF	CITATIONS
501	Breast Cancer: Molecular Mechanisms, Diagnosis, and Treatment. , 2015, , 155-200.		1
503	SEOM clinical guidelines in metastatic breast cancer 2015. Clinical and Translational Oncology, 2015, 17, 946-955.	1.2	25
504	Pertuzumab for the treatment of patients with human epidermal growth factor receptor 2-positive breast cancer in Japan. Molecular and Clinical Oncology, 2015, 3, 1268-1274.	0.4	2
505	Feasibility study of the Fab fragment of a monoclonal antibody against tissue factor as a diagnostic tool. International Journal of Oncology, 2015, 47, 2107-2114.	1.4	17
506	Gemcitabine treatment enhances HER2 expression in low HER2-expressing breast cancer cells and enhances the antitumor effects of trastuzumab emtansine. Oncology Reports, 2015, 34, 504-510.	1.2	20
507	Targeted Therapies in HER2-Positive Breast Cancer - a Systematic Review. Breast Care, 2015, 10, 173-178.	0.8	36
508	The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer " a systematic review. Breast Cancer Research, 2015, 17, 140.	2.2	143
509	Dose-Reduced Trastuzumab Emtansine: Active and Safe in Acute Hepatic Dysfunction. Case Reports in Oncology, 2015, 8, 113-121.	0.3	6
510	Potential Mechanisms for Thrombocytopenia Development with Trastuzumab Emtansine (T-DM1). Clinical Cancer Research, 2015, 21, 123-133.	3.2	142
511	Oral Ridaforolimus Plus Trastuzumab for Patients With HER2+ Trastuzumab-Refractory Metastatic Breast Cancer. Clinical Breast Cancer, 2015, 15, 60-65.	1.1	27
512	Pathologic diagnosis, immunohistochemistry, multigene assays and breast cancer treatment: progress toward "precision" cancer therapy. Biotechnic and Histochemistry, 2015, 90, 81-92.	0.7	12
513	Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer. Expert Review of Anticancer Therapy, 2015, 15, 17-26.	1.1	21
514	The cryptophycins as potent payloads for antibody drug conjugates. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 864-868.	1.0	48
515	PRKACA mediates resistance to HER2-targeted therapy in breast cancer cells and restores anti-apoptotic signaling. Oncogene, 2015, 34, 2061-2071.	2.6	87
516	HER2-family signalling mechanisms, clinical implications and targeting in breast cancer. Breast Cancer Research and Treatment, 2015, 149, 5-15.	1.1	67
517	Human Tumor Xenografts in Mouse as a Model for Evaluating Therapeutic Efficacy of Monoclonal Antibodies or Antibody-Drug Conjugate Targeting Receptor Tyrosine Kinases. Methods in Molecular Biology, 2015, 1233, 151-159.	0.4	4
518	Brain Metastasis and Response to Ado-Trastuzumab Emtansine: A Case Report and Literature Review. Clinical Breast Cancer, 2015, 15, e163-e166.	1.1	21
519	Intratatumoral heterogeneity and consequences for targeted therapies. Bulletin Du Cancer, 2015, 102, 17-23.	0.6	16

#	ARTICLE	IF	CITATIONS
520	Letter to the editor concerning Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA™. <i>Annals of Oncology</i> , 2015, 26, 1033-1034.	0.6	2
521	PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance. <i>Clinical Cancer Research</i> , 2015, 21, 2065-2074.	3.2	59
522	Raising the Bar for Antineoplastic Agents: How to Choose Threshold Values for Superiority Trials in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2015, 21, 1036-1043.	3.2	31
523	HER2-directed therapy: current treatment options for HER2-positive breast cancer. <i>Breast Cancer</i> , 2015, 22, 101-116.	1.3	149
524	The 21st Century Handbook of Clinical Ovarian Cancer. , 2015, , .		6
525	Emerging Strategies for Treating Brain Metastases from Breast Cancer. <i>Cancer Cell</i> , 2015, 27, 163-175.	7.7	119
526	Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients. <i>International Journal of Clinical Oncology</i> , 2015, 20, 709-722.	1.0	7
527	Emerging mAbs for the treatment of esophagogastric cancer. <i>Expert Opinion on Emerging Drugs</i> , 2015, 20, 63-74.	1.0	1
528	Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure. <i>EMBO Reports</i> , 2015, 16, 280-296.	2.0	200
529	Antibody-drug conjugates: a mini-review. The synopsis of two approved medicines. <i>Drug Delivery</i> , 2016, 23, 1-5.	2.5	15
530	Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody-Drug Conjugate SYD985. <i>Molecular Pharmaceutics</i> , 2015, 12, 1813-1835.	2.3	171
532	Designed Ankyrin Repeat Proteins (DARPs): Binding Proteins for Research, Diagnostics, and Therapy. <i>Annual Review of Pharmacology and Toxicology</i> , 2015, 55, 489-511.	4.2	468
533	Comparative Effectiveness Analysis of Monotherapy With Cytotoxic Agents in Triple-negative Metastatic Breast Cancer in a Community Setting. <i>Clinical Therapeutics</i> , 2015, 37, 134-144.	1.1	13
534	The future of breast cancer systemic therapy: the next 10 years. <i>Journal of Molecular Medicine</i> , 2015, 93, 119-125.	1.7	19
535	The Molecular Biology of Breast Cancer. , 2015, , 523-530.e3.		0
536	CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1564-1573.	0.8	201
537	Advances in Anticancer Immunotoxin Therapy. <i>Oncologist</i> , 2015, 20, 176-185.	1.9	161
538	Targeting HER2 for the Treatment of Breast Cancer. <i>Annual Review of Medicine</i> , 2015, 66, 111-128.	5.0	213

#	ARTICLE	IF	CITATIONS
539	Evolution of targeted therapies in cancer: opportunities and challenges in the clinic. <i>Future Oncology</i> , 2015, 11, 279-293.	1.1	20
540	Targeting HER family in HER2-positive metastatic breast cancer: potential biomarkers and novel targeted therapies. <i>Pharmacogenomics</i> , 2015, 16, 257-271.	0.6	24
541	Efficacy studies of an antibody-drug conjugate PSMA-ADC in patient-derived prostate cancer xenografts. <i>Prostate</i> , 2015, 75, 303-313.	1.2	31
542	Evolving Strategies for Target Selection for Antibody-Drug Conjugates. <i>Pharmaceutical Research</i> , 2015, 32, 3494-3507.	1.7	108
543	Development of the designed ankyrin repeat protein (DARPin) G3 for HER2 molecular imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 288-301.	3.3	70
544	The novel multispecies Fc-specific <i>Pseudomonas</i> exotoxin A fusion protein $\hat{\pm}$ -Fc-ETA ² enables screening of antibodies for immunotoxin development. <i>Journal of Immunological Methods</i> , 2015, 418, 75-83.	0.6	2
545	Predictive Biomarkers in Breast Cancer: ER, PR and Her-2/neu. , 2015, , 217-233.		0
547	Tau and PTEN status as predictive markers for response to trastuzumab and paclitaxel in patients with HER2-positive breast cancer. <i>Tumor Biology</i> , 2015, 36, 5865-5871.	0.8	17
548	Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 149, 151-161.	1.1	47
549	Disease progression pattern in metastatic breast cancer patients treated with anti-HER2 therapies. <i>Clinical and Translational Oncology</i> , 2015, 17, 530-538.	1.2	2
550	HER2-positive metastatic breast cancer: A changing scenario. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 95, 78-87.	2.0	29
551	Drug Targeting in Anticancer Chemotherapy. , 2015, , 595-653.		2
552	Targeting HER2 with T-DM1, an Antibody Cytotoxic Drug Conjugate, is Effective in HER2 Over Expressing Bladder Cancer. <i>Journal of Urology</i> , 2015, 194, 1120-1131.	0.2	64
553	Predictive Value of Positron Emission Tomography/Computed Tomography to Assess Early Treatment Response to Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade Without Chemotherapy for HER2-Positive Metastatic Breast Cancer: Are We Ready to Embrace This "Early Metabolic Look" Strategy?. <i>Journal of Clinical Oncology</i> , 2015, 33, 2591-2593.	0.8	6
554	What to expect from high throughput genomics in metastatic breast cancers?. <i>Breast</i> , 2015, 24, S19-S22.	0.9	4
555	A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity. <i>Breast Cancer Research and Treatment</i> , 2015, 153, 123-133.	1.1	76
556	Features of aggressive breast cancer. <i>Breast</i> , 2015, 24, 594-600.	0.9	52
557	Biomarkers of Tumour Radiosensitivity and Predicting Benefit from Radiotherapy. <i>Clinical Oncology</i> , 2015, 27, 561-569.	0.6	52

#	ARTICLE	IF	CITATIONS
558	Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors \leq 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials. <i>Journal of Clinical Oncology</i> , 2015, 33, 2600-2608.	0.8	91
559	T-DM1-related telangiectasias: a potential role in secondary bleeding events. <i>Annals of Oncology</i> , 2015, 26, 436-437.	0.6	13
560	Targeted Therapies in Non-Small Cell Lung Cancer—Beyond EGFR and ALK. <i>Cancers</i> , 2015, 7, 930-949.	1.7	83
561	Novel insights in folate receptors and transporters: implications for disease and treatment of immune diseases and cancer. <i>Pteridines</i> , 2015, 26, 41-53.	0.5	11
562	Targeted Therapy in her2-Positive Metastatic Breast Cancer: A Review of the Literature. <i>Current Oncology</i> , 2015, 22, 19-28.	0.9	30
563	Feasibility and Cardiac Safety of Trastuzumab Emtansine After Anthracycline-Based Chemotherapy As (neo)Adjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early-Stage Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1136-1142.	0.8	67
564	Potential of overcoming resistance to HER2-targeted therapies through the PI3K/Akt/mTOR pathway. <i>Breast</i> , 2015, 24, 548-555.	0.9	74
565	Changing Treatment Paradigms in Metastatic Breast Cancer. <i>JAMA Oncology</i> , 2015, 1, 528.	3.4	88
566	The Evolving Landscape of HER2 Targeting in Breast Cancer. <i>JAMA Oncology</i> , 2015, 1, 1154.	3.4	107
567	Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18 F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003). <i>Journal of Clinical Oncology</i> , 2015, 33, 2623-2631.	0.8	49
568	Safety Profile and Costs of Related Adverse Events of Trastuzumab Emtansine for the Treatment of HER2-Positive Locally Advanced or Metastatic Breast Cancer Compared to Capecitabine Plus Lapatinib from the Perspective of the Canadian Health-Care System. <i>Clinical Drug Investigation</i> , 2015, 35, 487-493.	1.1	7
569	Current and Future Therapies for Advanced Gastric Cancer. <i>Clinical Colorectal Cancer</i> , 2015, 14, 239-250.	1.0	28
570	Treatment of Metastatic Breast Cancer in a Real-World Scenario: Is Progression-Free Survival With First Line Predictive of Benefit From Second and Later Lines?. <i>Oncologist</i> , 2015, 20, 719-724.	1.9	46
571	Withdrawal of hormone replacement therapy might affect multigene signature results in early luminal breast cancer. <i>Annals of Oncology</i> , 2015, 26, 437-438.	0.6	3
572	The Therapeutic Challenge of Targeting HER2 in Endometrial Cancer. <i>Oncologist</i> , 2015, 20, 1058-1068.	1.9	56
575	Deciphering the Role of Phosphatidylinositol 3-Kinase Mutations in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1407-1409.	0.8	10
576	Microtubule disruption synergizes with oncolytic virotherapy by inhibiting interferon translation and potentiating bystander killing. <i>Nature Communications</i> , 2015, 6, 6410.	5.8	42
577	New frontiers in oncology: biosimilar monoclonal antibodies for the treatment of breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 331-338.	1.1	23

#	ARTICLE	IF	CITATIONS
578	Update on Metastatic Gastric and Esophageal Cancers. <i>Journal of Clinical Oncology</i> , 2015, 33, 1760-1769.	0.8	181
579	Câncer de mama metastásico. <i>EMC - Ginecología-Obstetricia</i> , 2015, 51, 1-14.	0.0	3
580	Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2â€“Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31. <i>Journal of Clinical Oncology</i> , 2015, 33, 1574-1583.	0.8	146
581	T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2. <i>Clinical and Experimental Metastasis</i> , 2015, 32, 29-38.	1.7	51
582	Using the Lessons Learned From the Clinic to Improve the Preclinical Development of Antibody Drug Conjugates. <i>Pharmaceutical Research</i> , 2015, 32, 3458-3469.	1.7	29
584	Phase I and pharmacokinetic study of trastuzumab emtansine in Japanese patients with HER2-positive metastatic breast cancer. <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, 12-18.	0.6	27
585	AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibodyâ€“Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1650-1660.	1.9	72
586	Molecular characterization and targeted therapeutic approaches in breast cancer. <i>Breast Cancer Research</i> , 2015, 17, 60.	2.2	132
587	EPMA position paper in cancer: current overview and future perspectives. <i>EPMA Journal</i> , 2015, 6, 9.	3.3	86
588	Targeting HER2 Positive Breast Cancer with Chemopreventive Agents. <i>Current Pharmacology Reports</i> , 2015, 1, 324-335.	1.5	22
589	Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane. <i>Journal of Clinical Oncology</i> , 2015, 33, 594-601.	0.8	365
590	Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2015, 93, 52-79.	2.0	1,278
591	How can I validate a nomogram? Show me the model. <i>Annals of Oncology</i> , 2015, 26, 1034-1035.	0.6	3
592	Effect of age on drug metabolism in women with breast cancer. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 757-766.	1.5	15
593	AMG 595, an Anti-EGFRvIII Antibodyâ€“Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1614-1624.	1.9	85
594	The Role of CDK4/6 Inhibition in Breast Cancer. <i>Oncologist</i> , 2015, 20, 483-490.	1.9	114
595	The Expanding Role of Therapeutic Antibodies. <i>International Reviews of Immunology</i> , 2015, 34, 202-264.	1.5	22
596	IMGN853, a Folate Receptor-1â€“ (FR1)â€“Targeting Antibodyâ€“Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FR1-Expressing Tumors. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1605-1613.	1.9	153

#	ARTICLE	IF	CITATIONS
597	Regulation of anti-apoptotic signaling by Kruppel-like factors 4 and 5 mediates lapatinib resistance in breast cancer. <i>Cell Death and Disease</i> , 2015, 6, e1699-e1699.	2.7	31
598	Dual Blockade with AFatinib and Trastuzumab as NEoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxane-Containing Anthracycline Containing Chemotherapy-DAFNE (GBG-70). <i>Clinical Cancer Research</i> , 2015, 21, 2924-2931.	3.2	38
599	Antibody-Drug Conjugates. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2015, , .	0.2	7
600	New targets in breast cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2015, 8, 86-91.	0.3	0
601	HER2 expression status in diverse cancers: review of results from 37,992 patients. <i>Cancer and Metastasis Reviews</i> , 2015, 34, 157-164.	2.7	310
602	A plug-and-play approach to antibody-based therapeutics via a chemoselective dual click strategy. <i>Nature Communications</i> , 2015, 6, 6645.	5.8	203
603	Patients' satisfaction in early breast cancer treatment: Change in treatment over time and impact of HER2-targeted therapy. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 94, 270-278.	2.0	5
604	Principles of cancer treatment by immunotherapy. <i>Surgery</i> , 2015, 33, 117-121.	0.1	0
605	Trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancer. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 749-760.	1.4	5
606	Pertuzumab: a new anti-HER2 drug in the management of women with breast cancer. <i>Future Oncology</i> , 2015, 11, 923-931.	1.1	11
607	Design of Coltuximab Ravtansine, a CD19-Targeting Antibody-Drug Conjugate (ADC) for the Treatment of B-Cell Malignancies: Structure-Activity Relationships and Preclinical Evaluation. <i>Molecular Pharmaceutics</i> , 2015, 12, 1703-1716.	2.3	45
609	Chemotherapy for Metastatic Breast Cancer - An Anachronism in the Era of Personalised and Targeted Oncological Therapy?. <i>Geburtshilfe Und Frauenheilkunde</i> , 2015, 75, 574-583.	0.8	19
610	Non-HER2 signaling pathways activated in resistance to anti-HER2 therapy in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 153, 493-505.	1.1	21
612	The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 692-703.	1.9	147
613	Multifunctional receptor-targeting antibodies for cancer therapy. <i>Lancet Oncology</i> , The, 2015, 16, e543-e554.	5.1	36
614	Eribulin mesylate in advanced breast cancer: retrospective review of a single institute experience. <i>Future Oncology</i> , 2015, 11, 31-36.	1.1	26
615	Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines <i>In Vitro</i> and <i>In Vivo</i> . <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2519-2526.	1.9	30
616	Failures in Phase III: Causes and Consequences. <i>Clinical Cancer Research</i> , 2015, 21, 4552-4560.	3.2	70

#	ARTICLE	IF	CITATIONS
617	Next-generation sequencing and empowering personalised cancer medicine. <i>Drug Discovery Today</i> , 2015, 20, 1470-1475.	3.2	22
618	Human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer: how the latest results are improving therapeutic options. <i>Therapeutic Advances in Medical Oncology</i> , 2015, 7, 321-339.	1.4	36
619	PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas. <i>British Journal of Cancer</i> , 2015, 113, 1020-1026.	2.9	33
620	The Actual Role of Receptors as Cancer Markers, Biochemical and Clinical Aspects: Receptors in Breast Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2015, 867, 327-337.	0.8	13
621	PARP inhibitors in the management of breast cancer: current data and future prospects. <i>BMC Medicine</i> , 2015, 13, 188.	2.3	221
622	Vertical Inhibition of HER2 Yields Horizontal Gains in the Clinic. <i>Clinical Cancer Research</i> , 2015, 21, 2663-2665.	3.2	2
623	Preclinical Efficacy and Safety Assessment of an Antibody-Drug Conjugate Targeting the c-RET Proto-Oncogene for Breast Carcinoma. <i>Clinical Cancer Research</i> , 2015, 21, 5552-5562.	3.2	23
624	Trastuzumab Rechallenge After Lapatinib- and Trastuzumab-Resistant Disease Progression in HER2-Positive Breast Cancer. <i>Clinical Breast Cancer</i> , 2015, 15, 432-439.	1.1	8
626	Risk of mucocutaneous toxicities in patients with solid tumors treated with lapatinib: a systematic review and meta-analysis. <i>Current Medical Research and Opinion</i> , 2015, 31, 975-986.	0.9	12
627	The future of targeted therapies for brain metastases. <i>Future Oncology</i> , 2015, 11, 2315-2327.	1.1	6
628	Imaging Radiation Doses and Associated Risks and Benefits in Subjects Participating in Breast Cancer Clinical Trials. <i>Oncologist</i> , 2015, 20, 702-712.	1.9	6
629	Mutations in the Kinase Domain of the HER2/ERBB2 Gene Identified in a Wide Variety of Human Cancers. <i>Journal of Molecular Diagnostics</i> , 2015, 17, 487-495.	1.2	53
630	Health-related quality-of-life as co-primary endpoint in randomized clinical trials in oncology. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 885-891.	1.1	12
631	A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). <i>Annals of Oncology</i> , 2015, 26, 1547-1573.	0.6	635
633	Design considerations for nanotherapeutics in oncology. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2015, 11, 1893-1907.	1.7	208
634	Site-selective multi-porphyrin attachment enables the formation of a next-generation antibody-based photodynamic therapeutic. <i>Chemical Communications</i> , 2015, 51, 15304-15307.	2.2	50
635	Pharmacokinetics, pharmacodynamics and clinical efficacy of pertuzumab in breast cancer therapy. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 1647-1663.	1.5	10
636	A novel peptide-based recognition probe for the sensitive detection of CD44 on breast cancer stem cells. <i>Molecular and Cellular Probes</i> , 2015, 29, 492-499.	0.9	15

#	ARTICLE	IF	CITATIONS
637	Oligoclonal antibodies to target the ErbB family. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 1015-1021.	1.4	6
638	<i>De novo</i> resistance biomarkers to anti-HER2 therapies in HER2-positive breast cancer. <i>Pharmacogenomics</i> , 2015, 16, 1411-1426.	0.6	7
639	Field Guide to Challenges and Opportunities in Antibody-Drug Conjugates for Chemists. <i>Bioconjugate Chemistry</i> , 2015, 26, 2198-2215.	1.8	75
640	Development of Anilino-Maytansinoid ADCs that Efficiently Release Cytotoxic Metabolites in Cancer Cells and Induce High Levels of Bystander Killing. <i>Bioconjugate Chemistry</i> , 2015, 26, 2261-2278.	1.8	33
641	Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer. <i>Journal of Hematology and Oncology</i> , 2015, 8, 98.	6.9	54
642	Weighing the Options for Human Epidermal Growth Factor Receptor 2-Directed Therapy in Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1530-1533.	0.8	2
643	Genetically Encoded Azide Containing Amino Acid in Mammalian Cells Enables Site-Specific Antibody-Drug Conjugates Using Click Cycloaddition Chemistry. <i>Bioconjugate Chemistry</i> , 2015, 26, 2249-2260.	1.8	106
644	A HER2-specific Modified Fc Fragment (Fcab) Induces Antitumor Effects Through Degradation of HER2 and Apoptosis. <i>Molecular Therapy</i> , 2015, 23, 1722-1733.	3.7	31
645	Systemic Therapy for HER2-Positive Central Nervous System Disease: Where We Are and Where Do We Go From Here?. <i>Current Oncology Reports</i> , 2015, 17, 46.	1.8	6
646	Therapeutic Implications of Cellular Heterogeneity and Plasticity in Breast Cancer. <i>Cell Stem Cell</i> , 2015, 17, 260-271.	5.2	328
647	Cancer targeted therapeutics: From molecules to drug delivery vehicles. <i>Journal of Controlled Release</i> , 2015, 219, 632-643.	4.8	89
648	Activity of T-DM1 in Her2-positive breast cancer brain metastases. <i>Clinical and Experimental Metastasis</i> , 2015, 32, 729-737.	1.7	103
649	Advancing pharmacological treatment options for advanced gastric cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2293-2305.	0.9	10
650	Renal toxicity of anticancer agents targeting HER2 and EGFR. <i>Journal of Nephrology</i> , 2015, 28, 647-657.	0.9	33
651	A review of HER2-targeted therapy in breast and ovarian cancer: lessons from antiquity - CLEOPATRA and PENELOPE. <i>Future Oncology</i> , 2015, 11, 3113-3131.	1.1	17
652	Pilot trial of paclitaxel-trastuzumab adjuvant therapy for early stage breast cancer: a trial of the ECOG-ACRIN cancer research group (E2198). <i>British Journal of Cancer</i> , 2015, 113, 1651-1657.	2.9	43
653	Recent Advances in the Development of Antineoplastic Agents Derived from Natural Products. <i>Drugs</i> , 2015, 75, 1993-2016.	4.9	51
654	Final overall survival analysis of a phase II trial evaluating vinorelbine and lapatinib in women with ErbB2 overexpressing metastatic breast cancer. <i>Breast</i> , 2015, 24, 769-773.	0.9	10

#	ARTICLE	IF	CITATIONS
655	Trastuzumab emtansine (T-DM1) renders HER2 ⁺ breast cancer highly susceptible to CTLA-4/PD-1 blockade. <i>Science Translational Medicine</i> , 2015, 7, 315ra188.	5.8	261
656	Benefit of eribulin in a patient with HER2+ breast cancer who progressed after trastuzumab and lapatinib: a case report. <i>Future Oncology</i> , 2015, 11, 9-15.	1.1	4
657	Correlation between progression-free survival and overall survival in metastatic breast cancer patients receiving anthracyclines, taxanes, or targeted therapies: a trial-level meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2015, 154, 591-608.	1.1	37
658	Patterns of Care and Clinical Outcomes of First-Line Trastuzumab-Based Therapy in HER2-Positive Metastatic Breast Cancer Patients Relapsing After (Neo)Adjuvant Trastuzumab: An Italian Multicenter Retrospective Cohort Study. <i>Oncologist</i> , 2015, 20, 880-889.	1.9	26
659	Lapatinib: An Oral Dual Tyrosine Kinase Inhibitor for HER-2-Positive Breast Cancer. <i>Women's Health</i> , 2015, 11, 281-294.	0.7	3
660	Advances in Cancer Biomarkers. <i>Advances in Experimental Medicine and Biology</i> , 2015, , .	0.8	14
661	Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications. <i>Journal of Controlled Release</i> , 2015, 200, 138-157.	4.8	1,477
662	Effects of Second and Subsequent Lines of Chemotherapy for Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2015, 15, e55-e62.	1.1	40
663	Synergistic co-targeting of prostate-specific membrane antigen and androgen receptor in prostate cancer. <i>Prostate</i> , 2015, 75, 242-254.	1.2	75
664	Antibody-targeted drugs and drug resistance—Challenges and solutions. <i>Drug Resistance Updates</i> , 2015, 18, 36-46.	6.5	113
665	Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA. <i>Annals of Oncology</i> , 2015, 26, 113-119.	0.6	327
666	Nanomaterials for Theranostics: Recent Advances and Future Challenges. <i>Chemical Reviews</i> , 2015, 115, 327-394.	23.0	1,063
667	Receptor Tyrosine Kinases: Structure, Functions and Role in Human Disease. , 2015, , .		7
668	Efficacy, safety, pharmacokinetics and biomarker findings in patients with HER2-positive advanced or metastatic breast cancer treated with lapatinib in combination with capecitabine: results from 51 Japanese patients treated in a clinical study. <i>Breast Cancer</i> , 2015, 22, 192-200.	1.3	7
669	Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer. <i>Journal of Oncology Pharmacy Practice</i> , 2015, 21, 132-142.	0.5	45
670	Systemic therapy for early-stage HER2-positive breast cancers: Time for a less-is-more approach?. <i>Cancer</i> , 2015, 121, 517-526.	2.0	19
671	Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity. <i>Molecular Oncology</i> , 2015, 9, 967-996.	2.1	119
672	Comparison of the 2007 and 2013 ASCO/CAP evaluation systems for HER2 amplification in breast cancer. <i>Pathology Research and Practice</i> , 2015, 211, 421-425.	1.0	30

#	ARTICLE	IF	CITATIONS
674	Gastric cancer: past progress and present challenges. <i>Gastric Cancer</i> , 2015, 18, 205-209.	2.7	7
675	Roles of signaling pathways in drug resistance, cancer initiating cells and cancer progression and metastasis. <i>Advances in Biological Regulation</i> , 2015, 57, 75-101.	1.4	100
676	Monoclonal antibodies for the treatment of non-haematological tumours: update of an expanding scenario. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 45-59.	1.4	8
677	Novel Points of Attack for Targeted Cancer Therapy. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2015, 116, 9-18.	1.2	61
678	Management of patients with HER2-positive metastatic breast cancer: Is there an optimal sequence of HER2-directed approaches?. <i>Cancer</i> , 2015, 121, 17-24.	2.0	8
679	The development of potential antibody-based therapies for myeloma. <i>Blood Reviews</i> , 2015, 29, 81-91.	2.8	33
680	A phase II trial of neoadjuvant doxorubicin plus cyclophosphamide followed by lapatinib plus docetaxel sequential with adjuvant trastuzumab for treatment of early HER2 positive breast cancers. <i>Journal of Solid Tumors</i> , 2016, 7, 28.	0.1	0
681	Nanoformulations. , 2016, , 307-330.		0
682	An Approach to Evaluate Payment-by-Results Agreements. <i>Global & Regional Health Technology Assessment</i> , 2016, 3, GRHTA.5000234.	0.2	1
683	Antibody Therapy. , 2016, , 550-559.		2
684	Novel approaches to target HER2-positive breast cancer: trastuzumab emtansine. <i>Cancer Management and Research</i> , 2016, 8, 57.	0.9	20
685	Current therapeutic strategies of anti-HER2 treatment in advanced breast cancer patients. <i>Wspolczesna Onkologia</i> , 2016, 1, 1-7.	0.7	3
686	Targeted therapies with companion diagnostics in the management of breast cancer: current perspectives. <i>Pharmacogenomics and Personalized Medicine</i> , 2016, 9, 7.	0.4	20
687	HER2-Targeted Antibody Treatment for Ovarian Cancer – Future Opportunities. <i>Journal of Molecular Pharmaceutics & Organic Process Research</i> , 2016, 4, .	2.0	4
688	Antibody Therapeutics in Oncology. <i>Immunotherapy (Los Angeles, Calif)</i> , 2016, 02, .	0.1	17
689	Clinical efficacy and safety of T-DM1 for patients with HER2-positive breast cancer. <i>OncoTargets and Therapy</i> , 2016, 9, 959.	1.0	8
690	Nanotherapeutic Platforms for Cancer Treatment: From Preclinical Development to Clinical Application. , 2016, , 813-869.		5
691	Pertuzumab and trastuzumab: the rationale way to synergy. <i>Anais Da Academia Brasileira De Ciencias</i> , 2016, 88, 565-577.	0.3	47

#	ARTICLE	IF	CITATIONS
692	Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [⁶⁸ Ga]ABY-025 Affibody PET/CT. <i>Theranostics</i> , 2016, 6, 262-271.	4.6	204
693	Microscopes and Mass Spectrometers. <i>Journal of Proteomics and Bioinformatics</i> , 2016, 01, .	0.4	0
694	When Can a Salvage Therapy (T-DM1) Take the Lead?. <i>Journal of Clinical Oncology</i> , 2016, 34, 3492-3494.	0.8	0
695	A Value-Based Approach to Treatment of HER2-Positive Breast Cancer: Examining the Evidence. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, e56-e63.	1.8	4
696	Durable Clinical Benefit of Pertuzumab in a Young Patient with BRCA2 Mutation and HER2-Overexpressing Breast Cancer Involving the Brain. <i>Case Reports in Oncological Medicine</i> , 2016, 2016, 1-5.	0.2	4
697	Trastuzumab in the management of gastroesophageal cancer: patient selection and perspectives. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 7235-7245.	1.0	22
698	Targeted Therapies for Brain Metastases from Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1543.	1.8	67
699	Response of Extensive Breast Cancer Skin Metastases to Rechallenge with Trastuzumab Together with Low-Dose Chemotherapy and Insulin. <i>Tumori</i> , 2016, 102, S26-S28.	0.6	1
700	Personalized medicine and treatment approaches in hypertension: current perspectives. <i>Integrated Blood Pressure Control</i> , 2016, 9, 59.	0.4	18
701	Identifying Cancer Driver Genes Using Replication-Incompetent Retroviral Vectors. <i>Cancers</i> , 2016, 8, 99.	1.7	4
702	An update on clinical oncology for the non-oncologist. <i>Einstein (Sao Paulo, Brazil)</i> , 2016, 14, 294-299.	0.3	2
703	Antibody-Drug Conjugates for Cancer Therapy. <i>Biomedicines</i> , 2016, 4, 14.	1.4	77
704	The Changing Landscape of Breast Cancer: How Biology Drives Therapy. <i>Medicines (Basel, Switzerland)</i> , 2016, 3, 2.	0.7	11
705	DeBouganin Diabody Fusion Protein Overcomes Drug Resistance to ADCs Comprised of Anti-Microtubule Agents. <i>Molecules</i> , 2016, 21, 1741.	1.7	6
706	Expansive hematoma in delayed cerebral radiation necrosis in patients treated with T-DM1: a report of two cases. <i>BMC Cancer</i> , 2016, 16, 391.	1.1	15
707	Predictive Factors of Lapatinib and Capecitabine Activity in Patients with HER2-Positive, Trastuzumab-Resistant Metastatic Breast Cancer: Results from the Italian Retrospective Multicenter HERLAPAC Study. <i>PLoS ONE</i> , 2016, 11, e0156221.	1.1	2
708	The Impacts of Inclusion in Clinical Trials on Outcomes among Patients with Metastatic Breast Cancer (MBC). <i>PLoS ONE</i> , 2016, 11, e0149432.	1.1	3
709	Targeting Strategies for Renal Cell Carcinoma: From Renal Cancer Cells to Renal Cancer Stem Cells. <i>Frontiers in Pharmacology</i> , 2016, 7, 423.	1.6	48

#	ARTICLE	IF	CITATIONS
710	Novel Treatments in Breast Cancer. <i>Clinical Medicine Insights Therapeutics</i> , 2016, 8, CMT.S18492.	0.4	1
712	Acute Pancreatitis Associated With Ado-Trastuzumab Emtansine. <i>American Journal of Therapeutics</i> , 2016, 23, e572-e574.	0.5	5
713	Surrogate end points for overall survival in breast cancer trials: A review. <i>Breast</i> , 2016, 29, 44-48.	0.9	11
714	Bioconjugation using selective chemistry to enhance the properties of proteins and peptides as therapeutics and carriers. <i>Organic and Biomolecular Chemistry</i> , 2016, 14, 8002-8013.	1.5	57
715	A randomized phase 2 study exploring the role of bevacizumab and a chemotherapy-free approach in HER2-positive metastatic breast cancer: The HAT study (BOOG 2008-2003), a Dutch Breast Cancer Research Group trial. <i>Cancer</i> , 2016, 122, 2961-2970.	2.0	7
716	Trastuzumab-deBouganin Conjugate Overcomes Multiple Mechanisms of T-DM1 Drug Resistance. <i>Journal of Immunotherapy</i> , 2016, 39, 117-126.	1.2	23
717	Media Reporting of Practice-Changing Clinical Trials in Oncology: A North American Perspective. <i>Oncologist</i> , 2016, 21, 269-278.	1.9	5
718	Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 1484-1499.	1.0	75
719	First-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces?. <i>Journal of Experimental and Clinical Cancer Research</i> , 2016, 35, 104.	3.5	33
720	Nonamplification <i>ERBB2</i> genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies. <i>Cancer</i> , 2016, 122, 2654-2662.	2.0	71
721	Use of trastuzumab for HER2-positive metastatic breast cancer in daily practice. <i>Anti-Cancer Drugs</i> , 2016, 27, 127-132.	0.7	6
723	Novel method for rapid in-situ hybridization of HER2 using non-contact alternating-current electric-field mixing. <i>Scientific Reports</i> , 2016, 6, 30034.	1.6	10
724	Personalized Clinical Trials in Hepatocellular Carcinoma Based on Biomarker Selection. <i>Liver Cancer</i> , 2016, 5, 221-232.	4.2	44
725	Immunotherapy for breast cancer: past, present, and future. <i>Cancer and Metastasis Reviews</i> , 2016, 35, 525-546.	2.7	49
726	Therapy Standards in HER2-Positive Breast Cancer. <i>Breast Care</i> , 2016, 11, 148-150.	0.8	0
727	Recent developments and translational aspects in targeted therapy for metastatic breast cancer. <i>ESMO Open</i> , 2016, 1, e000036.	2.0	1
729	Current challenges of metastatic breast cancer. <i>Cancer and Metastasis Reviews</i> , 2016, 35, 495-514.	2.7	63
732	Biomarkers in the Clinic. , 2016, , 415-426.		0

#	ARTICLE	IF	CITATIONS
734	Management of patients treated with pertuzumab in the Australian clinical practice setting. Asia-Pacific Journal of Clinical Oncology, 2016, 12, 5-15.	0.7	0
735	Mind the gap: An analysis of foregone health gains from unfunded cancer medicines in New Zealand. Seminars in Oncology, 2016, 43, 625-637.	0.8	13
736	Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models. Cancer Research, 2016, 76, 3003-3013.	0.4	347
737	Cardiac Complications of HER2-Targeted Therapies in Breast Cancer. Current Treatment Options in Cardiovascular Medicine, 2016, 18, 36.	0.4	4
738	DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1. Clinical Cancer Research, 2016, 22, 5097-5108.	3.2	599
739	Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates. MAbs, 2016, 8, 659-671.	2.6	340
740	Drug-induced hepatotoxicity in cancer patients - implication for treatment. Expert Opinion on Drug Safety, 2016, 15, 1219-1238.	1.0	52
741	Human epidermal growth factor antagonists and cardiotoxicity-A short review of the problem and preventative measures. Critical Reviews in Oncology/Hematology, 2016, 104, 42-51.	2.0	10
742	Telangiectasia and Pulmonary Arterial Hypertension Following Treatment With Trastuzumab Emtansine. Chest, 2016, 149, e103-e105.	0.4	15
743	A Review of Local and Systemic Therapy in Breast Cancer. , 2016, , 731-764.		0
744	Adjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Detour on the Road to a Cure. Journal of Clinical Oncology, 2016, 34, 1021-1023.	0.8	3
745	ABC1 C3435T gene polymorphism as a potential biomarker of clinical outcomes in HER2-positive breast cancer patients. Pharmacological Research, 2016, 108, 111-118.	3.1	12
746	Personalized Treatment of Breast Cancer. , 2016, , .		2
747	Classification, Treatment Strategy, and Associated Drug Resistance in Breast Cancer. Clinical Breast Cancer, 2016, 16, 335-343.	1.1	193
748	Targeted Therapy in HER2-Positive Breast Cancer. Oncology Research and Treatment, 2016, 39, 295-302.	0.8	4
749	Therapeutic Application of Pharmacogenomics in Oncology. AAPS Journal, 2016, 18, 819-829.	2.2	7
751	Design, Synthesis, and Preclinical Evaluation of 4-Substituted-5-methyl-furo[2,3-d]pyrimidines as Microtubule Targeting Agents That Are Effective against Multidrug Resistant Cancer Cells. Journal of Medicinal Chemistry, 2016, 59, 5752-5765.	2.9	29
752	Prospects and progress of antibody-drug conjugates in solid tumor therapies. Expert Opinion on Biological Therapy, 2016, 16, 883-893.	1.4	29

#	ARTICLE	IF	CITATIONS
753	Hormone Receptor/Human Epidermal Growth Factor Receptor 2-positive breast cancer: Where we are now and where we are going. <i>Cancer Treatment Reviews</i> , 2016, 46, 20-26.	3.4	87
754	Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer. <i>JAMA Oncology</i> , 2016, 2, 1557.	3.4	242
755	Editorial overview: Special section: New concepts in antibody therapeutics: What's in store for antibody therapy?. <i>Current Opinion in Immunology</i> , 2016, 40, vii-xiii.	2.4	20
756	Processes for Constructing Homogeneous Antibody Drug Conjugates. <i>Organic Process Research and Development</i> , 2016, 20, 852-866.	1.3	60
757	Targeting a Cancer-Specific Epitope of the Epidermal Growth Factor Receptor in Triple-Negative Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw028.	3.0	20
758	Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3. <i>Journal of Clinical Oncology</i> , 2016, 34, 2115-2124.	0.8	141
759	Nanotechnology for the delivery of phytochemicals in cancer therapy. <i>Biotechnology Advances</i> , 2016, 34, 343-353.	6.0	124
760	Parameterization of a disease progression simulation model for sequentially treated metastatic human epidermal growth factor receptor 2 positive breast cancer patients. <i>Current Medical Research and Opinion</i> , 2016, 32, 991-996.	0.9	14
761	Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study. <i>Annals of Oncology</i> , 2016, 27, 1249-1256.	0.6	29
762	Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using ¹⁷⁷ Lu- or ¹¹¹ In-Labeled Bispecific Radioimmunoconjugates. <i>Journal of Nuclear Medicine</i> , 2016, 57, 444-452.	2.8	38
763	Cancer drug related cardiotoxicity during breast cancer treatment. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 1063-1074.	1.0	12
764	Novel Therapies in Castration-Resistant Prostate Cancer. , 2016, , 259-269.		0
765	Dual Block with Lapatinib and Trastuzumab Versus Single-Agent Trastuzumab Combined with Chemotherapy as Neoadjuvant Treatment of HER2-Positive Breast Cancer: A Meta-analysis of Randomized Trials. <i>Clinical Cancer Research</i> , 2016, 22, 4594-4603.	3.2	32
766	Biodistribution and Radiation Dosimetry of the Anti-HER2 Affibody Molecule ⁶⁸ Ga-ABY-025 in Breast Cancer Patients. <i>Journal of Nuclear Medicine</i> , 2016, 57, 867-871.	2.8	88
767	The clinical value of HER-2 overexpression and PIK3CA mutations in the older breast cancer population: a FOCUS study analysis. <i>Breast Cancer Research and Treatment</i> , 2016, 156, 361-370.	1.1	11
768	Emerging Biomarkers of the Future: Changing Clinical Practice for 2020. <i>Current Breast Cancer Reports</i> , 2016, 8, 60-72.	0.5	1
769	An overview of the effective combination therapies for the treatment of breast cancer. <i>Biomaterials</i> , 2016, 97, 34-50.	5.7	117
770	ChAcNLS, a Novel Modification to Antibody-Conjugates Permitting Target Cell-Specific Endosomal Escape, Localization to the Nucleus, and Enhanced Total Intracellular Accumulation. <i>Molecular Pharmaceutics</i> , 2016, 13, 1915-1926.	2.3	17

#	ARTICLE	IF	CITATIONS
771	Cancer-specific uptake of a liganded protein nanocarrier targeting aggressive CXCR4 + colorectal cancer models. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2016, 12, 1987-1996.	1.7	34
774	ABC3 Consensus Commented from the Perspective of the German Guidelines. <i>Geburtshilfe Und Frauenheilkunde</i> , 2016, 76, 156-163.	0.8	6
776	Treatment of HER2-Overexpressing Metastatic Breast Cancer. , 2016, , 535-573.		0
777	Marriage of antibodyâ€“drug conjugate with gold nanorods to achieve multi-modal ablation of breast cancer cells and enhanced photoacoustic performance. <i>RSC Advances</i> , 2016, 6, 46594-46606.	1.7	4
778	Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases. <i>Breast Cancer Research and Treatment</i> , 2016, 157, 307-318.	1.1	101
779	Neratinib in HER-2-positive breast cancer: results to date and clinical usefulness. <i>Therapeutic Advances in Medical Oncology</i> , 2016, 8, 339-350.	1.4	30
781	Overcoming resistance to HER2 inhibitors through state-specific kinase binding. <i>Nature Chemical Biology</i> , 2016, 12, 923-930.	3.9	29
782	ErbB2 signaling at the crossing between heart failure and cancer. <i>Basic Research in Cardiology</i> , 2016, 111, 60.	2.5	68
783	Wide application of a novel topoisomerase I inhibitor-based drug conjugation technology. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 5069-5072.	1.0	34
784	Trends in endpoint selection in clinical trials of advanced breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 2403-2413.	1.2	3
785	Genomic profiling and treatment of HER2+, ER+, PgR+ â€œtriple positiveâ€œ breast cancer: A case report and literature review. <i>Cancer Treatment and Research Communications</i> , 2016, 9, 27-31.	0.7	5
786	Assessment of HER2 amplification status in breast cancer using a new automated HER2 IQFISH pharmDxâ„¢ (Dako Omnis) assay. <i>Pathology Research and Practice</i> , 2016, 212, 735-742.	1.0	11
788	Quantitative diagnosis of <sc>HER</sc>2 protein expressing breast cancer by singleâ€“particle quantum dot imaging. <i>Cancer Medicine</i> , 2016, 5, 2813-2824.	1.3	26
789	Mechanism of drug resistance in relation to site of metastasis: Meta-analyses of randomized controlled trials in advanced breast cancer according to anticancer strategy. <i>Cancer Treatment Reviews</i> , 2016, 50, 168-174.	3.4	12
790	Systemic therapy for HER2-positive early-stage breast cancer. <i>Current Problems in Cancer</i> , 2016, 40, 106-116.	1.0	7
791	Glutathione-Sensitive Hyaluronic Acid-SS-Mertansine Prodrug with a High Drug Content: Facile Synthesis and Targeted Breast Tumor Therapy. <i>Biomacromolecules</i> , 2016, 17, 3602-3608.	2.6	35
792	Cardiovascular Toxic Effects of Targeted Cancer Therapies. <i>New England Journal of Medicine</i> , 2016, 375, 1457-1467.	13.9	470
793	Metastatic human epidermal growth factor receptor 2-positive breast cancer: Management, challenges, and future directions. <i>Current Problems in Cancer</i> , 2016, 40, 117-129.	1.0	1

#	ARTICLE	IF	CITATIONS
794	ABC3 Consensus: Assessment by a German Group of Experts. <i>Breast Care</i> , 2016, 11, 61-70.	0.8	8
795	Cost-effectiveness analysis of 1st through 3rd line sequential targeted therapy in HER2-positive metastatic breast cancer in the United States. <i>Breast Cancer Research and Treatment</i> , 2016, 160, 187-196.	1.1	35
796	Assessment of dual-probe Her-2 fluorescent in situ hybridization in breast cancer by the 2013 ASCO/CAP guidelines produces more equivocal results than that by the 2007 ASCO/CAP guidelines. <i>Breast Cancer Research and Treatment</i> , 2016, 159, 31-39.	1.1	14
797	Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003). <i>Breast Diseases</i> , 2016, 27, 125-126.	0.0	1
798	Chemotherapy remains an essential element of personalized care for persons with lung cancers. <i>Annals of Oncology</i> , 2016, 27, 1829-1835.	0.6	83
799	Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review 18. <i>British Journal of Pharmacology</i> , 2016, 173, 1407-1424.	2.7	56
800	Bystander killing effect of <sc>DS</sc>-201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. <i>Cancer Science</i> , 2016, 107, 1039-1046.	1.7	394
801	Smart Materials for Controlled Drug Release. , 2016, , 98-135.		0
802	Nanoparticles in the clinic. <i>Bioengineering and Translational Medicine</i> , 2016, 1, 10-29.	3.9	1,003
803	Antibody-Drug Conjugates: A Clinical Pharmacy Perspective on an Emerging Cancer Therapy. <i>Pharmacotherapy</i> , 2016, 36, 99-116.	1.2	41
804	Human Serum Albumin and HER2-Binding Affibody Fusion Proteins for Targeted Delivery of Fatty Acid-Modified Molecules and Therapy. <i>Molecular Pharmaceutics</i> , 2016, 13, 3370-3380.	2.3	15
805	<i>HER2</i> Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials. <i>Journal of Clinical Oncology</i> , 2016, 34, 3518-3528.	0.8	113
806	Cost-effectiveness analysis of trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2): positive advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 159, 565-573.	1.1	31
807	Clinicopathological and surgical factors associated with long-term survival in patients with HER2-positive metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 159, 367-374.	1.1	23
808	Current and emerging therapies of HER2-positive metastatic breast cancer. <i>Breast</i> , 2016, 29, 170-177.	0.9	20
809	Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models. <i>Neoplasia</i> , 2016, 18, 775-784.	2.3	67
810	Human epidermal growth factor receptor 2 status of breast cancer patients in Asia: Results from a large, multicountry study. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2016, 12, 369-379.	0.7	23
811	Inconsistent Results With Different Secondary Reflex Assays for ResolvingHER2Status. <i>American Journal of Clinical Pathology</i> , 2016, 146, 618-626.	0.4	5

#	ARTICLE	IF	CITATIONS
812	Targeted therapy for breast cancer and molecular mechanisms of resistance to treatment. <i>Current Opinion in Pharmacology</i> , 2016, 31, 97-103.	1.7	126
813	Principles of Chemotherapy. , 2016, , 171-185.e2.		0
814	Resistance to therapy in estrogen receptor positive and human epidermal growth factor 2 positive breast cancers: progress with latest therapeutic strategies. <i>Therapeutic Advances in Medical Oncology</i> , 2016, 8, 429-449.	1.4	31
816	Ethnic sensitivity assessment of the antibody-drug conjugate trastuzumab emtansine (T-DM1) in patients with HER2-positive locally advanced or metastatic breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 547-558.	1.1	11
817	Endocrine therapy and strategies to overcome therapeutic resistance in breast cancer. <i>Current Problems in Cancer</i> , 2016, 40, 95-105.	1.0	18
818	Infertility risk and teratogenicity of molecularly targeted anticancer therapy: A challenging issue. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 107, 1-13.	2.0	17
819	Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) vs. treatment of physician's choice in previously treated HER2-positive advanced breast cancer. <i>International Journal of Cancer</i> , 2016, 139, 2336-2342.	2.3	69
820	Combination therapy approaches to target insulin-like growth factor receptor signaling in breast cancer. <i>Endocrine-Related Cancer</i> , 2016, 23, R527-R550.	1.6	17
821	Targeted Reconstitution of Cytokine Activity upon Antigen Binding using Split Cytokine Antibody Fusion Proteins. <i>Journal of Biological Chemistry</i> , 2016, 291, 18139-18147.	1.6	35
822	Targeted adjuvant therapy in breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 1263-1275.	1.1	11
823	Patritumab plus trastuzumab and paclitaxel in human epidermal growth factor receptor 2-overexpressing metastatic breast cancer. <i>Cancer Science</i> , 2016, 107, 1465-1470.	1.7	30
824	Safety and Efficacy of Trastuzumab Emtansine in Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: a Meta-analysis. <i>Scientific Reports</i> , 2016, 6, 23262.	1.6	24
825	Twenty years of anti-HER2 therapy-associated cardiotoxicity. <i>ESMO Open</i> , 2016, 1, e000073.	2.0	76
826	Targeted therapy and elderly people: A review. <i>European Journal of Cancer</i> , 2016, 69, 199-215.	1.3	34
827	The European Society for Medical Oncology Magnitude of Clinical Benefit Scale in daily practice: a single institution, real-life experience at the Medical University of Vienna. <i>ESMO Open</i> , 2016, 1, e000066.	2.0	17
831	Introducing Glycolinkers for the Functionalization of Cytotoxic Drugs and Applications in Antibody-Drug Conjugation Chemistry. <i>ChemMedChem</i> , 2016, 11, 2501-2505.	1.6	16
832	Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize. <i>Nature Communications</i> , 2016, 7, 13019.	5.8	51
833	Predictive Immunohistochemical Markers Related to Drug Selection for Patients Treated with Sunitinib or Sorafenib for Metastatic Renal Cell Cancer. <i>Scientific Reports</i> , 2016, 6, 30886.	1.6	16

#	ARTICLE	IF	CITATIONS
834	The Development of Systemic Therapies for Esophageal and Gastric Cancers. , 2016, , 153-170.		0
835	Autophagy and Apoptotic Crosstalk: Mechanism of Therapeutic Resistance in HER2-Positive Breast Cancer. Breast Cancer: Basic and Clinical Research, 2016, 10, BCBCR.S32791.	0.6	32
836	Preclinical study of Antibody/Drug Conjugated Micelle. Drug Delivery System, 2016, 31, 480-481.	0.0	0
839	Antibody drug conjugates: the future of chemotherapy?. Current Opinion in Oncology, 2016, 28, 429-436.	1.1	11
840	Prostate-Specific Membrane Antigen- Directed Therapy for Metastatic Castration-Resistant Prostate Cancer. Cancer Journal (Sudbury, Mass), 2016, 22, 347-352.	1.0	11
841	Mechanisms behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It. Clinical Medicine Insights: Oncology, 2016, 10s1, CMO.S34537.	0.6	105
842	Assessing the New American Society of Clinical Oncology/College of American Pathologists Guidelines for HER2 Testing by Fluorescence In Situ Hybridization: Experience of an Academic Consultation Practice. Archives of Pathology and Laboratory Medicine, 2016, 140, 1250-1258.	1.2	59
843	B7H6-derived peptides trigger TNF-dependent immunostimulatory activity of lymphocytic NK92-M1 cells. Biopolymers, 2016, 106, 658-672.	1.2	8
844	Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience. Molecular Cancer Therapeutics, 2016, 15, 743-752.	1.9	144
845	Anti-HER2 Therapy Beyond Second-Line for HER2- Positive Metastatic Breast Cancer: A Short Review and Recommendations for Several Clinical Scenarios from a Spanish Expert Panel. Breast Care, 2016, 11, 133-138.	0.8	3
846	Progress in Cancer Immunotherapy. Advances in Experimental Medicine and Biology, 2016, , .	0.8	6
847	Prognostic value of ERBB4 expression in patients with triple negative breast cancer. BMC Cancer, 2016, 16, 138.	1.1	39
848	Are nanotheranostics and nanodiagnostics-guided drug delivery stepping stones towards precision medicine?. Drug Resistance Updates, 2016, 27, 39-58.	6.5	38
849	HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients. Breast Cancer Research and Treatment, 2016, 158, 99-111.	1.1	37
850	Altering Antibody-Drug Conjugate Binding to the Neonatal Fc Receptor Impacts Efficacy and Tolerability. Molecular Pharmaceutics, 2016, 13, 2387-2396.	2.3	30
851	Metronomic Chemotherapy for Metastatic Breast Cancer - a Systematic Review of the Literature. Geburtshilfe Und Frauenheilkunde, 2016, 76, 525-534.	0.8	27
852	Antibody-drug conjugates for cancer therapy. Lancet Oncology, The, 2016, 17, e254-e262.	5.1	439
853	Les essais cliniques : leur apport dans le parcours de soins des patientes traitées pour un cancer du sein. Oncologie, 2016, 18, 103-108.	0.2	1

#	ARTICLE	IF	CITATIONS
854	Trastuzumab emtansine associated nodular regenerative hyperplasia: A case report and review of literature. <i>Cancer Treatment Communications</i> , 2016, 5, 26-30.	0.4	4
855	Phase II study on the efficacy and safety of Lapatinib administered beyond disease progression and combined with vinorelbine in HER-2/neu ⁺ positive advanced breast cancer: results of the CECOG LaVie trial. <i>BMC Cancer</i> , 2016, 16, 121.	1.1	4
856	Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 947-957.	1.5	23
857	HER2-Targeted Polyinosine/Polycytosine Therapy Inhibits Tumor Growth and Modulates the Tumor Immune Microenvironment. <i>Cancer Immunology Research</i> , 2016, 4, 688-697.	1.6	8
858	T-DM1 Activity in Metastatic Human Epidermal Growth Factor Receptor 2 ⁺ Positive Breast Cancers That Received Prior Therapy With Trastuzumab and Pertuzumab. <i>Journal of Clinical Oncology</i> , 2016, 34, 3511-3517.	0.8	64
859	A plant-expressed conjugate vaccine breaks CD4 ⁺ tolerance and induces potent immunity against metastatic Her2 ⁺ breast cancer. <i>Oncolimmunology</i> , 2016, 5, e1166323.	2.1	36
860	HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician [™] s choice plus trastuzumab in patients with previously treated, anthracycline-na ^{ve} , HER2-positive, locally advanced/metastatic breast cancer. <i>BMC Cancer</i> , 2016, 16, 352.	1.1	122
861	SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody [™] Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1900-1909.	1.9	55
862	Cardiac safety of simultaneous anti-HER2 and anthracycline therapy. <i>Breast Cancer Management</i> , 2016, 5, 21-29.	0.2	1
863	Successful treatment of lichen amyloidosis using capsaicin 8% patch. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 1236-1238.	1.3	5
864	The Role of mTOR Inhibitors in Breast Cancer. , 2016, , 67-92.		0
865	Demographic, tumor and clinical features of clinical trials versus clinical practice patients with HER2-positive early breast cancer: results of a prospective study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 669-678.	1.2	14
866	The future of antiviral immunotoxins. <i>Journal of Leukocyte Biology</i> , 2016, 99, 911-925.	1.5	24
867	Emerging drugs targeting human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer. <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 91-101.	1.0	26
868	Biological Characterization of an Improved Pyrrole-Based Colchicine Site Agent Identified through Structure-Based Design. <i>Molecular Pharmacology</i> , 2016, 89, 287-296.	1.0	9
869	First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 155-162.	1.1	66
870	Antibody-drug conjugates [™] an emerging class of cancer treatment. <i>British Journal of Cancer</i> , 2016, 114, 362-367.	2.9	395
871	Microscale screening of antibody libraries as maytansinoid antibody-drug conjugates. <i>MAbs</i> , 2016, 8, 513-523.	2.6	20

#	ARTICLE	IF	CITATIONS
872	Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experience. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 127-132.	1.1	7
873	NICE guidance on trastuzumab emtansine for HER2-positive advanced breast cancer. <i>Lancet Oncology</i> , 2016, 17, 143-144.	5.1	6
875	Antibody-mediated delivery of therapeutics for cancer therapy. <i>Expert Opinion on Drug Delivery</i> , 2016, 13, 401-419.	2.4	40
876	Lichens as natural sources of biotechnologically relevant bacteria. <i>Applied Microbiology and Biotechnology</i> , 2016, 100, 583-595.	1.7	48
877	Co-delivery of chemotherapeutics and proteins for synergistic therapy. <i>Advanced Drug Delivery Reviews</i> , 2016, 98, 64-76.	6.6	178
878	Nodular Regenerative Hyperplasia After Treatment With Trastuzumab Emtansine. <i>Journal of Clinical Oncology</i> , 2016, 34, e9-e12.	0.8	27
879	Covalent Chemical Ligation Strategy for Mono- and Polyclonal Immunoglobulins at Their Nucleotide Binding Sites. <i>Bioconjugate Chemistry</i> , 2016, 27, 159-169.	1.8	18
880	ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody-Drug Conjugate Treatment. <i>Clinical Cancer Research</i> , 2016, 22, 1642-1652.	3.2	74
881	Advances in Medical Management of Early Stage and Advanced Breast Cancer: 2015. <i>Seminars in Radiation Oncology</i> , 2016, 26, 59-70.	1.0	11
882	Pertuzumab for the treatment of breast cancer: a safety review. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 853-863.	1.0	16
883	Palbociclib: an approval at last for HER2-negative breast cancer. <i>Future Oncology</i> , 2016, 12, 1097-1100.	1.1	4
884	Structural characterization of antibody drug conjugate by a combination of intact, middle-up and bottom-up techniques using sheathless capillary electrophoresis and Tandem mass spectrometry as nanoESI infusion platform and separation method. <i>Analytica Chimica Acta</i> , 2016, 918, 50-59.	2.6	70
885	Cardio-Oncology. <i>Circulation Research</i> , 2016, 118, 1008-1020.	2.0	313
886	A phase 1 clinical trial of ASG-5ME, a novel drug-antibody conjugate targeting SLC44A4, in patients with advanced pancreatic and gastric cancers. <i>Investigational New Drugs</i> , 2016, 34, 319-328.	1.2	17
887	Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer. <i>Breast Cancer Research</i> , 2016, 18, 34.	2.2	34
889	Quantum dot nanoparticle for optimization of breast cancer diagnostics and therapy in a clinical setting. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2016, 12, 1581-1592.	1.7	39
890	Translating neoadjuvant therapy into survival benefits: one size does not fit all. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 566-579.	12.5	38
891	A phase I/II trial of the safety and clinical activity of a HER2-protein based immunotherapeutic for treating women with HER2-positive metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 156, 301-310.	1.1	37

#	ARTICLE	IF	CITATIONS
892	Impact of Geographic Region on Benefit of Approved Anticancer Drugs Evaluated in International Phase III Clinical Trials. <i>Clinical Oncology</i> , 2016, 28, 283-291.	0.6	3
893	Metastatic disease of the breast and local recurrence. <i>Surgery</i> , 2016, 34, 47-51.	0.1	0
894	Investigational ErbB-2 tyrosine kinase inhibitors for the treatment of breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 393-403.	1.9	3
895	Current advances in targeted therapies for metastatic gastric cancer: improving patient care. <i>Future Oncology</i> , 2016, 12, 839-854.	1.1	3
896	Patterns in target-directed breast cancer research. <i>SpringerPlus</i> , 2016, 5, 109.	1.2	1
897	Trastuzumab Emtansine for Treating HER2-Positive, Unresectable, Locally Advanced or Metastatic Breast Cancer After Treatment with Trastuzumab and a Taxane: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2016, 34, 673-680.	1.7	25
898	Clinically advanced and metastatic pure mucinous carcinoma of the breast: a comprehensive genomic profiling study. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 405-413.	1.1	17
899	Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer. <i>Annals of Oncology</i> , 2016, 27, 1029-1034.	0.6	39
900	A specific photoimmunotheranostics agent to detect and eliminate skin cancer cells expressing EGFR. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 1003-1011.	1.2	29
901	Non-antigenic regulators of targeting for imaging and therapy. <i>Advanced Drug Delivery Reviews</i> , 2016, 99, 1.	6.6	0
902	Targeted therapies in gastric cancer treatment: where we are and where we are going. <i>Investigational New Drugs</i> , 2016, 34, 378-393.	1.2	16
903	Crossroad between linear and nonlinear transcription concepts in the discovery of next-generation sequencing systems-based anticancer therapies. <i>Drug Discovery Today</i> , 2016, 21, 663-673.	3.2	16
904	Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 3755-3763.	3.2	167
905	A multicenter Phase II study evaluating the efficacy, safety and pharmacokinetics of trastuzumab emtansine in Japanese patients with heavily pretreated HER2-positive locally recurrent or metastatic breast cancer. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 407-414.	0.6	15
906	Mass-spectrometry-based quantitation of Her2 in gastroesophageal tumor tissue: comparison to IHC and FISH. <i>Gastric Cancer</i> , 2016, 19, 1066-1079.	2.7	40
907	Correlation between overall survival and other endpoints in metastatic breast cancer with second- or third-line chemotherapy: Literature-based analysis of 24 randomized trials. <i>Bulletin Du Cancer</i> , 2016, 103, 336-344.	0.6	12
908	MCAM and LAMA4 Are Highly Enriched in Tumor Blood Vessels of Renal Cell Carcinoma and Predict Patient Outcome. <i>Cancer Research</i> , 2016, 76, 2314-2326.	0.4	58
909	Development of ASG-15ME, a Novel Antibody-Drug Conjugate Targeting <i>SLITRK6</i> , a New Urothelial Cancer Biomarker. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1301-1310.	1.9	58

#	ARTICLE	IF	CITATIONS
910	Development of Novel Quaternary Ammonium Linkers for Antibody-Drug Conjugates. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 938-945.	1.9	49
911	Mcl-1 confers protection of Her2-positive breast cancer cells to hypoxia: therapeutic implications. <i>Breast Cancer Research</i> , 2016, 18, 26.	2.2	25
913	Phase II trial of dacomitinib in patients with HER2-positive gastric cancer. <i>Gastric Cancer</i> , 2016, 19, 1095-1103.	2.7	33
914	A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy. <i>Cancer Cell</i> , 2016, 29, 117-129.	7.7	281
915	Recent advances in the construction of antibody-drug conjugates. <i>Nature Chemistry</i> , 2016, 8, 114-119.	6.6	289
916	Ado-Trastuzumab Emtansine Targets Hepatocytes Via Human Epidermal Growth Factor Receptor 2 to Induce Hepatotoxicity. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 480-490.	1.9	46
917	AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 1989-1999.	3.2	35
918	Response of symptomatic brain metastases from HER-2 overexpressing breast cancer with T-DM1. <i>Journal of Neuro-Oncology</i> , 2016, 127, 401-403.	1.4	8
919	Cancer of the Breast: An Overview. , 2016, , 147-209.		0
920	Systemic therapy beyond first-line in advanced gastric cancer: An overview of the main randomized clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 99, 1-12.	2.0	19
921	Development of Companion Diagnostics. <i>Seminars in Nuclear Medicine</i> , 2016, 46, 47-56.	2.5	40
922	A Phase II Randomized Study of Lapatinib Combined With Capecitabine, Vinorelbine, or Gemcitabine in Patients With HER2-Positive Metastatic Breast Cancer With Progression After a Taxane (Latin American) Tj ETQq1 1.0.7843140gBT / Qv		
923	Preclinical Efficacy of Ado-trastuzumab Emtansine in the Brain Microenvironment. <i>Journal of the National Cancer Institute</i> , 2016, 108, .	3.0	56
924	Statistical controversies in clinical research: end points other than overall survival are vital for regulatory approval of anticancer agents. <i>Annals of Oncology</i> , 2016, 27, 373-378.	0.6	50
925	Enhanced Antitumor Activity of an Anti-5T4 Antibody-Drug Conjugate in Combination with PI3K/mTOR inhibitors or Taxanes. <i>Clinical Cancer Research</i> , 2016, 22, 383-394.	3.2	21
926	Current challenges in HER2-positive breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 98, 211-221.	2.0	33
927	Antibody Drug Conjugates for Cancer Therapy. <i>Pharmacological Reviews</i> , 2016, 68, 3-19.	7.1	272
928	Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort. <i>Annals of Oncology</i> , 2016, 27, 281-286.	0.6	254

#	ARTICLE	IF	CITATIONS
929	Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial. <i>Annals of Oncology</i> , 2016, 27, 619-624.	0.6	269
930	Use of Cytotoxic Chemotherapy in Metastatic Breast Cancer: Putting Taxanes in Perspective. <i>Clinical Breast Cancer</i> , 2016, 16, 73-81.	1.1	18
931	Next-generation disulfide stapling: reduction and functional re-bridging all in one. <i>Chemical Science</i> , 2016, 7, 799-802.	3.7	72
932	Comprehensive genomic profiling of extrahepatic cholangiocarcinoma reveals a long tail of therapeutic targets. <i>Journal of Clinical Pathology</i> , 2016, 69, 403-408.	1.0	56
933	Tâ€œscp>DM</scp>1 extravasation: first description. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 1235-1236.	1.3	6
935	Mutational and network level mechanisms underlying resistance to anti-cancer kinase inhibitors. <i>Seminars in Cell and Developmental Biology</i> , 2016, 50, 164-176.	2.3	31
936	New Life for Immunotoxin Cancer Therapy. <i>Clinical Cancer Research</i> , 2016, 22, 1055-1058.	3.2	38
937	Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 97, 96-106.	2.0	41
939	Defining the optimal sequence for the systemic treatment of metastatic breast cancer. <i>Clinical and Translational Oncology</i> , 2017, 19, 149-161.	1.2	24
940	Pertuzumab and breast cancer: another piece in the anti-HER2 puzzle. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 365-374.	1.4	27
941	Antibody Drug and Radionuclide Conjugates for GI Cancers. , 2017, , 79-99.		1
942	Splenic Enlargement and Bone Marrow Hyperplasia in Patients Receiving Trastuzumab-Emtansine for Metastatic Breast Cancer. <i>Targeted Oncology</i> , 2017, 12, 229-234.	1.7	5
943	Enabling the controlled assembly of antibody conjugates with a loading of two modules without antibody engineering. <i>Chemical Science</i> , 2017, 8, 2056-2060.	3.7	52
944	Investigation of Hydrophilic Auristatin Derivatives for Use in Antibody Drug Conjugates. <i>Bioconjugate Chemistry</i> , 2017, 28, 371-381.	1.8	33
945	Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2â€œPositive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 141-148.	0.8	327
946	Strategies to design clinical studies to identify predictive biomarkers in cancer research. <i>Cancer Treatment Reviews</i> , 2017, 53, 79-97.	3.4	80
947	Optimization of a PEGylated Glucuronide-Monomethylauristatin E Linker for Antibodyâ€œDrug Conjugates. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 116-123.	1.9	106
948	Targeting Epidermal Growth Factor Receptor in triple negative breast cancer: New discoveries and practical insights for drug development. <i>Cancer Treatment Reviews</i> , 2017, 53, 111-119.	3.4	134

#	ARTICLE	IF	CITATIONS
949	Antibodyâ€dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells. <i>Immunology and Cell Biology</i> , 2017, 95, 347-355.	1.0	160
950	Improved Lysosomal Trafficking Can Modulate the Potency of Antibody Drug Conjugates. <i>Bioconjugate Chemistry</i> , 2017, 28, 1102-1114.	1.8	35
951	Breast Cancer Metastasis. , 2017, , 13-31.		9
952	Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers Part 1: GI carcinomas. , 2017, 174, 145-172.		22
953	PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials. , 2017, 175, 91-106.		167
954	Cardio-oncology Related to Heart Failure. <i>Heart Failure Clinics</i> , 2017, 13, 297-309.	1.0	13
955	Targeting the tumour microenvironment with an enzyme-responsive drug delivery system for the efficient therapy of breast and pancreatic cancers. <i>Chemical Science</i> , 2017, 8, 3427-3433.	3.7	95
956	Standard of care in immunotherapy trials: Challenges and considerations. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 2164-2178.	1.4	4
957	TCR-like antibody drug conjugates mediate killing of tumor cells with low peptide/HLA targets. <i>MAbs</i> , 2017, 9, 603-614.	2.6	23
958	Systematic analysis of early phase clinical studies for patients with breast cancer: Inclusion of patients with brain metastasis. <i>Cancer Treatment Reviews</i> , 2017, 55, 10-15.	3.4	19
959	The significance of the trial outcome was associated with publication rate and time to publication. <i>Journal of Clinical Epidemiology</i> , 2017, 84, 78-84.	2.4	27
960	Evolving landscape of human epidermal growth factor receptor 2-positive breast cancer treatment and the future of biosimilars. <i>Breast</i> , 2017, 32, 199-216.	0.9	37
961	Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1255-1262.	1.2	19
962	Increased life expectancy as a result of non-hormonal targeted therapies for HER2 or hormone receptor positive metastatic breast cancer: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2017, 55, 16-25.	3.4	18
963	Albumin nanoparticle encapsulation of potent cytotoxic therapeutics shows sustained drug release and alleviates cancer drug toxicity. <i>Chemical Communications</i> , 2017, 53, 2618-2621.	2.2	36
964	Reactivation of dormant anti-tumor immunity â€“ a clinical perspective of therapeutic immune checkpoint modulation. <i>Cell Communication and Signaling</i> , 2017, 15, 5.	2.7	34
965	Designing nanomedicine for immuno-oncology. <i>Nature Biomedical Engineering</i> , 2017, 1, .	11.6	178
966	Inducible, Site-Specific Protein Labeling by Tyrosine Oxidationâ€Strain-Promoted (4 + 2) Cycloaddition. <i>Bioconjugate Chemistry</i> , 2017, 28, 1189-1193.	1.8	71

#	ARTICLE	IF	CITATIONS
967	Use and outcomes of targeted therapies in early and metastatic HER2-positive breast cancer in Australia: protocol detailing observations in a whole of population cohort. <i>BMJ Open</i> , 2017, 7, e014439.	0.8	15
968	Overall survival and the response to radiotherapy among molecular subtypes of breast cancer brain metastases treated with targeted therapies. <i>Cancer</i> , 2017, 123, 2283-2293.	2.0	51
969	<i>Cardio-Oncology</i> , 2017, , .		1
970	Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 41-54.	3.3	55
971	Prolonged Response to HER2-Directed Therapy in a Patient With HER2-Amplified, Rapidly Progressive Metastatic Colorectal Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 3-8.	2.3	25
972	Tackling endocrine resistance in ER-positive HER2-negative advanced breast cancer: A tale of imprecision medicine. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 114, 91-101.	2.0	15
973	<i>Geriatric Cardio-oncology</i> , 2017, , 281-301.		0
974	Trastuzumab uptake and its relation to efficacy in an animal model of HER2-positive breast cancer brain metastasis. <i>Breast Cancer Research and Treatment</i> , 2017, 164, 581-591.	1.1	52
975	The future of oncology therapeutics. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 563-565.	1.1	3
976	Trastuzumab emtansine in HER2-positive metastatic breast cancer. <i>Lancet Oncology</i> , The, 2017, 18, 696-697.	5.1	5
977	Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 732-742.	5.1	447
978	Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 743-754.	5.1	372
979	Targeting HER2/3 in Breast Cancer. <i>Current Breast Cancer Reports</i> , 2017, 9, 61-69.	0.5	0
980	HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 5123-5134.	3.2	85
981	Impact of serum HER2, TIMP-1, and CAIX on outcome for HER2+ metastatic breast cancer patients: CCTG MA.31 (lapatinib vs. trastuzumab). <i>Breast Cancer Research and Treatment</i> , 2017, 164, 571-580.	1.1	13
982	SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression. <i>Gynecologic Oncology</i> , 2017, 146, 179-186.	0.6	37
983	Whither Radioimmunotherapy: To Be or Not To Be?. <i>Cancer Research</i> , 2017, 77, 2191-2196.	0.4	60
984	Immunotherapy for the treatment of breast cancer. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 797-812.	1.4	12

#	ARTICLE	IF	CITATIONS
985	Do patient access schemes for high-cost cancer drugs deliver value to society?â€”lessons from the NHS Cancer Drugs Fund. <i>Annals of Oncology</i> , 2017, 28, 1738-1750.	0.6	102
986	3rd ESOâ€”ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). <i>Annals of Oncology</i> , 2017, 28, 16-33.	0.6	865
987	Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies. <i>Drugs</i> , 2017, 77, 1313-1336.	4.9	39
988	Antitumor activity and safety profile of weekly carboplatin plus paclitaxel in metastatic breast cancer: a ten-year, monocentric, retrospective study. <i>Breast Cancer Research and Treatment</i> , 2017, 165, 365-373.	1.1	12
989	Trastuzumab emtansine suppresses the growth of HER2-positive small-cell lung cancer in preclinical models. <i>Biochemical and Biophysical Research Communications</i> , 2017, 488, 596-602.	1.0	9
990	The use of systemic therapies to prevent progression of inflammatory breast cancer: which targeted therapies to add on cytotoxic combinations?. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 593-606.	1.1	3
991	A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer. <i>Breast Cancer Research</i> , 2017, 19, 54.	2.2	27
992	Advances in systemic therapy for metastatic breast cancer: future perspectives. <i>Medical Oncology</i> , 2017, 34, 119.	1.2	34
993	Discovery and Optimization of HKT288, a Cadherin-6â€”Targeting ADC for the Treatment of Ovarian and Renal Cancers. <i>Cancer Discovery</i> , 2017, 7, 1030-1045.	7.7	40
994	Breast cancer: updates and advances in 2016. <i>Current Opinion in Obstetrics and Gynecology</i> , 2017, 29, 12-17.	0.9	27
995	Cell Division Machinery and Disease. <i>Advances in Experimental Medicine and Biology</i> , 2017, , .	0.8	4
996	Therapeutic potential of an anti-HER2 single chain antibodyâ€”DM1 conjugates for the treatment of HER2-positive cancer. <i>Signal Transduction and Targeted Therapy</i> , 2017, 2, 17015.	7.1	30
997	Aberrant intracellular metabolism of Tâ€”DM</sc>1 confers Tâ€”DM</sc>1 resistance in human epidermal growth factor receptor 2â€”positive gastric cancer cells. <i>Cancer Science</i> , 2017, 108, 1458-1468.	1.7	44
998	Design, synthesis, and structureâ€”activity relationships of pyrimido[4,5- b]indole-4-amines as microtubule depolymerizing agents that are effective against multidrug resistant cells. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 3423-3430.	1.0	9
999	Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients. <i>Medicine (United States)</i> , 2017, 96, e6931.	0.4	3
1000	Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks. <i>Lancet Oncology</i> , The, 2017, 18, 887-894.	5.1	108
1001	Clinical Development of Anti-mitotic Drugs in Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1002, 125-152.	0.8	22
1002	Antibodyâ€”Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review. <i>Advances in Therapy</i> , 2017, 34, 1015-1035.	1.3	227

#	ARTICLE	IF	CITATIONS
1003	Galician consensus on management of cardiotoxicity in breast cancer: risk factors, prevention, and early intervention. <i>Clinical and Translational Oncology</i> , 2017, 19, 1067-1078.	1.2	11
1004	Drug-biomarker co-development in oncology â€“ 20 years and counting. <i>Drug Resistance Updates</i> , 2017, 30, 48-62.	6.5	48
1005	Management of breast cancer brain metastases: Focus on human epidermal growth factor receptor 2â€“positive breast cancer. <i>Chronic Diseases and Translational Medicine</i> , 2017, 3, 21-32.	0.9	15
1006	Future of Drug Discovery. , 2017, , 609-629.		3
1007	Targeted Treatment of Brain Metastases. <i>Current Neurology and Neuroscience Reports</i> , 2017, 17, 37.	2.0	28
1008	Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. <i>Lancet Oncology, The</i> , 2017, 18, 640-653.	5.1	383
1009	Tumor-Associated Macrophages Can Contribute to Antitumor Activity through FcÎ³R-Mediated Processing of Antibodyâ€“Drug Conjugates. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1347-1354.	1.9	50
1010	Application of a PK-PD Modeling and Simulation-Based Strategy for Clinical Translation of Antibody-Drug Conjugates: a Case Study with Trastuzumab Emtansine (T-DM1). <i>AAPS Journal</i> , 2017, 19, 1054-1070.	2.2	31
1011	Antibody-Based Cancer Therapy. <i>International Review of Cell and Molecular Biology</i> , 2017, 331, 289-383.	1.6	41
1012	Spatiotemporal diversification of inpatient genomic clones and early drug development concepts realize the roadmap of precision cancer medicine. <i>Drug Discovery Today</i> , 2017, 22, 1148-1164.	3.2	30
1013	Perspectives of HER2-targeting in gastric and esophageal cancer. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 531-540.	1.9	71
1014	Targeting HER2 beyond progression in gastroesophageal cancer. <i>Lancet Oncology, The</i> , 2017, 18, 562-564.	5.1	0
1015	Antibodies and associates: Partners in targeted drug delivery. , 2017, 177, 129-145.		52
1016	Preclinical Antitumor Efficacy of BAY 1129980â€“a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibodyâ€“Drug Conjugate for the Treatment of Nonâ€“Small Cell Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 893-904.	1.9	37
1017	Sequencing brain metastases and opportunities for targeted therapies. <i>Pharmacogenomics</i> , 2017, 18, 585-594.	0.6	8
1018	Pathologic diagnosis of breast cancer patients: evolution of the traditional clinical-pathologic paradigm toward â€œprecisionâ€“cancer therapy. <i>Biotechnic and Histochemistry</i> , 2017, 92, 175-200.	0.7	10
1019	Drug Resistance in Bacteria, Fungi, Malaria, and Cancer. , 2017, , .		13
1020	Intra-image referencing for simplified assessment of HER2-expression in breast cancer metastases using the Affibody molecule ABY-025 with PET and SPECT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1337-1346.	3.3	39

#	ARTICLE	IF	CITATIONS
1021	HER2-positive breast cancer. <i>Lancet, The</i> , 2017, 389, 2415-2429.	6.3	655
1023	Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 549-556.	1.1	147
1024	From Composition to Cure: A Systems Engineering Approach to Anticancer Drug Carriers. <i>Angewandte Chemie - International Edition</i> , 2017, 56, 6712-6733.	7.2	65
1025	Regression of metastatic, radiation/chemotherapy-resistant uterine serous carcinoma overexpressing HER2/neu with trastuzumab emtansine (TDM-1). <i>Gynecologic Oncology Reports</i> , 2017, 19, 10-12.	0.3	14
1026	Von der Zusammensetzung zur Heilung: ein systemtechnischer Ansatz zur Entwicklung von Trägern für Tumortherapeutika. <i>Angewandte Chemie</i> , 2017, 129, 6814-6837.	1.6	8
1028	Current Trends in Cancer Therapy. , 2017, , 1-24.		7
1029	3rd ESO/ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). <i>Breast</i> , 2017, 31, 244-259.	0.9	171
1030	Therapeutic Efficacy of a Family of pH-Responsive PLGA-MMAF Conjugates in Cancer Cells and Mouse Models. <i>Molecular Pharmaceutics</i> , 2017, 14, 415-422.	2.3	29
1031	Integrin-targeted reduction-sensitive micellar mertansine prodrug: Superb drug loading, enhanced stability, and effective inhibition of melanoma growth in vivo. <i>Journal of Controlled Release</i> , 2017, 259, 176-186.	4.8	26
1032	Preliminary experience of the concurrent use of radiosurgery and T-DM1 for brain metastases in HER2-positive metastatic breast cancer. <i>Journal of Neuro-Oncology</i> , 2017, 131, 69-72.	1.4	49
1033	Emerging Cancer Biomarkers for HNSCC Detection and Therapeutic Intervention. , 2017, , 281-308.		1
1034	Advances in chemical pharmacotherapy to manage advanced breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 95-103.	0.9	4
1036	The clinical development of vaccines for HER2 + breast cancer: Current landscape and future perspectives. <i>Cancer Treatment Reviews</i> , 2017, 61, 107-115.	3.4	32
1037	Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?. <i>British Journal of Cancer</i> , 2017, 117, 1736-1742.	2.9	281
1038	Defining what matters most to patients. <i>British Journal of Nursing</i> , 2017, 26, S15-S20.	0.3	1
1039	Current treatment of HER 2+ metastatic breast cancer. <i>British Journal of Nursing</i> , 2017, 26, S7-S14.	0.3	1
1040	Exposure-response analyses of trastuzumab emtansine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 1079-1090.	1.1	17
1041	Cardiotoxicity From Human Epidermal Growth Factor Receptor 2 (HER2) Targeted Therapies. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	58

#	ARTICLE	IF	CITATIONS
1042	PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer. <i>European Journal of Cancer</i> , 2017, 86, 28-36.	1.3	48
1043	Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. <i>Lancet Oncology</i> , The, 2017, 18, 1512-1522.	5.1	317
1044	Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC). <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 1147-1159.	1.1	11
1045	Antibody-drug conjugates: can the payload improve activity in HER2 expressing cancers?. <i>Lancet Oncology</i> , The, 2017, 18, 1433-1434.	5.1	0
1046	Advances in the management of HER2-positive early breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 119, 113-122.	2.0	42
1047	The antibody-drug conjugate target landscape across a broad range of tumour types. <i>Annals of Oncology</i> , 2017, 28, 3083-3091.	0.6	40
1048	ESMO-Magnitude of Clinical Benefit Scale version 1.1. <i>Annals of Oncology</i> , 2017, 28, 2340-2366.	0.6	451
1049	Foreword. <i>British Journal of Nursing</i> , 2017, 26, S3-S3.	0.3	0
1051	Economic evaluation of sequencing strategies in HER2-positive metastatic breast cancer in Mexico: a contrast between public and private payer perspectives. <i>Breast Cancer Research and Treatment</i> , 2017, 166, 951-963.	1.1	13
1052	Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 7006-7019.	3.2	61
1053	Chemotherapy for advanced gastric cancer. <i>The Cochrane Library</i> , 2017, 2017, CD004064.	1.5	662
1054	Antibody-Drug Conjugates as Cancer Therapeutics: Past, Present, and Future. <i>Journal of Clinical Pharmacology</i> , 2017, 57, S11-S25.	1.0	37
1055	Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer. <i>Pharmaceutical Research</i> , 2017, 34, 2579-2595.	1.7	30
1056	Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE). <i>European Journal of Cancer</i> , 2017, 85, 133-145.	1.3	84
1057	Multifunctional superparamagnetic nanoparticles conjugated with fluorescein-labeled designed ankyrin repeat protein as an efficient HER2-targeted probe in breast cancer. <i>Biomaterials</i> , 2017, 147, 86-98.	5.7	21
1058	Antibody-Drug Conjugates. <i>Topics in Medicinal Chemistry</i> , 2017, , 289-289.	0.4	1
1059	Overcoming key biological barriers to cancer drug delivery and efficacy. <i>Journal of Controlled Release</i> , 2017, 267, 15-30.	4.8	92
1060	Quantitative diagnostic imaging of cancer tissues by using phosphor-integrated dots with ultra-high brightness. <i>Scientific Reports</i> , 2017, 7, 7509.	1.6	30

#	ARTICLE	IF	CITATIONS
1061	Healthcare cost of HER2-positive and negative breast tumors in the United States (2012–2035). <i>Cancer Treatment Reviews</i> , 2017, 60, 12-17.	3.4	15
1062	New chemotherapies in breast cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2017, 10, 127-131.	0.3	1
1063	Immunoregulation by IL-7R-targeting antibody-drug conjugates: overcoming steroid-resistance in cancer and autoimmune disease. <i>Scientific Reports</i> , 2017, 7, 10735.	1.6	28
1064	Advances in cancer stem cell targeting: How to strike the evil at its root. <i>Advanced Drug Delivery Reviews</i> , 2017, 120, 89-107.	6.6	58
1065	An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	29
1067	Population pharmacokinetics and exposure–response of trastuzumab emtansine in advanced breast cancer previously treated with ≥ 2 HER2-targeted regimens. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 2767-2777.	1.1	18
1068	Concurrent administration of anti-HER2 therapy and radiotherapy: Systematic review. <i>Radiotherapy and Oncology</i> , 2017, 124, 190-199.	0.3	35
1069	DS-8201a, a new HER2-targeting antibody–drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance. <i>International Journal of Cancer</i> , 2017, 141, 1682-1689.	2.3	111
1070	Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression. <i>Gynecologic Oncology</i> , 2017, 147, 145-152.	0.6	18
1071	¹³¹ I-labeled Anti-HER2 Camelid sdAb as a Theranostic Tool in Cancer Treatment. <i>Clinical Cancer Research</i> , 2017, 23, 6616-6628.	3.2	124
1072	Precision medicine: the foundation of future cancer therapeutics. <i>Npj Precision Oncology</i> , 2017, 1, 12.	2.3	82
1073	HER2-positive breast cancer is lost in translation: time for patient-centered research. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 669-681.	12.5	59
1075	T-DM1 – an important agent in the history of breast cancer management. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 651-652.	12.5	6
1076	Targeting HER2 in Advanced Breast Cancer. <i>Methods in Molecular Biology</i> , 2017, 1652, 63-77.	0.4	4
1077	Emerging antibody-drug conjugates for treating lymphoid malignancies. <i>Expert Opinion on Emerging Drugs</i> , 2017, 22, 259-273.	1.0	20
1078	Polymer-Based Protein Engineering. <i>Methods in Enzymology</i> , 2017, 590, 347-380.	0.4	15
1079	Retrospective analysis of HER2 therapy interruption in patients responding to the treatment in metastatic HER2+ breast cancer. <i>ESMO Open</i> , 2017, 2, e000202.	2.0	10
1080	Precision medicine in gastric cancer: where are we now?. <i>Expert Review of Precision Medicine and Drug Development</i> , 2017, 2, 193-204.	0.4	0

#	ARTICLE	IF	CITATIONS
1081	Resistance to Targeted Therapies in Breast Cancer. Resistance To Targeted Anti-cancer Therapeutics, 2017, , .	0.1	1
1082	Adverse Events of Trastuzumab Emtansine (T-DM1) in the Treatment of HER2-Positive Breast Cancer Patients. Breast Care, 2017, 12, 401-408.	0.8	28
1083	Improving patient care: expert nursing and service development. British Journal of Nursing, 2017, 26, S21-S25.	0.3	0
1084	Systemic Treatment of Metastatic Breast Cancer (MBC) in Older Adults. Breast, 2017, 36, S24.	0.9	0
1085	Pharmacologic measures in the prevention of left ventricular dysfunction associated with molecular-targeted therapies in the treatment of cancer patients. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 1205-1215.	1.5	1
1086	Whatâ€™s new in chemotherapy for non-small cell lung cancer?. Memo - Magazine of European Medical Oncology, 2017, 10, 123-126.	0.3	0
1087	Antibodyâ€™Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments. Targeted Oncology, 2017, 12, 719-739.	1.7	71
1088	Treatment of Advanced Disease: Guidelines. , 2017, , 549-556.		0
1089	Chemotherapy Regimens in the Adjuvant and Advanced Disease Settings. , 2017, , 569-576.		0
1090	Anti-HER2 Therapies in the Adjuvant and Advanced Disease Settings. , 2017, , 577-591.		0
1091	Enzymatic conjugation using branched linkers for constructing homogeneous antibodyâ€™drug conjugates with high potency. Organic and Biomolecular Chemistry, 2017, 15, 5635-5642.	1.5	67
1092	Breast cancer treatment-induced cardiotoxicity. Expert Opinion on Drug Safety, 2017, 16, 1021-1038.	1.0	58
1093	Antibodyâ€™drug conjugates in glioblastoma therapy: the right drugs to the right cells. Nature Reviews Clinical Oncology, 2017, 14, 695-707.	12.5	90
1094	Getting under the skin. European Journal of Cancer, 2017, 82, 228-229.	1.3	0
1095	SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibodyâ€™Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression. Clinical Cancer Research, 2017, 23, 5836-5845.	3.2	51
1096	Resistance to the Antibodyâ€™Drug Conjugate T-DM1 Is Based in a Reduction in Lysosomal Proteolytic Activity. Cancer Research, 2017, 77, 4639-4651.	0.4	103
1097	Evolution of anti-HER2 therapies for cancer treatment. Cancer Treatment Reviews, 2017, 59, 1-21.	3.4	73
1098	Neratinib for the treatment of HER2-positive early stage breast cancer. Expert Review of Anticancer Therapy, 2017, 17, 669-679.	1.1	22

#	ARTICLE	IF	CITATIONS
1099	First report of eribulin in combination with pertuzumab and trastuzumab for advanced HER2-positive breast cancer. <i>Breast</i> , 2017, 35, 78-84.	0.9	23
1100	Precision medicine in breast cancer: reality or utopia?. <i>Journal of Translational Medicine</i> , 2017, 15, 139.	1.8	56
1101	Efficacy and safety of everolimus in combination with trastuzumab and paclitaxel in Asian patients with HER2+ advanced breast cancer in BOLERO-1. <i>Breast Cancer Research</i> , 2017, 19, 47.	2.2	19
1102	Monoclonal Antibodies in Multiple Myeloma: A New Wave of the Future. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 545-554.	0.2	29
1103	Locoregional therapy with β -emitting trastuzumab against peritoneal metastasis of human epidermal growth factor receptor 2-positive gastric cancer in mice. <i>Cancer Science</i> , 2017, 108, 1648-1656.	1.7	36
1104	The role of neratinib in HER2-driven breast cancer. <i>Future Oncology</i> , 2017, 13, 1931-1943.	1.1	13
1105	Antibody-drug conjugate directed against the guanylyl cyclase antigen for the treatment of gastrointestinal malignancies. , 2017, 170, 8-13.		11
1106	5T4-Targeted Therapy Ablates Cancer Stem Cells and Prevents Recurrence of Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2017, 23, 2516-2527.	3.2	39
1107	More than just the median: Calculating survival times for patients with HER2 positive, metastatic breast cancer using data from recent randomised trials. <i>Breast</i> , 2017, 31, 99-104.	0.9	17
1108	Escalating and de-escalating treatment in HER2-positive early breast cancer. <i>Cancer Treatment Reviews</i> , 2017, 52, 1-11.	3.4	24
1109	Pattern of metastatic spread and subcategories of breast cancer. <i>Archives of Gynecology and Obstetrics</i> , 2017, 295, 211-223.	0.8	21
1110	Evaluation of the first ^{44}Sc -labeled Affibody molecule for imaging of HER2-expressing tumors. <i>Nuclear Medicine and Biology</i> , 2017, 45, 15-21.	0.3	26
1111	Drug Hepatotoxicity. <i>Clinics in Liver Disease</i> , 2017, 21, 115-134.	1.0	58
1112	Entwicklung Pyrrolobenzodiazepin(PBD)-haltiger Antikörper-Wirkstoff-Konjugate (ADCs) ausgehend von Anthramycin. <i>Angewandte Chemie</i> , 2017, 129, 474-502.	1.6	13
1113	From Anthramycin to Pyrrolobenzodiazepine (PBD)-Containing Antibody-Drug Conjugates (ADCs). <i>Angewandte Chemie - International Edition</i> , 2017, 56, 462-488.	7.2	197
1114	A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM). <i>Clinical and Translational Oncology</i> , 2017, 19, 616-624.	1.2	3
1115	Breast cancer. <i>Lancet</i> , The, 2017, 389, 1134-1150.	6.3	1,568
1116	Preclinical Efficacy of an Antibody-Drug Conjugate Targeting Mesothelin Correlates with Quantitative ^{89}Zr -ImmunoPET. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 134-142.	1.9	30

#	ARTICLE	IF	CITATIONS
1117	Assessing HER2 testing quality in breast cancer: variables that influence HER2 positivity rate from a large, multicenter, observational study in Germany. <i>Modern Pathology</i> , 2017, 30, 217-226.	2.9	29
1118	How may targeted proteomics complement genomic data in breast cancer?. <i>Expert Review of Proteomics</i> , 2017, 14, 43-54.	1.3	11
1119	Recent trends in microRNA research into breast cancer with particular focus on the associations between microRNAs and intrinsic subtypes. <i>Journal of Human Genetics</i> , 2017, 62, 15-24.	1.1	122
1120	Intratumor and circulating clonal heterogeneity shape the basis of precision breast cancer therapy. <i>Future Oncology</i> , 2017, 13, 113-116.	1.1	4
1121	Developmental therapeutics for patients with breast cancer and central nervous system metastasis: current landscape and future perspectives. <i>Annals of Oncology</i> , 2017, 28, 44-56.	0.6	43
1122	Trastuzumab Emtansine in HER2+ Recurrent Metastatic Non-Small-Cell Lung Cancer: Study Protocol. <i>Clinical Lung Cancer</i> , 2017, 18, 92-95.	1.1	19
1123	Trastuzumab cardiotoxicity: from clinical trials to experimental studies. <i>British Journal of Pharmacology</i> , 2017, 174, 3727-3748.	2.7	95
1124	Leveraging Physiology for Precision Drug Delivery. <i>Physiological Reviews</i> , 2017, 97, 189-225.	13.1	125
1125	Targeted therapy of brain metastases: latest evidence and clinical implications. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 781-796.	1.4	46
1126	Introduction. <i>British Journal of Nursing</i> , 2017, 26, S4-S6.	0.3	0
1127	Engineering Antibodies as Drugs: Principles and Practice. <i>Molecular Biology</i> , 2017, 51, 772-781.	0.4	2
1128	Ado-trastuzumab emtansine (T-DM1) in HER2+ advanced breast cancer patients: does pretreatment with pertuzumab matter?. <i>Future Oncology</i> , 2017, 13, 2791-2797.	1.1	23
1130	Clinical development of T-DM1. <i>Drug Delivery System</i> , 2017, 32, 119-125.	0.0	0
1133	Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13. <i>BMJ: British Medical Journal</i> , 2017, 359, j4530.	2.4	423
1134	New agents for the management of resistant metastatic breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1815-1831.	0.9	5
1135	Antibody-Drug Conjugates. <i>Journal of the Nihon University Medical Association</i> , 2017, 76, 15-18.	0.0	0
1136	Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 3363-3372.	1.0	11
1137	Anti-cancer Activity of Novel TM4SF5-Targeting Antibodies through TM4SF5 Neutralization and Immune Cell-Mediated Cytotoxicity. <i>Theranostics</i> , 2017, 7, 594-613.	4.6	19

#	ARTICLE	IF	CITATIONS
1138	Clinical targeting recombinant immunotoxins for cancer therapy. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 3645-3665.	1.0	33
1139	Development and Properties of Valine-Alanine based Antibody-Drug Conjugates with Monomethyl Auristatin E as the Potent Payload. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1860.	1.8	30
1140	A Versatile Chemo-Enzymatic Conjugation Approach Yields Homogeneous and Highly Potent Antibody-Drug Conjugates. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2284.	1.8	19
1141	Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2420.	1.8	102
1142	Marine Antibody-Drug Conjugates: Design Strategies and Research Progress. <i>Marine Drugs</i> , 2017, 15, 18.	2.2	19
1143	Combination therapy of macromolecules and small molecules: approaches, advantages, and limitations. , 2017, , 541-561.		6
1144	Lapatinib. , 2017, , 243-264.		0
1145	Development of Antibody-Drug Conjugates Using DDS and Molecular Imaging. <i>Bioengineering</i> , 2017, 4, 78.	1.6	23
1146	Addressing the Immunogenicity of the Cargo and of the Targeting Antibodies with a Focus on Deimmunized Bacterial Toxins and on Antibody-Targeted Human Effector Proteins. <i>Biomedicines</i> , 2017, 5, 28.	1.4	9
1147	Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going?. <i>Frontiers in Immunology</i> , 2017, 8, 1245.	2.2	124
1148	MALDI IMS and Cancer Tissue Microarrays. <i>Advances in Cancer Research</i> , 2017, 134, 173-200.	1.9	38
1149	Safety and efficacy of the addition of pertuzumab to T-DM1 & plusmn; taxane in patients with HER2-positive, locally advanced or metastatic breast cancer: a pooled analysis. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 3235-3244.	2.0	3
1150	Ribosomal protein S3 regulates XIAP expression independently of the NF- κ B pathway in breast cancer cells. <i>Oncology Reports</i> , 2017, 38, 3205-3210.	1.2	20
1151	Identification of cell proliferation, immune response and cell migration as critical pathways in a prognostic signature for HER2+:ERL \pm breast cancer. <i>PLoS ONE</i> , 2017, 12, e0179223.	1.1	9
1152	Assessing the relationship between toxicity and economic cost of oncological target agents: A systematic review of clinical trials. <i>PLoS ONE</i> , 2017, 12, e0183639.	1.1	2
1153	Addressing the challenges of applying precision oncology. <i>Npj Precision Oncology</i> , 2017, 1, 28.	2.3	43
1154	A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO). <i>BMC Cancer</i> , 2017, 17, 499.	1.1	21
1155	Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?. <i>BMC Medicine</i> , 2017, 15, 134.	2.3	169

#	ARTICLE	IF	CITATIONS
1156	Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies. <i>Breast Cancer Research</i> , 2017, 19, 87.	2.2	29
1157	Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment. <i>Experimental Hematology and Oncology</i> , 2017, 6, 31.	2.0	64
1158	COST-EFFECTIVENESS ANALYSIS OF TRASTUZUMAB EMTANSINE IN THE TREATMENT OF METASTATIC BREAST CANCER. <i>International Journal of Pharmacy and Pharmaceutical Sciences</i> , 2017, 9, 155.	0.3	2
1159	Measuring the Value of New Drugs: Validity and Reliability of 4 Value Assessment Frameworks in the Oncology Setting. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2017, 23, S34-S48.	0.5	15
1160	α -v β 3 integrin-targeted micellar mertansine prodrug effectively inhibits triple-negative breast cancer in vivo. <i>International Journal of Nanomedicine</i> , 2017, Volume 12, 7913-7921.	3.3	24
1161	Cutaneous Metastasis due to Breast Cancer in a Patient with Primary Biliary Cirrhosis: A Case Report. <i>Case Reports in Oncology</i> , 2017, 9, 718-725.	0.3	5
1162	Assessment of HER-2 status in invasive breast cancer in Brazil. <i>Revista Da Associação Médica Brasileira</i> , 2017, 63, 566-574.	0.3	2
1163	A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study. <i>Oncotarget</i> , 2017, 8, 73144-73153.	0.8	24
1164	Optimal Management of Early and Advanced HER2 Breast Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 76-92.	1.8	17
1165	Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2 ⁺ Positive Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 3105-3112.	0.8	168
1166	Randomized Phase III Trial of Trastuzumab Plus Capecitabine With or Without Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2 ⁺ Positive Metastatic Breast Cancer Who Experienced Disease Progression During or After Trastuzumab-Based Therapy. <i>Journal of Clinical Oncology</i> , 2017, 35, 3030-3038.	0.8	90
1167	Exploration of the ASCO and ESMO Value Frameworks for Antineoplastic Drugs. <i>Journal of Oncology Practice</i> , 2017, 13, e653-e665.	2.5	31
1168	Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 2141-2148.	0.8	283
1169	Tyrosine Kinase Inhibitors for Human Epidermal Growth Factor Receptor 2 ⁺ Positive Metastatic Breast Cancer: Is Personalizing Therapy Within Reach?. <i>Journal of Clinical Oncology</i> , 2017, 35, 3089-3091.	0.8	14
1170	De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2) ⁺ Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor ⁺ Positive Phase II Randomized Trial ⁺ Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET. <i>Journal of Clinical Oncology</i> , 2017, 35, 3046-3054.	0.8	114
1171	Developmental therapeutics for inflammatory breast cancer: Biology and translational directions. <i>Oncotarget</i> , 2017, 8, 12417-12432.	0.8	24
1172	MARIANNE: Impact on Current Treatment of Human Epidermal Growth Factor Receptor 2 ⁺ Positive Metastatic Breast Cancer and Implications for the Future. <i>Journal of Clinical Oncology</i> , 2017, 35, 127-130.	0.8	4
1173	Skin Necrosis After Ado-Trastuzumab Emtansine Extravasation. <i>Journal of Oncology Practice</i> , 2017, 13, 555-556.	2.5	6

#	ARTICLE	IF	CITATIONS
1174	Therapeutic options for intrahepatic cholangiocarcinoma. <i>Hepatobiliary Surgery and Nutrition</i> , 2017, 6, 91-100.	0.7	13
1175	Cost-effectiveness of precision medicine in gastrointestinal stromal tumor and gastric adenocarcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 513-523.	0.6	12
1176	Molecular Testing in Breast Cancer. , 2017, , 257-269.		1
1177	Novel systemic therapy against malignant pleural mesothelioma. <i>Translational Lung Cancer Research</i> , 2017, 6, 295-314.	1.3	22
1178	Biliary cancer: intrahepatic cholangiocarcinoma vs. extrahepatic cholangiocarcinoma vs. gallbladder cancers: classification and therapeutic implications. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 293-301.	0.6	47
1179	Efficacy and safety of trastuzumab emtansine (T-DM1) in the treatment of HER2-positive metastatic breast cancer (MBC): a meta-analysis of randomized controlled trial. <i>Oncotarget</i> , 2017, 8, 102458-102467.	0.8	19
1180	Quest for Efficacious Next-Generation Taxoid Anticancer Agents and Their Tumor-Targeted Delivery. <i>Journal of Natural Products</i> , 2018, 81, 703-721.	1.5	40
1181	Fate of Antibody-Drug Conjugates in Cancer Cells. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 20.	3.5	125
1182	Association of anti-HER2 antibody with graphene oxide for curative treatment of osteosarcoma. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2018, 14, 581-593.	1.7	22
1183	Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 897-907.	1.9	77
1184	Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with trastuzumab. <i>Breast Cancer Research and Treatment</i> , 2018, 170, 169-177.	1.1	14
1185	Never too old to fight breast cancer. <i>Medicine (United States)</i> , 2018, 97, e9981.	0.4	3
1186	Molecular diagnosis in breast cancer. <i>Diagnostic Histopathology</i> , 2018, 24, 71-82.	0.2	4
1187	Metformin-induced caveolin-1 expression promotes T-DM1 drug efficacy in breast cancer cells. <i>Scientific Reports</i> , 2018, 8, 3930.	1.6	36
1188	Target Therapy for Esophageal Adenocarcinoma. <i>Methods in Molecular Biology</i> , 2018, 1756, 51-65.	0.4	2
1189	Use of the tumor-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to combination therapy with pertuzumab, trastuzumab, and docetaxel for advanced HER2-positive breast cancer. <i>Journal of Translational Medicine</i> , 2018, 16, 86.	1.8	33
1190	Inorganic kernel - Supported asymmetric hybrid vesicles for targeting delivery of STAT3-decoy oligonucleotides to overcome anti-HER2 therapeutic resistance of BT474R. <i>Journal of Controlled Release</i> , 2018, 279, 53-68.	4.8	18
1191	Next generation antibody drugs: pursuit of the 'high-hanging fruit'. <i>Nature Reviews Drug Discovery</i> , 2018, 17, 197-223.	21.5	595

#	ARTICLE	IF	CITATIONS
1192	Activity of Indatuximab Ravtansine against Triple-Negative Breast Cancer in Preclinical Tumor Models. <i>Pharmaceutical Research</i> , 2018, 35, 118.	1.7	19
1193	Cardioprotection in the Modern Era of Cancer Chemotherapy. <i>Cardiology in Review</i> , 2018, 26, 113-121.	0.6	9
1194	Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting. <i>Journal of Visualized Experiments</i> , 2018, , .	0.2	4
1195	Monoclonal antibody-based therapeutics, targeting the epidermal growth factor receptor family: from herceptin to Pan HER. <i>Journal of Pharmacy and Pharmacology</i> , 2018, 70, 841-854.	1.2	28
1196	Cardiotoxic effects of chemotherapy: A review of both cytotoxic and molecular targeted oncology therapies and their effect on the cardiovascular system. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 126, 186-200.	2.0	80
1197	MoFi: A Software Tool for Annotating Glycoprotein Mass Spectra by Integrating Hybrid Data from the Intact Protein and Glycopeptide Level. <i>Analytical Chemistry</i> , 2018, 90, 5728-5736.	3.2	21
1198	HER2-positive breast cancer: Current and new therapeutic strategies. <i>Breast</i> , 2018, 39, 80-88.	0.9	89
1199	Mechanisms of Action and Resistance of Trastuzumab in Breast Cancer. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2018, , 51-66.	0.1	0
1200	Systemic therapy for brain metastases. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2018, 149, 137-153.	1.0	23
1202	Pharmacotherapeutic Management of Breast Cancer in Elderly Patients: The Promise of Novel Agents. <i>Drugs and Aging</i> , 2018, 35, 93-115.	1.3	6
1203	Targeted cancer therapies. <i>Journal of the American Dental Association</i> , 2018, 149, 100-111.	0.7	12
1204	Magnetic iron oxide nanoparticles as drug carriers: clinical relevance. <i>Nanomedicine</i> , 2018, 13, 953-971.	1.7	151
1205	Cell membrane-coated nanocarriers: the emerging targeted delivery system for cancer theranostics. <i>Drug Discovery Today</i> , 2018, 23, 891-899.	3.2	112
1206	Ancillary Prognostic and Predictive Testing in Breast Cancer. <i>Surgical Pathology Clinics</i> , 2018, 11, 147-176.	0.7	6
1207	MI130004, a Novel Antibody-Drug Conjugate Combining Trastuzumab with a Molecule of Marine Origin, Shows Outstanding <i>In Vivo</i> Activity against HER2-Expressing Tumors. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 786-794.	1.9	17
1208	Highly homogeneous antibody modification through optimisation of the synthesis and conjugation of functionalised dibromopyridazinediones. <i>Organic and Biomolecular Chemistry</i> , 2018, 16, 1359-1366.	1.5	60
1209	Antibody-Drug Conjugates for Cancer Treatment. <i>Annual Review of Medicine</i> , 2018, 69, 191-207.	5.0	227
1210	Antibodies as Carrier Molecules: Encapsulating Anti-Inflammatory Drugs inside Herceptine. <i>Journal of Physical Chemistry B</i> , 2018, 122, 2064-2072.	1.2	8

#	ARTICLE	IF	CITATIONS
1211	Hepatotoxicity with antibody maytansinoid conjugates: A review of preclinical and clinical findings. <i>Journal of Applied Toxicology</i> , 2018, 38, 600-615.	1.4	19
1212	Targeting PLK1 overcomes T-DM1 resistance via CDK1-dependent phosphorylation and inactivation of Bcl-2/xL in HER2-positive breast cancer. <i>Oncogene</i> , 2018, 37, 2251-2269.	2.6	49
1213	Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in <i>ERBB2</i> and <i>ERBB3</i> . <i>Cancer</i> , 2018, 124, 1358-1373.	2.0	151
1214	An update on first line therapies for metastatic breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 243-252.	0.9	8
1215	Utilizing panels of patient derived xenografts to aid the development of antibody drug conjugates. <i>Molecular and Cellular Oncology</i> , 2018, 5, e1394422.	0.3	1
1216	Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group. <i>Lancet Oncology</i> , The, 2018, 19, 323-336.	5.1	94
1218	Synthesis and biological evaluation of anti-cancer agents that selectively inhibit Her2 over-expressed breast cancer cell growth via down-regulation of Her2 protein. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 727-731.	1.0	2
1219	Engineered cysteine antibodies: an improved antibody-drug conjugate platform with a novel mechanism of drug-linker stability. <i>Protein Engineering, Design and Selection</i> , 2018, 31, 47-54.	1.0	42
1220	Hyaluronic Acid-Shelled Disulfide-Cross-Linked Nanopolymersomes for Ultrahigh-Efficiency Reactive Encapsulation and CD44-Targeted Delivery of Mertansine Toxin. <i>ACS Applied Materials & Interfaces</i> , 2018, 10, 1597-1604.	4.0	45
1221	Progressively Enlarging Cerebellar Hematoma Concurrent with T-DM1 Treatment. <i>World Neurosurgery</i> , 2018, 111, 109-114.	0.7	7
1222	Network science in clinical trials: A patient-centered approach. <i>Seminars in Cancer Biology</i> , 2018, 52, 135-150.	4.3	9
1223	Molecular Oncology of Breast Cancer. , 2018, , 282-307.e5.		16
1224	Adjuvant and Neoadjuvant Systemic Therapies for Early-Stage Breast Cancer. , 2018, , 752-762.e4.		0
1225	HER2-Positive Breast Cancer. , 2018, , 763-768.e2.		2
1226	Chemotherapy and HER2-Directed Therapy for Metastatic Breast Cancer. , 2018, , 885-906.e8.		2
1227	Management of Central Nervous System Metastases in Breast Cancer. , 2018, , 942-960.e7.		0
1228	Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. <i>Lancet Oncology</i> , The, 2018, 19, e20-e32.	5.1	87
1229	Trastuzumab emtansine: determining its role in management of HER2+ breast cancer. <i>Future Oncology</i> , 2018, 14, 589-602.	1.1	12

#	ARTICLE	IF	CITATIONS
1230	Metastatic Breast Cancer: Prognosis, Diagnosis and Oncological Management. , 2018, , 579-594.		1
1231	A novel self-assembled pH-sensitive targeted nanoparticle platform based on antibody-4arm-polyethylene glycol-pterostilbene conjugates for co-delivery of anticancer drugs. Journal of Materials Chemistry B, 2018, 6, 656-665.	2.9	11
1232	Antibody-drug conjugates: Promising and efficient tools for targeted cancer therapy. Journal of Cellular Physiology, 2018, 233, 6441-6457.	2.0	67
1233	A Phase I/II study of the combination of lapatinib and oral vinorelbine in HER2-positive metastatic breast cancer. Japanese Journal of Clinical Oncology, 2018, 48, 242-247.	0.6	4
1234	A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 2018, 13, 273-279.	0.5	119
1235	Prostate cancer: updates on current strategies for screening, diagnosis and clinical implications of treatment modalities. Carcinogenesis, 2018, 39, 307-317.	1.3	32
1236	Novel biomarker-based model for the prediction of sorafenib response and overall survival in advanced hepatocellular carcinoma: a prospective cohort study. BMC Cancer, 2018, 18, 307.	1.1	18
1237	Study on the progression types of cancer in patients with breast cancer undergoing eribulin chemotherapy and tumor microenvironment. Journal of Translational Medicine, 2018, 16, 54.	1.8	12
1238	A Pharmacometric Analysis of Patient-Reported Outcomes in Breast Cancer Patients Through Item Response Theory. Pharmaceutical Research, 2018, 35, 122.	1.7	13
1239	Treatment of advanced HER2-positive breast cancer: 2018 and beyond. Cancer Treatment Reviews, 2018, 67, 10-20.	3.4	107
1240	The importance of greater speed in drug development for advanced malignancies. Cancer Medicine, 2018, 7, 1824-1836.	1.3	23
1241	HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer. Breast Cancer, 2018, 25, 605-613.	1.3	41
1242	Mechanisms of Acquired Resistance to Trastuzumab Emtansine in Breast Cancer Cells. Molecular Cancer Therapeutics, 2018, 17, 1441-1453.	1.9	120
1243	Differences in Breast Cancer Survival by Molecular Subtypes in the United States. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 619-626.	1.1	341
1244	p95HER2 Methionine 611 Carboxy-Terminal Fragment Is Predictive of Trastuzumab Adjuvant Treatment Benefit in the FinHer Trial. Clinical Cancer Research, 2018, 24, 3046-3052.	3.2	8
1245	Olaparib for the treatment of breast cancer. Expert Review of Anticancer Therapy, 2018, 18, 519-530.	1.1	37
1246	Near-infrared fluorescent sorbitol probe for tumor diagnosis in vivo. Journal of Industrial and Engineering Chemistry, 2018, 64, 80-84.	2.9	8
1247	Risk of Gastrointestinal Events During Lapatinib Therapy: A Meta-Analysis From 12,402 Patients With Cancer. American Journal of Therapeutics, 2018, 25, e412-e422.	0.5	0

#	ARTICLE	IF	CITATIONS
1248	Antibody-drug conjugates: recent advances in conjugation and linker chemistries. <i>Protein and Cell</i> , 2018, 9, 33-46.	4.8	494
1249	Antibody drug conjugates for treatment of breast cancer: Novel targets and diverse approaches in ADC design. , 2018, 181, 126-142.		97
1250	Comparison of HER2 testing among laboratories: Our experience with review cases retested at Moffitt Cancer Center in a two-year period. <i>Breast Journal</i> , 2018, 24, 139-147.	0.4	5
1251	Caveolae-Mediated Endocytosis as a Novel Mechanism of Resistance to Trastuzumab Emtansine (T-DM1). <i>Molecular Cancer Therapeutics</i> , 2018, 17, 243-253.	1.9	117
1252	Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs). <i>Oncolmmunology</i> , 2018, 7, e1395127.	2.1	117
1253	Progress in biopharmaceutical development. <i>Biotechnology and Applied Biochemistry</i> , 2018, 65, 306-322.	1.4	207
1254	Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads. <i>Investigational New Drugs</i> , 2018, 36, 121-135.	1.2	157
1255	Monosomy 17 in potentially curable HER2-amplified breast cancer: prognostic and predictive impact. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 547-554.	1.1	18
1256	Obesity and survival in the neoadjuvant breast cancer setting: role of tumor subtype in an ethnically diverse population. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 277-288.	1.1	35
1257	Development and responses of brain metastases during treatment with trastuzumab emtansine (T-DM1) for HER2 positive advanced breast cancer: A single institution experience. <i>Breast Journal</i> , 2018, 24, 253-259.	0.4	19
1258	Neurological Complications of Targeted Therapies. , 2018, , 311-333.		2
1259	Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 115-126.	5.1	333
1260	The target invites a foe: antibodyâ€“drug conjugates in gynecologic oncology. <i>Current Opinion in Obstetrics and Gynecology</i> , 2018, 30, 44-50.	0.9	15
1261	A review of the value of human epidermal growth factor receptor 2 (HER2)-targeted therapies in breast cancer. <i>European Journal of Cancer</i> , 2018, 89, 72-81.	1.3	25
1262	Stability assessment of antibody-drug conjugate Trastuzumab emtansine in comparison to parent monoclonal antibody using orthogonal testing protocol. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 150, 268-277.	1.4	31
1263	Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry. <i>Breast</i> , 2018, 37, 154-160.	0.9	56
1264	Designing a cancer therapeutic peptide by combining the mitochondrial targeting domain of Noxa and ErbB2â€“targeting moieties. <i>FEBS Letters</i> , 2018, 592, 103-111.	1.3	1
1265	Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+Â“locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 357-364.	1.1	46

#	ARTICLE	IF	CITATIONS
1266	Enhancing tumor response to targeted chemotherapy through up-regulation of folate receptor $\hat{\pm}$ expression induced by dexamethasone and valproic acid. <i>Journal of Controlled Release</i> , 2018, 269, 36-44.	4.8	15
1267	Targeting FGFR pathway in breast cancer. <i>Breast</i> , 2018, 37, 126-133.	0.9	89
1268	Survival outcomes for Australian women receiving trastuzumab for HER2-positive metastatic breast cancer following (neo)adjuvant trastuzumab: a national population-based observational study (2006â€“2014). <i>British Journal of Cancer</i> , 2018, 118, 441-447.	2.9	13
1269	Does Methodological Guidance Produce Consistency? A Review of Methodological Consistency in Breast Cancer Utility Value Measurement in NICE Single Technology Appraisals. <i>PharmacoEconomics - Open</i> , 2018, 2, 97-107.	0.9	5
1270	Breast Cancer Immunotherapy: Facts and Hopes. <i>Clinical Cancer Research</i> , 2018, 24, 511-520.	3.2	567
1271	National Cancer Institute Breast Cancer Steering Committee Working Group Report on Meaningful and Appropriate End Points for Clinical Trials in Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 3259-3268.	0.8	19
1272	Ado-Trastuzumab Emtansine for Patients With <i><i>HER2</i></i> -Mutant Lung Cancers: Results From a Phase II Basket Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 2532-2537.	0.8	381
1273	Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptorâ€“Positive Metastatic Breast Cancer: ALTERNATIVE. <i>Journal of Clinical Oncology</i> , 2018, 36, 741-748.	0.8	110
1274	Innovative Strategies: Targeting Subtypes in Metastatic Breast Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 65-77.	1.8	11
1275	Using a Neoadjuvant Approach for Evaluating Novel Therapies for Patients With Breast Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 47-55.	1.8	5
1277	Evolution of Targeted Therapy in Breast Cancer: Where Precision Medicine Began. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 78-86.	1.8	36
1278	Preclinical evaluation of a GFRA1 targeted antibody-drug conjugate in breast cancer. <i>Oncotarget</i> , 2018, 9, 22960-22975.	0.8	13
1279	Molecular mechanisms underlying cardiotoxicity of novel cancer therapeutics. <i>Journal of Thoracic Disease</i> , 2018, 10, S4335-S4343.	0.6	5
1280	A novel detection methodology for HER2 protein quantitation in formalin-fixed, paraffin embedded clinical samples using fluorescent nanoparticles: an analytical and clinical validation study. <i>BMC Cancer</i> , 2018, 18, 1266.	1.1	17
1282	Case of Metastatic Extramammary Paget Disease of the Vulva Treated Successfully With Trastuzumab Emtansine. <i>JCO Precision Oncology</i> , 2018, 2, 1-8.	1.5	4
1283	Prognostic Biomarkers for Breast Cancer Metastasis. , 0, , .		1
1284	Receptor Tyrosine Kinase-Targeted Cancer Therapy. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3491.	1.8	187
1285	Theranostic pretargeted radioimmunotherapy of internalizing solid tumor antigens in human tumor xenografts in mice: Curative treatment of HER2-positive breast carcinoma. <i>Theranostics</i> , 2018, 8, 5106-5125.	4.6	32

#	ARTICLE	IF	CITATIONS
1286	Monoclonal antibodies for the treatment of non-hematological tumors: a safety review. Expert Opinion on Drug Safety, 2018, 17, 1197-1209.	1.0	11
1287	How to design preclinical studies in nanomedicine and cell therapy to maximize the prospects of clinical translation. Nature Biomedical Engineering, 2018, 2, 797-809.	11.6	99
1288	Human epidermal growth factor receptor targeted inhibitors for the treatment of ovarian cancer. Cancer Biology and Medicine, 2018, 15, 375.	1.4	22
1289	HER2 inhibition in gastro-oesophageal cancer: A review drawing on lessons learned from breast cancer. World Journal of Gastrointestinal Oncology, 2018, 10, 159-171.	0.8	10
1290	Exceptional and Durable Responses to TDM-1 After Trastuzumab Failure for Breast Cancer Skin Metastases: Potential Implications of an Immunological Sanctuary. Frontiers in Oncology, 2018, 8, 581.	1.3	7
1291	Targeting Cancer Stem Cells to Overcome Chemoresistance. International Journal of Molecular Sciences, 2018, 19, 4036.	1.8	106
1292	CDK4/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative disease. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591881834.	1.4	33
1293	Safety Results and Analysis of Eribulin Efficacy according to Previous Microtubules-Inhibitors Sensitivity in the French Prospective Expanded Access Program for Heavily Pre-treated Metastatic Breast Cancer. Cancer Research and Treatment, 2018, 50, 1226-1237.	1.3	10
1294	Update Breast Cancer 2018 (Part 4) " Genomics, Individualized Medicine and Immune Therapies " in the Middle of a New Era: Treatment Strategies for Advanced Breast Cancer. Geburtshilfe Und Frauenheilkunde, 2018, 78, 1119-1128.	0.8	3
1295	CLT030, a leukemic stem cell"targeting CLL1 antibody-drug conjugate for treatment of acute myeloid leukemia. Blood Advances, 2018, 2, 1738-1749.	2.5	56
1296	ASCO 2018: highlights in HER2-positive metastatic breast cancer. Memo - Magazine of European Medical Oncology, 2018, 11, 280-283.	0.3	18
1297	Evaluation of TAK-264, an Antibody-Drug Conjugate in Pancreatic Cancer Cell Lines and Patient-Derived Xenograft Models. Clinical Cancer Drugs, 2018, 5, 42-49.	0.3	4
1298	Optimal treatment of early stage HER2"positive breast cancer. Cancer, 2018, 124, 4455-4466.	2.0	52
1299	Ado-Trastuzumab Emtansine-Induced Pulmonary Toxicity: A Single-Institution Retrospective Review. Case Reports in Oncology, 2018, 11, 527-533.	0.3	14
1300	Biomarkers in Breast Cancer. , 0, , .		2
1301	Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer. Cancers, 2018, 10, 342.	1.7	109
1302	MORAb-202, an Antibody"Drug Conjugate Utilizing Humanized Anti-human FR1± Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity. Molecular Cancer Therapeutics, 2018, 17, 2665-2675.	1.9	54
1303	Value Assessment in Oncology Drugs: Funding of Drugs for Metastatic Breast Cancer in Canada. Current Oncology, 2018, 25, 161-170.	0.9	9

#	ARTICLE	IF	CITATIONS
1304	Droplet digital PCR using HER2/EIF2C1 ratio for detection of HER2 amplification in breast cancer tissues. <i>Medical Oncology</i> , 2018, 35, 149.	1.2	12
1305	Systematic bias between blinded independent central review and local assessment: literature review and analyses of 76 phase III randomised controlled trials in 45 688 patients with advanced solid tumour. <i>BMJ Open</i> , 2018, 8, e017240.	0.8	20
1306	Multifunctional Cargo-Free Nanomedicine for Cancer Therapy. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2963.	1.8	21
1307	Antibody drug conjugates under investigation in phase I and phase II clinical trials for gastrointestinal cancer. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 901-916.	1.9	7
1308	Safety and pharmacokinetics of MM-302, a HER2-targeted antibody-liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study. <i>British Journal of Cancer</i> , 2018, 119, 1086-1093.	2.9	75
1309	Bioprocess development of antibody-drug conjugate production for cancer treatment. <i>PLoS ONE</i> , 2018, 13, e0206246.	1.1	23
1310	Changes in HER2 Expression and Amplification Status Following Preoperative Chemotherapy for Gastric Cancer. <i>In Vivo</i> , 2018, 32, 1491-1498.	0.6	8
1311	Phase I trial of afatinib and 3-weekly trastuzumab with optimal anti-diarrheal management in patients with HER2-positive metastatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 979-986.	1.1	10
1312	Patients who achieved long-term clinical complete response and subsequently terminated multidisciplinary and anti-HER2 therapy for metastatic breast cancer: A case series. <i>International Journal of Surgery Case Reports</i> , 2018, 52, 125-131.	0.2	3
1313	Application of omic technologies in cancer research. <i>Translational Medicine Reports</i> , 2018, 2, .	0.8	0
1314	Concordance with NCCN treatment guidelines: Relations with health care utilization, cost, and mortality in breast cancer patients with secondary metastasis. <i>Cancer</i> , 2018, 124, 4231-4240.	2.0	24
1315	Late Administration of Trastuzumab Emtansine Might Lead to Loss of Chance for Better Outcome in Patients with HER2-Positive Metastatic Breast Cancer. <i>Breast Care</i> , 2018, 13, 277-283.	0.8	4
1316	Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers. <i>Nature Communications</i> , 2018, 9, 4274.	5.8	25
1317	Neoadjuvant Model as a Platform for Research in Breast Cancer and Novel Targets under Development in this Field. <i>Breast Care</i> , 2018, 13, 251-262.	0.8	4
1318	Trastuzumab, not lapatinib, has therapeutic effects on Chinese patients with HER2-positive cholangiocarcinoma. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2018, 17, 477-479.	0.6	5
1320	Tumor uptake and tumor/blood ratios for [89Zr]Zr-DFO-trastuzumab-DM1 on microPET/CT images in NOD/SCID mice with human breast cancer xenografts are directly correlated with HER2 expression and response to trastuzumab-DM1. <i>Nuclear Medicine and Biology</i> , 2018, 67, 43-51.	0.3	10
1321	Noninvasive assessment of characteristics of novel anti-HER2 antibodies by molecular imaging in a human gastric cancer xenograft-bearing mouse model. <i>Scientific Reports</i> , 2018, 8, 13735.	1.6	15
1322	Antikörper-Wirkstoff-Konjugate mit Pyrrol-basierten KSP-Inhibitoren als Payload-Klasse. <i>Angewandte Chemie</i> , 2018, 130, 15463-15467.	1.6	2

#	ARTICLE	IF	CITATIONS
1323	Erlotinib for Progressive Brain and Leptomeningeal Metastases From HER2-positive Breast Cancer After Treatment Failure With Trastuzumab and Lapatinib: Experience and Review of Literature. <i>Clinical Breast Cancer</i> , 2018, 18, e759-e765.	1.1	4
1324	Trends in breast cancer mortality by stage at diagnosis among young women in the United States. <i>Cancer</i> , 2018, 124, 3500-3509.	2.0	106
1325	Dual targeting of HER2-positive breast cancer with trastuzumab emtansine and pertuzumab: understanding clinical trial results. <i>Oncotarget</i> , 2018, 9, 31915-31919.	0.8	14
1326	Androgen receptor expression inversely correlates with immune cell infiltration in human epidermal growth factor receptor 2-positive breast cancer. <i>European Journal of Cancer</i> , 2018, 103, 52-60.	1.3	16
1327	Antibody-drug conjugates in triple negative breast cancer. <i>Future Oncology</i> , 2018, 14, 2651-2661.	1.1	23
1328	Targeted agents for HER2-positive breast cancer in older adults: current and future perspectives. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 787-801.	1.9	15
1329	Antibody-Drug Conjugates with Pyrrole-Based KSP Inhibitors as the Payload Class. <i>Angewandte Chemie - International Edition</i> , 2018, 57, 15243-15247.	7.2	28
1331	Low neutrophil-lymphocyte ratio correlates with extended survival in patients with metastatic breast cancer who achieved clinically complete response following multidisciplinary therapy: A retrospective study. <i>Oncology Letters</i> , 2018, 15, 6681-6687.	0.8	12
1332	Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study. <i>Lancet Oncology</i> , The, 2018, 19, 880-888.	5.1	144
1333	<i>Molecular Biology of Breast Cancer</i> . , 2018, , 569-588.		6
1335	Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 371-381.	1.1	100
1336	Innovations for Next-Generation Antibody-Drug Conjugates. <i>Cancer Drug Discovery and Development</i> , 2018, , .	0.2	8
1337	Improving the Safety Profile of ADCs. <i>Cancer Drug Discovery and Development</i> , 2018, , 45-71.	0.2	1
1338	HER2-Targeted ADCs: At the Forefront of ADC Technology Development. <i>Cancer Drug Discovery and Development</i> , 2018, , 163-185.	0.2	2
1339	Updates in the Evaluation and Management of Breast Cancer. <i>Mayo Clinic Proceedings</i> , 2018, 93, 794-807.	1.4	39
1340	Chimeric Small Antibody Fragments as Strategy to Deliver Therapeutic Payloads. <i>Advances in Protein Chemistry and Structural Biology</i> , 2018, 112, 143-182.	1.0	11
1341	Emerging functional markers for cancer stem cell-based therapies: Understanding signaling networks for targeting metastasis. <i>Seminars in Cancer Biology</i> , 2018, 53, 90-109.	4.3	62
1342	Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2-Positive Metastatic Breast Cancer. <i>JAMA Oncology</i> , 2018, 4, 1214.	3.4	108

#	ARTICLE	IF	CITATIONS
1343	Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with ⁸⁹ Zr-Labeled Trastuzumab-DM1: A Comparison with ⁸⁹ Zr-Labeled Trastuzumab. Molecular Pharmaceutics, 2018, 15, 3383-3393.	2.3	16
1344	Development of an optimal imaging strategy for selection of patients for affibody-based PNA-mediated radionuclide therapy. Scientific Reports, 2018, 8, 9643.	1.6	11
1345	Glutamic acid- <i>valine</i> - <i>citrulline</i> linkers ensure stability and efficacy of antibody- <i>drug</i> conjugates in mice. Nature Communications, 2018, 9, 2512.	5.8	119
1346	Inhibitor-induced HER2-HER3 heterodimerisation promotes proliferation through a novel dimer interface. ELife, 2018, 7, .	2.8	55
1347	Clinical and molecular aspects of breast cancer: Targets and therapies. Biomedicine and Pharmacotherapy, 2018, 106, 14-34.	2.5	49
1348	Adnectin- <i>drug</i> conjugates for Glypican-3-specific delivery of a cytotoxic payload to tumors. Protein Engineering, Design and Selection, 2018, 31, 159-171.	1.0	19
1349	Small Molecules in Oncology. Recent Results in Cancer Research, 2018, , .	1.8	5
1350	Lapatinib. Recent Results in Cancer Research, 2018, 211, 19-44.	1.8	75
1351	Mechanisms of immune evasion in breast cancer. BMC Cancer, 2018, 18, 556.	1.1	180
1352	Minireview: Addressing the retro-Michael instability of maleimide bioconjugates. Drug Discovery Today: Technologies, 2018, 30, 27-34.	4.0	65
1353	Nanostructured lipid carriers co-delivering lapachone and doxorubicin for overcoming multidrug resistance in breast cancer therapy. International Journal of Nanomedicine, 2018, Volume 13, 4107-4119.	3.3	57
1354	Novel treatment strategies for patients with HER2- <i>positive</i> breast cancer who do not benefit from current targeted therapy drugs (Review). Experimental and Therapeutic Medicine, 2018, 16, 2183-2192.	0.8	14
1355	Everolimus. Recent Results in Cancer Research, 2018, 211, 101-123.	1.8	68
1356	Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients. Frontiers in Oncology, 2018, 8, 89.	1.3	64
1357	Precision Medicine in Hormone Receptor-Positive Breast Cancer. Frontiers in Oncology, 2018, 8, 144.	1.3	32
1358	Challenges in Optimising the Successful Construction of Antibody Drug Conjugates in Cancer Therapy. Antibodies, 2018, 7, 11.	1.2	10
1359	Cardiotoxicity. , 2018, , 367-406.		4
1360	Progress in targeted therapy for breast cancer. Chronic Diseases and Translational Medicine, 2018, 4, 164-175.	0.9	31

#	ARTICLE	IF	CITATIONS
1361	Survival Outcomes of Retreatment with Trastuzumab and Cytotoxic Chemotherapy for HER2-Positive Recurrent Patients With Breast Cancer Who Had Been Treated with Neo/adjuvant Trastuzumab Plus Multidrug Chemotherapy: A Japanese Multicenter Observational Study. <i>Breast Cancer: Basic and Clinical Research</i> , 2018, 12, 117822341878624.	0.6	2
1362	Overcoming Therapeutic Resistance of Triple Positive Breast Cancer with CDK4/6 Inhibition. <i>International Journal of Breast Cancer</i> , 2018, 2018, 1-11.	0.6	19
1363	Drug conjugates as an emerging approach to treat breast cancer. <i>Pharmacology Research and Perspectives</i> , 2018, 6, e00417.	1.1	31
1364	New Immunotherapies in Oncology Treatment and Their Side Effect Profiles. <i>Journal of the American Board of Family Medicine</i> , 2018, 31, 620-627.	0.8	7
1365	Cardiovascular sequelae of breast cancer treatments: A review. <i>Current Problems in Cancer</i> , 2018, 42, 409-421.	1.0	4
1366	Novel Systemic Therapies for Advanced Gastric Cancer. <i>Journal of Gastric Cancer</i> , 2018, 18, 1.	0.9	33
1367	Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges. <i>Molecular Cancer</i> , 2018, 17, 34.	7.9	221
1368	Cancer-derived exosomes from HER2-positive cancer cells carry trastuzumab-emtansine into cancer cells leading to growth inhibition and caspase activation. <i>BMC Cancer</i> , 2018, 18, 504.	1.1	56
1369	A randomized phase II trial of trastuzumab plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110B/ELTOP. <i>Breast</i> , 2018, 40, 67-75.	0.9	34
1370	Cancer stem cells: Regulation programs, immunological properties and immunotherapy. <i>Seminars in Cancer Biology</i> , 2018, 52, 94-106.	4.3	100
1372	The Real Impact of Target Therapy in Breast Cancer Patients: Between Hope and Reality. <i>Current Cancer Drug Targets</i> , 2018, 18, 480-498.	0.8	5
1373	Antibody-Drug Conjugates in Bladder Cancer. <i>Bladder Cancer</i> , 2018, 4, 247-259.	0.2	29
1374	Immunotherapy in Prostate Cancer: Teaching an Old Dog New Tricks. <i>Current Oncology Reports</i> , 2018, 20, 75.	1.8	55
1375	Adherence to prescribing restrictions for HER2-positive metastatic breast cancer in Australia: A national population-based observational study (2001-2016). <i>PLoS ONE</i> , 2018, 13, e0198152.	1.1	4
1376	Recent Updates on the Therapeutic Potential of HER2 Tyrosine Kinase Inhibitors for the Treatment of Breast Cancer. <i>Current Cancer Drug Targets</i> , 2018, 18, 306-327.	0.8	15
1377	Rates of ERBB2 Alterations across Melanoma Subtypes and a Complete Response to Trastuzumab Emtansine in an ERBB2-Amplified Acral Melanoma. <i>Clinical Cancer Research</i> , 2018, 24, 5815-5819.	3.2	25
1378	Current and future therapies for targeting HER2 mutations in gastrointestinal cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 1085-1092.	1.1	8
1379	Mechanisms of enhanced drug delivery in brain metastases with focused ultrasound-induced blood-tumor barrier disruption. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E8717-E8726.	3.3	159

#	ARTICLE	IF	CITATIONS
1380	Antibody-drug conjugates (ADCs): Potent biopharmaceuticals to target solid and hematological cancers- an overview. <i>Journal of Drug Delivery Science and Technology</i> , 2018, 48, 106-117.	1.4	16
1381	tRNA-Derived Fragments as Novel Predictive Biomarkers for Trastuzumab-Resistant Breast Cancer. <i>Cellular Physiology and Biochemistry</i> , 2018, 49, 419-431.	1.1	65
1382	Antibody drug conjugates in thoracic malignancies. <i>Lung Cancer</i> , 2018, 124, 260-269.	0.9	10
1383	Fn3 proteins engineered to recognize tumor biomarker mesothelin internalize upon binding. <i>PLoS ONE</i> , 2018, 13, e0197029.	1.1	7
1384	SLC46A3 as a Potential Predictive Biomarker for Antibody-Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine Warheads. <i>Clinical Cancer Research</i> , 2018, 24, 6570-6582.	3.2	56
1385	HER1-based vaccine: Simultaneous activation of humoral and cellular immune response. <i>Seminars in Oncology</i> , 2018, 45, 75-83.	0.8	6
1386	Emerging Trends in Clinical Research With Implications for Population Health and Health Policy. <i>Milbank Quarterly</i> , 2018, 96, 369-401.	2.1	5
1387	Trastuzumab-induced cardiotoxicity and its risk factors in real-world setting of breast cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1613-1621.	1.2	18
1388	HER2-targeted gold nanoparticles potentially overcome resistance to trastuzumab in gastric cancer. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2018, 14, 1919-1929.	1.7	52
1389	Single-site labeling of lysine in proteins through a metal-free multicomponent approach. <i>Chemical Communications</i> , 2018, 54, 7302-7305.	2.2	42
1390	Precision Medicine in Head and Neck Cancer: Myth or Reality?. <i>Clinical Medicine Insights: Oncology</i> , 2018, 12, 117955491877958.	0.6	18
1391	Could Women with Biopsy Proven Lymph Node Positive Breast Cancer and Response to Primary Chemotherapy Avoid Axillary Lymph Node Clearance?. <i>Clinical Oncology</i> , 2018, 30, e43-e44.	0.6	0
1392	Cancer symptom response as an oncology clinical trial end point. <i>Expert Review of Quality of Life in Cancer Care</i> , 2018, 3, 35-46.	0.6	10
1393	Second-Line Treatment of HER2-Positive Salivary Gland Tumor: Ado-Trastuzumab Emtansine (T-DM1) after Progression on Trastuzumab. <i>Case Reports in Oncology</i> , 2018, 11, 252-257.	0.3	25
1394	Targeting Members of the Epidermal Growth Factor Receptor Family to Improve Response to Chemotherapy. , 2019, , 1-23.		0
1395	Trastuzumab emtansine plus pertuzumab in Japanese patients with HER2-positive metastatic breast cancer: a phase Ib study. <i>Breast Cancer</i> , 2019, 26, 39-46.	1.3	1
1396	Oral Mucosal Injury Caused by Targeted Cancer Therapies. <i>Journal of the National Cancer Institute Monographs</i> , 2019, 2019, .	0.9	14
1397	Pyrotinib or Lapatinib Combined With Capecitabine in HER2-Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 2610-2619.	0.8	226

#	ARTICLE	IF	CITATIONS
1398	Lacrimal drainage system stenosis associated with Trastuzumab emtansine (Kadcyla® [®] , T-DM1) administration: a case report. <i>BMC Cancer</i> , 2019, 19, 774.	1.1	6
1399	Effect of early adverse events resulting in ado-trastuzumab emtansine dose adjustments on survival outcomes of HER2+ advanced breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2019, 178, 473-477.	1.1	4
1400	<p>Relative value assessment: characterizing the benefit of oncology therapies through diverse survival metrics from a US perspective</p>. <i>ClinicoEconomics and Outcomes Research</i> , 2019, Volume 11, 199-219.	0.7	1
1401	Biological Random Walks: Integrating heterogeneous data in disease gene prioritization. , 2019, , .		6
1402	U3-1402, a Novel HER3-Targeting Antibody-Drug Conjugate, for the Treatment of Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 2043-2050.	1.9	51
1403	The evolving role of trastuzumab emtansine (T-DM1) in HER2-positive breast cancer with brain metastases. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 143, 20-26.	2.0	10
1404	Incorporation of a Hydrophilic Spacer Reduces Hepatic Uptake of HER2-Targeting Affibody-DM1 Drug Conjugates. <i>Cancers</i> , 2019, 11, 1168.	1.7	12
1405	Excellent Response to Oral Etoposide in HER2-Positive Metastatic Breast Cancer (MBC). <i>Indian Journal of Gynecologic Oncology</i> , 2019, 17, 1.	0.1	2
1407	New advance in breast cancer pathology and imaging. <i>Future Oncology</i> , 2019, 15, 2707-2722.	1.1	3
1408	Brief update on endocytosis of nanomedicines. <i>Advanced Drug Delivery Reviews</i> , 2019, 144, 90-111.	6.6	251
1409	Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNE. <i>Cancer</i> , 2019, 125, 3974-3984.	2.0	67
1410	A Review of Local and Systemic Therapy in Breast Cancer. , 2019, , 637-690.		0
1411	A Novel Anti-HER2 Antibody-Drug Conjugate XMT-1522 for HER2-Positive Breast and Gastric Cancers Resistant to Trastuzumab Emtansine. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1721-1730.	1.9	47
1413	Precision pharmacology: Mass spectrometry imaging and pharmacokinetic drug resistance. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 141, 153-162.	2.0	21
1414	PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences Are Emerging. A Literature Review. <i>Cancers</i> , 2019, 11, 1033.	1.7	160
1415	Magnetic nanocarriers for the specific delivery of siRNA: Contribution of breast cancer cells active targeting for down-regulation efficiency. <i>International Journal of Pharmaceutics</i> , 2019, 569, 118572.	2.6	21
1416	Novel insights into breast cancer progression and metastasis: A multidisciplinary opportunity to transition from biology to clinical oncology. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2019, 1872, 138-148.	3.3	31
1417	Development of a human immuno-oncology therapeutic agent targeting HER2: targeted delivery of granzyme B. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 332.	3.5	12

#	ARTICLE	IF	CITATIONS
1418	Identification of New Mono/Dihydroxynaphthoquinone as Lead Agents That Inhibit the Growth of Refractive and Triple-Negative Breast Cancer Cell Lines. <i>ACS Omega</i> , 2019, 4, 10610-10619.	1.6	1
1419	Chemotherapy for Lung Cancer in the Era of Personalized Medicine. <i>Tuberculosis and Respiratory Diseases</i> , 2019, 82, 179.	0.7	48
1420	Active targeting carrier for breast cancer treatment: Monoclonal antibody conjugated epirubicin loaded nanoparticle. <i>Journal of Drug Delivery Science and Technology</i> , 2019, 53, 101136.	1.4	32
1421	An examination of the coverage of the SNOMED CT coded nursing problem list subset. <i>JAMIA Open</i> , 2019, 2, 386-391.	1.0	2
1422	Potent and specific fusion toxins consisting of a HER2-binding, ABD-derived affinity protein, fused to truncated versions of <i>Pseudomonas</i> exotoxin γ /A. <i>International Journal of Oncology</i> , 2019, 55, 309-319.	1.4	10
1423	Antibody drug conjugates against the receptor for advanced glycation end products (RAGE), a novel therapeutic target in endometrial cancer. , 2019, 7, 280.		17
1424	Smart cancer nanomedicine. <i>Nature Nanotechnology</i> , 2019, 14, 1007-1017.	15.6	776
1426	Misc. medical devices and technologies. <i>Side Effects of Drugs Annual</i> , 2019, , 573-615.	0.6	0
1427	Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2+ metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16). <i>British Journal of Cancer</i> , 2019, 121, 985-990.	2.9	9
1428	CAR-T –the living drugs–; immune checkpoint inhibitors, and precision medicine: a new era of cancer therapy. <i>Journal of Hematology and Oncology</i> , 2019, 12, 113.	6.9	69
1429	Targeting ERBB2 (HER2) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional Indications. <i>JCO Precision Oncology</i> , 2019, 3, 1-12.	1.5	20
1430	Patented therapeutic approaches targeting LRP/LR for cancer treatment. <i>Expert Opinion on Therapeutic Patents</i> , 2019, 29, 987-1009.	2.4	15
1431	Phase I Study of DSTP3086S, an Antibody-Drug Conjugate Targeting Six-Transmembrane Epithelial Antigen of Prostate 1, in Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 3518-3527.	0.8	47
1432	ASCO 2019: highlights in HER2-positive metastatic breast cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2019, 12, 308-311.	0.3	1
1433	Update Breast Cancer 2019 Part 4 –“ Diagnostic and Therapeutic Challenges of New, Personalised Therapies for Patients with Early Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2019, 79, 1079-1089.	0.8	18
1434	Targeted and novel therapy in advanced gastric cancer. <i>Experimental Hematology and Oncology</i> , 2019, 8, 25.	2.0	53
1435	Pertuzumab and Trastuzumab Emtansine for Human Epidermal Growth Factor Receptor-2+ Positive Metastatic Breast Cancer: Contemporary Population-Based Outcomes. <i>Breast Cancer: Basic and Clinical Research</i> , 2019, 13, 117822341987942.	0.6	7
1436	Reinforcement Learning-Enabled Intelligent Energy Management for Hybrid Electric Vehicles. <i>Synthesis Lectures on Advances in Automotive Technology</i> , 2019, 3, 1-99.	0.2	1

#	ARTICLE	IF	CITATIONS
1437	Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1926-1936.	1.9	37
1438	What therapies are on the horizon for HER2 positive breast cancer?. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 811-822.	1.1	3
1439	Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10. <i>Journal of Clinical Oncology</i> , 2019, 37, 2601-2609.	0.8	50
1441	A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL) Tj ETQq1 1 0.784314 rg8T /Over	1.1	6
1442	Long-term survival in HER2-positive metastatic breast cancer treated with first-line trastuzumab: results from the french real-life curie database. <i>Breast Cancer Research and Treatment</i> , 2019, 178, 505-512.	1.1	6
1443	Real-world data on T-DM1 efficacy “ results of a single-center retrospective study of HER2-positive breast cancer patients. <i>Scientific Reports</i> , 2019, 9, 12760.	1.6	17
1444	Combined targeting of HER-2 and HER-3 represents a promising therapeutic strategy in colorectal cancer. <i>BMC Cancer</i> , 2019, 19, 880.	1.1	13
1445	Radiological complete remission in HER2-positive metastatic breast cancer patients: what to do with trastuzumab?. <i>Breast Cancer Research and Treatment</i> , 2019, 178, 597-605.	1.1	15
1446	Antibody“drug conjugates for cancer. <i>Lancet, The</i> , 2019, 394, 793-804.	6.3	425
1447	Tumor-Targeted Drug Conjugates as an Emerging Novel Therapeutic Approach in Small Cell Lung Cancer (SCLC). <i>Cancers</i> , 2019, 11, 1297.	1.7	21
1448	Elimination of Osteosarcoma by Necroptosis with Graphene Oxide-Associated Anti-HER2 Antibodies. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4360.	1.8	26
1449	Principles of Cancer Treatment and Anticancer Drug Development. , 2019, , .		10
1450	Herceptin: A First Assault on Oncogenes that Launched a Revolution. <i>Cell</i> , 2019, 179, 8-12.	13.5	37
1451	First-in-Human Phase I Study of Aprutumab Ixadotin, a Fibroblast Growth Factor Receptor 2 Antibody“Drug Conjugate (BAY 1187982) in Patients with Advanced Cancer. <i>Targeted Oncology</i> , 2019, 14, 591-601.	1.7	43
1452	Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q. <i>Annals of Oncology</i> , 2019, 30, 1821-1830.	0.6	99
1453	Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data. <i>BMC Cancer</i> , 2019, 19, 902.	1.1	6
1454	Glycoscience: Basic Science to Applications. , 2019, , .		3
1455	Wood Transcriptome Profiling Identifies Critical Pathway Genes of Secondary Wall Biosynthesis and Novel Regulators for Vascular Cambium Development in Populus. <i>Genes</i> , 2019, 10, 690.	1.0	22

#	ARTICLE	IF	CITATIONS
1456	Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985). <i>European Journal of Medicinal Chemistry</i> , 2019, 183, 111682.	2.6	102
1458	GEF-H1 Signaling upon Microtubule Destabilization Is Required for Dendritic Cell Activation and Specific Anti-tumor Responses. <i>Cell Reports</i> , 2019, 28, 3367-3380.e8.	2.9	37
1459	Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Pozotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity. <i>Cancer Cell</i> , 2019, 36, 444-457.e7.	7.7	145
1460	The Use of Immunotherapy to Treat Metastatic Breast Cancer. <i>Current Medicinal Chemistry</i> , 2019, 26, 941-962.	1.2	14
1461	Breast Cancer Treatment. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 288.	3.8	2,785
1462	CDK4/6 inhibitor palbociclib enhances the effect of pyrotinib in HER2-positive breast cancer. <i>Cancer Letters</i> , 2019, 447, 130-140.	3.2	32
1463	A brief report of toxicity end points of HER2 vaccines for the treatment of patients with HER2⁺ breast cancer. <i>Drug Design, Development and Therapy</i> , 2019, Volume 13, 309-316.	2.0	15
1464	The FDA-Approved Breast Cancer HER2 Evaluation Kit (HercepTest; Dako) May Miss Some HER2-Positive Breast Cancers. <i>American Journal of Clinical Pathology</i> , 2019, 151, 504-510.	0.4	5
1465	A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer. , 2019, 7, 16.		68
1466	Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric/gastroesophageal junction cancer. <i>Gastric Cancer</i> , 2019, 22, 803-816.	2.7	36
1467	Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer: Primary results from the KAMILLA study cohort 1. <i>European Journal of Cancer</i> , 2019, 109, 92-102.	1.3	73
1468	Preclinical Evaluation of ¹¹¹ In-Labeled PEGylated Maytansine Nimotuzumab Drug Conjugates in EGFR-Positive Cancer Models. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1103-1110.	2.8	22
1469	A single dose of antibody-drug conjugate cures a stage 1 model of African trypanosomiasis. <i>PLoS Neglected Tropical Diseases</i> , 2019, 13, e0007373.	1.3	11
1470	Breast Cancer Pathology. , 2019, , 87-127.		1
1471	Update on Precision Medicine in Breast Cancer. <i>Cancer Treatment and Research</i> , 2019, 178, 45-80.	0.2	27
1472	Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan. <i>MAbs</i> , 2019, 11, 987-995.	2.6	74
1473	Immunogenicity of antibody-drug conjugates: observations across 8 molecules in 11 clinical trials. <i>Bioanalysis</i> , 2019, 11, 1555-1568.	0.6	25
1474	Treatment in real-life patients with HER2-positive metastatic breast cancer: What we learn from the KAMILLA trial?. <i>European Journal of Cancer</i> , 2019, 117, 1-4.	1.3	2

#	ARTICLE	IF	CITATIONS
1475	Investigational drugs in early stage clinical trials for the treatment of HER2+ breast cancer. Expert Opinion on Investigational Drugs, 2019, 28, 617-627.	1.9	6
1476	Challenges on Multiple Endpoints in Clinical Trials: An Industry Survey in Japan. Therapeutic Innovation and Regulatory Science, 2019, , 216847901985599.	0.8	0
1477	DNA Repair Deficiency in Breast Cancer: Opportunities for Immunotherapy. Journal of Oncology, 2019, 2019, 1-14.	0.6	18
1478	Ribociclib Plus Trastuzumab in Advanced HER2-Positive Breast Cancer: Results of a Phase 1b/2 Trial. Clinical Breast Cancer, 2019, 19, 399-404.	1.1	27
1479	HER2-targeted treatment for older patients with breast cancer: An expert position paper from the International Society of Geriatric Oncology. Journal of Geriatric Oncology, 2019, 10, 1003-1013.	0.5	40
1480	Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. Lancet Oncology, The, 2019, 20, 1124-1135.	5.1	339
1481	A new agent in the family of antibody-drug conjugates. Lancet Oncology, The, 2019, 20, 1043-1044.	5.1	0
1482	Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial. Clinical Cancer Research, 2019, 25, 5212-5220.	3.2	60
1483	Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer. BMC Cancer, 2019, 19, 517.	1.1	42
1484	Pharmacokinetics and Biodistribution of a [⁸⁹ Zr]-DFO-MSTP2109A Anti-STEAP1 Antibody in Metastatic Castration-Resistant Prostate Cancer Patients. Molecular Pharmaceutics, 2019, 16, 3083-3090.	2.3	26
1485	Therapeutic innovations in breast cancer. Presse Medicale, 2019, 48, 1131-1137.	0.8	5
1486	HER2+ breast cancer treatment and cardiotoxicity: monitoring and management. Breast Cancer Research and Treatment, 2019, 177, 237-250.	1.1	84
1487	Primary predictors of survival outcomes for HER2-positive advanced breast cancer patients initiating ado-trastuzumab emtansine. Breast, 2019, 46, 90-94.	0.9	6
1488	Adjuvant Systemic Therapy in Breast Cancer. , 2019, , 179-194.		0
1489	Production and Evaluation of an Avian IgY Immunotoxin against CD133+ for Treatment of Carcinogenic Stem Cells in Malignant Glioma: IgY Immunotoxin for the Treatment of Glioblastoma. Journal of Oncology, 2019, 2019, 1-15.	0.6	9
1490	Practical application of non-contact alternating current electric field mixing for reagent-saving in situ hybridisation of HER2. Journal of Clinical Pathology, 2019, 72, 603-608.	1.0	2
1492	Redrawing the Lines: The Next Generation of Treatment in Metastatic Breast Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, e8-e21.	1.8	22
1493	Conceptual Framework for Therapeutic Development Beyond Anti-PD-1/PD-L1 in Urothelial Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 284-300.	1.8	14

#	ARTICLE	IF	CITATIONS
1494	Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 175-185.	1.1	3
1495	Update Breast Cancer 2019 Part 2 – Implementation of Novel Diagnostics and Therapeutics in Advanced Breast Cancer Patients in Clinical Practice. <i>Geburtshilfe Und Frauenheilkunde</i> , 2019, 79, 268-280.	0.8	21
1496	Progress and challenges in HER2-positive gastroesophageal adenocarcinoma. <i>Journal of Hematology and Oncology</i> , 2019, 12, 50.	6.9	44
1497	Adjuvant therapeutic approaches of HER2-positive breast cancer with a focus on neratinib maleate. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 447-454.	1.1	8
1498	An overview of tubulin modulators deposited in protein data bank. <i>Medicinal Chemistry Research</i> , 2019, 28, 927-937.	1.1	23
1499	Antibody-drug conjugate T-DM1 treatment for HER2+ breast cancer induces ROR1 and confers resistance through activation of Hippo transcriptional coactivator YAP1. <i>EBioMedicine</i> , 2019, 43, 211-224.	2.7	22
1500	Cardiotoxicity of Contemporary Breast Cancer Treatments. <i>Current Treatment Options in Oncology</i> , 2019, 20, 51.	1.3	16
1501	Therapeutic potential of nimotuzumab PEGylated-maytansine antibody drug conjugates against EGFR positive xenograft. <i>Oncotarget</i> , 2019, 10, 1031-1044.	0.8	14
1502	Towards precision oncology for HER2 blockade in gastroesophageal adenocarcinoma. <i>Annals of Oncology</i> , 2019, 30, 1254-1264.	0.6	20
1503	Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 139, 53-66.	2.0	137
1504	Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study. <i>Lancet Oncology</i> , The, 2019, 20, 816-826.	5.1	252
1505	Expanding Therapeutic Options for Older Adults: Case-Based Updates in Breast and Lung Cancer. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 1012-1019.	1.3	2
1506	Efficacy and Safety Analysis of Nelipepimut-S Vaccine to Prevent Breast Cancer Recurrence: A Randomized, Multicenter, Phase III Clinical Trial. <i>Clinical Cancer Research</i> , 2019, 25, 4248-4254.	3.2	129
1507	Phase I Study of Intermittent High-Dose Lapatinib Alternating with Capecitabine for HER2-Positive Breast Cancer Patients with Central Nervous System Metastases. <i>Clinical Cancer Research</i> , 2019, 25, 3784-3792.	3.2	41
1508	Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma. <i>Biomarker Research</i> , 2019, 7, 9.	2.8	19
1509	Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer. <i>Breast Cancer Research</i> , 2019, 21, 43.	2.2	33
1510	Cancer Treatment in the Genomic Era. <i>Annual Review of Biochemistry</i> , 2019, 88, 247-280.	5.0	24
1511	Exposure-Response Analysis of Overall Survival for Tremelimumab in Unresectable Malignant Mesothelioma: The Confounding Effect of Disease Status. <i>Clinical and Translational Science</i> , 2019, 12, 450-458.	1.5	13

#	ARTICLE	IF	CITATIONS
1512	Targeting Molecular Pathways in Intracranial Metastatic Disease. <i>Frontiers in Oncology</i> , 2019, 9, 99.	1.3	10
1513	Trastuzumab Emtansine (T-DM1) Plus S-1 in Patients with Trastuzumab-Pretreated HER2-Positive Advanced or Metastatic Breast Cancer: A Phase Ib Study. <i>Oncology</i> , 2019, 96, 309-317.	0.9	2
1514	The Latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy. <i>Chemical and Pharmaceutical Bulletin</i> , 2019, 67, 173-185.	0.6	226
1515	Design and characterization of homogenous antibody-drug conjugates with a drug-to-antibody ratio of one prepared using an engineered antibody and a dual-maleimide pyrrolobenzodiazepine dimer. <i>MAbs</i> , 2019, 11, 500-515.	2.6	13
1516	HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1115.	1.8	144
1517	Metastatic disease of the breast and local recurrence. <i>Surgery</i> , 2019, 37, 181-185.	0.1	1
1518	Anti-CD24 Antibody-Nitric Oxide Conjugate Selectively and Potently Suppresses Hepatic Carcinoma. <i>Cancer Research</i> , 2019, 79, 3395-3405.	0.4	39
1519	HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591983351.	1.4	240
1520	Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 595-603.	1.1	106
1521	Disulfide Modified IgG1: An Investigation of Biophysical Profile and Clinically Relevant Fc Interactions. <i>Bioconjugate Chemistry</i> , 2019, 30, 1048-1054.	1.8	28
1522	Antibody-Drug Conjugate-Based Therapeutics: State of the Science. <i>Journal of the National Cancer Institute</i> , 2019, 111, 538-549.	3.0	257
1523	Antibody-Prodrug Conjugates with KSP Inhibitors and Legumain-Mediated Metabolite Formation. <i>Chemistry - A European Journal</i> , 2019, 25, 8208-8213.	1.7	13
1524	Biologics, biosimilars, and biobetters: different terms or different drugs?. <i>Eye</i> , 2019, 33, 1032-1034.	1.1	10
1526	Systemic Therapy of Central Nervous System Metastases of Breast Cancer. <i>Current Oncology Reports</i> , 2019, 21, 49.	1.8	26
1527	Broad consensus on the optimal sequence for the systemic treatment of metastatic breast cancer: results from a survey of Spanish medical oncologists. <i>Journal of Drug Assessment</i> , 2019, 8, 62-69.	1.1	0
1528	Neutralization of BCL-2/XL Enhances the Cytotoxicity of T-DM1 <i>In Vivo</i> . <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1115-1126.	1.9	20
1529	Discovery of a novel EGFR targeting antibody-drug conjugate, SHR-A1307, for the treatment of solid tumors resistant or refractory to anti-EGFR therapies. <i>Molecular Cancer Therapeutics</i> , 2019, 18, molcanther.0854.2018.	1.9	11
1530	Recent Chemical Approaches for Site-Specific Conjugation of Native Antibodies: Technologies toward Next-Generation Antibody-Drug Conjugates. <i>ChemBioChem</i> , 2019, 20, 2729-2737.	1.3	57

#	ARTICLE	IF	CITATIONS
1531	Lapatinib activity in metastatic human epidermal growth factor receptor 2-positive breast cancers that received prior therapy with trastuzumab, pertuzumab, and/or ado-trastuzumab emtansine (T-DM1). Breast Cancer Research and Treatment, 2019, 176, 227-234.	1.1	13
1532	Antibody-Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index. Clinical Cancer Research, 2019, 25, 5441-5448.	3.2	217
1533	Recent advances of therapeutic targets based on the molecular signature in breast cancer: genetic mutations and implications for current treatment paradigms. Journal of Hematology and Oncology, 2019, 12, 38.	6.9	66
1534	Clinical development of targeted and immune based anti-cancer therapies. Journal of Experimental and Clinical Cancer Research, 2019, 38, 156.	3.5	170
1535	Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer. , 2019, 7, 90.		80
1536	Antibody-Drug Conjugates in Breast Cancer: a Comprehensive Review. Current Treatment Options in Oncology, 2019, 20, 37.	1.3	60
1537	Next-Generation Sequencing of Tissue and Circulating Tumor DNA: The UC San Diego Moores Center for Personalized Cancer Therapy Experience with Breast Malignancies. Molecular Cancer Therapeutics, 2019, 18, 1001-1011.	1.9	34
1538	Combination of Trastuzumab Emtansine and Stereotactic Radiosurgery Results in High Rates of Clinically Significant Radionecrosis and Dysregulation of Aquaporin-4. Clinical Cancer Research, 2019, 25, 3946-3953.	3.2	46
1539	Pertuzumab in HER2-positive early breast cancer: current use and perspectives. Future Oncology, 2019, 15, 1823-1843.	1.1	14
1540	Comparison of 4th ESO-ESMO international consensus guidelines for advance breast cancer and Chinese anti-cancer association committee of Breast Cancer Society guideline. Breast, 2019, 45, 36-42.	0.9	8
1541	Single-domain antibody fusion proteins can target and shuttle functional proteins into macrophage mannose receptor expressing macrophages. Journal of Controlled Release, 2019, 299, 107-120.	4.8	17
1542	Translational highlights in breast cancer research and treatment: recent developments with clinical impact. Current Opinion in Obstetrics and Gynecology, 2019, 31, 67-75.	0.9	16
1543	Clinical Trial Outcomes. JACC: Heart Failure, 2019, 7, 272-273.	1.9	6
1544	Molecular alterations and poziotinib efficacy, a pan-HER inhibitor, in human epidermal growth factor receptor 2 (HER2)-positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2-positive breast cancer patients. International Journal of Cancer, 2019, 145, 1669-1678.	2.3	14
1545	HER2 Testing in the Era of Changing Guidelines. , 2019, , 13-39.		0
1546	Optimal First-Line Treatment of Advanced HER2-Positive Breast Cancer. , 2019, , 41-62.		0
1547	HER2-Positive Breast Cancer. , 2019, , 63-74.		1
1548	Central Nervous System Metastases in HER2-Positive Breast Cancer. , 2019, , 75-93.		0

#	ARTICLE	IF	CITATIONS
1549	Adjuvant Therapy. , 2019, , 107-118.		1
1550	Noncardiac Toxicity of HER2-Targeted Therapy. , 2019, , 171-178.		0
1551	Linear Desferrichrome-Linked Siliconâ€“Rhodamine Antibody Conjugate Enables Targeted Multimodal Imaging of HER2 in Vitro and in Vivo. Molecular Pharmaceutics, 2019, 16, 1412-1420.	2.3	17
1552	Pharmacotherapeutic options for patients with refractory breast cancer. Expert Opinion on Pharmacotherapy, 2019, 20, 851-861.	0.9	3
1553	Current Treatment Options for Breast Cancer Brain Metastases. Current Treatment Options in Oncology, 2019, 20, 19.	1.3	10
1554	Diffuse large Bâ€“cell lymphoma. Memo - Magazine of European Medical Oncology, 2019, 12, 7-11.	0.3	4
1555	Current situation and challenges regarding biosimilars in Japan: an example of trastuzumab biosimilars for breast cancer. Future Oncology, 2019, 15, 1353-1361.	1.1	12
1556	A phase I study of the antibody drug conjugate ASG-5ME, an SLC44A4-targeting antibody carrying auristatin E, in metastatic castration-resistant prostate cancer. Investigational New Drugs, 2019, 37, 1052-1060.	1.2	11
1557	Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population. Breast Cancer, 2019, 26, 492-498.	1.3	19
1558	Antibody-Mediated Endocytosis of Polysialic Acid Enables Intracellular Delivery and Cytotoxicity of a Glycan-Directed Antibodyâ€“Drug Conjugate. Cancer Research, 2019, 79, 1810-1821.	0.4	14
1559	Modeling ErbB2-p130Cas interaction to design new potential anticancer agents. Scientific Reports, 2019, 9, 3089.	1.6	4
1560	A RAGE-Targeted Antibody-Drug Conjugate: Surface Plasmon Resonance as a Platform for Accelerating Effective ADC Design and Development. Antibodies, 2019, 8, 7.	1.2	7
1561	Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer. New England Journal of Medicine, 2019, 380, 741-751.	13.9	542
1562	Further Progress for Patients with Breast Cancer. New England Journal of Medicine, 2019, 380, 676-677.	13.9	13
1563	Significance of baseline neutrophil-to-lymphocyte ratio for progression-free survival of patients with HER2-positive breast cancer treated with trastuzumab emtansine. Scientific Reports, 2019, 9, 1811.	1.6	22
1564	Photosensitizer Antibodyâ€“Drug Conjugates: Past, Present, and Future. Bioconjugate Chemistry, 2019, 30, 975-993.	1.8	61
1565	Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?. Oncologist, 2019, 24, 1469-1478.	1.9	25
1566	Precision medicine for human cancers with Notch signaling dysregulation (Review). International Journal of Molecular Medicine, 2020, 45, 279-297.	1.8	105

#	ARTICLE	IF	CITATIONS
1567	A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab-pretreated patients with HER-2-positive metastatic breast cancer (E-VITA). <i>Anti-Cancer Drugs</i> , 2019, 30, 394-401.	0.7	3
1568	Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial. <i>Breast Cancer Research</i> , 2019, 21, 121.	2.2	42
1569	Deciphering HER2 Breast Cancer Disease: Biological and Clinical Implications. <i>Frontiers in Oncology</i> , 2019, 9, 1124.	1.3	52
1570	Validation of HER2 Amplification as a Predictive Biomarker for Anti-Epidermal Growth Factor Receptor Antibody Therapy in Metastatic Colorectal Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-13.	1.5	46
1571	FDA and the medical device clinical drug trials. , 2019, , 301-357.		0
1572	When to Add Additional Anti-HER2 Therapy to Adjuvant Trastuzumab. <i>Current Oncology Reports</i> , 2019, 21, 109.	1.8	3
1573	Efficacy and Safety of Gemcitabine With Trastuzumab and Pertuzumab After Prior Pertuzumab-Based Therapy Among Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. <i>JAMA Network Open</i> , 2019, 2, e1916211.	2.8	7
1574	Cancer biomarkers for targeted therapy. <i>Biomarker Research</i> , 2019, 7, 25.	2.8	72
1575	Trastuzumab-Induced Cardiomyopathy. <i>Cardiology Clinics</i> , 2019, 37, 407-418.	0.9	47
1576	New strategies in ovarian cancer treatment. <i>Cancer</i> , 2019, 125, 4623-4629.	2.0	92
1578	Recent Developments in HER2-Directed Therapy in Breast Cancer. <i>Current Breast Cancer Reports</i> , 2019, 11, 311-325.	0.5	0
1579	Human epidermal growth factor receptor 2-positive digestive tumors. <i>Current Opinion in Oncology</i> , 2019, 31, 354-361.	1.1	4
1580	Antibody Structure and Function: The Basis for Engineering Therapeutics. <i>Antibodies</i> , 2019, 8, 55.	1.2	273
1581	Preclinical Studies of ADC Therapy for Solid Tumors. , 2019, , 125-154.		0
1582	ADCs on the Market and in Clinical Development. , 2019, , 155-174.		2
1584	Recent Progress in Linker Technology for Antibody-Drug Conjugates: Methods for Connection and Release. , 2019, , 93-123.		2
1585	Reagent-saving immunohistochemistry for HER2 using non-contact alternating current electric field mixing. <i>Journal of Clinical Pathology</i> , 2019, 72, 25-30.	1.0	9
1586	Recent Advances in Subcellular Targeted Cancer Therapy Based on Functional Materials. <i>Advanced Materials</i> , 2019, 31, e1802725.	11.1	230

#	ARTICLE	IF	CITATIONS
1587	Progress in adjuvant systemic therapy for breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 27-44.	12.5	175
1588	Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry. <i>Cancers</i> , 2019, 11, 10.	1.7	43
1589	Pathological Complete Response (PCR) with TDM1 (Trastuzumab Emtansine) in Refractory HER2-Positive Locally Advanced Breast Cancer (LABC). <i>Indian Journal of Gynecologic Oncology</i> , 2019, 17, 1.	0.1	1
1590	What is the added value of digital image analysis of HER2 immunohistochemistry in breast cancer in clinical practice? A study with multiple platforms. <i>Histopathology</i> , 2019, 74, 917-924.	1.6	24
1591	Uncialamycin as a novel payload for antibody drug conjugate (ADC) based targeted cancer therapy. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 466-470.	1.0	21
1592	What is the best pharmacotherapeutic strategy for HER-2 positive breast cancer?. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 5-9.	0.9	7
1593	Impact of the 2018 ASCO/CAP HER2 guidelines update for HER2 testing by FISH in breast cancer. <i>Pathology Research and Practice</i> , 2019, 215, 251-255.	1.0	39
1594	Antibody-drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes. <i>Journal of Cellular Physiology</i> , 2019, 234, 5628-5642.	2.0	157
1595	APOMAB Antibody-Drug Conjugates Targeting Dead Tumor Cells are Effective <i>In Vivo</i> . <i>Molecular Cancer Therapeutics</i> , 2019, 18, 335-345.	1.9	16
1596	HER2-Positive Early Breast Cancer. , 2019, , 371-382.		0
1597	Interstitial pneumonitis associated with trastuzumab emtansine. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 1798-1800.	0.5	12
1598	Conditional knockout of SHP2 in ErbB2 transgenic mice or inhibition in HER2-amplified breast cancer cell lines blocks oncogene expression and tumorigenesis. <i>Oncogene</i> , 2019, 38, 2275-2290.	2.6	18
1599	Vaccine-Induced Memory CD8+ T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study. <i>Clinical Cancer Research</i> , 2019, 25, 2725-2736.	3.2	50
1600	Hydrophilic Monomethyl Auristatin E Derivatives as Novel Candidates for the Design of Antibody-Drug Conjugates. <i>Separations</i> , 2019, 6, 1.	1.1	20
1601	Safety and Tolerability of Antibody-Drug Conjugates in Cancer. <i>Drug Safety</i> , 2019, 42, 295-314.	1.4	75
1602	Reductive Desulfuration as an Important Tool in Detection of Small Molecule Modifications to Payload of Antibody Drug Conjugates. <i>Analytical Chemistry</i> , 2019, 91, 2368-2375.	3.2	4
1603	GRB7 dependent proliferation of basal-like, HER2 positive human breast cancer cell lines is mediated in part by HER1 signaling. <i>Molecular Carcinogenesis</i> , 2019, 58, 699-707.	1.3	9
1604	Comparative and combined effectiveness of innovative therapies in cancer: a literature review. <i>Journal of Comparative Effectiveness Research</i> , 2019, 8, 205-216.	0.6	3

#	ARTICLE	IF	CITATIONS
1605	QOL-enhancing surgery for patients with HER2-positive metastatic breast cancer. <i>BMJ Supportive and Palliative Care</i> , 2019, 9, 151-154.	0.8	4
1606	Immunotherapeutic Approaches in Cancer. , 2019, , 19-44.		4
1607	Targeting the extracellular matrix for delivery of bioactive molecules to sites of arthritis. <i>British Journal of Pharmacology</i> , 2019, 176, 26-37.	2.7	18
1608	Assessment of <i>ERBB2</i> / <i>HER2</i> Status in <i>HER2</i> -Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines. <i>JAMA Oncology</i> , 2019, 5, 366.	3.4	26
1609	Natural Product Bis-Intercalator Depsipeptides as a New Class of Payloads for Antibody-Drug Conjugates. <i>Bioconjugate Chemistry</i> , 2019, 30, 200-209.	1.8	15
1610	Cancer Immunotherapy: The Dawn of Antibody Cocktails. <i>Methods in Molecular Biology</i> , 2019, 1904, 11-51.	0.4	25
1611	Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. <i>New England Journal of Medicine</i> , 2019, 380, 617-628.	13.9	1,610
1612	T-Type voltage gated calcium channels: a target in breast cancer?. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 11-21.	1.1	25
1613	First case of trastuzumab emtansine-associated hemorrhagic telangiectasias treated with propranolol. <i>Dermatologic Therapy</i> , 2019, 32, e12756.	0.8	1
1614	Long-Term Survival of De Novo Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with HER2-Targeted Therapy. <i>Oncologist</i> , 2019, 24, 313-318.	1.9	39
1615	Current status and contemporary approaches to the discovery of antitumor agents from higher plants. <i>Biotechnology Advances</i> , 2020, 38, 107337.	6.0	72
1616	A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study. <i>Clinical and Translational Oncology</i> , 2020, 22, 420-428.	1.2	9
1617	Targeted therapy for breast cancer in older patients. <i>Journal of Geriatric Oncology</i> , 2020, 11, 380-388.	0.5	9
1618	Antibody therapeutics and immunoregulation in cancer and autoimmune disease. <i>Seminars in Cancer Biology</i> , 2020, 64, 1-12.	4.3	93
1619	Intracellular Signaling. , 2020, , 24-46.e12.		0
1620	Therapeutic Antibodies and Immunologic Conjugates. , 2020, , 486-499.e8.		2
1621	Cardiovascular Effects of Cancer Therapy. , 2020, , 649-664.e4.		1
1622	Pertuzumab for the treatment of breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 85-95.	1.1	5

#	ARTICLE	IF	CITATIONS
1623	HER2-targeted therapies – a role beyond breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 33-48.	12.5	569
1624	A Roundtable Discussion of the Breast Cancer Therapy Expert Group (BCTEG): Clinical Developments and Practice Guidance on Human Epidermal Growth Factor Receptor 2 (HER2)-positive Breast Cancer. <i>Clinical Breast Cancer</i> , 2020, 20, e251-e260.	1.1	15
1625	Regenerative nodular hyperplasia after T-DM1: consequences from sinusoidal endothelium damages. <i>Acta Oncologica</i> , 2020, 59, 306-309.	0.8	4
1626	Descriptive comparison of hospital formulary decisions with published oncology valuation methods. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 891-905.	0.5	0
1627	HER2-Overexpressing/Amplified Breast Cancer as a Testing Ground for Antibody-Drug Conjugate Drug Development in Solid Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 775-786.	3.2	36
1628	Metastatic heterogeneity of breast cancer: Molecular mechanism and potential therapeutic targets. <i>Seminars in Cancer Biology</i> , 2020, 60, 14-27.	4.3	460
1629	The interaction between RUNX2 and core binding factor beta as a potential therapeutic target in canine osteosarcoma. <i>Veterinary and Comparative Oncology</i> , 2020, 18, 52-63.	0.8	5
1631	Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting. <i>International Journal of Cancer</i> , 2020, 146, 1917-1929.	2.3	4
1632	Current Immunotherapeutic Strategies in Cancer. <i>Recent Results in Cancer Research</i> , 2020, , .	1.8	4
1633	Current Development of Monoclonal Antibodies in Cancer Therapy. <i>Recent Results in Cancer Research</i> , 2020, 214, 1-70.	1.8	16
1634	Near-Infrared Photoimmunotherapy: Photoactivatable Antibody-Drug Conjugates (ADCs). <i>Bioconjugate Chemistry</i> , 2020, 31, 28-36.	1.8	45
1635	Effectiveness and normal tissue toxicity of Auger electron (AE) radioimmunotherapy (RIT) with [111In]In-Bn-DTPA-nimotuzumab in mice with triple-negative or trastuzumab-resistant human breast cancer xenografts that overexpress EGFR. <i>Nuclear Medicine and Biology</i> , 2020, 80-81, 37-44.	0.3	7
1636	Antibody-Drug Conjugates: A Comprehensive Review. <i>Molecular Cancer Research</i> , 2020, 18, 3-19.	1.5	442
1637	Sinusoidal obstruction syndrome post-treatment with trastuzumab emtansine (T-DM1) in advanced breast cancer. <i>International Cancer Conference Journal</i> , 2020, 9, 18-23.	0.2	6
1638	T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study. <i>Clinical Breast Cancer</i> , 2020, 20, e181-e187.	1.1	30
1639	Overcoming trastuzumab resistance in HER2-positive breast cancer using combination therapy. <i>Journal of Cellular Physiology</i> , 2020, 235, 3142-3156.	2.0	65
1640	Mechanisms and potential interventions associated with the cardiotoxicity of ErbB2-targeted drugs: Insights from in vitro, in vivo, and clinical studies in breast cancer patients. <i>Cellular and Molecular Life Sciences</i> , 2020, 77, 1571-1589.	2.4	25
1641	Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1. <i>Molecular Cancer Research</i> , 2020, 18, 644-656.	1.5	17

#	ARTICLE	IF	CITATIONS
1642	Trastuzumab emtansine (T-DM1)-associated cardiotoxicity: Pooled analysis in advanced HER2-positive breast cancer. <i>European Journal of Cancer</i> , 2020, 126, 65-73.	1.3	58
1643	Portoamides A and B are mitochondrial toxins and induce cytotoxicity on the proliferative cell layer of in vitro microtumours. <i>Toxicol</i> , 2020, 175, 49-56.	0.8	12
1644	Efficacy of trastuzumab emtansine in Japanese patients with previously treated HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma: A subgroup analysis of the GATSBY study. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, 5-13.	0.7	12
1645	ARX788, a novel anti-HER2 antibody-drug conjugate, shows anti-tumor effects in preclinical models of trastuzumab emtansine-resistant HER2-positive breast cancer and gastric cancer. <i>Cancer Letters</i> , 2020, 473, 156-163.	3.2	39
1646	Identification of potential key genes for HER-2 positive breast cancer based on bioinformatics analysis. <i>Medicine (United States)</i> , 2020, 99, e18445.	0.4	19
1647	Cancer of the Esophagus. , 2020, , 1174-1196.e6.		5
1648	Immunological role and underlying mechanisms of B7-1 in tumorigenesis. <i>Clinica Chimica Acta</i> , 2020, 502, 191-198.	0.5	17
1649	A cost-effectiveness analysis of trastuzumab-containing treatment sequences for HER-2 positive metastatic breast cancer patients in Taiwan. <i>Breast</i> , 2020, 49, 141-148.	0.9	10
1650	Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer. <i>British Journal of Cancer</i> , 2020, 122, 603-612.	2.9	126
1651	In Vitro and MD Simulation Study to Explore Physicochemical Parameters for Antibacterial Peptide to Become Potent Anticancer Peptide. <i>Molecular Therapy - Oncolytics</i> , 2020, 16, 7-19.	2.0	42
1652	Predicting Thrombocytopenia in Patients With Breast Cancer Treated With Ado-trastuzumab Emtansine. <i>Clinical Breast Cancer</i> , 2020, 20, e220-e228.	1.1	10
1653	Targeting human epidermal growth factor receptor 2 (HER2) in gynecologic malignancies. <i>Current Opinion in Obstetrics and Gynecology</i> , 2020, 32, 57-64.	0.9	27
1654	⁶⁸ Ga-ZHER2 PET/CT Reveals HER2-Positive Metastatic Gastric Cancer With Better Image Quality Than ¹⁸ F-FDG. <i>Clinical Nuclear Medicine</i> , 2020, 45, e101-e102.	0.7	4
1655	Metastatic Breast Cancer: Is There a Differential Therapy Efficacy between Visceral and Non-Visceral Metastatic Breast Cancer?. <i>Breast Care</i> , 2020, 15, 527-533.	0.8	2
1656	Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 610-621.	13.9	1,143
1657	Contextualizing pertuzumab approval in the treatment of HER2-positive breast cancer patients. <i>Cancer Treatment Reviews</i> , 2020, 83, 101944.	3.4	3
1658	INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma. <i>Neuro-Oncology</i> , 2020, 22, 684-693.	0.6	126
1659	Antibody drug conjugates: Development, characterization, and regulatory considerations. <i>Polymers for Advanced Technologies</i> , 2020, 31, 1177-1193.	1.6	11

#	ARTICLE	IF	CITATIONS
1660	Last but not least: antibody-drug conjugates in hormone receptor-positive metastatic breast cancer. <i>Annals of Oncology</i> , 2020, 31, 1594-1596.	0.6	1
1661	Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial. <i>Lancet Oncology</i> , 2020, 21, 1283-1295.	5.1	213
1662	Trastuzumab Deruxtecan (DS-8201a): The Latest Research and Advances in Breast Cancer. <i>Clinical Breast Cancer</i> , 2021, 21, e212-e219.	1.1	39
1663	Systemic therapy for metastatic HER2-positive breast cancer. <i>Seminars in Oncology</i> , 2020, 47, 259-269.	0.8	50
1664	Molecular Mechanism of HER2 Rapid Internalization and Redirected Trafficking Induced by Anti-HER2 Biparatopic Antibody. <i>Antibodies</i> , 2020, 9, 49.	1.2	21
1665	Understanding the influence of experimental factors on bio-interactions of nanoparticles: Towards improving correlation between in vitro and in vivo studies. <i>Archives of Biochemistry and Biophysics</i> , 2020, 694, 108592.	1.4	13
1666	Immunomodulatory activity of IR700-labelled affibody targeting HER2. <i>Cell Death and Disease</i> , 2020, 11, 886.	2.7	20
1667	Antibody-Drug Conjugates for Cancer Therapy. <i>Molecules</i> , 2020, 25, 4764.	1.7	187
1668	An antibody-drug conjugate targeting a GSTA glycosite signature epitope of MUC1 expressed by non-small cell lung cancer. <i>Cancer Medicine</i> , 2020, 9, 9529-9540.	1.3	9
1669	Attenuation of p53 mutant as an approach for treatment Her2-positive cancer. <i>Cell Death Discovery</i> , 2020, 6, 100.	2.0	17
1670	Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab. <i>Cancers</i> , 2020, 12, 3021.	1.7	6
1671	Lower response to trastuzumab emtansine in metastatic breast cancer patients with human epidermal growth factor receptor 2 immunohistochemistry score of 2 and fluorescence in situ hybridization positive compared with immunohistochemistry score of 3: a retrospective study. <i>Anti-Cancer Drugs</i> , 2020, 31, 973-978.	0.7	8
1672	Preparation and characterization of antibody-drug conjugates acting on HER2-positive cancer cells. <i>PLoS ONE</i> , 2020, 15, e0239813.	1.1	9
1673	An overview of antibody-drug conjugates in oncological practice. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592096299.	1.4	15
1674	Neoadjuvant Pyrotinib plus Trastuzumab and Chemotherapy for Stage III HER2-Positive Breast Cancer: A Phase II Clinical Trial. <i>Oncologist</i> , 2020, 25, e1909-e1920.	1.9	25
1675	Targeting HER2 in Breast Cancer: Latest Developments on Treatment Sequencing and the Introduction of Biosimilars. <i>Drugs</i> , 2020, 80, 1811-1830.	4.9	23
1676	Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. <i>Annals of Oncology</i> , 2020, 31, 1491-1505.	0.6	658
1677	Thiol-based michael-type addition. A systematic evaluation of its controlling factors. <i>Tetrahedron</i> , 2020, 76, 131637.	1.0	19

#	ARTICLE	IF	CITATIONS
1678	Should triple-positive breast cancer be recognized as a distinct subtype?. Expert Review of Anticancer Therapy, 2020, 20, 1011-1014.	1.1	15
1679	Stimuli-responsive prodrug-based cancer nanomedicine. EBioMedicine, 2020, 56, 102821.	2.7	103
1680	Diagnosis and management of uterine serous carcinoma: current strategies and clinical challenges. Expert Opinion on Orphan Drugs, 2020, 8, 343-355.	0.5	1
1681	ERBB2 mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer. Cancers, 2020, 12, 1902.	1.7	29
1682	Tailored Linker Chemistries for the Efficient and Selective Activation of ADCs with KSPi Payloads. Bioconjugate Chemistry, 2020, 31, 1893-1898.	1.8	13
1683	Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With 2 HER2-Directed Regimens: Phase III NALA Trial. Journal of Clinical Oncology, 2020, 38, 3138-3149.	0.8	355
1684	Improving Receptor-Mediated Intracellular Access and Accumulation of Antibody Therapeuticsâ€”The Tale of HER2. Antibodies, 2020, 9, 32.	1.2	15
1685	ARX788, a Site-specific Anti-HER2 Antibodyâ€”Drug Conjugate, Demonstrates Potent and Selective Activity in HER2-low and T-DM1â€”resistant Breast and Gastric Cancers. Molecular Cancer Therapeutics, 2020, 19, 1833-1843.	1.9	81
1686	Synchronous and Metachronous Metastatic Breast Cancer, with Different Histology and Opposite Immunophenotype, Treated with Combination of Chemotherapy, Anti-Her2, and Endocrine Therapy: A Case Report. Case Reports in Oncology, 2020, 13, 544-549.	0.3	5
1687	Update Breast Cancer 2020 Part 3 â€” Early Breast Cancer. Geburtshilfe Und Frauenheilkunde, 2020, 80, 1105-1114.	0.8	12
1688	Loco-regional therapy for isolated locoregional lymph node recurrence of breast cancer: focusing on surgical treatment with combined therapy. Translational Cancer Research, 2020, 9, 5038-5043.	0.4	2
1689	The Role of ERBB2/HER2 Tyrosine Kinase Receptor in the Regulation of Cell Death. Biochemistry (Moscow), 2020, 85, 1277-1287.	0.7	4
1690	Therapeutic Strategies for the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Positive (HR+/HER2+) Breast Cancer: A Review of the Current Literature. Cancers, 2020, 12, 3317.	1.7	19
1691	Pathological complete response to neoadjuvant trastuzumab and pertuzumab therapy is related to human epidermal growth factor receptor 2 (HER2) amplification level in HER2-amplified breast cancer. Medicine (United States), 2020, 99, e23053.	0.4	11
1692	Trastuzumab Emtansine Plus Non-Pegylated Liposomal Doxorubicin in HER2-Positive Metastatic Breast Cancer (Thelma): A Single-Arm, Multicenter, Phase Ib Trial. Cancers, 2020, 12, 3509.	1.7	7
1693	Guidelines of Chinese Society of Clinical Oncology (CSCO) on Diagnosis and Treatment of Breast Cancer (2020 version). Translational Breast Cancer Research, 0, 1, 27-27.	0.4	11
1694	The Cellular Prion Protein: A Promising Therapeutic Target for Cancer. International Journal of Molecular Sciences, 2020, 21, 9208.	1.8	19
1695	Clinical Significance of ARID1A and ANXA1 in HER-2 Positive Breast Cancer. Journal of Clinical Medicine, 2020, 9, 3911.	1.0	5

#	ARTICLE	IF	CITATIONS
1696	Characterization of the genomic landscape and actionable mutations in Chinese breast cancers by clinical sequencing. <i>Nature Communications</i> , 2020, 11, 5679.	5.8	41
1697	Treatment Landscape and Prognosis After Treatment with Trastuzumab Emtansine. <i>Geburtshilfe Und Frauenheilkunde</i> , 2020, 80, 1134-1142.	0.8	4
1698	Heregulin (HRC) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany. <i>BMC Cancer</i> , 2020, 20, 1091.	1.1	1
1699	Trastuzumab emtansine: a game changer in HER2-positive early breast cancer. <i>Future Oncology</i> , 2020, 16, 2595-2609.	1.1	3
1700	The Evolving Landscape of HER2-Directed Breast Cancer Therapy. <i>Current Treatment Options in Oncology</i> , 2020, 21, 82.	1.3	17
1702	Clinicopathologic features of breast cancer reclassified as HER2-amplified by fluorescence in situ hybridization with alternative chromosome 17 probes. <i>Annals of Diagnostic Pathology</i> , 2020, 48, 151576.	0.6	0
1703	Monoclonal Antibodies in Cancer Therapy. <i>Antibodies</i> , 2020, 9, 34.	1.2	325
1704	Trastuzumab-deruxtecan: an investigational agent for the treatment of HER2-positive breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 901-910.	1.9	18
1705	Clinical implications of breast cancer tumor genomic testing. <i>Breast Journal</i> , 2020, 26, 1565-1571.	0.4	3
1706	The Influence of Pre-Existing Beta-Blockers Use on Survival Outcomes in HER2 Positive Advanced Breast Cancer: Pooled Analysis of Clinical Trial Data. <i>Frontiers in Oncology</i> , 2020, 10, 1130.	1.3	10
1707	Pyrotinib plus capecitabine for human epidermal growth factor receptor 2-positive metastatic breast cancer after trastuzumab and taxanes (PHENIX): a randomized, double-blind, placebo-controlled phase 3 study. <i>Translational Breast Cancer Research</i> , 0, 1, 13-13.	0.4	41
1708	Novel HER2-targeted therapies for HER2-positive metastatic breast cancer. <i>Cancer</i> , 2020, 126, 4278-4288.	2.0	103
1709	lncRNA ZNF649-AS1 Induces Trastuzumab Resistance by Promoting ATG5 Expression and Autophagy. <i>Molecular Therapy</i> , 2020, 28, 2488-2502.	3.7	34
1710	Antibody-Drug Conjugates in Thoracic Malignancies: Clinical Trials Reveal Both Promise and Challenges. <i>Targeted Oncology</i> , 2020, 15, 429-448.	1.7	0
1711	Rapid Microfluidic Formation of Uniform Patient-Derived Breast Tumor Spheroids. <i>ACS Applied Bio Materials</i> , 2020, 3, 6273-6283.	2.3	27
1712	Novel Anti-CD70 Antibody Drug Conjugate for the Treatment of Adult T-Cell Leukemia (ATL). <i>Anticancer Research</i> , 2020, 40, 4471-4479.	0.5	2
1713	Novel targeted therapies for metastatic breast cancer. <i>Annals of Translational Medicine</i> , 2020, 8, 907-907.	0.7	10
1714	Antibody-drug conjugates in breast cancer: the chemotherapy of the future?. <i>Current Opinion in Oncology</i> , 2020, 32, 494-502.	1.1	25

#	ARTICLE	IF	CITATIONS
1715	<p>Further Understanding of High-Grade Serous Ovarian Carcinogenesis: Potential Therapeutic Targets</p>. Cancer Management and Research, 2020, Volume 12, 10423-10437.	0.9	2
1716	A Novel Proteomic Method Reveals NLS Tagging of T-DM1 Contravenes Classical Nuclear Transport in a Model of HER2-Positive Breast Cancer. Molecular Therapy - Methods and Clinical Development, 2020, 19, 99-119.	1.8	8
1717	Antibody-drug conjugates in metastatic triple negative breast cancer: a spotlight on sacituzumab govitecan, ladiratuzumab vedotin, and trastuzumab deruxtecan. Expert Opinion on Biological Therapy, 2021, 21, 903-913.	1.4	28
1718	A phase I study of pharmacokinetics of trastuzumab emtansine in Chinese patients with locally advanced inoperable or metastatic human epidermal growth factor receptor 2-positive breast cancer who have received prior trastuzumab-based therapy. Medicine (United States), 2020, 99, e22886.	0.4	3
1719	B-cell clonogenic activity of HIV-1 p17 variants is driven by PAR1-mediated EGF transactivation. Cancer Gene Therapy, 2021, 28, 649-666.	2.2	6
1720	Prevention of brain metastases in human epidermal growth factor receptor 2-positive breast cancer. Current Opinion in Oncology, 2020, 32, 555-560.	1.1	4
1721	Neratinib plus capecitabine for the treatment of advanced HER2-positive breast cancer. Expert Review of Anticancer Therapy, 2020, 20, 731-741.	1.1	6
1722	Realâ€world impact of antiâ€HER2 therapyâ€related cardiotoxicity in patients with advanced HER2â€positive breast cancer. Asia-Pacific Journal of Clinical Oncology, 2020, 16, 356-362.	0.7	4
1723	<scp>HER2â€positive</scp> breast cancer brain metastasis: A new and exciting landscape. Cancer Reports, 2022, 5, e1274.	0.6	54
1724	Synthesis and Biological Evaluation of a Carbamate-Containing Tubulysin Antibodyâ€Drug Conjugate. Bioconjugate Chemistry, 2020, 31, 2350-2361.	1.8	8
1725	Survival outcomes in patients with human epidermal growth factor receptor 2 positive metastatic breast cancer administered a therapy following trastuzumab emtansine treatment. Medicine (United) Tj ETQq0 0 0ogBT /Overlock 10 Tf		
1726	A novel HER2-targeting antibody 5G9 identified by large-scale trastuzumab-based screening exhibits potent synergistic antitumor activity. EBioMedicine, 2020, 60, 102996.	2.7	3
1727	Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy. Npj Precision Oncology, 2020, 4, 27.	2.3	16
1728	Smart stimuli-responsive biopolymeric nanomedicines for targeted therapy of solid tumors. Nanomedicine, 2020, 15, 2171-2200.	1.7	29
1729	Managing therapeutic resistance in breast cancer: from the lncRNAs perspective. Theranostics, 2020, 10, 10360-10377.	4.6	30
1730	Diffuse Spontaneous Laryngeal Hemorrhage with Trastuzumab. Case Reports in Otolaryngology, 2020, 2020, 1-3.	0.1	0
1731	Selective targeting of cancer signaling pathways with nanomedicines: challenges and progress. Future Oncology, 2020, 16, 2959-2979.	1.1	22
1732	Targeting molecular subtypes in solid cancers: successes and failures. Current Opinion in Oncology, 2020, 32, 488-493.	1.1	2

#	ARTICLE	IF	CITATIONS
1733	Therapy Algorithms for the Diagnosis and Treatment of Patients with Early and Advanced Breast Cancer. <i>Breast Care</i> , 2020, 15, 608-618.	0.8	8
1734	Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Current Treatment Standards and Future Perspectives. <i>Breast Care</i> , 2020, 15, 570-578.	0.8	7
1735	Dose-reduced trastuzumab deruxtecan can be safely used in liver failure and active leptomeningeal metastases. <i>Current Problems in Cancer Case Reports</i> , 2020, 2, 100034.	0.1	1
1736	Evolution in the real-world therapeutic strategies in more than 20,000 women with breast cancer having received human epidermal growth factor receptor 2-targeted treatments: Results from the french personalized reimbursement model database (2011-2018). <i>European Journal of Cancer</i> , 2020, 141, 209-217.	1.3	5
1737	Utilizing Data Visualization to Identify Survival and Treatment Differences Between Women With De Novo and Recurrent Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2021, 21, 292-301.	1.1	4
1738	Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 279.	3.5	32
1739	A Rationally Designed ICAM1 Antibody Drug Conjugate for Pancreatic Cancer. <i>Advanced Science</i> , 2020, 7, 2002852.	5.6	10
1740	Design, Synthesis, and Structure-Activity Relationships of Novel Tetrahydroisoquinolino Benzodiazepine Dimer Antitumor Agents and Their Application in Antibody-Drug Conjugates. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 13913-13950.	2.9	7
1741	<p>Treatment Landscape for Patients with HER2-Positive Metastatic Breast Cancer: A Review on Emerging Treatment Options</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 10615-10629.	0.9	11
1742	National comprehensive cancer network recommendations for drugs without US food and drug administration approval in metastatic breast cancer: A cross-sectional study. <i>Cancer Treatment Reviews</i> , 2020, 91, 102113.	3.4	4
1743	Development and preclinical evaluation of cixutumumab drug conjugates in a model of insulin growth factor receptor I (IGF-1R) positive cancer. <i>Scientific Reports</i> , 2020, 10, 18549.	1.6	7
1744	Recent Developments of Systemic Chemotherapy for Gastric Cancer. <i>Cancers</i> , 2020, 12, 1100.	1.7	31
1745	Trastuzumab Beyond Progression in Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: UK Practice now and in the Future. <i>Clinical Oncology</i> , 2020, 32, 636-638.	0.6	1
1746	What's the Price? Toxicities of Targeted Therapies in Breast Cancer Care. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 55-70.	1.8	13
1747	The tumor targeting performance of anti-CD166 Probody drug conjugate CX-2009 and its parental derivatives as monitored by ⁸⁹ Zr-immuno-PET in xenograft bearing mice. <i>Theranostics</i> , 2020, 10, 5815-5828.	4.6	25
1748	Heterogeneous Drug Efficacy of an Antibody-Drug Conjugate Visualized Using Simultaneous Imaging of Its Delivery and Intracellular Damage in Living Tumor Tissues. <i>Translational Oncology</i> , 2020, 13, 100764.	1.7	1
1749	Targeted anticancer prodrug therapy using dextran mediated enzyme-antibody conjugate and β -cyclodextrin-curcumin inclusion complex. <i>International Journal of Biological Macromolecules</i> , 2020, 160, 1029-1041.	3.6	11
1750	The strategic combination of trastuzumab emtansine with oncolytic rhabdoviruses leads to therapeutic synergy. <i>Communications Biology</i> , 2020, 3, 254.	2.0	11

#	ARTICLE	IF	CITATIONS
1751	Temozolomide in secondary prevention of HER2-positive breast cancer brain metastases. <i>Future Oncology</i> , 2020, 16, 899-909.	1.1	22
1752	Novel antibody-drug conjugates for triple negative breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592091598.	1.4	74
1753	The role of chemotherapy in treatment of advanced breast cancer: an overview for clinical practice. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 153, 102988.	2.0	25
1754	T-DM1-induced thrombocytopenia in breast cancer patients: New perspectives. <i>Biomedicine and Pharmacotherapy</i> , 2020, 129, 110407.	2.5	12
1755	<p><p>Prognostic Value of Plasma HER2 Gene Copy Number in HER2-Positive Metastatic Breast Cancer Treated with First-Line Trastuzumab<p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 4385-4395.	1.0	6
1756	The emerging role of antibody-drug conjugates in urothelial carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 551-561.	1.1	23
1757	Effectiveness and Safety of Pyrotinib, and Association of Biomarker With Progression-Free Survival in Patients With HER2-Positive Metastatic Breast Cancer: A Real-World, Multicentre Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 811.	1.3	37
1758	Clinical development of immunotherapies for HER2+ breast cancer: a review of HER2-directed monoclonal antibodies and beyond. <i>Npj Breast Cancer</i> , 2020, 6, 10.	2.3	106
1759	The Second Generation Antibody-Drug Conjugate SYD985 Overcomes Resistances to T-DM1. <i>Cancers</i> , 2020, 12, 670.	1.7	31
1760	Improved survival in metastatic breast cancer: results from a 20-year study involving 1033 women treated at a single comprehensive cancer center. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 1559-1566.	1.2	12
1761	DNA Origami-Enabled Engineering of Ligand-Drug Conjugates for Targeted Drug Delivery. <i>Small</i> , 2020, 16, e1904857.	5.2	58
1762	(Radio)Theranostic Patient Management in Oncology Exemplified by Neuroendocrine Neoplasms, Prostate Cancer, and Breast Cancer. <i>Pharmaceuticals</i> , 2020, 13, 39.	1.7	10
1763	Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. <i>Lancet Oncology</i> , The, 2020, 21, 519-530.	5.1	441
1764	Role of innate and adaptive immunity in the efficacy of anti-HER2 monoclonal antibodies for HER2-positive breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 149, 102927.	2.0	15
1765	Immunotherapy: Newer Therapeutic Armamentarium against Cancer Stem Cells. <i>Journal of Oncology</i> , 2020, 2020, 1-15.	0.6	11
1766	The Impact of Primary Tumor Surgery on Survival in HER2 Positive Stage IV Breast Cancer Patients in the Current Era of Targeted Therapy. <i>Annals of Surgical Oncology</i> , 2020, 27, 2711-2720.	0.7	18
1767	Pilot evaluation of a HER2 testing in non-small-cell lung cancer. <i>Journal of Clinical Pathology</i> , 2020, 73, 353-357.	1.0	12
1768	Antibody-Drug Conjugate Payloads; Study of Auristatin Derivatives. <i>Chemical and Pharmaceutical Bulletin</i> , 2020, 68, 201-211.	0.6	37

#	ARTICLE	IF	CITATIONS
1769	4. Supportivtherapie. , 2020, , 127-216.		0
1770	Beyond the Paclitaxel and Vinca Alkaloids: Next Generation of Plant-Derived Microtubule-Targeting Agents with Potential Anticancer Activity. <i>Cancers</i> , 2020, 12, 1721.	1.7	43
1771	Lapatinib plus Capecitabine versus Trastuzumab plus Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer with Central Nervous System Metastases for Patients Currently or Previously Treated with Trastuzumab (LANTERN): a Phase II Randomised Trial. <i>Clinical Oncology</i> , 2020, 32, 656-664.	0.6	11
1772	Differential prognostic value of positive HER2 status determined by immunohistochemistry or fluorescence in situ hybridization in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 183, 311-319.	1.1	9
1773	Antibody-Drug Conjugates and Targeted Treatment Strategies for Hepatocellular Carcinoma: A Drug-Delivery Perspective. <i>Molecules</i> , 2020, 25, 2861.	1.7	14
1774	Efficacy and Safety of Trastuzumab Emtansine Plus Capecitabine vs Trastuzumab Emtansine Alone in Patients With Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer. <i>JAMA Oncology</i> , 2020, 6, 1203.	3.4	19
1775	Roles for receptor tyrosine kinases in tumor progression and implications for cancer treatment. <i>Advances in Cancer Research</i> , 2020, 147, 1-57.	1.9	32
1776	Stimuli-Responsive Polymeric Systems for Smart Drug Delivery. <i>Advances in Material Research and Technology</i> , 2020, , 115-134.	0.3	9
1777	Safety and efficacy of T-DM1 in patients with advanced HER2-positive breast cancer The Royal Marsden experience. <i>Cancer Treatment and Research Communications</i> , 2020, 24, 100188.	0.7	13
1778	Anti-HER2 therapy for breast cancer in older patients. <i>Future Oncology</i> , 2020, 16, 1393-1407.	1.1	0
1779	Functional nanostructures for drug resistance breast cancer theranostics. , 2020, , 131-152.		1
1780	Analysis of the StoRM cohort reveals physical activity to be associated with survival in metastatic breast cancer. <i>Scientific Reports</i> , 2020, 10, 10757.	1.6	8
1781	Characterization of T-DM1-resistant breast cancer cells. <i>Pharmacology Research and Perspectives</i> , 2020, 8, e00617.	1.1	9
1782	Management of brain metastases in breast cancer: a review of current practices and emerging treatments. <i>Breast Cancer Research and Treatment</i> , 2020, 180, 279-300.	1.1	52
1783	An overview of precision oncology basket and umbrella trials for clinicians. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 125-137.	157.7	116
1784	Real-World Evidence in Oncology: Opportunities and Limitations. <i>Oncologist</i> , 2020, 25, e746-e752.	1.9	74
1785	Prognostic factors and outcome of HER2+ breast cancer with CNS metastases. <i>Future Oncology</i> , 2020, 16, 269-279.	1.1	8
1786	Evaluating the clinical effectiveness and safety of various HER2-targeted regimens after prior taxane/trastuzumab in patients with previously treated, unresectable, or metastatic HER2-positive breast cancer: a systematic review and network meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2020, 180, 597-609.	1.1	24

#	ARTICLE	IF	CITATIONS
1787	Update on targeted cancer therapies, single or in combination, and their fine tuning for precision medicine. <i>Biomedicine and Pharmacotherapy</i> , 2020, 125, 110009.	2.5	62
1788	Real-world data of lapatinib and treatment after lapatinib in patients with previously treated HER2-positive metastatic breast cancer: A multicenter, retrospective study. <i>Cancer Medicine</i> , 2020, 9, 2981-2988.	1.3	4
1789	Dataset used in the economic evaluation trastuzumab-based regimens for HER-2 positive metastatic breast cancer patients in the Taiwanese healthcare setting. <i>Data in Brief</i> , 2020, 29, 105194.	0.5	1
1790	Neratinib: the emergence of a new player in the management of HER2+ breast cancer brain metastasis. <i>Future Oncology</i> , 2020, 16, 247-254.	1.1	15
1791	Trastuzumab Emtansine: Mechanisms of Action and Resistance, Clinical Progress, and Beyond. <i>Trends in Cancer</i> , 2020, 6, 130-146.	3.8	58
1792	<p>Analysis of the Cost-Effectiveness of Liquid Biopsy to Determine Treatment Change in Patients with Her2-Positive Advanced Breast Cancer in Colombia</p>. <i>ClinicoEconomics and Outcomes Research</i> , 2020, Volume 12, 115-122.	0.7	20
1793	Major Strides in HER2 Blockade for Metastatic Breast Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 669-671.	13.9	6
1794	Emerging Targeted Therapies for HER2 Positive Gastric Cancer That Can Overcome Trastuzumab Resistance. <i>Cancers</i> , 2020, 12, 400.	1.7	50
1795	Precision Chemoradiotherapy for HER2 Tumors Using Antibody Conjugates of an Auristatin Derivative with Reduced Cell Permeability. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 157-167.	1.9	21
1796	Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients: extended follow-up of JBCRG-cohort study 01. <i>Breast Cancer</i> , 2020, 27, 631-641.	1.3	6
1798	Stable Pyrrole-Linked Bioconjugates through Tetrazine-Triggered Azanorbornadiene Fragmentation. <i>Angewandte Chemie - International Edition</i> , 2020, 59, 6196-6200.	7.2	15
1799	Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence. <i>Journal of Cellular Physiology</i> , 2020, 235, 7900-7910.	2.0	19
1800	Statistical modelling of HER2-positivity in breast cancer: Final analyses from two large, multicentre, non-interventional studies in Germany. <i>Breast</i> , 2020, 49, 246-253.	0.9	2
1801	HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2020, 84, 101965.	3.4	92
1802	Stable Pyrrole-Linked Bioconjugates through Tetrazine-Triggered Azanorbornadiene Fragmentation. <i>Angewandte Chemie</i> , 2020, 132, 6255-6259.	1.6	7
1803	Protease-activated prodrugs: strategies, challenges, and future directions. <i>FEBS Journal</i> , 2020, 287, 1936-1969.	2.2	71
1804	Challenges on Multiple Endpoints in Clinical Trials: An Industry Survey in Japan. <i>Therapeutic Innovation and Regulatory Science</i> , 2020, 54, 528-533.	0.8	0
1805	Designing Chimeric Molecules for Drug Discovery by Leveraging Chemical Biology. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 1908-1928.	2.9	32

#	ARTICLE	IF	CITATIONS
1807	Structure-Activity Relationship of HER2 Receptor Targeting Peptide and Its Derivatives in Targeted Tumor Therapy. <i>Biomolecules</i> , 2020, 10, 183.	1.8	9
1808	Differential Expression and Clinicopathological Significance of HER2, Indoleamine 2,3-Dioxygenase and PD-L1 in Urothelial Carcinoma of the Bladder. <i>Journal of Clinical Medicine</i> , 2020, 9, 1265.	1.0	18
1809	Drug Conjugates for Targeting Eph Receptors in Glioblastoma. <i>Pharmaceuticals</i> , 2020, 13, 77.	1.7	7
1810	HER2-Specific Pseudomonas Exotoxin A PE25 Based Fusions: Influence of Targeting Domain on Target Binding, Toxicity, and In Vivo Biodistribution. <i>Pharmaceutics</i> , 2020, 12, 391.	2.0	7
1811	Acquired resistance to trastuzumab/pertuzumab or to T-DM1 in vivo can be overcome by HER2 kinase inhibition with TAS0728. <i>Cancer Science</i> , 2020, 111, 2123-2131.	1.7	17
1812	Application of trastuzumab emtansine in HER2-positive and KRAS/BRAF-mutated colon cancer cells. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13255.	1.7	5
1813	Recent advances of antibody drug conjugates for clinical applications. <i>Acta Pharmaceutica Sinica B</i> , 2020, 10, 1589-1600.	5.7	102
1814	Redirecting extracellular proteases to molecularly guide radiosensitizing drugs to tumors. <i>Biomaterials</i> , 2020, 248, 120032.	5.7	14
1816	Comparison of outcomes in a population-based cohort of metastatic breast cancer patients receiving anti-HER2 therapy with clinical trial outcomes. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 155-165.	1.1	14
1817	Personalized Medicine: Recent Progress in Cancer Therapy. <i>Cancers</i> , 2020, 12, 1009.	1.7	123
1818	Breast cancer nanomedicine market update and other industrial perspectives of nanomedicine. , 2020, , 371-404.		6
1819	Kinetic and structural characterization of therapeutic albumin chemical functionalization using complementary mass spectrometry techniques. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020, 185, 113242.	1.4	4
1820	Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 871-885.	1.4	57
1821	The Resurgence of Antibody Drug Conjugates in Cancer Therapeutics: Novel Targets and Payloads. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, e58-e74.	1.8	36
1822	The Use of Genomics to Drive Kidney Disease Drug Discovery and Development. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 1342-1351.	2.2	5
1823	FDA Approval Summary: Ado-Trastuzumab Emtansine for the Adjuvant Treatment of HER2-positive Early Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4180-4185.	3.2	41
1824	Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors. <i>Cancer Discovery</i> , 2020, 10, 688-701.	7.7	212
1825	Escalating and De-escalating Therapy for Early-Stage HER2-Positive Breast Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 3-13.	1.8	8

#	ARTICLE	IF	CITATIONS
1826	Antibody-Drug Conjugates: Patient and Treatment Selection. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, 105-114.	1.8	12
1827	Early Adverse Events predict Survival Outcomes in HER2-positive Advanced Breast Cancer Patients treated with Lapatinib plus Capecitabine. Journal of Cancer, 2020, 11, 3327-3333.	1.2	4
1828	Antibody-drug conjugates for the treatment of ovarian cancer. Expert Opinion on Biological Therapy, 2021, 21, 875-887.	1.4	11
1829	Prognostic factors of ado-trastuzumab emtansine treatment in patients with metastatic HER-2 positive breast cancer. Journal of Oncology Pharmacy Practice, 2021, 27, 547-554.	0.5	6
1830	Identification of potential anti-leishmanial agents using computational investigation and biological evaluation against trypanothione reductase. Journal of Biomolecular Structure and Dynamics, 2021, 39, 960-969.	2.0	12
1831	Prognostic and predictive parameters in breast pathology: a pathologist's primer. Modern Pathology, 2021, 34, 94-106.	2.9	14
1832	Actively targeted nanomedicines for precision cancer therapy: Concept, construction, challenges and clinical translation. Journal of Controlled Release, 2021, 329, 676-695.	4.8	111
1833	The root cause of drug resistance in HER2-positive breast cancer and the therapeutic approaches to overcoming the resistance. , 2021, 218, 107677.		31
1834	Mechanistic Modeling of Intra-Tumor Spatial Distribution of Antibody-Drug Conjugates: Insights into Dosing Strategies in Oncology. Clinical and Translational Science, 2021, 14, 395-404.	1.5	8
1835	Anti-EGFR antibody-drug conjugate for triple-negative breast cancer therapy. Engineering in Life Sciences, 2021, 21, 37-44.	2.0	20
1836	The cost-effectiveness of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer is supported by clinical evidence. Breast Journal, 2021, 27, 75-76.	0.4	3
1837	FDA Approval Summary: Tucatinib for the Treatment of Patients with Advanced or Metastatic HER2-positive Breast Cancer. Clinical Cancer Research, 2021, 27, 1220-1226.	3.2	36
1838	HER2-directed antibodies, affibodies and nanobodies as drug-delivery vehicles in breast cancer with a specific focus on radioimmunotherapy and radioimmunoimaging. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1371-1389.	3.3	63
1839	Third-line treatment of HER2-positive advanced breast cancer: From no standard to a Pandora's box. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1875, 188487.	3.3	16
1840	Margetuximab for the treatment of HER2-positive metastatic breast cancer. Expert Opinion on Biological Therapy, 2021, 21, 127-133.	1.4	21
1842	Treatment strategies for breast cancer brain metastases. British Journal of Cancer, 2021, 124, 142-155.	2.9	117
1843	Amplification of 8p11.23 in cancers and the role of amplicon genes. Life Sciences, 2021, 264, 118729.	2.0	12
1844	Concurrent Radiation and Modern Systemic Therapies for Breast Cancer: An Ever-Expanding Frontier. Clinical Breast Cancer, 2021, 21, 120-127.	1.1	2

#	ARTICLE	IF	CITATIONS
1845	Novel Auristatins with High Bystander and Cytotoxic Activities in Drug Efflux ⁺ positive Tumor Models. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 320-328.	1.9	17
1846	Experimental HER2- targeted therapies for biliary tract cancer. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 389-399.	1.9	9
1847	How can the potential of the duocarmycins be unlocked for cancer therapy?. <i>Drug Discovery Today</i> , 2021, 26, 577-584.	3.2	18
1848	Rapid HER2 cytologic fluorescence in situ hybridization for breast cancer using noncontact alternating current electric field mixing. <i>Cancer Medicine</i> , 2021, 10, 586-594.	1.3	0
1849	Phase I Study of Everolimus, Letrozole, and Trastuzumab in Patients with Hormone Receptor ⁺ positive Metastatic Breast Cancer or Other Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 1247-1255.	3.2	5
1850	Comparative effectiveness of trastuzumab emtansine versus lapatinib plus chemotherapy for HER2+ metastatic breast cancer. <i>Journal of Comparative Effectiveness Research</i> , 2021, 10, 595-602.	0.6	4
1851	Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor ⁺ Positive Metastatic Breast Cancer: Updated Results of ALTERNATIVE. <i>Journal of Clinical Oncology</i> , 2021, 39, 79-89.	0.8	67
1852	Development and biological assessment of MMAE-trastuzumab antibody ⁺ drug conjugates (ADCs). <i>Breast Cancer</i> , 2021, 28, 216-225.	1.3	10
1853	The efficacy and safety of pertuzumab plus trastuzumab and docetaxel as a first-line therapy in Japanese patients with inoperable or recurrent HER2-positive breast cancer: the COMACHI study. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 125-134.	1.1	4
1854	Novel therapeutic interventions in cancer treatment using protein and peptide-based targeted smart systems. <i>Seminars in Cancer Biology</i> , 2021, 69, 249-267.	4.3	26
1855	The Impact of Education on Knowledge Attitude and Practice of Breast Self-Examination Among Adolescents Girls at the Fiwasaye Girls Grammar School Akure, Nigeria. <i>Journal of Cancer Education</i> , 2021, 36, 39-46.	0.6	14
1856	Antibody ⁺ drug conjugates for lung cancer in the era of personalized oncology. <i>Seminars in Cancer Biology</i> , 2021, 69, 268-278.	4.3	17
1857	Inhibitory effects of combinations of trastuzumab and cytotoxic chemotherapy drugs in HER2-positive gastric cancer. <i>International Journal of Transgender Health</i> , 2021, 14, 226-235.	1.1	1
1858	Research advances and new challenges in overcoming triple-negative breast cancer. , 2021, 4, 517-542.		11
1859	Systemic Therapy for the Treatment of Breast Cancer. , 2021, , 81-87.		0
1860	Prolonged Responses With Trastuzumab Emtasine Treatment of Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer Refractory to Trastuzumab and Pertuzumab: Systematic Review of Evidence. <i>Clinical Breast Cancer</i> , 2021, 21, 391-398.	1.1	0
1861	Prolonged Survival in Patients with Human Epidermal Growth Factor Receptor-2-Overexpressed Metastatic Breast Cancer after Targeted Therapy is Dominantly Contributed by Luminal-Human Epidermal Growth Factor Receptor-2 Population. <i>Oncologie</i> , 2021, 23, 229-239.	0.2	1
1862	Adverse event profiles of epidermal growth factor receptor ⁺ tyrosine kinase inhibitors in cancer patients: A systematic review and meta ⁺ analysis. <i>Clinical and Translational Science</i> , 2021, 14, 919-933.	1.5	8

#	ARTICLE	IF	CITATIONS
1863	Chemical technologies for precise protein bioconjugation interfacing biology and medicine. Chemical Communications, 2021, 57, 7083-7095.	2.2	13
1864	Ado-trastuzumab emtansine: Avoiding side-effects of traditional HER2 positive breast cancer treatment. Journal of Oncology Pharmacy Practice, 2021, 27, 1770-1774.	0.5	0
1865	Cancer Vaccines, Treatment of the Future: With Emphasis on HER2-Positive Breast Cancer. International Journal of Molecular Sciences, 2021, 22, 779.	1.8	53
1866	Unlocking the Power of Exosomes for Crossing Biological Barriers in Drug Delivery. Pharmaceutics, 2021, 13, 122.	2.0	112
1867	Results from the FeDeriCa trial: are we reducing the burden of breast cancer treatment?. Lancet Oncology, The, 2021, 22, 5-6.	5.1	0
1868	Cancer Immunology. , 2021, , .		0
1869	Clinical benefit of treatment after trastuzumab emtansine for HER2-positive metastatic breast cancer: a real-world multi-centre cohort study in Japan (WJOG12519B). Breast Cancer, 2021, 28, 581-591.	1.3	7
1870	Efficacy of second-line treatments for patients with advanced human epidermal growth factor receptor 2 positive breast cancer after trastuzumab-based treatment: a systematic review and bayesian network analysis. Journal of Cancer, 2021, 12, 1687-1697.	1.2	5
1871	Targeting breast cancer. , 2021, , 341-350.		0
1872	Clinical significance of quantitative categorization of HER2 fluorescent in situ hybridization results in invasive breast cancer patients treated with HER2-targeted agents. Modern Pathology, 2021, 34, 720-734.	2.9	4
1873	Leucine-rich alpha-2-glycoprotein 1 (LRG1) as a novel ADC target. RSC Chemical Biology, 2021, 2, 1206-1220.	2.0	15
1874	Translational aspects of biologicals: monoclonal antibodies and antibody-drug conjugates as examples. , 2021, , 329-350.		0
1875	Recent advances in the treatment of hormone receptor-positive/human epidermal growth factor 2-positive advanced breast cancer. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110133.	1.4	9
1876	HER2-Positive (HER2 +) Breast Cancer. , 2021, , .		0
1877	The renaissance of chemically generated bispecific antibodies. Nature Reviews Chemistry, 2021, 5, 78-92.	13.8	32
1878	Real-life prognosis of 5041 bone-only metastatic breast cancer patients in the multicenter national observational ESME program. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592098765.	1.4	13
1879	CardioOncology. , 2021, , 505-537.		0
1880	Recent Discoveries of Macromolecule- and Cell-Based Biomarkers and Therapeutic Implications in Breast Cancer. International Journal of Molecular Sciences, 2021, 22, 636.	1.8	29

#	ARTICLE	IF	CITATIONS
1881	Antibody-drug conjugates in solid tumors: a look into novel targets. <i>Journal of Hematology and Oncology</i> , 2021, 14, 20.	6.9	129
1882	The Development of Antibody-Drug Conjugates for Urothelial Carcinoma Treatment. <i>The Korean Journal of Urological Oncology</i> , 2021, 19, 30-39.	0.1	0
1883	The changing treatment of metastatic her2-positive breast cancer (Review). <i>Oncology Letters</i> , 2021, 21, 287.	0.8	5
1884	Recent progress in immunotherapy of breast cancer targeting the human epidermal growth factor receptor 2 (HER2). <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 1235-1244.	0.5	6
1885	Extracellular vesicles as modifiers of antibody-drug conjugate efficacy. <i>Journal of Extracellular Vesicles</i> , 2021, 10, e12070.	5.5	17
1886	Unlocking the potential of antibody-drug conjugates for cancer therapy. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 327-344.	12.5	498
1887	Cost-effectiveness of pertuzumab and trastuzumab biosimilar combination therapy as initial treatment for HER2-positive metastatic breast cancer in Singapore. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021, 21, 449-456.	0.7	11
1888	Profile of Trastuzumab Deruxtecan in the Management of Patients with HER2-Positive Unresectable or Metastatic Breast Cancer: An Evidence-Based Review. <i>Breast Cancer: Targets and Therapy</i> , 2021, Volume 13, 151-159.	1.0	10
1889	Smart Nanocarriers for Targeted Cancer Therapy. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2021, 21, 546-557.	0.9	3
1890	The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 187, 155-165.	1.1	18
1891	Safety, tolerability, and pharmacokinetics of BAT8001 in patients with HER2-positive breast cancer: An open-label, dose-escalation, phase I study. <i>Cancer Communications</i> , 2021, 41, 171-182.	3.7	15
1892	Impact of tumor cellularity on the HER2 amplification assay by OncoScan [®] in breast cancer. <i>Breast Cancer</i> , 2021, 28, 977-982.	1.3	0
1893	Intensity of metastasis screening and survival outcomes in patients with breast cancer. <i>Scientific Reports</i> , 2021, 11, 2851.	1.6	6
1894	Improving Antibody-Tubulysin Conjugates through Linker Chemistry and Site-Specific Conjugation. <i>ChemMedChem</i> , 2021, 16, 1077-1081.	1.6	7
1895	The Effect of the EGFR - Targeting Compound 3-[(4-Phenylpyrimidin-2-yl) Amino] Benzene-1-Sulfonamide (13f) against Cholangiocarcinoma Cell Lines. <i>Asian Pacific Journal of Cancer Prevention</i> , 2021, 22, 381-390.	0.5	2
1896	Optimal Strategies for Successful Initiation of Neratinib in Patients with HER2-Positive Breast Cancer. <i>Clinical Breast Cancer</i> , 2021, 21, e575-e583.	1.1	7
1897	Targeted immunotherapy for HER2-low breast cancer with 17p loss. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	14
1898	Dual- versus single-agent HER2 inhibition and incidence of intracranial metastatic disease: a systematic review and meta-analysis. <i>Npj Breast Cancer</i> , 2021, 7, 17.	2.3	2

#	ARTICLE	IF	CITATIONS
1899	What makes a good antibody-drug conjugate?. Expert Opinion on Biological Therapy, 2021, 21, 841-847.	1.4	22
1900	A Phase I/II Trial of PD 0332991 (Palbociclib) and T-DM1 in HER2-Positive Advanced Breast Cancer After Trastuzumab and Taxane Therapy. Clinical Breast Cancer, 2021, 21, 417-424.	1.1	10
1901	Clinical Development of New Antibody-Drug Conjugates in Breast Cancer: To Infinity and Beyond. BioDrugs, 2021, 35, 159-174.	2.2	30
1903	Clinical application of circulating tumor DNA in breast cancer. Journal of Cancer Research and Clinical Oncology, 2021, 147, 1431-1442.	1.2	5
1904	Development of the CK18-resistant trastuzumab-resistant HER2-positive breast cancer cell line and xenograft animal models. Cancer Medicine, 2021, 10, 2370-2379.	1.3	0
1905	Risk and prognostic factors of breast cancer with liver metastases. BMC Cancer, 2021, 21, 238.	1.1	31
1906	Survival before and after the introduction of pertuzumab and T-DM1 in HER2-positive advanced breast cancer, a study of the SONABRE Registry. Breast Cancer Research and Treatment, 2021, 188, 571-581.	1.1	5
1908	The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data. Npj Breast Cancer, 2021, 7, 30.	2.3	22
1909	Targeting HER2 in breast cancer: new drugs and paradigms on the horizon. Exploration of Targeted Anti-tumor Therapy, 0, , .	0.5	1
1910	The evolving paradigm of biomarker actionability: Histology-agnosticism as a spectrum, rather than a binary quality. Cancer Treatment Reviews, 2021, 94, 102169.	3.4	14
1911	HER2-/HER3-Targeting Antibody-Drug Conjugates for Treating Lung and Colorectal Cancers Resistant to EGFR Inhibitors. Cancers, 2021, 13, 1047.	1.7	27
1912	Integrating Adjuvant Radiation with Post-Neoadjuvant Therapies in Early Breast Cancer. Current Oncology Reports, 2021, 23, 58.	1.8	1
1914	Biosimilar medicines uptake: The role of the clinical pharmacist. Exploratory Research in Clinical and Social Pharmacy, 2021, 1, 100008.	0.6	8
1915	FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for the Treatment of Unresectable or Metastatic HER2-Positive Breast Cancer. Clinical Cancer Research, 2021, 27, 4478-4485.	3.2	67
1916	The Discovery of a Novel Antimetastatic Bcl3 Inhibitor. Molecular Cancer Therapeutics, 2021, 20, 775-786.	1.9	7
1917	Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncology, The, 2021, 22, 351-360.	5.1	188
1918	Taxane versus vinorelbine in combination with trastuzumab and pertuzumab for first-line treatment of metastatic HER2-positive breast cancer: a retrospective two-center study. Breast Cancer Research and Treatment, 2021, 188, 379-387.	1.1	3
1919	Effects of Ado-Trastuzumab Emtansine and Fam-Trastuzumab Deruxtecan on Metastatic Breast Cancer Harboring <i>HER2</i> Amplification and the L755S Mutation. Oncologist, 2021, 26, 635-639.	1.9	11

#	ARTICLE	IF	CITATIONS
1920	Implementation of Precision Oncology for Patients with Metastatic Breast Cancer in an Interdisciplinary MTB Setting. <i>Diagnostics</i> , 2021, 11, 733.	1.3	13
1921	Cardiovascular toxicity of breast cancer treatment: an update. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 15-24.	1.1	7
1922	Revisiting antibody-drug conjugates and their predictive biomarkers in platinum-resistant ovarian cancer. <i>Seminars in Cancer Biology</i> , 2021, 77, 42-55.	4.3	10
1923	Biodegradable Flexible Electronic Device with Controlled Drug Release for Cancer Treatment. <i>ACS Applied Materials & Interfaces</i> , 2021, 13, 21067-21075.	4.0	14
1925	An evaluation of the healthcare costs associated with adverse events in patients with breast cancer. <i>International Journal of Health Planning and Management</i> , 2021, 36, 1465-1475.	0.7	1
1926	Pyrotinib Combined With Vinorelbine in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study. <i>Frontiers in Oncology</i> , 2021, 11, 664429.	1.3	16
1927	CATCH: A Prospective Precision Oncology Trial in Metastatic Breast Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 676-686.	1.5	20
1928	Amplification of the human epidermal growth factor receptor 2 (HER2) gene is associated with a microsatellite stable status in Chinese gastric cancer patients. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 377-387.	0.6	4
1929	Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 811-824.	1.4	16
1930	Routine Molecular Pathology Diagnostics in Precision Oncology. <i>Deutsches A&#x0308;rztblatt International</i> , 2021, 118, .	0.6	2
1931	In vitro effects of Trastuzumab Emtansine (T-DM1) and concurrent irradiation on HER2-positive breast cancer cells. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2021, 25, 126-134.	0.6	10
1932	T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study. <i>ESMO Open</i> , 2021, 6, 100099.	2.0	12
1933	The evolution of commercial drug delivery technologies. <i>Nature Biomedical Engineering</i> , 2021, 5, 951-967.	11.6	539
1934	Systematic review of the use of translated patient-reported outcome measures in cancer trials. <i>Trials</i> , 2021, 22, 306.	0.7	8
1935	The EMA review of trastuzumab emtansine (T-DM1) for the adjuvant treatment of adult patients with HER2-positive early breast cancer. <i>ESMO Open</i> , 2021, 6, 100074.	2.0	7
1936	PCA062, a P-cadherin Targeting Antibody-Drug Conjugate, Displays Potent Antitumor Activity Against P-cadherin-expressing Malignancies. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1270-1282.	1.9	10
1937	Precision Oncology via NMR-Based Metabolomics: A Review on Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4687.	1.8	23
1938	Update Breast Cancer 2020 Part 5 - Moving Therapies From Advanced to Early Breast Cancer Patients. <i>Geburtshilfe Und Frauenheilkunde</i> , 2021, 81, 469-480.	0.8	6

#	ARTICLE	IF	CITATIONS
1939	Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4774.	1.8	55
1940	Th1 cytokine interferon gamma improves response in HER2 breast cancer by modulating the ubiquitin proteasomal pathway. <i>Molecular Therapy</i> , 2021, 29, 1541-1556.	3.7	20
1941	Ppar γ 3 Facilitates ErbB2-Mammary Adenocarcinoma in Mice. <i>Cancers</i> , 2021, 13, 2171.	1.7	5
1942	T-DM1 for advanced breast cancer after multi-anti-HER2-target therapy: a case report. <i>Translational Breast Cancer Research</i> , 2021, 2, 15-15.	0.4	1
1943	Recent Progress in the Development of Quinoline Derivatives for the Exploitation of Anti-Cancer Agents. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2021, 21, 825-838.	0.9	15
1944	Harnessing the Physiological Functions of Cellular Prion Protein in the Kidneys: Applications for Treating Renal Diseases. <i>Biomolecules</i> , 2021, 11, 784.	1.8	4
1945	The Synergistic Effects of Pyrotinib Combined With Adriamycin on HER2-Positive Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 616443.	1.3	9
1946	Prolonged Response to HER2-Directed Therapy in Three Patients with HER2-Amplified Metastatic Carcinoma of the Biliary System: Case Study and Review of the Literature. <i>Oncologist</i> , 2021, 26, 640-646.	1.9	6
1947	The Landscape of Antibody-drug Conjugates in Urothelial Cancer. <i>Advances in Oncology</i> , 2021, 1, 273-282.	0.1	0
1948	Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (â€œMETRICâ€): a randomized multicenter study. <i>Npj Breast Cancer</i> , 2021, 7, 57.	2.3	26
1949	Current Treatment Approaches for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in Adjuvant and Neoadjuvant Settings. <i>Indian Journal of Medical and Paediatric Oncology</i> , 0, 42, .	0.1	1
1950	Current treatment options for HER2-positive breast cancer patients with brain metastases. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 161, 103329.	2.0	14
1951	Systemic toxicities of trastuzumabâ€emtansine predict tumor response in <sc>HER2</sc>+ metastatic breast cancer. <i>International Journal of Cancer</i> , 2021, 149, 909-916.	2.3	5
1952	JosÃ© Baselga M.D., Ph.D. (1959â€“2021) leading cancer researcher and oncologist. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 156.	3.5	0
1954	The Expanding Role of Chemistry in Optimizing Proteins for Human Health Applications. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 7179-7188.	2.9	8
1955	Treating Advanced Unresectable or Metastatic HER2-Positive Breast Cancer: A Spotlight on Tucatinib. <i>Breast Cancer: Targets and Therapy</i> , 2021, Volume 13, 361-381.	1.0	8
1956	Efficacy and Safety of Pyrotinib Versus T-DM1 in HER2+ Metastatic Breast Cancer Patients Pre-Treated With Trastuzumab and a Taxane: A Bayesian Network Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 608781.	1.3	5
1957	Immunotherapy for Breast Cancer Treatment. <i>Iranian Biomedical Journal</i> , 2021, 25, 140-156.	0.4	2

#	ARTICLE	IF	CITATIONS
1958	Treating Bladder Cancer: Engineering of Current and Next Generation Antibody-, Fusion Protein-, mRNA-, Cell- and Viral-Based Therapeutics. <i>Frontiers in Oncology</i> , 2021, 11, 672262.	1.3	11
1959	Cost-effectiveness Analysis of Ado-trastuzumab Emtansine (T-DM1) for the Adjuvant Treatment of Patients With Residual Invasive HER2+ Early Breast Cancer in the United States. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, 44, 340-349.	0.6	9
1960	Precision Oncology. <i>Advances in Oncology</i> , 2021, 1, 97-112.	0.1	0
1961	Immunoconjugates for Cancer Targeting: A Review of Antibody-Drug Conjugates and Antibody-Functionalized Nanoparticles. <i>Current Medicinal Chemistry</i> , 2021, 28, 2485-2520.	1.2	18
1962	Kinase drug discovery 20 years after imatinib: progress and future directions. <i>Nature Reviews Drug Discovery</i> , 2021, 20, 551-569.	21.5	497
1963	Systems pharmacogenomics identifies novel targets and clinically actionable therapeutics for medulloblastoma. <i>Genome Medicine</i> , 2021, 13, 103.	3.6	10
1964	Reactivity and Selectivity Principles in Native Protein Bioconjugation. <i>Chemical Record</i> , 2021, 21, 1941-1956.	2.9	8
1965	Antibody-Drug Conjugates for the Treatment of Breast Cancer. <i>Cancers</i> , 2021, 13, 2898.	1.7	34
1966	Current and Future Management of HER2-Positive Metastatic Breast Cancer. <i>JCO Oncology Practice</i> , 2021, 17, 594-604.	1.4	102
1967	Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies. <i>Breast Cancer Research and Treatment</i> , 2021, 188, 21-36.	1.1	62
1968	Efficacy and Safety of Trastuzumab Emtansine in Her2 Positive Metastatic Breast Cancer: Real-World Experience. <i>Cancer Investigation</i> , 2021, 39, 473-481.	0.6	9
1969	The past, present, and future of breast cancer models for nanomedicine development. <i>Advanced Drug Delivery Reviews</i> , 2021, 173, 306-330.	6.6	65
1970	Barriers to antibody therapy in solid tumors, and their solutions. <i>Cancer Science</i> , 2021, 112, 2939-2947.	1.7	13
1971	Molecular Perspective of Nanoparticle Mediated Therapeutic Targeting in Breast Cancer: An Odyssey of Endoplasmic Reticulum Unfolded Protein Response (UPRER) and Beyond. <i>Biomedicines</i> , 2021, 9, 635.	1.4	8
1972	The Clinical Efficacy and Safety of Neratinib in Combination with Capecitabine for the Treatment of Adult Patients with Advanced or Metastatic HER2-Positive Breast Cancer. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 2711-2720.	2.0	11
1973	Targeting mTOR and Glycolysis in HER2-Positive Breast Cancer. <i>Cancers</i> , 2021, 13, 2922.	1.7	29
1974	The promising role of antibody drug conjugate in cancer therapy: Combining targeting ability with cytotoxicity effectively. <i>Cancer Medicine</i> , 2021, 10, 4677-4696.	1.3	25
1975	Brain Metastases in HER2-Positive Breast Cancer: Current and Novel Treatment Strategies. <i>Cancers</i> , 2021, 13, 2927.	1.7	54

#	ARTICLE	IF	CITATIONS
1976	Precision Medicine in Oncology: A Review of Multi-Tumor Actionable Molecular Targets with an Emphasis on Non-Small Cell Lung Cancer. <i>Journal of Personalized Medicine</i> , 2021, 11, 518.	1.1	8
1977	Imaging of Endocytic Trafficking and Extracellular Vesicles Released Under Neratinib Treatment in ERBB2+ Breast Cancer Cells. <i>Journal of Histochemistry and Cytochemistry</i> , 2021, 69, 461-473.	1.3	7
1978	Multilineal treatment strategy of HER2-positive metastatic breast cancer (clinical case). <i>Opuholi Zenskoj Reproktivnoj Sistemy</i> , 2021, 17, 35-44.	0.1	0
1979	Targeting HER2 genomic alterations in non-small cell lung cancer. <i>Journal of the National Cancer Center</i> , 2021, 1, 58-73.	3.0	13
1980	The Evolving Landscape of Antibody-Drug Conjugates for Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 183-193.	0.9	6
1981	Locally Advanced Breast Cancer: Treatment Patterns and Predictors of Survival in a Saudi Tertiary Center. <i>Cureus</i> , 2021, 13, e15526.	0.2	0
1982	A new option for Richter syndrome. <i>Blood</i> , 2021, 137, 3318-3319.	0.6	0
1983	HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase. <i>Molecular Cancer Research</i> , 2021, 19, 1699-1711.	1.5	5
1984	Tyrosine Kinase Inhibitors, Antibody-Drug Conjugates, and Proteolysis-Targeting Chimeras: The Pharmacology of Cutting-Edge Lung Cancer Therapies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, e286-e293.	1.8	2
1985	HER3 PET Imaging Identifies Dynamic Changes in HER3 in Response to HER2 Inhibition with Lapatinib. <i>Molecular Imaging and Biology</i> , 2021, 23, 930-940.	1.3	2
1986	Identification of cell surface targets for CAR-T cell therapies and antibody-drug conjugates in breast cancer. <i>ESMO Open</i> , 2021, 6, 100102.	2.0	24
1987	Investigational antibody-drug conjugates in clinical trials for the treatment of breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 1-7.	1.9	3
1988	Progress in Gynecologic Cancers with Antibody Drug Conjugates. <i>Current Oncology Reports</i> , 2021, 23, 89.	1.8	3
1989	Mechanisms of Therapeutic Antitumor Monoclonal Antibodies. <i>Cancer Research</i> , 2021, 81, 4641-4651.	0.4	67
1991	The successful application of pyrotinib in the treatment of primary trastuzumab-resistant HER-2-positive breast cancer with bilateral axillary lymph node metastasis: a case report. <i>Annals of Palliative Medicine</i> , 2021, 10, 7138-7145.	0.5	1
1992	Current approaches to the treatment of HER2-positive breast cancer with brain metastases. <i>Opuholi Zenskoj Reproktivnoj Sistemy</i> , 2021, 17, 27-34.	0.1	2
1993	Immunotherapy in endometrial cancer: rationale, practice and perspectives. <i>Biomarker Research</i> , 2021, 9, 49.	2.8	53
1994	Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 945-962.	1.4	26

#	ARTICLE	IF	CITATIONS
1995	Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer: Clinical Overview and Management of Potential Toxicities. <i>Oncologist</i> , 2021, 26, 827-834.	1.9	28
1996	Targeting lipid metabolism is an emerging strategy to enhance the efficacy of anti-HER2 therapies in HER2-positive breast cancer. <i>Cancer Letters</i> , 2021, 511, 77-87.	3.2	22
1997	Effect of the 2013 ASCO-CAP HER2 Testing Guideline on the Management of IHC/HER2 2+ Invasive Breast Cancer. <i>Anticancer Research</i> , 2021, 41, 4143-4149.	0.5	1
1998	Exosome-mediated transfer of circHIPK3 promotes trastuzumab chemoresistance in breast cancer. <i>Journal of Drug Targeting</i> , 2021, 29, 1004-1015.	2.1	16
2001	Prolonged Survival in Patients with Metastatic HER2-Positive Inflammatory Breast Cancer: A Case Report and Review of the Literature. <i>Case Reports in Oncology</i> , 2021, 14, 1071-1079.	0.3	5
2002	Antibody Drug Conjugates in Lung Cancer: State of the Current Therapeutic Landscape and Future Developments. <i>Clinical Lung Cancer</i> , 2021, 22, 483-499.	1.1	11
2003	A phase II study of efficacy, toxicity, and the potential impact of genomic alterations on response to eribulin mesylate in combination with trastuzumab and pertuzumab in women with human epidermal growth factor receptor 2 (HER2)+ metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 411-423.	1.1	3
2004	Building bridges between drug development and cancer science: a tribute to JosÃ© Baselga's legacy. <i>Annals of Oncology</i> , 2021, 32, 825-828.	0.6	0
2005	Asymmetric Epoxidation of Enones Promoted by Dinuclear Magnesium Catalyst. <i>Advanced Synthesis and Catalysis</i> , 2021, 363, 4247-4255.	2.1	3
2006	Assessment of racial differences in the incidence of thrombocytopenia induced by trastuzumab emtansine: a systematic review and meta-analysis. <i>Annals of Translational Medicine</i> , 2021, 9, 1139-1139.	0.7	4
2007	Functional genomics for breast cancer drug target discovery. <i>Journal of Human Genetics</i> , 2021, 66, 927-935.	1.1	9
2008	Landmark trials in the medical oncology management of metastatic breast cancer. <i>Seminars in Oncology</i> , 2021, 48, 246-258.	0.8	4
2009	A randomized phase III study comparing trastuzumab emtansine with trastuzumab, pertuzumab and docetaxel in elderly patients with advanced stage HER2-positive breast cancer: Japan Clinical Oncology Group Study (JCOG1607, HERB TEA study). <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 1471-1474.	0.6	2
2010	Precision medicine in breast cancer: From clinical trials to clinical practice. <i>Cancer Treatment Reviews</i> , 2021, 98, 102223.	3.4	34
2011	Real-world effectiveness of post-trastuzumab emtansine treatment in patients with HER2-positive, unresectable and/or metastatic breast cancer: a retrospective observational study (KBCSG-TR 1917). <i>BMC Cancer</i> , 2021, 21, 795.	1.1	3
2012	A Review of Therapeutic Antibodies in Breast Cancer. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2021, 24, 363-380.	0.9	1
2013	A Companion Diagnostic With Significant Clinical Impact in Treatment of Breast and Gastric Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 676939.	1.3	20
2014	Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine in Patients With Previously Treated HER2-Positive Metastatic Breast Cancer: A Multicenter, Retrospective Study. <i>Frontiers in Oncology</i> , 2021, 11, 699333.	1.3	5

#	ARTICLE	IF	CITATIONS
2015	DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo. <i>Gynecologic Oncology</i> , 2021, 163, 334-341.	0.6	10
2016	HER2-Directed Therapy in Advanced Gastric and Gastroesophageal Adenocarcinoma: Triumphs and Troubles. <i>Current Treatment Options in Oncology</i> , 2021, 22, 88.	1.3	13
2017	Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody-drug conjugates in the breast cancer treatment landscape. <i>ESMO Open</i> , 2021, 6, 100204.	2.0	30
2018	Efficacy and Safety of Anti-HER2 Agents in Combination With Chemotherapy for Metastatic HER2-Positive Breast Cancer Patient: A Network Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 731210.	1.3	5
2019	The Efficacy of Pyrotinib as a Third- or Higher-Line Treatment in HER2-Positive Metastatic Breast Cancer Patients Exposed to Lapatinib Compared to Lapatinib-Naive Patients: A Real-World Study. <i>Frontiers in Pharmacology</i> , 2021, 12, 682568.	1.6	7
2020	Pharmacological Basis of Breast Cancer Resistance to Therapies - An Overview. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2022, 22, 760-774.	0.9	1
2021	Pyrotinib treatment enhances the radiosensitivity in HER2-positive brain metastatic breast cancer patients. <i>Anti-Cancer Drugs</i> , 2022, 33, e622-e627.	0.7	12
2022	Efficacy and safety of trastuzumab emtansine in older patients with HER2-positive advanced breast cancer: a real-world study. <i>Tumori</i> , 2022, 108, 19-25.	0.6	2
2023	Is Molecular Tailored-Therapy Changing the Paradigm for CNS Metastases in Breast Cancer?. <i>Clinical Drug Investigation</i> , 2021, 41, 757-773.	1.1	1
2024	C3 ester side chain plays a pivotal role in the antitumor activity of Maytansinoids. <i>Biochemical and Biophysical Research Communications</i> , 2021, 566, 197-203.	1.0	6
2025	Efficacy of tucatinib for HER2-positive metastatic breast cancer after HER2-targeted therapy: a network meta-analysis. <i>Future Oncology</i> , 2021, 17, 4635-4647.	1.1	6
2026	Manejo actual de las metástasis vertebrales: un trabajo en equipo. <i>Revista Chilena De Ortopedia Y Traumatología</i> , 2021, 62, e136-e142.	0.0	0
2027	Cardiovascular Toxicity of Novel HER2-Targeted Therapies in the Treatment of Breast Cancer. <i>Current Oncology Reports</i> , 2021, 23, 128.	1.8	18
2028	The Effects of HER2 on CDK4/6 Activity in Breast Cancer. <i>Clinical Breast Cancer</i> , 2022, 22, e278-e285.	1.1	8
2029	Targeted Agents for HER2-Positive Breast Cancer: Optimal Use in Older Patients. <i>Drugs and Aging</i> , 2021, 38, 829-844.	1.3	0
2030	HER2-targeted therapies in gastric cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1876, 188549.	3.3	76
2031	Trastuzumab emtansine for HER2-positive metastatic breast cancer: Outcomes from a whole-of-population Australian cohort. <i>Breast</i> , 2021, 58, 106-112.	0.9	6
2032	Outcomes of extra-cranial stereotactic body radiotherapy for metastatic breast cancer: Treatment indication matters. <i>Radiotherapy and Oncology</i> , 2021, 161, 159-165.	0.3	14

#	ARTICLE	IF	CITATIONS
2033	Targeted Therapies for Breast Cancer Brain Metastases. <i>Clinical Breast Cancer</i> , 2021, 21, 263-270.	1.1	3
2034	Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 103.	2.3	17
2035	The role of tyrosine kinase inhibitors in the treatment of HER2+ metastatic breast cancer. <i>European Journal of Cancer</i> , 2021, 154, 175-189.	1.3	24
2036	Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer. <i>Cancers</i> , 2021, 13, 4884.	1.7	11
2037	Neu Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer. <i>Breast Cancer: Targets and Therapy</i> , 2021, Volume 13, 539-557.	1.0	4
2038	Adverse Drug Reactions with HER2-Positive Breast Cancer Treatment: An Analysis from the Italian Pharmacovigilance Database. <i>Drugs - Real World Outcomes</i> , 2022, 9, 91-107.	0.7	15
2039	Circulating and Intracellular miRNAs as Prognostic and Predictive Factors in HER2-Positive Early Breast Cancer Treated with Neoadjuvant Chemotherapy: A Review of the Literature. <i>Cancers</i> , 2021, 13, 4894.	1.7	6
2040	An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy. <i>Molecules</i> , 2021, 26, 5847.	1.7	158
2041	Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer. <i>Cancers</i> , 2021, 13, 4421.	1.7	12
2042	Defueling the cancer: ATP synthase as an emerging target in cancer therapy. <i>Molecular Therapy - Oncolytics</i> , 2021, 23, 82-95.	2.0	25
2044	Prevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2021, 16, e0257976.	1.1	10
2045	Cardiac Toxicity Associated with Cancer Immunotherapy and Biological Drugs. <i>Cancers</i> , 2021, 13, 4797.	1.7	12
2046	Brain Metastasis Treatment: The Place of Tyrosine Kinase Inhibitors and How to Facilitate Their Diffusion across the Blood-Brain Barrier. <i>Pharmaceutics</i> , 2021, 13, 1446.	2.0	11
2047	Trastuzumab deruxtecan and other HER2-targeting agents for the treatment of HER2-positive gastric cancer. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1193-1201.	1.1	6
2048	A novel humanized MUC1 antibody–drug conjugate for the treatment of trastuzumab-resistant breast cancer. <i>Acta Biochimica Et Biophysica Sinica</i> , 2021, 53, 1625-1639.	0.9	10
2050	Practice Patterns and Outcomes of Novel Targeted Agents for the Treatment of <i>ERBB2</i>-Positive Metastatic Breast Cancer. <i>JAMA Oncology</i> , 2021, 7, e212140.	3.4	12
2051	Rehabilitaci3n oncol3gica en cardiotoxicidad: rompiendo paradigmas en la atenci3n al sobreviviente de c4ncer. <i>Revista Colombiana De M4dicina F4sica Y Rehabilitaci3n</i> , 2021, 31, .	0.0	0
2052	Dissecting the biological heterogeneity of HER2-positive breast cancer. <i>Breast</i> , 2021, 59, 339-350.	0.9	41

#	ARTICLE	IF	CITATIONS
2053	Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations. <i>ESMO Open</i> , 2021, 6, 100260.	2.0	70
2054	Anti-HER2 antibody prolongs overall survival disproportionately more than progression-free survival in HER2-Positive metastatic breast cancer patients. <i>Breast</i> , 2021, 59, 211-220.	0.9	2
2055	Targeting HER2 heterogeneity in breast cancer. <i>Cancer Treatment Reviews</i> , 2021, 100, 102286.	3.4	46
2056	The effects of anticancer therapies on bone metastases in breast cancer. , 2022, , 987-1002.		0
2057	Innate and adaptive immunity in cancer. , 2022, , 19-61.		0
2058	Research Progress of Antibody-Drug Conjugate. <i>Advances in Clinical Medicine</i> , 2021, 11, 4135-4143.	0.0	2
2059	B-cell maturation antigen (BCMA) in multiple myeloma: the new frontier of targeted therapies. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 204062072198958.	1.1	24
2060	Antitumour immunity regulated by aberrant ERBB family signalling. <i>Nature Reviews Cancer</i> , 2021, 21, 181-197.	12.8	141
2061	Clinicopathological utility of human epidermal growth factor receptor 2 (HER2)-heterogeneity for next-generation treatments of triple-negative breast cancer. <i>Oncotarget</i> , 2021, 12, 2302-2304.	0.8	2
2062	Safety and efficacy of trastuzumab emtansine (TDM-1) in a patient on hemodialysis for renal failure. <i>Cancer Treatment and Research Communications</i> , 2021, 27, 100314.	0.7	2
2063	The Progress and Safety Assessment of T-DM1 in Solid Tumor Research. <i>Advances in Clinical Medicine</i> , 2021, 11, 2663-2669.	0.0	0
2064	Breast Cancer Therapeutics and Biomarkers: Past, Present, and Future Approaches. <i>Breast Cancer: Basic and Clinical Research</i> , 2021, 15, 117822342199585.	0.6	22
2065	From Anthramycin to Pyrrolobenzodiazepine (PBD)-Containing Antibody-Drug Conjugates (ADCs). <i>Angewandte Chemie - International Edition</i> , 2017, 56, 462-488.	7.2	2
2067	Antibody-Drug Conjugates: Can Coupling Cytotoxicity and Specificity Overcome Therapeutic Resistance?. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2013, , 183-200.	0.1	3
2068	Targeting Receptor Tyrosine Kinases in Cancer. , 2015, , 225-278.		11
2069	Evaluation of Human Epidermal Growth Factor Receptor 2 (HER2) Gene Status in Human Breast Cancer Formalin-Fixed Paraffin-Embedded (FFPE) Tissue Specimens by Fluorescence In Situ Hybridization (FISH). <i>Methods in Molecular Biology</i> , 2016, 1406, 61-70.	0.4	3
2070	Clinical Aspects of Estrogen and Progesterone Receptors and ERBB2 Testing. , 2016, , 161-185.		1
2071	Resistance to HER2-Targeted Therapy. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2017, , 35-88.	0.1	2

#	ARTICLE	IF	CITATIONS
2073	Onkologika. , 2016, , 583-619.		1
2074	Onkologika. , 2017, , 597-639.		1
2075	Antibody Therapies in Cancer. Advances in Experimental Medicine and Biology, 2016, 909, 1-67.	0.8	8
2076	Membrane Proteins as Targets for Biological Drugs. , 2019, , 49-65.		2
2078	HER2-positive advanced breast cancer treatment in 2020. Cancer Treatment Reviews, 2020, 88, 102033.	3.4	70
2079	Epoxide containing molecules: A good or a bad drug design approach. European Journal of Medicinal Chemistry, 2020, 201, 112327.	2.6	43
2080	Maleimideâ€“thiol adducts stabilized through stretching. Nature Chemistry, 2019, 11, 310-319.	6.6	154
2081	Pyridazinediones deliver potent, stable, targeted and efficacious antibodyâ€“drug conjugates (ADCs) with a controlled loading of 4 drugs per antibody. RSC Advances, 2017, 7, 9073-9077.	1.7	62
2082	Novel therapeutic targets for cancer metastasis. Expert Review of Anticancer Therapy, 2020, 20, 97-109.	1.1	53
2083	The magic bullet as cancer therapeuticâ€“has nanotechnology failed to find its mark?. Progress in Biomedical Engineering, 2020, 2, 042004.	2.8	5
2084	Molecular Subtypes of Breast Cancer: A Review for Breast Radiologists. Journal of Breast Imaging, 2021, 3, 12-24.	0.5	82
2085	HER2-targeted therapy prolongs survival in patients with HER2-positive breast cancer and intracranial metastatic disease: a systematic review and meta-analysis. Neuro-Oncology Advances, 2020, 2, vdaa136.	0.4	6
2086	Adjuvant Trastuzumab Emtansine (T-DM1) and Concurrent Radiotherapy for Residual Invasive HER2-positive Breast Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 895-901.	0.6	16
2087	A Novel Staging System for De Novo Metastatic Breast Cancer Refines Prognostic Estimates. Annals of Surgery, 2020, Publish Ahead of Print, .	2.1	15
2088	Effect of a Breast-Self Examination (BSE) Educational Intervention among Female University Students. American Journal of Nursing Science, 2015, 4, 159.	0.3	10
2089	Tofacitinib enhances delivery of antibody-based therapeutics to tumor cells through modulation of inflammatory cells. JCI Insight, 2019, 4, .	2.3	17
2090	U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation. Journal of Clinical Investigation, 2019, 130, 374-388.	3.9	43
2091	Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells. Journal of Clinical Investigation, 2016, 126, 4640-4653.	3.9	74

#	ARTICLE	IF	CITATIONS
2092	Impact of obesity on safety outcomes and treatment modifications with ado-trastuzumab emtansine in breast cancer patients. <i>Journal of Oncology Pharmacy Practice</i> , 2022, 28, 49-54.	0.5	5
2093	Genomic Alteration in Metastatic Breast Cancer and Its Treatment. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 30-43.	1.8	107
2094	Beyond Trastuzumab and Lapatinib: New Options for HER2-Positive Breast Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, 33, e2-e11.	1.8	16
2095	Developments in the Use of Antibody-Drug Conjugates. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, 33, e99-e102.	1.8	4
2096	Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2017, 2017, 2141-2148.	0.8	6
2097	Advances in managing breast cancer: a clinical update. <i>F1000prime Reports</i> , 2014, 6, 66.	5.9	11
2098	Long-term Complete Response with Lapatinib Plus Capecitabine in a Patient with HER2-Positive Breast Cancer Metastasized to the Pancreas. <i>The Ewha Medical Journal</i> , 2015, 38, 138.	0.1	1
2099	Sacituzumab govitecan: antibody-drug conjugate in triple-negative breast cancer and other solid tumors. <i>Drugs of Today</i> , 2019, 55, 575.	0.7	30
2100	Media Coverage of Medical Journals: Do the Best Articles Make the News?. <i>PLoS ONE</i> , 2014, 9, e85355.	1.1	44
2101	TFDP3 Regulates Epithelial-Mesenchymal Transition in Breast Cancer. <i>PLoS ONE</i> , 2017, 12, e0170573.	1.1	5
2102	Long-term exposure to estrogen enhances chemotherapeutic efficacy potentially through epigenetic mechanism in human breast cancer cells. <i>PLoS ONE</i> , 2017, 12, e0174227.	1.1	6
2103	Emerging Therapeutic Strategies in Breast Cancer. <i>Southern Medical Journal</i> , 2017, 110, 632-637.	0.3	5
2104	Value of Cancer Care: Ethical Considerations for the Practicing Oncologist. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014, , e146-e149.	1.8	8
2105	Novel Formulations and New Mechanisms of Delivering Chemotherapy. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014, , e381-e386.	1.8	1
2106	Adjuvant! Online: Mind the Gap!. <i>Klinicka Onkologie</i> , 2013, 26, 110-113.	0.1	1
2107	Pathophysiological mechanisms of cardiotoxicity in chemotherapeutic agents. <i>Russian Open Medical Journal</i> , 2020, 9, .	0.1	44
2108	Multiple spider telangiectasias in a breast cancer patient on T-DM1 treatment. <i>Anais Brasileiros De Dermatologia</i> , 2018, 93, 938-939.	0.5	4
2109	Potential Life-Years Lost: The Impact of the Cancer Drug Regulatory and Funding Process in Canada. <i>Oncologist</i> , 2020, 25, e130-e137.	1.9	19

#	ARTICLE	IF	CITATIONS
2110	Targeting HER2 expression in cancer: New drugs and new indications. <i>Bosnian Journal of Basic Medical Sciences</i> , 2021, 21, 1-4.	0.6	25
2111	CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models. <i>Genes and Cancer</i> , 2014, 5, 261-272.	0.6	101
2112	Photoimmunotheranostic agents for triple-negative breast cancer diagnosis and therapy that can be activated on demand. <i>Oncotarget</i> , 2016, 7, 54925-54936.	0.8	24
2113	CTMP, a predictive biomarker for trastuzumab resistance in HER2-enriched breast cancer patient. <i>Oncotarget</i> , 2017, 8, 29699-29710.	0.8	15
2114	Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer. <i>Oncotarget</i> , 2016, 7, 56295-56308.	0.8	83
2115	Dysadherin specific drug conjugates for the treatment of thyroid cancers with aggressive phenotypes. <i>Oncotarget</i> , 2017, 8, 24457-24468.	0.8	4
2116	A bispecific enediyne-energized fusion protein targeting both epidermal growth factor receptor and insulin-like growth factor 1 receptor showing enhanced antitumor efficacy against non-small cell lung cancer. <i>Oncotarget</i> , 2017, 8, 27286-27299.	0.8	13
2117	Efficacy and safety of T-DM1 in the "common-practice" of HER2+ advanced breast cancer setting: a multicenter study. <i>Oncotarget</i> , 2017, 8, 64481-64489.	0.8	22
2118	A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience. <i>Oncotarget</i> , 2017, 8, 56921-56931.	0.8	53
2119	BET inhibitors as novel therapeutic agents in breast cancer. <i>Oncotarget</i> , 2017, 8, 71285-71291.	0.8	33
2120	Gemcitabine-based chemotherapy as a viable option for treatment of advanced breast cancer patients: a meta-analysis and literature review. <i>Oncotarget</i> , 2018, 9, 7148-7161.	0.8	21
2121	Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers. <i>Oncotarget</i> , 2018, 9, 9741-9750.	0.8	12
2122	Identification of key pathways and genes in response to trastuzumab treatment in breast cancer using bioinformatics analysis. <i>Oncotarget</i> , 2018, 9, 32149-32160.	0.8	9
2123	Esophageal cancer cells resistant to T-DM1 display alterations in cell adhesion and the prostaglandin pathway. <i>Oncotarget</i> , 2018, 9, 21141-21155.	0.8	17
2124	Oncodriver inhibition and CD4+ Th1 cytokines cooperate through Stat1 activation to induce tumor senescence and apoptosis in HER2+ and triple negative breast cancer: implications for combining immune and targeted therapies. <i>Oncotarget</i> , 2018, 9, 23058-23077.	0.8	27
2125	Development and evaluation of a novel antibody-photon absorber conjugate reveals the possibility of photoimmunotherapy-induced vascular occlusion during treatment <i>in vivo</i> . <i>Oncotarget</i> , 2018, 9, 31422-31431.	0.8	6
2126	Anetumab ravtansine inhibits tumor growth and shows additive effect in combination with targeted agents and chemotherapy in mesothelin-expressing human ovarian cancer models. <i>Oncotarget</i> , 2018, 9, 34103-34121.	0.8	38
2127	Payload of T-DM1 binds to cell surface cytoskeleton-associated protein 5 to mediate cytotoxicity of hepatocytes. <i>Oncotarget</i> , 2018, 9, 37200-37215.	0.8	23

#	ARTICLE	IF	CITATIONS
2128	The impact of systemic precision medicine and immunotherapy treatments on brain metastases. <i>Oncotarget</i> , 2019, 10, 6739-6753.	0.8	13
2129	Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas. <i>Oncotarget</i> , 2020, 11, 560-570.	0.8	32
2130	Second line trastuzumab emtansine following horizontal dual blockade in a real-life setting. <i>Oncotarget</i> , 2020, 11, 2083-2091.	0.8	7
2131	Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancer. <i>Oncotarget</i> , 2015, 6, 5678-5694.	0.8	30
2132	Membrane associated cancer-oocyte neoantigen SAS1B/ovastacin is a candidate immunotherapeutic target for uterine tumors. <i>Oncotarget</i> , 2015, 6, 30194-30211.	0.8	14
2133	Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses. <i>Oncotarget</i> , 2015, 6, 39538-39549.	0.8	27
2134	Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer. <i>Oncotarget</i> , 2016, 7, 64431-64446.	0.8	161
2135	ImmunoPET helps predicting the efficacy of antibody-drug conjugates targeting TENB2 and STEAP1. <i>Oncotarget</i> , 2016, 7, 25103-25112.	0.8	27
2136	Phase 1B/2 study of the HSP90 inhibitor AUY922 plus trastuzumab in metastatic HER2-positive breast cancer patients who have progressed on trastuzumab-based regimen. <i>Oncotarget</i> , 2016, 7, 37680-37692.	0.8	37
2137	Outcomes of re-treatment with first-line trastuzumab plus a taxane in HER2 positive metastatic breast cancer patients after (neo)adjuvant trastuzumab: A prospective multicenter study. <i>Oncotarget</i> , 2016, 7, 50643-50655.	0.8	10
2138	New insights into acquired endocrine resistance of breast cancer. , 2019, 2, 198-209.		32
2139	When better still might not be good enough. <i>Translational Cancer Research</i> , 2017, 6, S1244-S1247.	0.4	3
2140	Can trastuzumab emtansine be replaced by additional chemotherapy plus targeted therapy for HER2-overexpressing breast cancer patients with residual disease after neoadjuvant chemotherapy?. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2019, 31, 878-891.	0.7	5
2141	Effectiveness of second-line anti-HER2 treatment in HER2-positive metastatic breast cancer patients previously treated with trastuzumab: A real-world study. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2020, 32, 361-369.	0.7	4
2142	Studies on the Safety and Efficacy of Pyrotinib in the Treatment of HER2- Positive Advanced Solid Tumors Excluding Breast Cancer. <i>Cancer Management and Research</i> , 2020, Volume 12, 13479-13487.	0.9	12
2143	Diverse Targeted Approaches to Battle Multidrug Resistance in Cancer. <i>Current Medicinal Chemistry</i> , 2019, 26, 7059-7080.	1.2	22
2144	Tubulin Maytansine Site Binding Ligands and their Applications as MTAs and ADCs for Cancer Therapy. <i>Current Medicinal Chemistry</i> , 2020, 27, 4567-4576.	1.2	9
2145	ADCs, as Novel Revolutionary Weapons for Providing a Step Forward in Targeted Therapy of Malignancies. <i>Current Drug Delivery</i> , 2020, 17, 23-51.	0.8	16

#	ARTICLE	IF	CITATIONS
2146	Toxicology of Trastuzumab: An Insight into Mechanisms of Cardiotoxicity. <i>Current Cancer Drug Targets</i> , 2019, 19, 400-407.	0.8	17
2147	Using TILs to Predict Therapeutic Effect of Chemotherapy (Pertuzumab, Trastuzumab, Docetaxel) on HER2-positive Breast Cancer. , 2017, 37, 5623-5630.		5
2148	Safety Evaluation of Trastuzumab Emtansine in Japanese Patients with HER2-Positive Advanced Breast Cancer. <i>In Vivo</i> , 2017, 31, 493-500.	0.6	13
2149	An Electronic Patient-Reported Outcome Tool for the FACT-B (Functional Assessment of Cancer) Tj ETQq1 1 0.784314 rgBT /Overlock Breast Cancer: Reliability Study. <i>Journal of Medical Internet Research</i> , 2019, 21, e10004.	2.1	29
2150	Reliability of an e-PRO Tool of EORTC QLQ-C30 for Measurement of Health-Related Quality of Life in Patients With Breast Cancer: Prospective Randomized Trial. <i>Journal of Medical Internet Research</i> , 2017, 19, e322.	2.1	48
2151	Development of CAST therapy based on the EPR effect: lesson from clinical trials.. <i>Drug Delivery System</i> , 2018, 33, 139-149.	0.0	2
2152	Drug Conjugates Based on a Monovalent Affibody Targeting Vector Can Efficiently Eradicate HER2 Positive Human Tumors in an Experimental Mouse Model. <i>Cancers</i> , 2021, 13, 85.	1.7	16
2153	Personalizing therapies for gastric cancer: Molecular mechanisms and novel targeted therapies. <i>World Journal of Gastroenterology</i> , 2013, 19, 6383.	1.4	26
2154	Genomic diversity of colorectal cancer: Changing landscape and emerging targets. <i>World Journal of Gastroenterology</i> , 2016, 22, 5668.	1.4	14
2155	Changing strategies for target therapy in gastric cancer. <i>World Journal of Gastroenterology</i> , 2016, 22, 1179.	1.4	32
2156	Mass spectrometry imaging for early discovery and development of cancer drugs. <i>AIMS Medical Science</i> , 2018, 5, 162-180.	0.2	2
2157	Dysregulation of the Met pathway in non-small cell lung cancer: implications for drug targeting and resistance. <i>Translational Lung Cancer Research</i> , 2015, 4, 242-52.	1.3	22
2158	Lung cancer biomarkers, targeted therapies and clinical assays. <i>Translational Lung Cancer Research</i> , 2015, 4, 503-14.	1.3	23
2159	Chemotherapy for advanced cancers. <i>Annals of Palliative Medicine</i> , 2014, 3, 203-28.	0.5	11
2160	Recent advances in the development of anti-HER2 antibodies and antibody-drug conjugates. <i>Annals of Translational Medicine</i> , 2014, 2, 122.	0.7	32
2161	Novel molecular multilevel targeted antitumor agents. <i>Cancer Translational Medicine</i> , 2017, 3, 69.	0.2	11
2162	Trastuzumab deruxtecan: A quantum leap in HER2-positive breast cancer. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2019, 40, 556.	0.1	1
2163	Recent advances and optimal management of human epidermal growth factor receptor-2-positive early-stage breast cancer. <i>Journal of Carcinogenesis</i> , 2019, 18, 5.	2.5	4

#	ARTICLE	IF	CITATIONS
2164	Practical consensus recommendations regarding the management of HER2 neu positive metastatic breast cancer. South Asian Journal of Cancer, 2018, 07, 146-150.	0.2	3
2165	BioPATH: A Biomarker Study in Asian Patients with HER2+ Advanced Breast Cancer Treated with Lapatinib and Other Anti-HER2 Therapy. Cancer Research and Treatment, 2019, 51, 1527-1539.	1.3	5
2166	Genetically Targeted Fractionated Chemotherapy. Journal of Cancer Therapy, 2015, 06, 182-198.	0.1	4
2167	Impressive Objective Response to Nab-Paclitaxel plus Trastuzumab as Fifth Line Therapy in an Elderly HER-2 Positive Breast Cancer Patient. Journal of Cancer Therapy, 2017, 08, 933-940.	0.1	1
2168	Gastric cancer: The times they are a-changinâ€™™. World Journal of Gastrointestinal Oncology, 2015, 7, 303.	0.8	16
2169	Surviving Cancer without a Broken Heart. Rambam Maimonides Medical Journal, 2019, 10, e0012.	0.4	5
2170	Targeted approaches for HER2 breast cancer therapy: News from nanomedicine?. World Journal of Pharmacology, 2014, 3, 72.	1.3	8
2171	Molecular targeted agents--where we are and where we are going. Chinese Journal of Cancer, 2013, 32, 225-232.	4.9	4
2172	Cancer immunotherapy in clinical practice: 1/2the past, present, and future. Chinese Journal of Cancer, 2014, 33, 445-457.	4.9	38
2173	Cardiac Toxicity of HER2-Directed Therapy in Women with Breast Cancer: Epidemiology, Etiology, Risk Factors, and Management. , 0, , .		1
2174	Non-Invasive Monitoring of HER2 Expression in Breast Cancer Patients with 99mTc-Affibody SPECT/CT. Iranian Journal of Radiology, 2020, 17, .	0.1	4
2175	Response Rates and Durations of Response for Biomarker-Based Cancer Drugs in Nonrandomized Versus Randomized Trials. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 36-43.	2.3	21
2176	Quantifying the Survival Benefits of Oncology Drugs With a Focus on Immunotherapy Using Restricted Mean Survival Time. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 278-285.	2.3	12
2177	Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 452-478.	2.3	848
2178	Molecular docking analysis of Cianidanol from Ginkgo biloba with HER2+ breast cancer target. Bioinformation, 2018, 14, 482-487.	0.2	7
2179	Types of Cancers Prevailing in Pakistan and their Management Evaluation. Asian Pacific Journal of Cancer Prevention, 2015, 16, 3605-3616.	0.5	6
2180	Understanding EGFR Signaling in Breast Cancer and Breast Cancer Stem Cells: Overexpression and Therapeutic Implications. Asian Pacific Journal of Cancer Prevention, 2016, 17, 445-453.	0.5	32
2181	Mechanistic considerations for the use of monoclonal antibodies for cancer therapy. Cancer Biology and Medicine, 2014, 11, 20-33.	1.4	109

#	ARTICLE	IF	CITATIONS
2182	Biomarkers. UNIPA Springer Series, 2021, , 43-64.	0.1	0
2183	Treatment Toxicity. UNIPA Springer Series, 2021, , 291-308.	0.1	0
2184	Metastatic Breast Cancer. UNIPA Springer Series, 2021, , 467-479.	0.1	0
2185	EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment. Nature Reviews Clinical Oncology, 2022, 19, 51-69.	12.5	101
2186	Antibody drug conjugates for patients with breast cancer. Current Problems in Cancer, 2021, 45, 100795.	1.0	3
2187	An Elaborate New Linker System Significantly Enhances the Efficacy of an HER2-antibody-Drug Conjugate against Refractory HER2-Positive Cancers. Advanced Science, 2021, 8, e2102414.	5.6	10
2188	Identification of a risk prediction model for clinical prognosis in HER2 positive breast cancer patients. Genomics, 2021, 113, 4088-4097.	1.3	8
2189	The frequency of low HER2 expression in breast cancer and a comparison of prognosis between patients with HER2-low and HER2-negative breast cancer by HR status. Breast Cancer, 2022, 29, 234-241.	1.3	90
2190	Modelling hypersensitivity to trastuzumab defines biomarkers of response in HER2 positive breast cancer. Journal of Experimental and Clinical Cancer Research, 2021, 40, 313.	3.5	6
2191	Effectiveness and safety of pyrotinib-based therapy in patients with HER2-positive metastatic breast cancer: A real-world retrospective study. Cancer Medicine, 2021, 10, 8352-8364.	1.3	18
2192	Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab. BMC Cancer, 2021, 21, 1150.	1.1	3
2193	Gallbladder Cancer: Current Insights in Genetic Alterations and Their Possible Therapeutic Implications. Cancers, 2021, 13, 5257.	1.7	22
2194	Antibody-Antineoplastic Conjugates in Gynecological Malignancies: Current Status and Future Perspectives. Pharmaceutics, 2021, 13, 1705.	2.0	11
2195	Discovery of targeted expression data for novel antibody-based and chimeric antigen receptor-based therapeutics in soft tissue sarcomas using RNA-sequencing: clinical implications. Current Problems in Cancer, 2021, 45, 100794.	1.0	4
2196	Changes in the detection of human epidermal growth factor receptor 2 gene (Her-2) status for Her-2 fluorescent in situ hybridization testing. Chinese Medical Journal, 2021, Publish Ahead of Print, .	0.9	0
2197	Antibody drug conjugates in gastrointestinal cancer: From lab to clinical development. Journal of Controlled Release, 2021, 340, 1-34.	4.8	11
2198	Cancer Stromal Targeting (CAST) Therapy and Tailored Antibody Drug Conjugate Therapy Depending on the Nature of Tumor Stroma. , 2013, , 161-181.		0
2199	HER2-Positive Metastatic Breast Cancer: Second-Line Treatment. , 2013, , 61-74.		0

#	ARTICLE	IF	CITATIONS
2200	Breast cancer and molecular targeted drugs. Okayama Igakkai Zasshi, 2013, 125, 243-250.	0.0	0
2201	Median Survival, Hazard Ratios and Bounding Drug Effectiveness. SSRN Electronic Journal, 0, , .	0.4	0
2202	Beyond Trastuzumab and Lapatinib: New Options for HER2-Positive Breast Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , e2-e11.	1.8	6
2203	Developments in the Use of Antibody-Drug Conjugates. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , e99-e102.	1.8	2
2204	Systemic Therapy. , 2014, , 381-420.		0
2205	HER2 Inhibition and Clinical Achievements. , 2013, , 51-80.		0
2206	Evaluating the evolving evidence: The challenges of molecular-targeted therapy in management of gastric cancer. Open Journal of Gastroenterology, 2014, 04, 6-15.	0.1	0
2207	Current Status of Immunotherapy in Gastroesophageal Cancer. , 2014, , 179-191.		0
2211	Neue Medikamente bei Melanom und Mammakarzinom. Pharma-Kritik (discontinued), 2014, 36, .	0.0	0
2212	Ado-Trastuzumab Emtansine in Metastatic HER2-Positive Breast Cancer. Journal of the Advanced Practitioner in Oncology, 2014, 5, 134-9.	0.2	1
2213	Antibody Drug Conjugates: A Leap Ahead in Cancer Treatment. Journal of Drug Delivery and Therapeutics, 2014, 4, .	0.2	1
2214	Management of Metastatic Breast Cancer. , 2015, , 473-497.		0
2215	Early Biomarkers in Breast Cancer. , 2015, , 61-142.		0
2216	Pharmacogenetics and Antineoplastic Therapies. Advances in Predictive, Preventive and Personalised Medicine, 2015, , 275-305.	0.6	0
2217	A modern paradigm for treating HER2-positive advanced breast cancer: Dual HER2 blockade and antibody-drug conjugates. Onkologiya Zhurnal Imeni P A Gertsena, 2015, 4, 78.	0.0	0
2218	Targeted Therapies for HER2-positive Breast Cancer. Current Clinical Pathology, 2015, , 57-72.	0.0	0
2219	Copy Number Changes in Carcinomas: Applications. , 2015, , 95-104.		0
2220	Molecular targeted therapy of breast cancer. Tenri Medical Bulletin, 2015, 18, 65-69.	0.1	0

#	ARTICLE	IF	CITATIONS
2222	Targeting Key Stemness-Related Pathways in Human Cancers. , 2015, , 393-443.		0
2223	Neue Arzneimittel 2014. , 2015, , 37-198.		3
2224	Translation: Companion Biomarkers: Paving the Pathway to Personalized Treatment for Cancer. Laboratory Medicine Online, 2015, 5, 44.	0.0	0
2225	Molecular Pathology of HER Family of Oncogenes in Breast Cancer: HER-2 Evaluation and Role in Targeted Therapy. Molecular Pathology Library, 2015, , 119-136.	0.1	0
2226	Detection of Chromosomal Abnormalities with Different In Situ Hybridisation Techniques - the Usefulness in Cancer Patients Qualification for Molecularly-Targeted Therapies. Advances in Clinical and Experimental Medicine, 2015, 24, 715-723.	0.6	0
2227	Role of HER2 in Gastric Cancers. , 2015, , 77-89.		0
2228	Ewolucja systemowego leczenia przeciwnowotworowego. Nowotwory, 2015, 65, 1-6.	0.1	0
2230	Trastuzumab-based Retreatment after Lapatinib in Heavily Pretreated HER2 Positive Metastatic Breast Cancer: an Anatolian Society of Medical Oncology Study. Asian Pacific Journal of Cancer Prevention, 2015, 16, 4127-4131.	0.5	3
2231	HER2-positive metastatic breast cancer: second-line treatment. , 2016, , 71-86.		0
2232	Diagnostic Applications of Nuclear Medicine: Breast Cancer. , 2016, , 1-25.		0
2233	Molecular Prognostic and Predictive Assays in Breast Cancer. AJSP Review and Reports, 2016, 21, 4-10.	0.0	0
2234	HER2-Targeted Therapy. , 2016, , 391-410.		0
2235	Metastatic Breast Cancer. , 2016, , 451-474.		0
2236	Systemic Therapy. , 2016, , 335-390.		0
2237	Essence of Neoadjuvant Therapy. , 2016, , 235-246.		0
2238	Breast Cancer in Younger Women. , 2016, , 529-564.		0
2239	Human Epidermal Growth Factor Receptor 2 (HER2): Translating the Lab to the Clinic. , 2016, , 59-70.		0
2240	Therapie ciblée anti-HER2: principes, validation, indication. , 2016, , 89-94.		0

#	ARTICLE	IF	CITATIONS
2241	Whether HER2-positive non-breast cancers are candidates for treatment with Ado-trastuzumab emtansine?. Journal of Research in Pharmacy Practice, 2016, 5, 227.	0.2	0
2242	Resposta prolongada durante 43 ciclos de trastuzumabe entansina (T-DM1) em paciente com c�ncer de mama metast�tico com superexpress�o de HER2: relato de caso. Revista Brasileira De Mastologia, 2016, 26, 31-36.	0.0	0
2243	Mammatumoren. , 2017, , 419-444.		0
2244	Principles of Cancer Targeted Therapy in Older Adults. , 2017, , 1-15.		0
2245	Mammaerkrankungen. , 2017, , 297-358.		0
2246	Diagnostic Applications of Nuclear Medicine: Breast Cancer. , 2017, , 613-637.		0
2247	Diagnostic Value of Serum Human Epidermal Growth Factor Receptor 2 Extracellular Domain (HER2) Tj ETQqO O O rgBT /Overlock 10 Tf 5 Drugs: A Case Report. Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons), 2017, 42, 912-922.	0.0	0
2249	Invasive Breast Cancer Therapy 2017: How Well Are We Hitting the Target?. Resistance To Targeted Anti-cancer Therapeutics, 2017, , 1-34.	0.1	0
2250	Mammakarzinom bei der alten und geriatrischen Patientin. , 2017, , 1-16.		0
2252	Invasive Carcinomas. , 2018, , 191-232.		1
2254	Excellent Response with Ado-Trastuzumab Emtansine in a Patient with Relapsed Metastatic Breast Cancer Presenting with Pulmonary Lymphangitic Carcinomatosis. Cureus, 2017, 9, e1473.	0.2	2
2255	Left Ventricular Ejection Fraction Screening and Clinical Decision-making in Metastatic HER2-positive Breast Cancer. Anticancer Research, 2017, 37, 3751-3755.	0.5	5
2256	Antibody-Drug Conjugates in Head and Neck Cancer. Korean Journal of Otorhinolaryngology-Head and Neck Surgery, 2017, 60, 331-335.	0.0	0
2257	Management of HER2-positive breast cancer, escalation and de-escalation of the therapy. Onkologie (Czech Republic), 2017, 11, 186-191.	0.0	0
2258	CLINICAL CASE OF SUCCESFUL APPLICATION OF KADSYLA APPLICATION IN METASTATIC HER2 POSITIVE BREAST CANCER. Meditsinskiy Sovet, 2017, , 56-58.	0.1	0
2259	Victims of Our Own Success: Cardiac Toxicities from Conventional and Emerging Cancer Therapies. , 2018, , 165-179.		0
2260	Trastuzumab Emtansine: Antibody-drug Conjugate in Treatment of Human Epidermal Growth Factor Receptor-2-Positive Metastatic Breast Cancer. Indian Journal of Medical and Paediatric Oncology, 2018, 39, 79-87.	0.1	0
2261	Current Treatment Options for Human Epidermal Growth Factor Receptor 2-Directed Therapy in Metastatic Breast Cancer: An Indian Perspective. Indian Journal of Medical and Paediatric Oncology, 2018, 39, 368-379.	0.1	1

#	ARTICLE	IF	CITATIONS
2263	Systemic Treatment of Metastatic Breast Cancer in Older Adults. , 2018, , 1-12.		0
2264	Diarrhea, Constipation, and Obstruction in Cancer Management. , 2018, , 421-436.		1
2265	Onkologika. , 2018, , 645-691.		1
2266	Mammakarzinom bei der alten und geriatrischen Patientin. , 2018, , 401-416.		0
2267	Analysis of HER Family (HER1-4) Expression as a Biomarker in Combination Therapy with Pertuzumab, Trastuzumab and Docetaxel for Advanced HER2-positive Breast Cancer. Anticancer Research, 2018, 38, 2285-2294.	0.5	7
2268	Anticorps monoclonaux en oncologie : d'occlencher une r'ponse immunitaire en plus de la r'duction tumorale sp'cifique.. Bulletin De L'Academie Nationale De Medecine, 2018, 202, 707-735.	0.0	0
2269	An update on antibody drug conjugates. Pharmacy & Pharmacology International Journal, 2018, 6, .	0.1	0
2271	Caracter'sticas y supervivencia de pacientes con c'ncer de seno metast'sico HER2-positivo en la era post-trastuzumab. Revista Colombiana De Cancerolog'aa, 2018, 22, 112-118.	0.0	2
2272	Adjuvant Therapy for HER2-Positive Early-Stage Breast Cancer. , 2019, , 383-411.		0
2273	Systemic Treatment Drugs and Regimens. , 2019, , 587-608.		0
2274	Glycoengineering. , 2019, , 145-166.		0
2275	Systemic Treatment Drugs/Regimens and Dose Modifications. , 2019, , 789-801.		0
2276	Clinical Aspects of Estrogen and Progesterone Receptors and ERBB2 Testing. , 2019, , 143-161.		0
2278	Onkologika. , 2019, , 817-875.		0
2279	Splicing Inhibitors as Antibody'Drug Conjugate (ADC) Payloads. RSC Drug Discovery Series, 2019, , 364-379.	0.2	0
2280	Magneto-Responsive Nanomaterials for Medical Therapy in Preclinical and Clinical Settings. , 2019, , 241-297.		0
2281	CAST Therapy. , 2019, , 269-288.		0
2282	Novel Therapies to Overcome HER2 Therapy Resistance in Breast Cancer. Resistance To Targeted Anti-cancer Therapeutics, 2019, , 191-221.	0.1	2

#	ARTICLE	IF	CITATIONS
2283	The Current Status of Cancer Drug Delivery Systems and Future Directions. , 2019, , 311-319.		0
2284	Treatment of HER2-Overexpressing Metastatic Breast Cancer. , 2019, , 463-494.		0
2285	Tyrosine Kinase Inhibitors. , 2019, , 529-539.		0
2286	Cancer Therapy. , 2019, , 7-76.		0
2287	Emerging Novel Therapies in Overcoming Resistance to Targeted Therapy. Resistance To Targeted Anti-cancer Therapeutics, 2019, , 223-258.	0.1	0
2289	Efficacy and tolerability of eribulin mesylate in the treatment of anthracycline and taxane resistance to metastatic breast cancer. Single center experience. Ortado Yu Táp Dergisi, 2019, 11, 10-14.	0.1	0
2291	Journal of Otolaryngology of Japan, 2010, 122, 836-840.		
2292	Evaluación y Manejo del Cáncer de Mama Metastásico, Irreseccable o Recurrente: 1er Consenso Nacional del Cáncer de Mama de la Sociedad Panameña de Oncología (SPO). Revista Medica De Panama, 2019, 39, .	0.0	0
2293	Long-time Response with Ado-trastuzumab Emtansine in a Recurrent Metastatic Breast Cancer. Cureus, 2019, 11, e6036.	0.2	4
2294	Current Treatment Strategies in Breast Cancer Brain Metastases. , 2020, , 267-279.		0
2297	Postneoadjuvant therapy: a new approach to the treatment of HER2-positive breast cancer (KATHERINE) Tj ETQq0 0.0 rgBT /Qverlock 10	0.1	0
2298	Paradigms in Cancer Drug Development: A Universe with Many Galaxies. , 2020, , 17-44.		0
2299	Onkologika. , 2020, , 671-732.		2
2301	Narrowing the focus: Therapeutic cell surface targets for refractory triple-negative breast cancer. World Journal of Clinical Oncology, 2020, 11, 169-179.	0.9	1
2302	AJICAPâ,ç: Development of a Chemical Site-Specific Conjugation Technology for Antibody-Drug Conjugates. Yuki Gosei Kagaku Kyokaiishi/Journal of Synthetic Organic Chemistry, 2020, 78, 495-502.	0.0	0
2303	2020 consensus guideline for optimal approach to the diagnosis and treatment of HER2-positive breast cancer in Bosnia and Herzegovina. Bosnian Journal of Basic Medical Sciences, 2021, 21, 120-135.	0.6	2
2305	Novel antibodyâ€“drug conjugates: current and future roles in gynecologic oncology. Current Opinion in Obstetrics and Gynecology, 2021, 33, 26-33.	0.9	1
2306	New Insights to Reshape the Management of Patients with Metastatic Breast Cancer - Focus on Overcoming Challenges in HER2 Status Interpretation. Open Biomarkers Journal, 2020, 10, 38-46.	0.1	0

#	ARTICLE	IF	CITATIONS
2307	Residual disease after neoadjuvant systemic anti-HER2 therapy: the KATHERINE trial. <i>Onkologie (Czech) Tj ETQq0 0,0rgBT /Oylock 10</i>	0.0	0
2309	Nuclear medicine in precision oncology: a foreword. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 64, 231-233.	0.4	0
2310	Surgical therapy for breast cancer liver metastases. <i>Translational Cancer Research</i> , 2020, 9, 5053-5062.	0.4	2
2311	Trastuzumab does not bind rat or mouse ErbB2/neu: implications for selection of non-clinical safety models for trastuzumab-based therapeutics. <i>Breast Cancer Research and Treatment</i> , 2022, 191, 303-317.	1.1	10
2312	U.S. FDA Drug Approvals for Breast Cancer: A Decade in Review. <i>Clinical Cancer Research</i> , 2022, 28, 1072-1086.	3.2	31
2313	A Tetravalent Biparatopic Antibody Causes Strong HER2 Internalization and Inhibits Cellular Proliferation. <i>Life</i> , 2021, 11, 1157.	1.1	2
2314	Emerging combination immunotherapy strategies for breast cancer: dual immune checkpoint modulation, antibody-drug conjugates and bispecific antibodies. <i>Breast Cancer Research and Treatment</i> , 2022, 191, 291-302.	1.1	18
2315	Adverse events of targeted therapies approved for women's cancers. <i>International Journal of Women's Dermatology</i> , 2021, 7, 552-559.	1.1	0
2316	Current understandings and clinical translation of nanomedicines for breast cancer therapy. <i>Advanced Drug Delivery Reviews</i> , 2022, 180, 114034.	6.6	32
2317	Cardiotoxicity of Epidermal Growth Factor Receptor 2-Targeted Drugs for Breast Cancer. <i>Frontiers in Pharmacology</i> , 2021, 12, 741451.	1.6	7
2318	Chapter 2: Challenges and Considerations in the Design of Antibody-Drug Conjugates. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2020, , 27-48.	0.2	0
2319	Trastuzumab emtansine of the treatment of HER2-positive breast cancer with brain metastases. <i>Meditsinskiy Sovet</i> , 2020, , 174-180.	0.1	0
2321	HER2-targeted regimens after prior trastuzumab for patients with HER2-positive unresectable, locally advanced or metastatic breast cancer: a network meta-analysis of randomized controlled trials. <i>Annals of Translational Medicine</i> , 2020, 8, 1634-1634.	0.7	3
2322	Nanotechnology in Medicine. <i>Ecoproduction</i> , 2020, , 57-64.	0.8	2
2323	Chapter 17: Oncology: Somatic Disease and Pharmacogenomics. , 2020, , .		0
2324	Heart Failure in Relation to Tumor-Targeted Therapies and Immunotherapies. <i>Methodist DeBakey Cardiovascular Journal</i> , 2021, 15, 250.	0.5	7
2326	Treatment options for HER2-positive metastatic breast cancer. <i>Oncolog-Hematolog Ro</i> , 2020, 2, 28.	0.0	0
2327	Targeted Therapies. , 2020, , 1-13.		0

#	ARTICLE	IF	CITATIONS
2328	Principles of Cancer Targeted Therapy in Older Adults. , 2020, , 881-894.		0
2329	Systemic Treatment of Metastatic Breast Cancer in Older Adults. , 2020, , 643-654.		0
2330	Immunopathology and Immunotherapy for Breast Cancer. , 2020, , 541-555.		1
2331	Thirteen-year analyses of medical oncology outpatient day clinic data: a changing field. ESMO Open, 2020, 5, e000880.	2.0	4
2332	Neurological Toxicities of Immunotherapy. , 2020, , 223-242.		0
2333	Cancer Immunotherapy Confers a Global Benefit. , 2020, , 1-48.		0
2335	Ado-Trastuzumab Emtansine â€“ The Monoclonal Drug Conjugate in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. Indian Journal of Medical and Paediatric Oncology, 2020, 41, 218-220.	0.1	0
2336	ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Annals of Oncology, 2021, 32, 1475-1495.	0.6	454
2337	Patient Eligibility and Results for Brain Metastasis in Phase 3 Trials of Advanced Breast Cancer: A Scoping Review. Cancers, 2021, 13, 5306.	1.7	0
2338	Immune Modulating Antibodyâ€“Drug Conjugate (IM-ADC) for Cancer Immunotherapy. Journal of Medicinal Chemistry, 2021, 64, 15716-15726.	2.9	35
2339	RAB5A expression is a predictive biomarker for trastuzumab emtansine in breast cancer. Nature Communications, 2021, 12, 6427.	5.8	8
2340	Advances with antibody-drug conjugates in breast cancer treatment. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 169, 241-255.	2.0	3
2341	Personomics â€“ an innovative tool of precision medicine and its role in the individualized treatment of patients with breast cancer. Asia-Pacific Journal of Oncology, 2020, , 1-8.	0.2	0
2342	Molecular Mechanisms of Early Breast Cancer. , 2021, , 59-83.		0
2343	Antibody-drug conjugates: an evolving approach for melanoma treatment. Melanoma Research, 2021, 31, 1-17.	0.6	4
2344	Rate of reclassification of HER2-equivocal breast cancer cases to HER2-negative per the 2018 ASCO/CAP guidelines and response of HER2-equivocal cases to anti-HER2 therapy. PLoS ONE, 2020, 15, e0241775.	1.1	3
2345	Treatment options for patients with brain metastatic disease in HER2-positive breast cancer. Indian Journal of Medical and Paediatric Oncology, 2020, 41, 735-737.	0.1	0
2346	Therapeutic Monoclonal Antibodies in Clinical Practice against Cancer. Anti-Cancer Agents in Medicinal Chemistry, 2020, 20, 1895-1907.	0.9	2

#	ARTICLE	IF	CITATIONS
2348	Current and Emerging Treatment Regimens for HER2-Positive Breast Cancer. <i>P and T</i> , 2014, 39, 206-12.	1.0	5
2349	Alternative targeted therapy for early Her2 positive breast cancer. <i>Gland Surgery</i> , 2013, 2, 42-5.	0.5	2
2350	A critical role for HER3 in HER2-amplified and non-amplified breast cancers: function of a kinase-dead RTK. <i>American Journal of Translational Research (discontinued)</i> , 2015, 7, 733-50.	0.0	41
2351	Antibody Therapeutics in Oncology. <i>Immunotherapy (Los Angeles, Calif)</i> , 2016, 2, .	0.1	9
2352	Good manufacturing practice production of [(68)Ga]Ga-ABY-025 for HER2 specific breast cancer imaging. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 6, 135-53.	1.0	15
2353	Breast Cancer Immunotherapy. <i>Mã dica</i> , 2015, 10, 185-191.	0.4	5
2355	New Agents for the Management of Advanced HER2-Positive Breast Cancer. <i>Journal of the Advanced Practitioner in Oncology</i> , 2016, 7, 295-298.	0.2	1
2356	Editors' Choice Practice management for elderly patients with breast cancer; Findings from a survey by the Japan Breast Cancer Study Group. <i>Nagoya Journal of Medical Science</i> , 2018, 80, 217-226.	0.6	2
2357	Effect of Patho- Biological Factors on the Survival of Recurrent Breast Cancer Cases. <i>Asian Pacific Journal of Cancer Prevention</i> , 2018, 19, 949-953.	0.5	1
2358	Diagnostic HER2-binding radiopharmaceutical, [Ga]Ga-ABY-025, for routine clinical use in breast cancer patients. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 9, 12-23.	1.0	15
2359	Spider Telangiectases and Palmar Erythema as Harbingers of Structural Liver Changes in Three Breast Cancer Patients on Ado-trastuzumab Emtansine. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2019, 12, 23-26.	0.1	0
2360	The Dual Blockade in the Neoadjuvant Setting of HER-2 Positive Early-Stage Breast Cancer. <i>Journal of Medicine and Life</i> , 2019, 12, 329-331.	0.4	3
2362	Two engineered site-specific antibody-drug conjugates, HLM4 and HLM4, have potent therapeutic activity in two DLL4-positive tumour xenograft models. <i>American Journal of Cancer Research</i> , 2020, 10, 2387-2408.	1.4	1
2363	Efficacy of lapatinib combined with capecitabine in patients with HER2-positive metastatic breast cancer in a real-world study. <i>Oncology Letters</i> , 2020, 20, 378.	0.8	1
2364	Hormone receptor status influences the impact of body mass index and hyperglycemia on the risk of tumor relapse in early-stage HER2-positive breast cancer patients. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 17588359211006960.	1.4	2
2365	Exosomal long noncoding RNA AGAP2-AS1 regulates trastuzumab resistance via inducing autophagy in breast cancer. <i>American Journal of Cancer Research</i> , 2021, 11, 1962-1981.	1.4	2
2366	A tipping-point for apoptosis following dual inhibition of HER2 signaling network by T-DM1 plus GDC-0980 maximizes anti-tumor efficacy. <i>American Journal of Cancer Research</i> , 2021, 11, 2867-2892.	1.4	1
2367	Comparison of pyrotinib or lapatinib with chemotherapy for patients with HER2 positive breast cancer after first-line treatment failure: a retrospective study. <i>American Journal of Translational Research (discontinued)</i> , 2021, 13, 10863-10870.	0.0	0

#	ARTICLE	IF	CITATIONS
2368	PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110598.	1.4	6
2369	How We Treat HER2-Positive Metastatic Breast Cancer. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2021, 42, 370-375.	0.1	0
2371	Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologies. <i>Ca-A Cancer Journal for Clinicians</i> , 2022, 72, 165-182.	157.7	132
2372	The efficacy of lapatinib in patients with metastatic HER2 positive breast cancer who received prior therapy with monoclonal antibodies and antibody-drug conjugate: a single institutional experience. <i>Journal of Chemotherapy</i> , 2021, , 1-8.	0.7	0
2373	Pyrotinib in Patients with HER2-Amplified Advanced Non-Small Cell Lung Cancer: A Prospective, Multicenter, Single-Arm Trial. <i>Clinical Cancer Research</i> , 2022, 28, 461-467.	3.2	24
2374	Impact of the line of treatment on progression-free survival in patients treated with T-DM1 for metastatic breast cancer. <i>BMC Cancer</i> , 2021, 21, 1204.	1.1	2
2375	Molecular Targets and Emerging Therapies for Advanced Gallbladder Cancer. <i>Cancers</i> , 2021, 13, 5671.	1.7	9
2376	Advances in the management of breast cancer brain metastases. <i>Neuro-Oncology Advances</i> , 2021, 3, v63-v74.	0.4	10
2377	Case Report: Collapsing Focal Segmental Glomerulosclerosis After Initiation of Ado-Trastuzumab Emtansine Therapy. <i>Frontiers in Oncology</i> , 2021, 11, 796223.	1.3	3
2378	Proteolysis-targeting chimeras and their implications in breast cancer. <i>Exploration of Targeted Anti-tumor Therapy</i> , 2021, 2, .	0.5	3
2379	Management of Diarrhea in Patients with HER2-Positive Breast Cancer Treated with Neratinib: A Case Series and Summary of the Literature. <i>Oncology and Therapy</i> , 2021, , 1.	1.0	4
2380	Combination of HER2-targeted agents with immune checkpoint inhibitors in the treatment of HER2-positive breast cancer. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 385-395.	1.4	5
2381	Immunotherapy in Breast Cancer: When, How, and What Challenges?. <i>Biomedicines</i> , 2021, 9, 1687.	1.4	31
2382	The first reported case of trastuzumab induced interstitial lung disease associated with anti-neutrophil cytoplasmic antibody vasculitis – A case report and a prospective cohort study on the usefulness of neutrophil derived biomarkers in monitoring vasculitis disease activity during follow-up. <i>Breast</i> , 2021, 61, 35-42.	0.9	6
2383	Her2-Positive Cancers and Antibody-Based Treatment: State of the Art and Future Developments. <i>Cancers</i> , 2021, 13, 5771.	1.7	6
2384	Comparison of the Efficacy, Safety, Pharmacokinetic and Immunogenicity of UJVIRA (ZRC-3256,) Tj ETQq1 1 0.784314 rgBT /Overlooked Metastatic Breast Cancer: A Randomized, Open-Label, Multicenter Study in India. <i>Clinical Breast Cancer</i> , 2022, 22, 300-307.	1.1	7
2385	A Case of Multiple Liver Metastases after Surgery in Elderly HER2-Positive Breast Cancer in Which Anastrozole + Trastuzumab Was Ineffective but T-DM1 Was Effective. <i>Case Reports in Oncology</i> , 2021, 14, 1632-1637.	0.3	1
2386	A bispecific antibody targeting HER2 and PD-L1 inhibits tumor growth with superior efficacy. <i>Journal of Biological Chemistry</i> , 2021, 297, 101420.	1.6	15

#	ARTICLE	IF	CITATIONS
2387	Antibody-drug conjugates in treating older patients suffering from cancer: what is the real value?. Human Vaccines and Immunotherapeutics, 2024, 17, 5575-5578.	1.4	2
2389	Protease-sensitive Linkers. RSC Drug Discovery Series, 2021, , 173-212.	0.2	0
2390	Non-cleavable Linkers: Permanently Linked, for Better or for Worse. RSC Drug Discovery Series, 2021, , 136-172.	0.2	0
2391	Introduction to Antibody-Drug Conjugates. RSC Drug Discovery Series, 2021, , 1-31.	0.2	2
2392	Trastuzumab Deruxtecan Targeting HER2-expressing Cancers with a DXd-ADC System Consisting of a Novel Protease-sensitive Linker and DNA Topoisomerase I Inhibitor with a Hydroxyl Group. RSC Drug Discovery Series, 2021, , 422-450.	0.2	2
2393	Targeted Therapies. , 2021, , 4895-4908.		0
2394	Antibody-drug conjugates: Resurgent anticancer agents with multi-targeted therapeutic potential. , 2022, 236, 108106.		16
2395	High score of LDH plus dNLR predicts poor survival in patients with HER2-positive advanced breast cancer treated with trastuzumab emtansine. BMC Cancer, 2022, 22, 29.	1.1	4
2396	The emerging role of real-world data in advanced breast cancer therapy: Recommendations for collaborative decision-making. Breast, 2022, 61, 118-122.	0.9	8
2397	Case series of docetaxel, trastuzumab, and pertuzumab (DTP) as first line anti-HER2 therapy and ado-trastuzumab emtansine (T-DM1) as second line for recurrent or metastatic HER2-positive salivary duct carcinoma. Oral Oncology, 2022, 125, 105703.	0.8	15
2398	Trastuzumab emtansine for patients with non-small cell lung cancer positive for human epidermal growth factor receptor 2 exon-20 insertion mutations. European Journal of Cancer, 2022, 162, 99-106.	1.3	30
2399	Impacts of clinicopathological factors on efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer. Breast, 2022, 61, 136-144.	0.9	10
2400	Efficacy of lapatinib combined with capecitabine in patients with HER2-positive metastatic breast cancer in a real-world study. Oncology Letters, 2020, 20, 1-1.	0.8	6
2401	ANTI-HER2 ANTIBODIES IN COMBINATION WITH CHEMOTHERAPY OR CHEMOTHERAPY-FREE REGIMENS TARGETING HER2-POSITIVE BREAST CANCER: A SYSTEMATIC REVIEW. Malaysian Journal of Public Health Medicine, 2020, 20, 285-306.	0.1	1
2402	Molecular Diagnostic and Precision Medicine in Non-Small Cell Lung Cancer. An Update on the Treatment of the Most Important Actionable Oncogenic Driver Alterations. Healthbook TIMES Oncology Hematology, 2020, , .	0.1	3
2403	Race Against Time: Addressing the Unmet Needs of Patients with HER2-Positive Metastatic Breast Cancer. European Medical Journal Oncology, 0, , 96-104.	0.0	0
2404	Antibody-drug conjugates in HER2-positive breast cancer. Chinese Medical Journal, 2022, 135, 261-267.	0.9	21
2405	A Small Molecule-Drug Conjugate (SMDC) Consisting of a Modified Camptothecin Payload Linked to an Î±VÎ³3 Binder for the Treatment of Multiple Cancer Types. Cancers, 2022, 14, 391.	1.7	12

#	ARTICLE	IF	CITATIONS
2406	Updated Austrian treatment algorithm in HER2+ metastatic breast cancer. Wiener Klinische Wochenschrift, 2022, 134, 63-72.	1.0	1
2408	Real-World Evidence of Trastuzumab, Pertuzumab, and Docetaxel Combination as a First-Line Treatment for Korean Patients with HER2-Positive Metastatic Breast Cancer. Cancer Research and Treatment, 2022, 54, 1130-1137.	1.3	4
2409	From AVATAR Mice to Patients: RC48-ADC Exerted Promising Efficacy in Advanced Gastric Cancer With HER2 Expression. Frontiers in Pharmacology, 2021, 12, 757994.	1.6	10
2410	Targeted nuclear medicine. Seek and destroy. Russian Chemical Reviews, 2022, 91, .	2.5	19
2411	Hormonal and Targeted Treatments in Breast Cancer. , 2022, , 443-463.		3
2412	FTY720 in resistant human epidermal growth factor receptor 2-positive breast cancer. Scientific Reports, 2022, 12, 241.	1.6	5
2413	Targeting HER2+ Breast Cancer Brain Metastases: A Review of Brain-Directed HER2-Directed Therapies. CNS Drugs, 2022, 36, 167-179.	2.7	6
2414	Caveolae-Associated Molecules, Tumor Stroma, and Cancer Drug Resistance: Current Findings and Future Perspectives. Cancers, 2022, 14, 589.	1.7	8
2415	Prioritising systemic cancer therapies applying ESMOâ€™s tools and other resources to assist in improving cancer care globally: the Kazakh experience. ESMO Open, 2022, 7, 100362.	2.0	8
2416	The initial hormone receptor/HER2 subtype is the main determinant of subtype discordance in advanced breast cancer: a study of the SONABRE registry. Breast Cancer Research and Treatment, 2022, 192, 331.	1.1	3
2417	Current and future landscape of targeted therapy in HER2-positive advanced breast cancer: redrawing the lines. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592110666.	1.4	16
2418	TROP-2, Nectin-4, GPNMB, and B7-H3 Are Potentially Therapeutic Targets for Anaplastic Thyroid Carcinoma. Cancers, 2022, 14, 579.	1.7	4
2419	Treatment of locally recurrent and advanced breast cancer. Surgery, 2022, 40, 147-151.	0.1	0
2420	Emerging new therapeutic antibody derivatives for cancer treatment. Signal Transduction and Targeted Therapy, 2022, 7, 39.	7.1	158
2421	Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2â€™Positive Early Breast Cancer: The Phase III KAITLIN Study. Journal of Clinical Oncology, 2022, 40, 438-448.	0.8	35
2422	Clinical outcomes in patients with triple negative or HER2 positive lobular breast cancer: a single institution experience. Breast Cancer Research and Treatment, 2022, 192, 563-571.	1.1	2
2423	Anti-HER2 therapy in metastatic breast cancer: many choices and future directions. Cancer and Metastasis Reviews, 2022, 41, 193-209.	2.7	23
2424	Antibodyâ€™Pattern Recognition Receptor Agonist Conjugates: A Promising Therapeutic Strategy for Cancer. Advanced Biology, 2022, , 2101065.	1.4	4

#	ARTICLE	IF	CITATIONS
2425	Afatinib alone and in combination with vinorelbine or paclitaxel, in patients with HER2-positive breast cancer who failed or progressed on prior trastuzumab and/or lapatinib (LUX-Breast 2): an open-label, multicenter, phase II trial. <i>Breast Cancer Research and Treatment</i> , 2022, 192, 593-602.	1.1	5
2426	FDA Approval Summary: Margetuximab plus Chemotherapy for Advanced or Metastatic HER2-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1487-1492.	3.2	23
2427	Cardiotoxicity of trastuzumab emtansine (T-DM1): a single-center experience. <i>Journal of International Medical Research</i> , 2021, 49, 030006052110537.	0.4	5
2428	A case report of a patient with plasmacytoid urothelial cancer with significant response to HER2-targeting therapy and enfortumab vedotin. <i>American Journal of Clinical and Experimental Urology</i> , 2021, 9, 390-396.	0.4	0
2429	Mammaerkrankungen. , 2021, , 297-361.		0
2430	Klinische Studien auf der Basis molekularer Charakterisierung von Tumoren. <i>Springer Reference Medizin</i> , 2021, , 1-57.	0.0	0
2431	Neurological complications of immunotherapy and monoclonal antibody therapy. , 2022, , 521-536.		0
2432	Prognostic impact of body mass index (BMI) in HER2+ breast cancer treated with anti-HER2 therapies: from preclinical rationale to clinical implications. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210791.	1.4	3
2434	Neurological complications of systemic cancer and antineoplastic therapy. , 2022, , 479-500.		0
2435	Actively Targeted Nanomedicines in Breast Cancer: From Pre-Clinical Investigation to Clinic. <i>Cancers</i> , 2022, 14, 1198.	1.7	29
2436	Emetogenicity of Antibody-Drug Conjugates (ADCs) in Solid Tumors with a Focus on Trastuzumab Deruxtecan: Insights from an Italian Expert Panel. <i>Cancers</i> , 2022, 14, 1022.	1.7	10
2437	Breast cancer management in 2021: A primer for the obstetrics and gynecology. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2022, 82, 30-45.	1.4	18
2438	Antibody-drug Conjugate Targets, Drugs, and Linkers. <i>Current Cancer Drug Targets</i> , 2022, 22, 463-529.	0.8	9
2439	Naturally occurring, natural product inspired and synthetic heterocyclic anti-cancer drugs. <i>ChemistrySelect</i> , 2022, .	0.7	3
2440	Intracranial Response Rate in Patients with Breast Cancer Brain Metastases after Systemic Therapy. <i>Cancers</i> , 2022, 14, 965.	1.7	2
2441	Integrated multiple analytes and semi-mechanistic population pharmacokinetic model of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2022, 49, 381-394.	0.8	6
2442	Durable Effect of Pyrotinib and Metronomic Vinorelbine in HER2-Positive Breast Cancer With Leptomeningeal Disease: A Case Report and Literature Review. <i>Frontiers in Oncology</i> , 2022, 12, 811919.	1.3	4
2443	The microbiome and precision oncology: an emerging paradigm in anticancer therapy. <i>Critical Reviews in Microbiology</i> , 2022, 48, 770-783.	2.7	1

#	ARTICLE	IF	CITATIONS
2444	New antibody-drug conjugates (ADCs) in breast cancer—an overview of ADCs recently approved and in later stages of development. Exploration of Targeted Anti-tumor Therapy, 0, , 27-36.	0.5	15
2445	Retrospective Study on the Efficacy and Safety of Pyrotinib-Based Therapy for HER2-Positive Nonbreast Advanced Solid Tumors. Journal of Oncology, 2022, 2022, 1-8.	0.6	0
2446	MUC1 is a potential target to overcome trastuzumab resistance in breast cancer therapy. Cancer Cell International, 2022, 22, 110.	1.8	13
2447	The efficacy of human epidermal growth factor receptor 2 (HER2) blockade switching mode in refractory patients with HER2-positive metastatic breast cancer: a phase II, multicenter, single-arm study (SYSUCC-005). BMC Cancer, 2022, 22, 271.	1.1	0
2448	Bystander effect of antibody–drug conjugates: fact or fiction?. Current Oncology Reports, 2022, 24, 809-817.	1.8	35
2449	Evolving management of HER2+ breast cancer brain metastases and leptomeningeal disease. Journal of Neuro-Oncology, 2022, 157, 249-269.	1.4	9
2450	Antibody mutations favoring pH-dependent binding in solid tumor microenvironments: Insights from large-scale structure-based calculations. Proteins: Structure, Function and Bioinformatics, 2022, 90, 1538-1546.	1.5	4
2451	Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. New England Journal of Medicine, 2022, 386, 1143-1154.	13.9	474
2452	mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer. Molecular Cancer Research, 2022, 20, 1108-1121.	1.5	5
2453	Margetuximab Versus Trastuzumab in Patients With Advanced Breast Cancer: A Cost-effectiveness Analysis. Clinical Breast Cancer, 2022, 22, e629-e635.	1.1	4
2454	Improving Brain Metastases Outcomes Through Therapeutic Synergy Between Stereotactic Radiosurgery and Targeted Cancer Therapies. Frontiers in Oncology, 2022, 12, 854402.	1.3	12
2455	Dalpiciclib Combined With Pyrotinib and Letrozole in Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer (LORDSHIPS): A Phase Ib Study. Frontiers in Oncology, 2022, 12, 775081.	1.3	8
2456	Investigating the role of peptides in effective therapies against cancer. Cancer Cell International, 2022, 22, 139.	1.8	13
2457	Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival. ESMO Open, 2022, 7, 100409.	2.0	25
2458	An Innovative Site-Specific Anti-HER2 Antibody-Drug Conjugate with High Homogeneity and Improved Therapeutic Index. OncoTargets and Therapy, 2022, Volume 15, 331-343.	1.0	4
2459	Specific targeting of cancer stem cells by immunotherapy: A possible stratagem to restrain cancer recurrence and metastasis. Biochemical Pharmacology, 2022, 198, 114955.	2.0	12
2460	Developments in the Management of Metastatic HER2-Positive Breast Cancer: A Review. Current Oncology, 2022, 29, 2539-2549.	0.9	12
2461	Clinical trial data and emerging strategies: HER2-positive breast cancer. Breast Cancer Research and Treatment, 2022, 193, 281-291.	1.1	12

#	ARTICLE	IF	CITATIONS
2462	Cardioprotection for Anti-HER2 Therapy: Considerations for Primary Prevention and Use in Mildly Reduced Left Ventricular Ejection Fraction. <i>Current Oncology Reports</i> , 2022, 24, 1063-1070.	1.8	3
2463	Treatment of small (T1mic, T1a, and T1b) node-negative HER2+ breast cancer – a review of current evidence for and against the use of anti-HER2 treatment regimens. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 505-522.	1.1	1
2464	A Patent Review on FDA-Approved Antibody-Drug Conjugates, Their Linkers and Drug Payloads. <i>ChemMedChem</i> , 2022, 17, e202200032.	1.6	29
2465	Critical clinical gaps in cancer precision nanomedicine development. <i>Journal of Controlled Release</i> , 2022, 345, 811-818.	4.8	13
2466	Efficacy of trastuzumab emtansine (T-DM1) and lapatinib after dual HER2 inhibition with trastuzumab and pertuzumab in patient with metastatic breast cancer: Retrospective data from a French multicenter real-life cohort. <i>Breast</i> , 2022, 63, 54-60.	0.9	3
2467	Central nervous system disease in phase III studies for advanced HER2 positive breast cancer: A review. <i>Breast</i> , 2022, 63, 85-100.	0.9	5
2468	The management of toxicities from immune, targeted and ADCs treatments in patients with urothelial cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2023, 41, 410-419.	0.8	3
2470	Updates on targeting human epidermal growth factor receptor 2-positive breast cancer: what's to know in 2021. <i>Current Opinion in Obstetrics and Gynecology</i> , 2022, 34, 41-45.	0.9	5
2471	Pneumonitis associated with Trastuzumab emtansine in a patient with metastatic breast cancer. <i>Journal of Oncology Pharmacy Practice</i> , 2022, 28, 740-745.	0.5	4
2472	The efficacy and safety of pyrotinib in treating HER2-positive breast cancer patients with brain metastasis: A multicenter study. <i>Cancer Medicine</i> , 2022, 11, 735-742.	1.3	15
2473	Neuroendocrine Neoplasms of the Breast: The Latest WHO Classification and Review of the Literature. <i>Cancers</i> , 2022, 14, 196.	1.7	4
2475	Eribulin-trastuzumab combination in HER2-positive metastatic breast cancer: updated results from a Russian observational study. <i>Meditinskiy Sovet</i> , 2021, , 36-46.	0.1	0
2476	No evidence of disease versus residual disease in long-term responders to first-line HER2-targeted therapy for metastatic breast cancer. <i>British Journal of Cancer</i> , 2022, 126, 881-888.	2.9	5
2477	Novel ADCs and Strategies to Overcome Resistance to Anti-HER2 ADCs. <i>Cancers</i> , 2022, 14, 154.	1.7	30
2478	The value of anticancer drugs – a regulatory view. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 207-215.	12.5	14
2479	Dual anti-HER2 blockade in late-line treatment of metastatic HER2-positive breast cancer. <i>Meditinskiy Sovet</i> , 2021, , 156-159.	0.1	0
2480	Dynamics of Endocytosis and Degradation of Antibody-Drug Conjugate T-DM1 in HER2 Positive Cancer Cells. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 5135-5150.	2.0	10
2481	Antibody Drug Conjugates in Glioblastoma – Is There a Future for Them?. <i>Frontiers in Oncology</i> , 2021, 11, 718590.	1.3	14

#	ARTICLE	IF	CITATIONS
2482	Targeting MDR1-P-glycoprotein (MDR1-Pgp) in immunochemotherapy of acute myeloid leukemia (AML). <i>Annali Dell'Istituto Superiore Di Sanita</i> , 2013, 49, 190-208.	0.2	9
2483	Long-term survival in the patient with generalized HER-2 positive, hormone-independent breast cancer - the importance of a multimodal approach. <i>Onkologie (Czech Republic)</i> , 2020, 14, 156-158.	0.0	0
2485	Therapeutic Advances and Challenges in the Management of HER2-Positive Gastroesophageal Cancers. <i>Diseases (Basel, Switzerland)</i> , 2022, 10, 23.	1.0	1
2486	Novel Therapies for the Treatment of HER2-Positive Advanced Breast Cancer: A Canadian Perspective. <i>Current Oncology</i> , 2022, 29, 2720-2734.	0.9	9
2487	Advancing antibody-drug conjugates in gynecological malignancies: myth or reality?. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, , 149-171.	0.5	3
2488	Tucatinib has Selective Activity in HER2-Positive Cancers and Significant Combined Activity with Approved and Novel Breast Cancer Targeted Therapies. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 751-761.	1.9	10
2489	An overview of the preclinical discovery and development of trastuzumab deruxtecan: a novel gastric cancer therapeutic. <i>Expert Opinion on Drug Discovery</i> , 2022, 17, 427-436.	2.5	2
2490	Brain radiotherapy, tremelimumab-mediated CTLA-4-directed blockade +/â trastuzumab in patients with breast cancer brain metastases. <i>Npj Breast Cancer</i> , 2022, 8, 50.	2.3	17
2491	Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives. <i>Cancer Treatment Reviews</i> , 2022, 106, 102395.	3.4	60
2497	Long-term disease control with lapatinib and capecitabine in a patient with HER2-positive metastatic breast cancer pretreated with trastuzumab and trastuzumab-emtansine. <i>Tumori</i> , 2013, 99, e131-3.	0.6	1
2500	A phase III trial of alpelisib + Trastuzumab + Fulvestrant versus trastuzumab + chemotherapy in HER2+ <i>PIK3CA</i>-mutated breast cancer. <i>Future Oncology</i> , 2022, 18, 2339-2349.	1.1	15
2501	The Dual Blockade in the Neoadjuvant Setting of HER-2 Positive Early-Stage Breast Cancer. <i>Journal of Medicine and Life</i> , 2019, 12, 329-331.	0.4	7
2504	Brain metastases in HER2 positive breast cancer: the next hurdle. <i>Annals of Palliative Medicine</i> , 2012, 1, 198-201.	0.5	1
2506	Cardiac morbidity & mortality in patients with breast cancer: A review.. <i>Indian Journal of Medical Research</i> , 2022, , .	0.4	2
2507	Trastuzumab emtansine in locally advanced or metastatic HER2 positive breast cancer; GENESIS-SEFH drug evaluation report. <i>Farmacia Hospitalaria</i> , 2015, 39, 171-5.	0.6	7
2508	Long-Term Prognostic Significance of HER2-Low and HER2-Zero in Node-Negative Breast Cancer. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
2509	Effectiveness and cost-effectiveness of trastuzumab emtansine in women with HER2-positive locally advanced or metastatic breast cancer: A systematic review and meta-analysis. <i>Journal of Cancer Research and Therapeutics</i> , 2022, 18, 1061.	0.3	2
2510	Therapeutic Landscape of Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer. <i>Cancer Control</i> , 2022, 29, 107327482210992.	0.7	11

#	ARTICLE	IF	CITATIONS
2512	Emerging Systemic Treatment Perspectives on Brain Metastases: Moving Toward a Better Outlook for Patients. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, 42, 147-165.	1.8	12
2513	Profile of Margetuximab: Evidence to Date in the Targeted Treatment of Metastatic HER2-positive Breast Cancer. OncoTargets and Therapy, 2022, Volume 15, 471-478.	1.0	7
2514	Immunotherapy for HER2-Positive Breast Cancer: Clinical Evidence and Future Perspectives. Cancers, 2022, 14, 2136.	1.7	21
2516	Oral Etoposide and Trastuzumab Use for HER2-Positive Metastatic Breast Cancer: A Retrospective Study from the Institut Curie Hospitals. Cancers, 2022, 14, 2114.	1.7	2
2517	Multicenter phase II trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial. Future Oncology, 2022, 18, 2351-2360.	1.1	22
2518	Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy. Drug Delivery, 2022, 29, 1335-1344.	2.5	72
2519	Patient-reported outcomes predict survival and adverse events following anticancer treatment initiation in advanced HER2-positive breast cancer. ESMO Open, 2022, 7, 100475.	2.0	7
2520	Distinct clinical and somatic mutational features of breast tumors with high-, low-, or non-expressing human epidermal growth factor receptor 2 status. BMC Medicine, 2022, 20, 142.	2.3	55
2521	N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer. Nature Communications, 2022, 13, 2672.	5.8	80
2523	T-DM1 after Pertuzumab plus Trastuzumab: Treatment Sequence-Induced Selection Bias in HER2-Positive Metastatic Breast Cancer. Cancers, 2022, 14, 2468.	1.7	5
2524	Oncological Treatment-Related Fatigue in Oncogeriatrics: A Scoping Review. Cancers, 2022, 14, 2470.	1.7	4
2525	Current status and future prospects of antibody-drug conjugates in urological malignancies. International Journal of Urology, 2022, 29, 1100-1108.	0.5	3
2526	Integrating radiation therapy with targeted treatments for breast cancer: From bench to bedside. Cancer Treatment Reviews, 2022, 108, 102417.	3.4	11
2527	Long term outcome data from the EORTC 75111-10114 ETF/BCG randomized phase II study: Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer, followed by T-DM1 after progression. Breast, 2022, 64, 100-111.	0.9	5
2528	A novel strategy for treatment of bladder cancer: Antibody-drug conjugates. Investigative and Clinical Urology, 2022, 63, 373.	1.0	5
2530	Therapeutics Targeting the Metastatic Breast Cancer Bone Microenvironment. SSRN Electronic Journal, 0, , .	0.4	0
2531	Cardiotoxicity of Biological Therapies in Cancer Patients: An In-depth Review. Current Cardiology Reviews, 2023, 19, .	0.6	3
2532	The History of Early Breast Cancer Treatment. Genes, 2022, 13, 960.	1.0	16

#	ARTICLE	IF	CITATIONS
2533	New Insights on the Toxicity on Heart and Vessels of Breast Cancer Therapies. <i>Medical Sciences (Basel)</i> , 2022, 10, 1243-1263.	1.3	4
2534	Cell Surface Markers and Their Targeted Drugs in Breast Cancer. <i>Current Protein and Peptide Science</i> , 2022, 23, .	0.7	0
2535	Treatment of chemotherapy-induced thrombocytopenia in patients with non-hematologic malignancies. <i>Haematologica</i> , 2022, 107, 1243-1263.	1.7	28
2536	Treatment of drug-induced immune thrombocytopenias. <i>Haematologica</i> , 2022, 107, 1264-1277.	1.7	17
2537	Targeting Tumor Cells Overexpressing the Human Epidermal Growth Factor Receptor 3 with Potent Drug Conjugates Based on Affibody Molecules. <i>Biomedicines</i> , 2022, 10, 1293.	1.4	2
2538	Comparison of adverse effects of trastuzumab with other drug combinations for the treatment of breast cancer: A review. <i>Indian Journal of Physiology and Pharmacology</i> , 0, 66, 1-15.	0.4	1
2539	Molecular Assessment of HER2 to Identify Signatures Associated with Therapy Response in HER2-Positive Breast Cancer. <i>Cancers</i> , 2022, 14, 2795.	1.7	7
2540	Cytotoxicity of phenylpironetin analogs and the metabolic fate of pironetin and phenylpironetin. <i>Bioorganic Chemistry</i> , 2022, 125, 105915.	2.0	2
2542	Perioperative HER2 targeted treatment in early stage HER2-positive breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211065.	1.4	3
2543	Systemic Therapy for HER2-Positive Metastatic Breast Cancer: Moving Into a New Era. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, , 82-92.	1.8	6
2544	Research Trend of Publications Concerning Antibody-Drug Conjugate in Solid Cancer: A Bibliometric Study. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	4
2546	T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis. <i>BMC Cancer</i> , 2022, 22, .	1.1	5
2547	Recently approved treatment options for patients with metastatic triple-negative and HER2-neu-positive breast cancer. <i>Journal of Investigative Medicine</i> , 2022, 70, 1329-1341.	0.7	2
2549	Breast Cancer Epidemiology and Contemporary Breast Cancer Care: A Review of the Literature and Clinical Applications. <i>Clinical Obstetrics and Gynecology</i> , 2022, 65, 461-481.	0.6	6
2550	Accumulation Technology: A Novel Conjugable Primer for Onco-Immunotherapy. <i>Molecules</i> , 2022, 27, 3807.	1.7	4
2551	Trastuzumab emtansine increases the risk of stereotactic radiosurgery-induced radionecrosis in HER2-positive breast cancer. <i>Journal of Neuro-Oncology</i> , 2022, 159, 177-183.	1.4	10
2552	Targeting Cell Cycle Progression in HER2+ Breast Cancer: An Emerging Treatment Opportunity. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6547.	1.8	11
2553	Systemic Treatment of Breast Cancer. 1st Central-Eastern European Professional Consensus Statement on Breast Cancer. <i>Pathology and Oncology Research</i> , 0, 28, .	0.9	12

#	ARTICLE	IF	CITATIONS
2554	Pertuzumab retreatment for HER2-positive advanced breast cancer: A randomized, open-label phase III study (PRECIOUS). <i>Cancer Science</i> , 2022, 113, 3169-3179.	1.7	8
2555	Local and systemic therapy in breast cancer patients with central nervous system metastases. <i>Breast Cancer Research and Treatment</i> , 2022, 194, 365-384.	1.1	0
2556	Therapeutic Response Monitoring with ⁸⁹ Zr-DFO-Pertuzumab in HER2-Positive and Trastuzumab-Resistant Breast Cancer Models. <i>Pharmaceutics</i> , 2022, 14, 1338.	2.0	3
2557	Molecular Landscape of ERBB2 Alterations in 14,956 Solid Tumors. <i>Pathology and Oncology Research</i> , 0, 28, .	0.9	6
2558	Targeted Therapeutic Options and Future Perspectives for HER2-Positive Breast Cancer. <i>Cancers</i> , 2022, 14, 3305.	1.7	11
2559	Beyond HER2: Targeting the ErbB receptor family in breast cancer. <i>Cancer Treatment Reviews</i> , 2022, 109, 102436.	3.4	13
2560	Monomethyl auristatin antibody and peptide drug conjugates for trimodal cancer chemo-radio-immunotherapy. <i>Nature Communications</i> , 2022, 13, .	5.8	14
2561	Comparative Efficacy of Tyrosine Kinase Inhibitors and Antibody-Drug Conjugates in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A Systematic Review and Network Meta-Analysis. <i>Cancers</i> , 2022, 14, 3372.	1.7	4
2562	Real-world outcomes in patients with brain metastases secondary to HER2-positive breast cancer: An Australian multi-centre registry-based study. <i>Clinical Breast Cancer</i> , 2022, , .	1.1	0
2563	Histology-agnostic approvals for antibody-drug conjugates in solid tumours: is the time ripe?. <i>European Journal of Cancer</i> , 2022, 171, 25-42.	1.3	9
2564	Long-term prognostic significance of HER2-low and HER2-zero in node-negative breast cancer. <i>European Journal of Cancer</i> , 2022, 173, 10-19.	1.3	42
2565	Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling. <i>Nature Cancer</i> , 2022, 3, 821-836.	5.7	9
2566	Hitting the target in HER2 mutant cancers. <i>Nature Cancer</i> , 2022, 3, 785-786.	5.7	1
2567	Current State of Cell Therapies for Breast Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2022, 28, 301-309.	1.0	5
2568	Antibody-Drug Conjugates Containing Payloads from Marine Origin. <i>Marine Drugs</i> , 2022, 20, 494.	2.2	7
2569	Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2-Activating Mutations: Results From the National Cancer Institute-Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-B. <i>JCO Precision Oncology</i> , 2022, , .	1.5	7
2570	HER2-Targeted Antibody-Drug Conjugates Display Potent Antitumor Activities in Preclinical Extramammary Paget's Disease Models: In Vivo and Immunohistochemical Analyses. <i>Cancers</i> , 2022, 14, 3519.	1.7	1
2571	Current challenges and unmet needs in treating patients with human epidermal growth factor receptor 2-positive advanced breast cancer. <i>Breast</i> , 2022, 66, 145-156.	0.9	3

#	ARTICLE	IF	CITATIONS
2572	Research Progress of Conjugated Nanomedicine for Cancer Treatment. <i>Pharmaceutics</i> , 2022, 14, 1522.	2.0	11
2573	Neratinib in advanced HER2-positive breast cancer: experience from the royal Marsden hospital. <i>Breast Cancer Research and Treatment</i> , 2022, 195, 333-340.	1.1	4
2574	Cancer cell membrane cloaked nanocarriers: A biomimetic approach towards cancer theranostics. <i>Materials Today Communications</i> , 2022, 33, 104289.	0.9	2
2575	Temporal Heterogeneity of HER2 Expression and Spatial Heterogeneity of 18F-FDG Uptake Predicts Treatment Outcome of Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer. <i>Cancers</i> , 2022, 14, 3973.	1.7	2
2576	Cost-Effectiveness Analysis of Trastuzumab Deruxtecan versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer in the USA. <i>Advances in Therapy</i> , 2022, 39, 4583-4593.	1.3	11
2577	Tailoring antiHer2 treatment strategies in breast cancer and beyond. <i>Current Problems in Cancer</i> , 2022, 46, 100892.	1.0	4
2578	Adverse Renal Effects of Anticancer Immunotherapy: A Review. <i>Cancers</i> , 2022, 14, 4086.	1.7	3
2579	Noncirrhotic Portal Hypertension after Trastuzumab Emtansine in HER2-positive Breast Cancer as Determined by Deep Learningâ€“measured Spleen Volume at CT. <i>Radiology</i> , 2022, 305, 606-613.	3.6	2
2580	Comparative review of pharmacological therapies in individuals with HER2-positive advanced breast cancer with focus on hormone receptor subgroups. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
2581	Treatment Strategies for Residual Disease following Neoadjuvant Chemotherapy in Patients with Early-Stage Breast Cancer. <i>Current Oncology</i> , 2022, 29, 5810-5822.	0.9	4
2582	Antibody drug conjugates (ADCs): an expanding rational treatment paradigm in breast cancer (CME) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.8	0
2583	Pan-cancer distribution of cleaved cell-surface amphiregulin, the target of the GMF-1A3 antibody drug conjugate. <i>Antibody Therapeutics</i> , 2022, 5, 226-231.	1.2	0
2584	TROP2 (trophoblast cell-surface antigen 2): a drug target for breast cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2022, 26, 593-602.	1.5	6
2585	Advances in neoadjuvant therapy for HER2-positive breast cancers: a narrative review. <i>Gland Surgery</i> , 2022, 11, 1415-1423.	0.5	3
2586	An update on antibodyâ€“drug conjugates in urothelial carcinoma: state of the art strategies and what comes next. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 90, 191-205.	1.1	4
2587	Safety and efficacy profile of Trastuzumab deruxtecan in solid cancer: pooled reanalysis based on clinical trials. <i>BMC Cancer</i> , 2022, 22, .	1.1	1
2588	A novel ADC targeting cell surface fibromodulin in a mouse model of triple-negative breast cancer. <i>Breast Cancer</i> , 2022, 29, 1121-1132.	1.3	2
2589	Targeting the mTOR Pathway for the Prevention of ER-Negative Breast Cancer. <i>Cancer Prevention Research</i> , 2022, 15, 791-802.	0.7	3

#	ARTICLE	IF	CITATIONS
2590	Racial disparities in breast cancer preclinical and clinical models. <i>Breast Cancer Research</i> , 2022, 24, .	2.2	5
2591	Potential of antibody-drug conjugates (ADCs) for cancer therapy. <i>Cancer Cell International</i> , 2022, 22, .	1.8	36
2592	Prognostic and predictive biomarkers with therapeutic targets in breast cancer: A 2022 update on current developments, evidence, and recommendations. <i>Journal of Oncology Pharmacy Practice</i> , 2023, 29, 1343-1360.	0.5	3
2593	Targeted therapy for breast cancer: An overview of drug classes and outcomes. <i>Biochemical Pharmacology</i> , 2022, 204, 115209.	2.0	38
2594	Sacituzumab govitecan: past, present and future of a new antibody-drug conjugate and future horizon. <i>Future Oncology</i> , 2022, 18, 3199-3215.	1.1	10
2595	Final results of the global and Asia cohorts of KAMILLA, a phase IIIB safety trial of trastuzumab emtansine in patients with HER2-positive advanced breast cancer. <i>ESMO Open</i> , 2022, 7, 100561.	2.0	6
2596	Therapeutics targeting the metastatic breast cancer bone microenvironment. , 2022, 239, 108280.		8
2597	Systemic Therapy for Patients with HER2-Positive Breast Cancer and Brain Metastases: A Systematic Review and Meta-Analysis. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
2598	Current status of nanomedicine for breast cancer treatment. , 2022, , 65-110.		0
2599	Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. <i>Cancer Research Statistics and Treatment</i> , 2022, 5, 393.	0.1	0
2600	Substanzen gegen molekulare Zielstrukturen. <i>Springer Reference Medizin</i> , 2022, , 1-14.	0.0	0
2601	Diagnostic Applications of Nuclear Medicine: Breast Cancer. , 2022, , 715-741.		0
2602	Efficacy and safety of trastuzumab emtansine treatment in patients with metastatic HER-2 positive breast cancer: a single center study. <i>Iberoamerican Journal of Medicine</i> , 2022, 4, 191-198.	0.1	0
2603	Chapter 21: Oncology: Rasburicase/ <i>G6PD</i> Case. , 2022, , .		0
2605	Chapter 29: Pharmacogenomics in Ethical and Social Contexts. , 2022, , .		0
2607	Chapter 27: Rheumatology/Musculoskeletal Pain: Codeine/ <i>CYP2D6</i> Case. , 2022, , .		0
2608	Chapter 8: Cardiology: Simvastatin/ <i>SLCO1B1</i> Case. , 2022, , .		0
2609	Chapter 28: Information Resources for Pharmacogenomics. , 2022, , .		0

#	ARTICLE	IF	CITATIONS
2610	Chapter 18: Oncology: Somatic Disease and Pharmacogenomics. , 2022, , .		0
2611	Chapter 17: Neurology: Fosphenytoin/Phenytoin/<i>CYP2C9</i>, <i>HLA-B</i> Case. , 2022, , .		0
2612	Chapter 9: Cardiology: Warfarin/<i>CYP2C9</i>, <i>VKORC1</i>, <i>CYP4F2</i> Case. , 2022, , .		0
2613	Chapter 25: Rheumatology/Musculoskeletal Pain: Allopurinol/<i>HLA-B</i> Case. , 2022, , .		0
2614	Chapter 12: Infectious Diseases: Abacavir/<i>HLA-B</i> Case. , 2022, , .		0
2615	Chapter 15: Infectious Diseases: Gentamicin/<i>MT-RNR1</i> Case. , 2022, , .		0
2617	Chapter 13: Infectious Diseases: Atazanavir/<i>UGT1A1</i> Case. , 2022, , .		0
2618	Chapter 30: Pharmacogenomics and Secondary/Incidental Findings. , 2022, , .		0
2619	Chapter 16: Neurology: Carbamazepine/<i>HLA-A</i>, <i>HLA-B</i> Case. , 2022, , .		0
2621	Chapter 3: Pharmacogenomics Testing. , 2022, , .		0
2622	Chapter 24: Metabolic/Respiratory: Ivacaftor/<i>CFTR</i> Case. , 2022, , .		0
2623	Chapter 23: Psychiatry: Paroxetine/<i>CYP2D6</i> Case. , 2022, , .		0
2625	Chapter 2: Pharmacogenomics: Drug Exposure and Response. , 2022, , .		0
2626	Chapter 22: Psychiatry: Amitriptyline/<i>CYP2C19</i>, <i>CYP2D6</i> Case. , 2022, , .		0
2627	Chapter 6: The Pharmacists' Patient Care Process (PPCP). , 2022, , .		0
2628	Chapter 10: Endocrinology: Glipizide/<i>G6PD</i> Case. , 2022, , .		0
2629	Chapter 1: Foundations of Pharmacogenomics. , 2022, , .		0
2630	Chapter 20: Oncology: Capecitabine/<i>DPYD</i> Case. , 2022, , .		0

#	ARTICLE	IF	CITATIONS
2632	Chapter 14: Infectious Diseases: Voriconazole/ <i>CYP2C19</i> Case. , 2022, , .		0
2633	Chapter 19: Oncology: Mercaptopurine/ <i>TPMT</i> , <i>NUDT15</i> Case. , 2022, , .		0
2634	Chapter 7: Cardiology: Clopidogrel/ <i>CYP2C19</i> Case. , 2022, , .		0
2635	Chapter 4: Pharmacists' Competencies in Genomics. , 2022, , .		0
2637	Chapter 5: Implementation of Pharmacogenomics across Practice Settings. , 2022, , .		0
2638	Chapter 26: Rheumatology/Musculoskeletal Pain: Azathioprine/ <i>TPMT</i> , <i>NUDT15</i> ; Celecoxib/ <i>CYP2C9</i> Case. , 2022, , .		0
2639	Chapter 11: Immunology: Tacrolimus/ <i>CYP3A5</i> Case. , 2022, , .		0
2641	Incidence and risk of severe adverse events associated with trastuzumab emtansine (T-DM1) in the treatment of breast cancer: an up-to-date systematic review and meta-analysis of randomized controlled clinical trials. <i>Expert Review of Clinical Pharmacology</i> , 2022, 15, 1343-1350.	1.3	5
2642	TP53-positive clones are responsible for drug-tolerant persister and recurrence of HER2-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 196, 255-266.	1.1	3
2643	Efficacy and Safety of Pyrotinib in Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A Multicenter, Retrospective, Real-World Study. <i>OncoTargets and Therapy</i> , 0, Volume 15, 1067-1078.	1.0	2
2644	Systemic Therapy Approaches for Breast Cancer Brain and Leptomeningeal Metastases. <i>Current Treatment Options in Oncology</i> , 2022, 23, 1457-1476.	1.3	1
2645	Economic evaluation of margetuximab vs. trastuzumab for pretreated ERBB2-positive advanced breast cancer in the US and China. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	2
2646	Computational Studies on Antibody Drug Conjugates (ADCs) for Precision Oncology. <i>ChemistrySelect</i> , 2022, 7, .	0.7	1
2647	Antibody-Drug Conjugates for Melanoma and Other Skin Malignancies. <i>Current Treatment Options in Oncology</i> , 2022, 23, 1428-1442.	1.3	1
2648	Sacituzumab govitecan and other antibody-drug conjugates targeting trophoblast cell-surface antigen 2 (Trop-2) in breast cancer. <i>Annals of Translational Medicine</i> , 2022, 10, 1031-1031.	0.7	2
2649	Performance of Cox proportional hazard models on recovering the ground truth of confounded exposure-response relationships for large-molecule oncology drugs. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2022, 11, 1511-1526.	1.3	6
2650	Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	8
2651	Effect of Ado-Trastuzumab Emtansine on Autologous Platelet Kinetics and Function. <i>JCO Precision Oncology</i> , 2022, , .	1.5	1

#	ARTICLE	IF	CITATIONS
2652	Applying interpretable machine learning workflow to evaluate exposure-response relationships for large-molecule oncology drugs. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2022, 11, 1614-1627.	1.3	3
2653	Cost-Effectiveness Analysis of Pertuzumab Plus Trastuzumab and Docetaxel Compared With Trastuzumab and Docetaxel in the Adjuvant Treatment of Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer in Colombia. <i>Value in Health Regional Issues</i> , 2022, 32, 109-118.	0.5	2
2654	Data collection framework for electronic medical record-based real-world data to evaluate the effectiveness and safety of cancer drugs: a nationwide real-world study of the Korean Cancer Study Group. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211326.	1.4	1
2655	NMR-Based Metabolomics to Evaluate Individual Response to Treatments. <i>Handbook of Experimental Pharmacology</i> , 2022, , 209-245.	0.9	4
2656	Development of Antibody-Drug Conjugates: Future Perspective Towards Solid Tumor Treatment. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2023, 23, 642-657.	0.9	1
2657	Targeting breast and pancreatic cancer metastasis using a dual-cadherin antibody. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	6
2658	Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options. <i>BioDrugs</i> , 2022, 36, 717-729.	2.2	3
2659	New treatment strategies for human epidermal growth factor receptor 2-positive breast cancer in 2023. <i>Current Opinion in Obstetrics and Gynecology</i> , 2023, 35, 54-61.	0.9	2
2660	Imaging of Drug-Related Pneumonitis in Oncology. <i>Seminars in Respiratory and Critical Care Medicine</i> , 0, , .	0.8	0
2661	Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	59
2662	The Present and Future of Clinical Management in Metastatic Breast Cancer. <i>Journal of Clinical Medicine</i> , 2022, 11, 5891.	1.0	7
2663	Resistance to Trastuzumab. <i>Cancers</i> , 2022, 14, 5115.	1.7	23
2664	Plasma Exchange May Enhance Antitumor Effects by Removal of Soluble Programmed Death-Ligand 1 and Extracellular Vesicles: Preliminary Study. <i>Biomedicines</i> , 2022, 10, 2483.	1.4	1
2665	Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer. , 2022, 10, e005119.		8
2666	HER2 expression in urothelial carcinoma, a systematic literature review. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	16
2667	Management of Brain Metastases from Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Cancer. <i>Cancers</i> , 2022, 14, 5136.	1.7	0
2668	Breaking the Bottleneck in Anticancer Drug Development: Efficient Utilization of Synthetic Biology. <i>Molecules</i> , 2022, 27, 7480.	1.7	6
2669	A Case of Sustained Tumor Regression With MPO274, a Novel DARPIn Therapeutic Targeting Human Epidermal Growth Factor Receptor 2 Signaling, in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Prior Trastuzumab and Pertuzumab. <i>JCO Precision Oncology</i> , 2022, .	1.5	3

#	ARTICLE	IF	CITATIONS
2670	Evolving therapeutic proteins to precisely kill cancer cells. <i>Journal of Controlled Release</i> , 2022, 351, 779-804.	4.8	2
2671	Trastuzumab deruxtecan versus trastuzumab emtansine for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: A cost-effectiveness analysis. <i>Breast</i> , 2022, 66, 191-198.	0.9	10
2672	Antibody drug conjugates targeting HER2: Clinical development in metastatic breast cancer. <i>Breast</i> , 2022, 66, 217-226.	0.9	17
2673	<i>Breast diseases.</i> , 2023, , 311-344.e7.		0
2674	Pharmacological profile - trastuzumab emtansine. <i>Onkologie (Czech Republic)</i> , 2022, 16, 273-275.	0.0	0
2675	Promise of Real-World Evidence for Patient Centricity in Gulf Cooperation Council Countries: Call to Action. <i>Drugs - Real World Outcomes</i> , 0, , .	0.7	0
2676	Antibody-Drug Conjugates and Tissue-Agnostic Drug Development. <i>Cancer Journal (Sudbury, Mass)</i> , 2022, 28, 462-468.	1.0	0
2677	Prognostic and clinical significance of HER-2 low expression in early-stage gastric cancer. <i>BMC Cancer</i> , 2022, 22, .	1.1	10
2678	Resistance to antibody-drug conjugates in breast cancer: mechanisms and solutions. <i>Cancer Communications</i> , 2023, 43, 297-337.	3.7	18
2679	Antibody-Drug Conjugates in Breast Cancer: What Is Beyond HER2?. <i>Cancer Journal (Sudbury, Mass)</i> , 2022, 28, 436-445.	1.0	6
2680	Strategies for Mitigating Antibody-Drug Conjugate Related Adverse Events for Precision Therapy. <i>Cancer Journal (Sudbury, Mass)</i> , 2022, 28, 496-507.	1.0	1
2681	Systemic Therapy for Patients with HER2-Positive Breast Cancer and Brain Metastases: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2022, 14, 5612.	1.7	1
2682	Antibody-Drug Conjugates in Breast Cancer: Spotlight on HER2. <i>Cancer Journal (Sudbury, Mass)</i> , 2022, 28, 423-428.	1.0	4
2683	Antibody Drug Conjugates in Lung Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2022, 28, 429-435.	1.0	0
2684	Antibody-Drug Conjugates for the Treatment of HER2-Positive Breast Cancer. <i>Genes</i> , 2022, 13, 2065.	1.0	19
2685	Toxicities From Antibody-Drug Conjugates. <i>Cancer Journal (Sudbury, Mass)</i> , 2022, 28, 469-478.	1.0	2
2686	The engineering challenges and opportunities when designing potent ionizable materials for the delivery of ribonucleic acids. <i>Expert Opinion on Drug Delivery</i> , 2022, 19, 1650-1663.	2.4	2
2687	Targeted Therapy and Immunotherapy for Heterogeneous Breast Cancer. <i>Cancers</i> , 2022, 14, 5456.	1.7	8

#	ARTICLE	IF	CITATIONS
2688	Unexpected Cardiotoxicity in Patients With HER2-Mutant NSCLC Treated With Trastuzumab Deruxtecan: A Case Report. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100432.	0.6	0
2689	Current Standard Clinical Predictive Markers. , 2022, , 873-894.		0
2690	Chemical modification of proteins â€“ challenges and trends at the start of the 2020s. <i>Biomaterials Science</i> , 2023, 11, 719-748.	2.6	10
2691	Ultrasml silica nanoparticles in translational biomedical research: Overview and outlook. <i>Advanced Drug Delivery Reviews</i> , 2023, 192, 114638.	6.6	7
2692	Acute skin radiation toxicity seen with concurrent T-DM1: A single institutional report of 35 patients. <i>Breast</i> , 2023, 67, 26-29.	0.9	3
2693	Systemic Therapy for Early- and Late-Stage, Human Epidermal Growth Factor Receptor-2-Positive Breast Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2023, 37, 103-115.	0.9	1
2694	Survival and prognostic factors in oligometastatic breast cancer. <i>Breast</i> , 2023, 67, 14-20.	0.9	2
2695	Comparison of clinicopathological characteristics and response to neoadjuvant chemotherapy between HER2-low and HER2-zero breast cancer. <i>Breast</i> , 2023, 67, 1-7.	0.9	15
2696	Antibody-Drug Conjugates in Breast Cancer: Searching for Magic Bullets. <i>Journal of Clinical Oncology</i> , 2023, 41, 732-735.	0.8	1
2697	Treatmentâ€related adverse events of antibodyâ€drug conjugates in clinical trials: A systematic review and metaâ€analysis. <i>Cancer</i> , 2023, 129, 283-295.	2.0	27
2698	Biologic Evaluation of a Heterodimeric HER2-Albumin Targeted Affibody Molecule Produced by Chemo-Enzymatic Peptide Synthesis. <i>Pharmaceutics</i> , 2022, 14, 2519.	2.0	1
2699	The evolving therapeutic landscape of antibodyâ€drug conjugates in breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 1325-1331.	1.1	1
2700	Development of therapeutic antibodies for the treatment of diseases. <i>Molecular Biomedicine</i> , 2022, 3, .	1.7	19
2701	Combined Vaccination with B Cell Peptides Targeting Her-2/neu and Immune Checkpoints as Emerging Treatment Option in Cancer. <i>Cancers</i> , 2022, 14, 5678.	1.7	1
2702	Therapeutic Landscape Beyond Immunotherapy in Advanced Urothelial Carcinoma: Moving Past the Checkpoint. <i>Drugs</i> , 2022, 82, 1649-1662.	4.9	5
2703	Efficacy and safety of pyrotinib and radiotherapy vs. pyrotinib-based therapy in patients with HER2+ breast cancer with brain metastasis: a retrospective cohort study. <i>Annals of Translational Medicine</i> , 2022, 10, 1228-1228.	0.7	1
2704	Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) credit. <i>Annals of Oncology</i> , 2023, 34, 431-439.	0.6	7
2705	Deep Learning-Based Prediction of Molecular Tumor Biomarkers from H&E: A Practical Review. <i>Journal of Personalized Medicine</i> , 2022, 12, 2022.	1.1	7

#	ARTICLE	IF	CITATIONS
2706	Using the HER2/CEP17 FISH Ratio to Predict Pathologic Complete Response Following Neoadjuvant Anti-HER2 Doublet Therapy in HER2+ Breast Cancer. <i>Oncologist</i> , 2023, 28, 123-130.	1.9	2
2707	A review of recent advances on single use of antibody-drug conjugates or combination with tumor immunology therapy for gynecologic cancer. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	2
2708	Branched Poly(μ -caprolactone)-Based Copolyesters of Different Architectures and Their Use in the Preparation of Anticancer Drug-Loaded Nanoparticles. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15393.	1.8	6
2709	A second-generation antibody-drug conjugate to treat HER2-positive breast cancer. <i>Lancet</i> , The, 2023, 401, 80-81.	6.3	2
2710	Retrospective Observational Study of Outcomes in HER2-Positive Metastatic Breast Cancer (mBC) Patients Treated with Ado-Trastuzumab Emtansine (T-DM1) and Subsequent Treatments After T-DM1 in the United States. <i>Drugs - Real World Outcomes</i> , 2023, 10, 177-186.	0.7	1
2711	Immunoregulatory framework and the role of miRNA in the pathogenesis of NSCLC – A systematic review. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
2712	Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. <i>Lancet</i> , The, 2023, 401, 105-117.	6.3	144
2713	Neurologic complications of breast cancer. <i>Cancer</i> , 0, , .	2.0	0
2714	Real-World Outcome and Prognostic Factors Among HER2-Positive Metastatic Breast Cancer Patients Receiving Pyrotinib-Based Therapy: A Multicenter Retrospective Analysis. <i>Breast Cancer: Targets and Therapy</i> , 0, Volume 14, 491-504.	1.0	0
2715	Systemic Therapy for HER2-Positive Metastatic Breast Cancer: Current and Future Trends. <i>Cancers</i> , 2023, 15, 51.	1.7	6
2716	Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	46
2717	Prognostic effect of HER2 evolution from primary breast cancer to breast cancer metastases. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 5417-5428.	1.2	3
2718	Current Standards and Future Outlooks in Metastatic Her2-Positive Breast Cancer. <i>Breast Care</i> , 2023, 18, 69-75.	0.8	4
2719	Formulation of a kit under Good Manufacturing Practices (GMP) for preparing [¹¹¹ In]In-BnDTPA-trastuzumab-NLS injection: a theranostic agent for imaging and Meitner-Auger Electron (MAE) radioimmunotherapy of HER2-positive breast cancer. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2022, 7, .	1.8	2
2720	Treatment strategies for hormone receptor-positive, human epidermal growth factor receptor 2-positive (HR+/HER2+) metastatic breast cancer: A review. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
2721	Targeted Therapy for Locally Advanced or Metastatic Urothelial Cancer (mUC): Therapeutic Potential of Sacituzumab Govitecan. <i>OncoTargets and Therapy</i> , 0, Volume 15, 1531-1542.	1.0	4
2722	The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer. <i>Cancer Treatment Reviews</i> , 2023, 113, 102500.	3.4	15
2723	Clinical updates on tyrosine kinase inhibitors in HER2-positive breast cancer. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	3

#	ARTICLE	IF	CITATIONS
2724	Addition of endocrine therapy to dual anti-HER2 targeted therapy in initial treatment of HER2+HR+metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2023, 198, 67-74.	1.1	4
2725	Clinical best practices in optimal monitoring, early diagnosis, and effective management of antibody-drug conjugate-induced interstitial lung disease or pneumonitis: a multidisciplinary team approach in Singapore. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2022, 18, 805-815.	1.5	3
2726	Augmenter of Liver Regeneration Monoclonal Antibody Promotes Apoptosis of Hepatocellular Carcinoma Cells. <i>Journal of Clinical and Translational Hepatology</i> , 2023, 000, 000-000.	0.7	1
2727	Cardiotoxicity with human epidermal growth factor receptor-2 inhibitors in breast cancer: Disproportionality analysis of the FDA adverse event reporting system. <i>International Journal of Cardiology</i> , 2023, 375, 87-93.	0.8	3
2728	Pharmacovigilance Analysis of Heart Failure Associated With Anti-HER2 Monotherapies and Combination Regimens for Cancer. <i>JACC: CardioOncology</i> , 2023, 5, 85-98.	1.7	4
2729	Outcomes for the first four lines of therapy in patients with HER2-positive advanced breast cancer: results from the SONABRE registry. <i>Breast Cancer Research and Treatment</i> , 0, , .	1.1	2
2730	Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine+pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE). <i>Breast Cancer Research</i> , 2023, 25, .	2.2	6
2731	Knowledge atlas of antibody-drug conjugates on CiteSpace and clinical trial visualization analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
2732	Trastuzumab emtansine vs lapatinib and capecitabine in HER2-positive metastatic breast cancer brain metastases: A real-world study. <i>Breast</i> , 2023, 69, 441-450.	0.9	2
2733	The change of paradigm in the treatment of HER2-positive breast cancer with the development of new generation antibody-drug conjugates. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2023, 6, 45-58.	0.9	3
2734	Antibody-drug conjugates in lung cancer: dawn of a new era?. <i>Npj Precision Oncology</i> , 2023, 7, .	2.3	21
2735	Tumor-specific intracellular delivery: peptide-guided transport of a catalytic toxin. <i>Communications Biology</i> , 2023, 6, .	2.0	1
2736	TDM-1 en cáncer de mama metastásico her2 positivo. , 2022, 21, .		0
2737	Tumor Targeting of ²¹¹ At-Labeled Antibody under Sodium Ascorbate Protection against Radiolysis. <i>Molecular Pharmaceutics</i> , 2023, 20, 1156-1167.	2.3	3
2738	Molecular Pathways and Mechanisms of HER2 in Cancer Therapy. <i>Clinical Cancer Research</i> , 2023, 29, 2351-2361.	3.2	2
2739	Phase I study of LZM005 in patients with HER2-positive metastatic breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, .	2.3	1
2740	HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1. <i>Journal of the National Cancer Institute</i> , 2023, 115, 332-336.	3.0	6
2741	Treatment-related adverse events associated with HER2-Targeted antibody-drug conjugates in clinical trials: a systematic review and meta-analysis. <i>EClinicalMedicine</i> , 2023, 55, 101795.	3.2	7

#	ARTICLE	IF	CITATIONS
2742	The Impact of Breast Cancer Type, Staging, and Treatment on Vascular Complications of Immediate Free-Flap Breast Reconstruction. <i>Annals of Plastic Surgery</i> , 2023, 90, S556-S562.	0.5	0
2743	Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability. <i>Cancers</i> , 2023, 15, 713.	1.7	25
2744	Trastuzumab emtansina (T-DM1) en c�ncer de mama HER2 positivo. , 2013, 18, .		0
2745	Development of Next-Generation Antibody Therapeutics Using DDS and Molecular Imaging. , 2023, , 1-31.		0
2746	Antibody-drug conjugates for cancer therapy: An up-to-date review on the chemistry and pharmacology. <i>Comprehensive Analytical Chemistry</i> , 2023, , .	0.7	0
2747	Current Treatment Approaches to Breast Cancer. , 2023, , 23-51.		0
2748	Resistance to Antibody-Drug Conjugates Targeting HER2 in Breast Cancer: Molecular Landscape and Future Challenges. <i>Cancers</i> , 2023, 15, 1130.	1.7	7
2749	Deciphering breast cancer: from biology to the clinic. <i>Cell</i> , 2023, 186, 1708-1728.	13.5	72
2750	The evolving landscape of antibody-drug conjugates in gynecologic cancers. <i>Cancer Treatment Reviews</i> , 2023, 116, 102546.	3.4	13
2751	Drug-Induced Interstitial Lung Diseases. <i>Immunology and Allergy Clinics of North America</i> , 2023, 43, 341-357.	0.7	9
2752	Future potential targets of antibody-drug conjugates in breast cancer. <i>Breast</i> , 2023, 69, 312-322.	0.9	2
2753	Current Updates in Management of HER2-Positive and HER2-Low Breast Cancer. <i>Current Breast Cancer Reports</i> , 2023, 15, 135-141.	0.5	1
2754	Monoclonal antibodies in breast cancer: A critical appraisal. <i>Critical Reviews in Oncology/Hematology</i> , 2023, 183, 103915.	2.0	5
2755	Cardiovascular toxicity of tyrosine kinase inhibitors during cancer treatment: Potential involvement of TRPM7. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	1.1	2
2756	Cell death regulation in myocardial toxicity induced by antineoplastic drugs. <i>Frontiers in Cell and Developmental Biology</i> , 0, 11, .	1.8	7
2757	The Value of Tucatinib in Metastatic HER2-Positive Breast Cancer Patients: An Italian Cost-Effectiveness Analysis. <i>Cancers</i> , 2023, 15, 1175.	1.7	1
2758	HER2 Amplification Level Predicts Pathological Complete Response in the Neoadjuvant Setting of HER2-Overexpressing Breast Cancer: A Meta-Analysis and Systematic Review. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3590.	1.8	3
2759	The activation of <sc><i>EP300</i></sc> by <sc>F11R</sc> leads to <sc>EMT</sc> and acts as a prognostic factor in triple�negative breast cancers. <i>Journal of Pathology: Clinical Research</i> , 2023, 9, 165-181.	1.3	1

#	ARTICLE	IF	CITATIONS
2760	Comparison of HER2-targeted affibody conjugates loaded with auristatin- and maytansine-derived drugs. <i>Journal of Controlled Release</i> , 2023, 355, 515-527.	4.8	1
2761	Mechanisms of Resistance to Antibody-Drug Conjugates. <i>Cancers</i> , 2023, 15, 1278.	1.7	10
2762	HER Receptor, Current, and Emerging Therapeutic Targets. , 2023, , 1-32.		0
2763	HER2-Directed Therapy in Advanced Breast Cancer: Benefits and Risks. <i>OncoTargets and Therapy</i> , 0, Volume 16, 115-132.	1.0	2
2765	Nanotechnology - a robust tool for fighting the challenges of drug resistance in non-small cell lung cancer. <i>Beilstein Journal of Nanotechnology</i> , 0, 14, 240-261.	1.5	1
2766	Cardiotoxicity from neoadjuvant targeted treatment for breast cancer prior to surgery. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	1.1	1
2767	Unlocking the Resistance to Anti-HER2 Treatments in Breast Cancer: The Issue of HER2 Spatial Distribution. <i>Cancers</i> , 2023, 15, 1385.	1.7	5
2768	Discordance of HER2-Low between Primary Tumors and Matched Distant Metastases in Breast Cancer. <i>Cancers</i> , 2023, 15, 1413.	1.7	4
2769	Optimizing treatment for HER2-positive HR-positive breast cancer. <i>Cancer Treatment Reviews</i> , 2023, 115, 102529.	3.4	2
2770	Assessment of the expression pattern of HER2 and its correlation with HER2-targeting antibody-drug conjugate therapy in urothelial cancer. <i>Journal of the National Cancer Center</i> , 2023, 3, 121-128.	3.0	1
2771	Favorable Outcome and Safety of Neoadjuvant Trastuzumab Emtansine (T-DM1) in a HER2-Positive Early Breast Cancer Patient with Severe Renal Disease on Hemodialysis Ineligible for Conventional Chemotherapy: A Case Report. <i>Reports</i> , 2023, 6, 13.	0.2	0
2772	Genetic Code Expansion for Site-Specific Labeling of Antibodies with Radioisotopes. <i>ACS Chemical Biology</i> , 2023, 18, 443-448.	1.6	4
2773	HER2-Positive Metastatic Breast Cancer: Available Treatments and Current Developments. <i>Cancers</i> , 2023, 15, 1738.	1.7	6
2774	Novel Nanotherapeutics for Cancer Immunotherapy by PD-L1-Aptamer-Functionalized and Fexofenadine-Loaded Albumin Nanoparticles. <i>Molecules</i> , 2023, 28, 2556.	1.7	5
2775	Prognostic and Predictive Value of LIV1 Expression in Early Breast Cancer and by Molecular Subtype. <i>Pharmaceutics</i> , 2023, 15, 938.	2.0	1
2776	Data reproducibility issues on evidence synthesis of adverse events associated with HER2-targeted antibody-drug conjugates. <i>EClinicalMedicine</i> , 2023, 58, 101904.	3.2	1
2777	Integrating antibody drug conjugates in the management of gynecologic cancers. <i>International Journal of Gynecological Cancer</i> , 2023, 33, 420-429.	1.2	8
2778	Target Antigen Attributes and Their Contributions to Clinically Approved Antibody-Drug Conjugates (ADCs) in Haematopoietic and Solid Cancers. <i>Cancers</i> , 2023, 15, 1845.	1.7	9

#	ARTICLE	IF	CITATIONS
2779	Case Studies of Basket Trials and Umbrella Trials. , 2023, , 127-139.		0
2780	What Is Known about Breast Cancer in Young Women?. <i>Cancers</i> , 2023, 15, 1917.	1.7	18
2782	Antibodyâ€“Drug Conjugate Revolution in Breast Cancer: The Road Ahead. Current Treatment Options in <i>Oncology</i> , 2023, 24, 442-465.	1.3	6
2783	Emerging Targeted Therapies for HER2-Positive Breast Cancer. <i>Cancers</i> , 2023, 15, 1987.	1.7	18
2784	HER2-Low Breast Cancer: a New Subtype?. <i>Current Treatment Options in Oncology</i> , 2023, 24, 468-478.	1.3	8
2785	Clinical management of drug-induced cardiotoxicity in patients with HER-2+ breast cancer: current recommendations and future outlook. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2023, 19, 109-119.	1.5	1
2786	Recent trends of characteristics and treatments in adults with newly diagnosed brain metastases. <i>Japanese Journal of Clinical Oncology</i> , 0, , .	0.6	2
2787	Antibody Drug Conjugates. , 0, , .		0
2788	Interaction between Radiation Therapy and Targeted Therapies in HER2-Positive Breast Cancer: Literature Review, Levels of Evidence for Safety and Recommendations for Optimal Treatment Sequence. <i>Cancers</i> , 2023, 15, 2278.	1.7	7
2789	Detailed curriculum vitae of HER2-targeted therapy. , 2023, 245, 108417.		4
2790	Phase I study of A166, an antibodyâ€“drug conjugate in advanced HER2-expressing solid tumours. <i>Npj Breast Cancer</i> , 2023, 9, .	2.3	9
2791	High risks adverse events associated with trastuzumab emtansine and trastuzumab deruxtecan for the treatment of HER2-positive/mutated malignancies: a pharmacovigilance study based on the FAERS database. <i>Expert Opinion on Drug Safety</i> , 2023, 22, 685-696.	1.0	1
2792	Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial. <i>Lancet, The</i> , 2023, 401, 1773-1785.	6.3	58
2793	Identifying the optimal therapeutics for patients with hormone receptor-positive, HER2-positive advanced breast cancer: a systematic review and network meta-analysis. <i>ESMO Open</i> , 2023, 8, 101216.	2.0	0
2794	Understanding the activity of antibodyâ€“drug conjugates in primary and secondary brain tumours. <i>Nature Reviews Clinical Oncology</i> , 2023, 20, 372-389.	12.5	18
2795	Targeted therapy. , 2023, , 459-488.		0
2801	Bioconjugates: Preparation methods and therapeutic applications. <i>Comprehensive Analytical Chemistry</i> , 2023, , 43-91.	0.7	0
2809	Drug targeting in anticancer chemotherapy. , 2023, , 823-899.		0

#	ARTICLE	IF	CITATIONS
2815	Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship. <i>Nature Reviews Clinical Oncology</i> , 2023, 20, 527-542.	12.5	13
2818	The major clinical components of cancer immunotherapy (modulating cell-mediated immune) Tj ETQq1 1 0.784314 rgBT /Overlock 10		
2827	Antibody- α drug conjugates come of age in oncology. <i>Nature Reviews Drug Discovery</i> , 2023, 22, 641-661.	21.5	82
2893	Polymer-mediated nanoformulations: a promising strategy for cancer immunotherapy. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2024, 397, 1311-1326.	1.4	0
2901	Molecular testing in breast cancer. , 2024, , 303-318.		0
2944	Gold Nanoparticles: Clinical Applications. <i>Engineering Materials</i> , 2023, , 563-578.	0.3	0
2958	A Review of the Current FDA-Approved Antibody-Drug Conjugates: Landmark Clinical Trials and Indications. <i>Pharmaceutical Medicine</i> , 0, , .	1.0	1
2983	Innovative Therapeutic Approaches for Patients with HER2-Positive Breast Cancer. <i>Cancer Treatment and Research</i> , 2023, , 237-281.	0.2	0
2990	New Concepts in Cardio-Oncology. <i>Cancer Treatment and Research</i> , 2023, , 303-341.	0.2	0
3011	Advancing Precision Medicine. , 2024, , 1-31.		0
3012	Trastuzumab for Active Targeting in Cancer Therapy. , 2024, , 1-30.		0